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Abstract
.Abstract
Erythrovirus B19 is the only parvovirus known to cause disease in humans and
represents a concern in transfusion medicine since several blood products were shown
to contain B19 despite various inactivation steps and some products have even
transmitted viral infection. The aim of the study was to establish a reliable and
reproducible infectivity assay that could be used to evaluate the efficiency of viral
removal/inactivation methods. This assay was based on the detection of B 19-specific
mRNA transcripts from susceptible cells inoculated with virus: the human leukaemic
cell line UT-7/EPO-S1. B19 DNA concentrations were also determined using an
optimised quantitative real-time PCR assay. Both assays were used to assess the
efficacy of one virus removal method, nanofiltration, and four virus inactivation
techniques, dry heating treatment, supercritical fluids, INACTINE™ system and
Helinx® technology. Nanofiltration of a spiked solution of 0.5% albumin with 15N and
20N filters resulted in the removal of more than logio 5 and logio 6 of infectious B19,
respectively. Dry heat treatment of factor VIE showed a reduction of infectivity greater
than logio 2 after 24 hours and below the limit of detection of the assay after 72 hours.
The treatment of plasma with the SuperFluids™ system removed more than logio 5
infectious viruses. Two chemicals methods used novel small molecules which target and
crosslink nucleic acids: PEN 110 (INACTINE™ system) and Psoralen S-59 (Helinx®
technology). Treatment of red cells with PEN 110 showed a reduction of infectivity
below the detection limit while platelet concentrates treated with S-59 resulted in a
reduction greater than logio 5. Although chemical methods can be used on cells which
do not have a nucleus (red cells and platelets), they also introduce potential toxicity. In
contrast, physical methods of removal and inactivation are less toxic but would damage
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red cells and platelets. Overall, this research work allowed the establishment of a 
reproducible infectivity assay that was successfully used to perform preliminary studies 
on the efficacy of various viral removal/inactivation methods.
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Chapter I: Introduction
 Chapter I
1.1. Human parvovirus B19
1.1.1. Discovery, classification and structure of human parvovirus B19
I .l.l .l. Discovery
In 1975, during routine screening for hepatitis B surface antigen (HBsAg) of sera from 
healthy blood donors, Dr Y. Cossart and coworkers noticed abnormal results in the 
counterimmunoelectrophoresis (CIE) assay of several samples that tested negative for 
hepatitis B by confirmatory methods (radioimmunoassay and haemagglutination) 
(Cossart et al., 1975). The precipitin line from the CIE was cut out and electron 
microscopy showed the presence of spherical particles, with a diameter varying from 
20.5nm to 25nm (mean 23nm). Their characteristic features included disrupted 
fragments and empty shells. Cossart et al. observed a resemblance with animal 
parvoviruses on account of the similar size and morphology of the particles, and 
because the antigen bands in caesium chloride were at a density within the parvovirus 
range (1.36 to 1.40) (Cossart et al., 1975; Siegl et al., 1985). Similar observations were 
later made in France in 1982, where the “Aurillac” virus (named after the town in 
which it originated) was described (Courcouce et al., 1984a; Courcouce et al., 1984b). 
Subsequently, both “Aurillac” and “Nakatani” (from Japan) viruses were shown to be 
identical to the “serum parvovirus-like virus” (SPLV) discovered by Cossart and 
colleagues (Cossart et al., 1975; Courcouce et al., 1984a; Courcouce et al., 1984b; 
Okochi et al., 1984).
For some time, the isolates could not be related to naturally occurring diseases (Harley 
and Rotbart, 1990). However, in 1980, a brief publication reported the detection by 
electron microscopy (EM) of human parvovirus in the sera of two soldiers from the 
same unit, who presented with an uneventful and self-limited febrile episode (Shneerson 
et al., 1980). In 1981, B19 was also detected in two children with sickle cell anemia
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hospitalised for aplastic crisis (Pattison et al., 1981). A few years later, B19 was
reported in association with an outbreak of erythema infectiosum (El) in a London
school, UK (Anderson et al., 1983). Moreover, the fetal damage in animals known to
result from in utero infection with parvoviruses encouraged research, which led to the
first report of B19 as a cause of human hydrops fetalis (Brown et al, 1984).
Additionally, investigations on the link between B19 and arthritis started in 1985 (White
et al., 1985; Reid et al., 1985; Lefrere et al., 1985a). In the last twenty years, human
parvovirus has been associated with a wide range of clinical diseases, from El to
hydrops fetalis and new links between this infectious agent and various conditions are
still being found.
I.I.I.2. Taxonomy
Since parvoviruses are among the smallest DNA-containing viruses (18-26nm) able to 
infect mammalian cells, the Latin word for small, “parvum”, was used to designate this 
group of linear, single-stranded DNA viruses related by their morphology and 
functional characteristics (Berns, 1996). The International Committee on Taxonomy of 
Viruses (ICTV) has divided the family Parvoviridae into two sub-families, the 
Parvovirinae and Densovirinae, according to their ability to infect vertebrate or 
invertebrate cells, respectively (ICTV, 2005). Parvovirinae is further divided into five 
genera, including Parvovirus, Dependovirus, Erythrovirus, Amdovirus and Bocavirus. 
The genus Parvovirus comprises all animal parvoviruses able to replicate autonomously 
in susceptible cells. These viruses do not require the presence of a helper virus 
(adenovirus, herpesvirus or even vaccinia virus) to undergo a complete cycle of 
replication. Most vertebrate disease-causing parvoviruses belong to the Parvovirus 
genus, including rat virus (RV): H-l virus, minute virus of mice (MVM), porcine
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(PPV), feline (FPV) and lapine (LPV) paroviruses (Siegl et al., 1985). The second 
genus, Dependovirus, consists of parvoviruses that cannot replicate efficiently under 
standard in vitro culture conditions whereas they can multiply successfully when target 
cells are co-infected by either adenovirus or herpesvirus. Viruses in this genus have 
never been shown to cause disease, either in their natural host or under experimental 
conditions. The only member of the Amdovirus genus is Aleutian mink disease virus 
(ADV), which has been detected in most mustelids, skunks and racoons (ICTV, 2005). 
The Bocavirus genus includes bovine parvovirus (BPV) and canine minute virus 
species. Finally, several members of the Densovirinae, the so-called densonucleosis 
viruses, have been isolated from a variety of insect host species and are autonomously 
replicating pathogenic parvoviruses of insects. The organisation of the parvoviridae 
family is shown on figure 1.1.
Figure 1.1: Organisation chart of the Parvoviridae family (constructed using 
data from the ICTV 8th report of virus taxonomy, 2005)
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In 1985, when human parvovirus B19 was officially recognised as a member of the
Parvoviridae family, it was classified in the Parvovirus genus (Siegl et al., 1985). 
Although the acronym “HPV” for human parvovirus would have been in accordance 
with long-standing practice of the naming of autonomous parvoviruses, the acronym 
was already in use for human papillomavirus. Therefore, in order to avoid confusion, 
the ICTV recommended the use of the name “B19”, which refers to the coding of this 
first isolate, number 19 in panel B (Cossart et al., 1975; Siegl et al., 1985). Since 
parvovirus B19 has a high erythroid tropism, it was reclassified in the genus 
Erythrovirus (ICTV, 2000). The other species recently classified in this genus are pig­
tailed macaque parvovirus, rhesus macaque parvovirus and simian parvovirus (SPV) 
(ICTV, 2005) due to their predilection for host bone marrow in vitro and capacity to 
cause serious anaemia in infected animals, namely pig-tailed and rhesus macaques 
(Green et al., 2000) and cynomolgus monkeys (O’Sullivan et al., 1994; O’Sullivan et 
al., 1997), respectively. Moreover, a Korean group identified a parvovirus in 
Manchurian chipmunks highly similar to B19 and SPV on the molecular level (Yoo et 
al., 1999). This virus has thus been proposed as an additional member of the 
Erythrovirus genus.
I.I.I.3. Morphology
Parvovirus B19 has a simple structure made of only two capsid proteins, VP1 (-5%) 
and VP2 (-95%), and a linear, 5.5 kb single-stranded DNA molecule. Equal numbers of 
complementary DNA strands (positive and negative sense DNA) are packaged into 
separate virions (Summers et al., 1983). In contrast, most other autonomous 
parvoviruses, such as LuIII (Muller and Siegl, 1983), and members of the Dependovirus 
genus (Bems and Adler, 1972), package only one type of complementary single-
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stranded DNA, preferentially of negative polarity, in different types of particles. The
B19 virus particles are non-enveloped and measure between 22 and 24 nm in diameter
(Cossart et al., 1975). Negative staining and EM revealed that often both empty and full
capsids are present in the host’s serum. The molecular weights of the mature virion and
f f\of empty particles are 5.5-6.2x10 and 4.2x10 Da, respectively (Agbandje et al., 1994). 
Moreover, the buoyant density of a full particle in a caesium chloride gradient is 1.43 
g/mL (Clewley, 1984). Empty B19 capsids have been expressed from genetically 
engineered Chinese hamster ovary cell line (Kajigaya et al., 1989), as well as in 
baculovirus expression systems (Kajigaya et al., 1991; Brown CS et al., 1991; 
Kaufmann et al, 2004), and have been used as antigens for diagnosis assays, to develop 
a vaccine and for use in X-ray crystallographic analyses. A few years after successfully 
crystallising B19 empty capsids in a baculovirus expression system, Agbandje and 
coworkers established the structure of parvovirus B19 at 8A resolution (Agbandje et al., 
1991; Agbandje et al., 1994). More recently, the structure of B 19-like particles was 
determined to about 3.5A resolution (Kaufmann et al., 2004).
The three-dimensional X-ray crystal structures of canine parvovirus (CPV) and FPV 
had already been determined to the atomic resolution (Tsao et al., 1991; Agbandje et 
al., 1993). Although CPV and FPV have similar antigenic properties, there is no cross­
reactivity of antibodies to CPV or FPV with B19, indicating different surface structures 
(Agbandje et al., 1994). However, sequence alignments suggest a distant, yet common 
origin of CPV, FPV and B19 (Chapman and Rossmann, 1993). Electron density maps 
of these viruses were therefore compared, keeping in mind that the resolution of the B 19 
map was lower than that of CPV and FPV (Agbandje et al., 1994). All three viruses 
consist of 60 copies of the capsid protein arranged in icosahedral symmetry. Although 
the polypeptide folds of CPV and FPV contain 8 anti-parallel p-barrel structural motifs
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(“jelly roll”), most of their structure is made of insertions between the strands of the P-
barrel. These insertions form elaborate loops on the viral surface that are important as
antigen recognition sites. The most prominent of these insertions forms a spike on the
icosahedral threefold axes. A 15A canyon-like depression circulates around the fivefold
axis.
As far as parvovirus B19 is concerned, the central p-barrel structural motif is easily 
recognisable in the same region as that of FPV (Agbandje et al., 1994). However, the 
surface of B19 seems significantly different from the other parvoviruses since the 
prominent spikes on the icosahedral threefold axes are lacking. These two findings were 
in agreement with the amino acid sequence analyses by Chapman and Rossmann, 
showing a greater conservation in the central p-barrel structure of parvoviruses than in 
the surface insertions (Chapman and Rossmann, 1993). Another region of density in 
B19 that was very similar to that of FPV and Adeno-Associated Virus (AAV) (Xie et 
al., 2002) was a hollow cylindrical structure about the fivefold icosahedral axis, which 
appears to penetrate inside the virion (Agbandje et al., 1994). It is formed by the DE 
loop (amino acids 129-148) shown on figure 1.2, but in B19, the tip of the loop is bent 
towards the central axis of the channel (Kaufmann et al., 2004). It was suggested that 
the unique region of the larger protein VP1 might extend through this cylinder to 
outside the virion. This hypothesis might be plausible since Bansal et al. had already 
suggested that at least part of the unique region of VP1 is exposed at the surface of the 
virion (Bansal et al., 1993). This proposition originated from an experiment performed 
using altered concentrations of VP1 and VP2 proteins in baculovirus-produced empty 
capsids. The authors showed that antisera specific for the unique region of VP1 was 
able to precipitate both plasma-derived virions and these recombinant empty capsids. It 
is also important to note that VP1 alone cannot form empty capsids whereas severely
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shortened VP1 did not seem to alter the capsid formation (Wong et al., 1994). Although
longer versions of VP1 also formed capsids, they did so less efficiently and the capsids
were less ordered in appearance than the native empty capsids, recombinant empty
capsids, VP2 only capsids and capsids formed by the truncated versions of VP1.
When the structure of recombinant B19 particles was investigated at 3.5A resolution, it
was found to be most similar to that of AAV-2 (Kaufmann et al., 2004; Xie et al.,
2002). Moreover, both viruses require an integrin as a coreceptor: aVpi integrin for
AAV-2 (Summerford et al., 1999) and a5pi for B19 (Weigel-Kelley et al., 2003).
However, the degree of similarity between these two viruses (26% identity between
major structural proteins) is much less than between B19 and other human parvoviruses,
such as LaLi (97%) and V9 (98%) -which will be detailed in section 1.1.6-, and SPV
(67%) (Servant et al., 2002). Although AAV-2 and B19 share a common host
(vertebrates), this low sequence similarity suggests a host-independent evolution
(Kaufmann et al., 2004).
Figure 1.2 shows the ribbon diagram of VP2 (a) and the surface topography of 
parvovirus B19 (Kaufmann et al., 2004).
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Figure 1.2: Secondary structure of parvovirus B19 (from Kaufmann et al.,
d
HI
(a) Ribbon diagram of VP2. The strands of the p-barrel (grey) are labelled sequentially A through I. The 
surface loops connecting the strands of the p-barrel are labelled by colour: dark blue, BC loop; dark 
green, DE loop; light blue, EF loop; red, GH loop; light green, HI loop; yellow, C-terminal amino acids. 
The position of the disordered loop (amino acids 301-313) (dashed line) was modelled based on the 
corresponding AAV-2 loop.
(b) Surface topography of B19. The surface loops are colour-coded according to the ribbon diagram. 
The disordered loop has been omitted.
I.I.I.4. Genomic organisation
Particles found in viremic plasma contain single-stranded DNA, either positive or 
negative sense, each of which being fully capable of infection and replication (Summers 
et al., 1983, Cotmore and Tattersall, 1984). MVM DNA is known for its terminal 
palindromic sequences, which allows the formation of hairpin structures at both ends of 
single-stranded DNA (Bourguignon et al., 1976). The hairpin situated at the 3’ end of 
each DNA molecule could serve as a primer for various prokaryotic and eukaryotic
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DNA polymerases, resulting in the synthesis of the complementary strand in vitro.
Similar 3’ terminal hairpin structures have been demonstrated in parvovirus B19,
making cloning of the complete genome into plasmid vectors difficult (Cotmore and
Tattersall, 1984). An incomplete clone was obtained from the serum of a child with
homozygous sickle cell disease who was in the early phase of reticulocytopenic aplastic
crisis (isolate Au) (Shade et al., 1986).
The clone, named pYT103, was lacking the extreme left and right ends known as 
terminal hairpin structures. The nucleotide sequence of pYT103 suggested that the 
organisation of the B19 transcription units is similar, although not identical, to that of 
other parvoviruses. The Au isolate was also cloned using two expression constructs 
containing B19 sequences from different halves of the viral genome (Cotmore et al., 
1986). These clones allowed the identification of the two major capsid proteins, VP1 
and VP2, with apparent molecular weights of 83 kDa and 58kDa, respectively. These 
capsid sequences were located in a major stretch of open reading frame on the right- 
hand half of the viral genome. The next step in discovering the genomic structure of 
B19 was made by Mori and colleagues, who examined the virus by electron microscopy 
and observed double-stranded molecules with characteristic “fold-back” or forked ends, 
as shown in figure 1.3 (Mori et al., 1987; Anderson and Young, 1997). The latter were 
assumed to be due to the terminal hairpin structures which had previously been 
predicted to be substantially longer than those of AAV (125 nucleotides) (Shade et al., 
1986; Lusby et al., 1980). This large size was therefore thought to account for the 
ability to visualise the “fold-back” termini by EM whereas this phenomenon cannot be 
observed with other parvoviruses.
The exact measurement and the structural analysis of the palindromic termini were only 
possible in 1990, when the instability of these termini in bacterial cells was overcome
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and the entire B19 genome cloned in plasmids (Deiss et al., 1990). The 383 terminal
nucleotides at each end of the genome were found to be identical inverted repeats, the
distal 365 nucleotides being an almost perfect palindrome that can fold over to give a
hairpin structure. Due to some mismatching between nucleotides 147 and 217, it is
typical for terminal hairpins to occur in two distinct sequence configurations, which
have been referred to as “flip” and “flop”. These configurations, which are related since
one is the inverted complement of the other, have been described in all parvoviruses
analysed to date and are essential for viral replication. Thus the B 19 genome consists of
a linear, 5,596 nucleotides long, single-stranded DNA molecule that includes an internal
coding sequence of 4830 nucleotides and flanked, on either ends, by inverted repeats of
383 nucleotides each (Deiss et al., 1990).
Figure 1.3: B19 viral DNA showing terminal hairpin structures (published by
Anderson and Young, 1997)
A C
A and B are electron microscopic views. A Both ends of the molecule are folded hack to form hairpins 
(x57,000). B One end of the molecule is folded back and the other end is annealed in an extended form 
(x68,000). C and D are drawings of the plus and minus strands with terminal hairpin structures.
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I.I.I.5. Proteins
I.I.I.5.I. Protein synthesis
The genome of human parvovirus B19 encodes only three proteins of known function, 
namely the capsid proteins VP1 (83 kDa) and VP2 (58 kDa) and the nonstructural 
protein NS1 (77 kDa). The VP1 and VP2 open reading frames (ORFs) overlap 
completely, with approximately 990 extra nucleotides included in the VP1 ORF.
The sizes of these proteins, which were identified in various cell expression systems, are 
summarised in table 1.1 (Astell et al., 1997), while figure 1.4 shows the transcription 
map described by Ozawa and colleagues (Ozawa et al., 1987a).
Table 1.1: Summary of B19 NS1 and VP1, VP2 proteins identified in different
expression systems (Astell et al., 1997)
NS1
(kDa)
VP1 (minor) and VP2 
(major) (kDa)
Cell system Authors, year
71,63,52 83 (minor), 58 (major) Clinical isolate
Cotmore et al., 
1986
77, 52, 34 84 (minor), 58 (major)
B19-infected human 
erythroid bone marrow
Ozawa and 
Young, 1987
77, 68 N/A
HeLa cells transfected with 
B19 expression plasmid
Ozawa et al., 
1988a
71,63 83 (minor), 58 (major)
COS cells transfected with 
B19 expression plasmid
Beard etal., 1989
71,55, 34 84 (minor), 58 (major)
COS cells transfected with 
B19 expresssion plasmid
Astell et al., 1997
Although the sizes for the VP1 and VP2 proteins were reasonably consistent (83 kDa 
and 58 kDa respectively), those of the NS1 protein were considerably different, ranging
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in size from 77 kDa to 71 kDa. It is probable that these are the same protein and the
difference in molecular weight is due to the use of different protein markers and/or gel
composition. In addition, several smaller proteins were detected (ranging in size from
34 kDa to 68 kDa). These smaller NS proteins might arise due to post-translational
cleavage or, less likely, internal initiation. It is also possible that they are degradation
products of NS1. However, in other parvoviruses (MVM and AAV), alternate splicing
generates mRNAs, which encode smaller NS or Rep proteins (Berns, 1990).
Nevertheless, the transcription map suggests that these splicing sites do not exist in B 19.
Figure 1.4: Human parvovirus B19 transcription map showing open reading 
frames and viral proteins (proposed by Ozawa et al., 1987a)
reading
frame
map units o 
nucleotides o
(kb) 
a 3.15
a' 3.03 
b 2.31
c 2.29 
d 2.18 
e 0.81 
f 0.69 
g 0.63 
h 0.51
CZ3
40—r1- 
1000 2000
—I—
3000
ATG (rrt 2444)
80
4000
7B1 >3.
I M l
I M l
TATA 11
re
i l l . _LL
AATAAA J_L
/ A T T A A A  \ 
\ A A T A A C  )
5000
TAA
100H
ATG (nt 4361 671 u
ATG Crrt 3125) 5 5 4  „
B19 proteins
VP1 (84 kdl 
NS1 (77 kd)
VP2 (58 kd)
(nt 4731) 
ATG TAA 
£12*
ATG TAA 87 B3.
Shown is the location of the P6 promoter, functional polyadenylation signals, splice donor and acceptor 
sites, ORF (boxes), ATG sequences (vertical lines).
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In addition to structural and nonstructural proteins, some smaller proteins (11- and 
7.5kDa) are translated from the small abundant mRNAs, which are unique among 
parvoviruses (Astell et al, 1995). Both size classes are polyadenylated RNAs with a 
small ORF (St Amand et al., 1991). The 700- to 800-nt class includes an 807- and 687- 
nt RNA while the 500- to 600-nt class includes the 638- and 518-nt RNAs. These last 
two RNAs express a family of three 11-kDa proteins (St Amand et al., 1991; St Amand 
and Astell, 1993) while the 807-nt RNAs express a 7.5kDa protein (Luo and Astell, 
1993). Although the latter is within the NS coding region of the genome, it is in a 
different ORF to that of the NS protein. When transfected COS cells and infected 
human leukemic or peripheral blood mononuclear cells were investigated, the 11 kDa 
proteins were found mainly in the nucleus, but also associated to a reticular network of 
the cytoplasm of COS cells (Luo and Astell, 1993). The 7.5kDa protein was both 
nuclear and cytoplasmic in COS cells whereas it was predominantly cytoplasmic in 
infected human peripheral blood mononuclear cells.
I.I.I.5.2. Role of structural proteins
Structural proteins have three important functions: to interact with the cellular receptor, 
to translocate the genetic material to appropriate sites of transcription and replication 
and to permit the assembly of infectious particles. The full B19 capsid is icosahedral 
and composed of 60 copies of the capsid proteins, 96% of which being VP2 and the 
remainder VP1 (Cotmore et al., 1986; Ozawa and Young, 1987). This difference in the 
relative percentages of VP1 and VP2 is thought to be due to a translational regulation of 
capsid protein production (Ozawa et al, 1988b). After translation of its mRNA in the 
cytoplasm, VP2 has to reach the nucleus where new B19 capsids are assembled (Pillet
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et al., 2003). Due to its molecular weight (58kDa), VP2 is unlikely to diffuse passively
into the nucleus and is thus probably transported by specific cellular transporters called
karyopherins. This kind of transport was described previously for many cellular and
viral proteins (Macara, 2001). The karyopherins recognise the proteins to be transported
through specific peptides present on the proteins surface called nuclear localisation
signals (NLS) (Pillet et al., 2003). The latter have been found in the capsid proteins of
several parvoviruses: within the N-terminal of the VP1 capsid protein of CPV (Vihinen-
Ranta et al., 1997), in VP2 of AAV-2 (Hoque et al., 1999) and in both VP1 and VP2 of
MVM, which are involved in cooperative cytoplasmic interactions for nuclear
cotransport (Lombardo et al., 2000; Lombardo et al., 2002). The VP1 NLS was
therefore shown to play a role in transport into the nucleus. However, no data has been
reported to date regarding NLS in B19 VP1. A nonconsensus basic motif,
KLGPRKATGRW, located in the C-terminal region of VP2, has been proposed as the
main NLS of B19 VP2 capsid protein (Pillet et al., 2003). This conserved sequence was
shown to be necessary for the nuclear localisation of VP2 and is exposed on the surface
of an isolated VP2 subunit where it can be recognised by the cellular import (Kaufmann
et al., 2004). Once in the nucleus, VP2 proteins are able to self-assemble alone or with
VP1, whereas VP1 alone cannot self-assemble (Kajigaya et al., 1991). After assembly,
the NLS is hidden because it is on the inner capsid surface (Kaufmann et al., 2004). In
addition, the 226-amino acid unique terminal region of VP1 interferes progressively
with particle assembly when more than 70 amino acids of that region are present (Wong
et al., 1994). As far as the small 11-kDa proteins are concerned, they were shown not to
affect the self-assembly of the viral particles (Cohen CS et al., 1991).
Although predictions concerning the surface structure of B19 could be made from the
resolution at the atomic level of canine parvovirus capsid, B19 VP proteins expressed in
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insect cells using recombinant baculovirus expression vectors were crystallised and the
three-dimensional structure was elucidated (Agbandje et al., 1991; Agbandje et al.,
1994; Chapman and Rossmann, 1993).
Several studies have been carried out to identify neutralising epitopes on the virus 
capsid. Heamagglutination was inhibited by means of a monoclonal antibody directed 
against amino acids 57-77 of the VP2 protein. This epitope was found to contribute to 
the spike on the three-fold axes of the capsid (Brown et al., 1992). It is still not clear 
whether these regions represent viral attachment sites or whether deep canyons around 
the five-fold axes are the best candidates for interaction with the P receptor (Agbandje 
et al., 1994). The 226-amino acid unique amino-terminal region of VP1 is known to be 
on the surface of the virus particles (Rosenfeld et al., 1992) and antibodies to the capsid 
are directed predominantly against this region (Kurtzman et al., 1989a; Schwarz et al., 
1988). Although neutralisation epitopes were also mapped to regions within VP2 
protein, the latter is less immunodominant than VP1 (Sato et al., 1991a; Sato et al., 
1991b; Yoshimoto et al., 1991). The influence of B19 virus structure on antibody 
responses is not well defined. A strongly cross-linking antigen can activate B cells in 
the absence of T-cell help, whereas poorly cross-linking antigens need T-cell help for B- 
cell activation. A CD4+ T-cell response was found to be directed against B19 capsid 
proteins (Von Poblotzki et al., 1996). This cellular immune response was restricted by 
HLAII molecules and might support specific B-cells in producing antibodies.
I.I.I.5.3. Role of non-structural proteins
Few functions for B19 NS1 have been directly demonstrated and a number of reports 
have suggested the important role of NS1 in the replication of viral DNA, as well as in 
the transactivation of promoter P6 and in cytotoxicity.
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1.1.1.5.3.1. Role in DNA replication
Viral DNA replication is initiated from short double-stranded regions provided by self­
annealed, terminal hairpin structures. DNA synthesis then proceeds from these 
palindromes to produce high molecular weight intermediates through a rolling hairpin 
model (Bems, 1990). By analogy with the major NS1 protein of MVM (Wilson et al., 
1991; Jindal et al., 1994) and the nonstructural proteins Rep of AAV-2 (Im and 
Muzyczka, 1990; Synder et al., 1990), it is likely that the nucleotide binding fold 
domain is involved in ATP hydrolysis. The energy derived from it might be used to 
drive an intrinsic helicase activity. In addition, resolution of terminal (and internal 
dimer bridge) hairpin structures during MVM (Cotmore et al, 1992; Cotmore et al., 
1993; Liu et al., 1994) and AAV (Snyder et al., 1990) replication was found to be 
dependent on the NS1 and Rep68 and 78 proteins. This resolution has been predicted to 
reside in a protein motif found in enzymes functional in rolling circle replication (Ilyina 
and Koonin, 1992). This motif is located within the first third of the NS proteins.
Overall, it seems that parvovirus NS1 has a direct role in viral replication by providing 
the activities required for the resolution of covalently joined B19 termini, namely 
endonuclease and helicase activities. In the work of Jindal et al., some of the mutants 
tested appeared to retain ATP-binding and ATPase activities but not helicase activities 
and some mutations in the NTP-binding site decreased viral replication but did not 
affect trans-activating activity (Jindal et al., 1994).
1.1.1.5.3.2. Transactivation of the P6 promoter
When the B19 P6 promoter was used to drive expression of a reporter CAT gene in 
transfected Hela cells, promoter activity was upregulated by the B19 NS1 protein 
(Doerig et al., 1990). In addition, in vitro translated B19 NS1 was shown to stimulate
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transcription from the same promoter. Although studies to map the transactivational
domain of the B19 NS protein have not been reported, the same activity in MVM NS1
protein was found in the C-terminal region (Legendre and Rommelaere, 1994). More
recent studies showed that transcriptional regulation by the NS1 protein was likely to
involve both the interaction with Spl/Sp3 that can bind to the promoter region and
direct binding of NS1 to the promoter DNA (Raab et al., 2002).
The roles of NS1 in replication and transcription seem to be consistent with the nuclear 
localisation of this protein in infected cells. In addition, a nuclear localisation signal 
(NLS) (i.e. KKPR) was described at amino acid positions 177-180 (Cotmore et al., 
1986). However, the localisation of NS1 during the cell cycle may also be cytoplasmic, 
suggesting that it may be a shuttle protein (Morinet et al., 2000).
I.I.I.5.3.3. Cytotoxicity
Between 1988 and 1998, several papers were published regarding NS1 cytotoxicity. 
During an attempt to obtain stable transfected HeLa cell lines containing the B19 
genome, transformation occurred only when NS1 protein expression was blocked by 
mutation (Ozawa et al., 1988a). Other studies using recombinant AAV-B19 particles 
showed that growth of megakaryocytic cells and erythroid progenitors was inhibited by 
NS1 (Srivastava et al., 1990). Thus, NS-1 cytotoxicity was suggested in both erythroid 
and non-erythroid cells. Additionally, viral replication did not seem necessary since no 
DNA replicative forms were detected in megakaryocytic cells. The link between 
cytotoxicity and apoptosis was suggested in erythroid lineage cells transfected with the 
NS1 gene (Moffatt et al., 1998). Caspase 3 participates in this process. In addition, the 
induction of erythroid cells apoptosis by human parvovirus B19 may involve the tumour 
necrosis factor alpha (TNF-a) receptor signalling pathway (Sol et al., 1999). Moreover,
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infected cells showed ultrastructural features typical of apoptosis (Morey et al., 1993).
Computer analysis allowed the identification of a NTP-binding motif in the middle of
the B19 parvovirus nonstructural protein (Gorbalenya and Koonin, 1989). Studies have
shown that mutations within this motif seem to moderate the cytotoxicity of NS1
(Momoeda et al., 1994a). Lysine 334 in this domain was shown particularly critical for
cell killing. Similar results had already been observed for homologous NS1 protein of
parvovirus H-l, also responsible for cytotoxicity of rat host cells (Li and Rhode, 1990)
and in the MVM NS1 protein (Legendre and Rommelaere, 1992). However, the effects
of the latter on cellular transformation, as an indirect measure of cytotoxicity, were
found not only on the nucleotide binding fold motif but also localised within the amino-
and carboxyl-terminal domains.
Some authors suggested that the functions of transactivation of the P6 promoter and 
cytotoxicity are not localised in the same protein domain (Moffatt et al., 1996; Moffatt 
et al., 1998). These results concern B19-infected and NS1-transfected erythoid cells. 
Until now, B19-induced apoptosis in HeLa cells and megakaryocytic progenitors, where 
cytotoxicity was also observed (Srivastava et al., 1990; Ozawa et al., 1988a; Leruez- 
Vill et al., 1997), has not been documented. NS1 mutants with a disruption of the NTP- 
binding domain have a dramatically suppressed cytotoxic activity, although complete 
abrogation of cell death was not observed (Moffat et al., 1998).
I.I.I.5.4. Role of small 11-kDa proteins
The function of both the 11- and 7.5-kDa proteins still remains to be determined. 
However, a recent study showed that the amino acid sequence of the 11-kDa proteins 
present an unusually high proportion (15%) of proline residues (Fan et al, 2001). Some 
of these residues can be grouped into three regions that share similarity with sequences
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known to bind to Src homology 3 (SH3) domains in a variety of signal-transducing
molecules. In addition, the B 19 11-kDa proteins were shown to interact in vitro with the
growth factor receptor-binding protein 2 (Grb2), an adaptor protein implicated in
receptor tyrosine kinase-mediated signalling of mitogenic and stress stimuli.
Consequently, it was suggested that the 11-kDa proteins could be involved in viral
pathogenesis through perturbation of normal cellular signalling pathways by binding
Grb2 or another as yet unidentified SH3 domain-containing protein.
I.I.I.6. Sequence variability
Unlike other parvoviruses such as ADV, human parvovirus B19 was first thought to
have a highly conserved genome (Gottschalck et al., 1991). One of the first attempts to
explore the genetic variability of B19 virus was made in 1986 using restriction enzyme
(RE) analysis to compare 17 isolates collected over a 12 year-period in France and
Great Britain (Morinet et al., 1986). Variant patterns characterised by altered sites for at
least one RE, were observed in only 5 of the 17 isolates. However, the remaining 12
isolates had the same map, suggesting a high genetic stability of the parvovirus B19
genome. Shortly after these findings, the DNAs of over 40 isolates were mapped with
13 REs and a classification into several genome types was proposed (Mori et al., 1987).
Group I comprised blood donations collected between 1973 in Great Britain and 1979 in
France and included the first published isolate (Cossart et al., 1975), as well as the Wi
isolate (Cotmore and Tattersall, 1984). Some isolates in circulation from 1978 in France
to 1986 in the UK were classified in group II genome type (Mori et al., 1987). A third
restriction pattern was present in the UK from 1979 to 1986, namely group Ilia, while
group mb genome type was first observed in a French blood donor in 1978 and from a
case of aplastic crisis in Scotland in 1986. Only strains from Japan were included in
group IV genome type while many strains remained unassigned. This classification of
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genotypes suggested a possible epidemiological relationship among strains, which was
investigated further with the study of 12 strains of parvovirus B19 isolated in Japan at
two different time periods: 1981 and between 1981 and 1986 (Umene and Nunoue,
1990). The former were similar to that of the group IV genome type whereas the latter
were related to that of group II, indicating a correlation between the genome type and
the time of isolation, or prevalence.
A later publication reported a single-stranded conformational polymorphism (SSCP) 
assay, which was able to detect a mutated nucleotide sequence as a change of mobility 
in polyacrylamide gel electrophoresis caused by an altered folded structure (Kerr et al., 
1995a). These findings were consistent with those of Umene and Nunoue, since there 
was a correlation between the SSCP type and the country of origin, as well as time of 
isolation (Kerr et al., 1995a; Umene and Nunoue, 1990). Within the Japanese group, 
strains isolated from 1981 to 1987 consisted of SSCP types 1 (-13%), 2 (-7%), 3 
(-53%) and 4 (-27%), whereas strains isolated from 1990 to 1994 were mostly of type 
3 (-91%) (Kerr et al., 1995a). Type 3 strains were therefore predominantly found in 
Japan (-69%) but also in the UK (75%), whereas SSCP type 4 was mostly present in the 
USA (75%). Moreover, sequence analysis of the VP1/VP2 gene implied that the 
sequence variation was minimal among isolates obtained from a single community-wide 
B19 outbreak (Erdman et al., 1996). Investigations of the VP1 unique sequence and of 
the C terminal region of NS1 of Japanese isolates, both by direct nucleotide sequencing 
and a mismatch detection method using the Non-Isotopic RNase Cleavage Assay™ 
(NIRCA™) and by amino acid polymorphism, also indicated a correlation between 
genome type and prevalence (Haseyama et al., 1998, Fukada et al., 2000).
However, although restriction site polymorphism (RSP) analysis may prove useful to 
define such epidemiological correlations between viral isolates, it does not give much
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information about the degree of variation of the B19 genome. Indeed, sequencing of the
region of viral genome coding for structural proteins of isolates collected in Italy
between 1989 and 1994 showed that this region was stably conserved (Gallinella et al.,
1995a).
The first isolate of a divergent B19 sequence was reported in 1998 (Nguyen et al., 
1998). This variant was isolated from a French child with transient aplastic anaemia and 
found to have greater than 11% nucleotide divergence in the VP1 unique region 
compared with other B19 virus isolates (compared with <6% divergence between B19 
isolates). When the almost full-length sequence of this new isolate, termed V9, was 
determined, the genome variability was found to extend outside the VP1 unique region 
with more than 12% nucleotide divergence between the entire genomes of V9 and B19 
virus isolates (Heegaard et al., 2001). Only one other V9-related isolate has been 
reported to date, namely the R1 isolate, which has sequence homology to the V9 isolate 
in a 346bp fragment of the VP1 unique region (Nguyen et al., 1999).
A second B19 variant, K71, was identified in skin biopsies in Finland and found to 
differ, within the protein-coding region, by 10.8% and 8.6% from the B19 reference 
sequences and the V9 variant respectively. The variation in the noncoding region 
(covering nucleotides 189-435 of the promoter region), was 26.5% and 17.2%, 
respectively (Hokynar et al., 2002). A further isolate found persistently in human skin 
was named LaLi (Hokynar et al., 2002).
In a search for additional parvovirus variants, 225 serum and bone marrow samples and 
62 plasma pools were screened, resulting in the identification of a new atypical 
parvovirus sequence, A6, from an anaemic HIV-positive patient (Nguyen et al., 2002).
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The A6 isolate exhibited 88% and 92% similarity to B19 and V9 respectively,
compared with >98% overall similarity between reported B19 isolates.
Another variant, termed D91.1, was recovered in France from a child with transient 
aplastic crisis and, although related to V9 sequence, was found to be notably divergent 
(5.3% divergence) (Servant et al., 2002). A Phylogenetic tree for erythroviruses 
proposed by Servant and colleagues (figure 1.5) shows the isolates distributed into three 
very distinct clusters corresponding to genotype 1 (prototype strain Pvbaua), genotype 2 
(prototype strain LaLi) and genotype 3 (prototype strain V9). Although the isolation of 
V9 revealed the need for specific and differential screening techniques, serologic cross­
reactivity between V9 and B19 was demonstrated, suggesting that antibody response 
from both genotypes can be diagnosed equally well by ELISA using either V9 or B19 
recombinant capsids as antigen source (Heegaard et al., 2002). As far as DNA of the 
variant erythroviruses is concerned, the commercial assay Real Art™ Parvo B19 LC 
PCR was found suitable for detection, quantification, and differentiation of all three 
B19 virus genotypes classified by Servant et al. (Hokynar et al., 2004; Servant et al., 
2002).
Figure 1.5: Phylogenetic tree for erythroviruses (proposed by Servant et al., 2002)
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The other important issue discussed over the years has been the possible association of
B19 variants with distinct clinical manifestations (Umene and Nunoue, 2002). Several
groups failed to demonstrate a correlation between genome type and clinical illness
(Morinet et al., 1986; Mori et al., 1987; Kerr et al., 1995a; Erdman et al., 1996).
However, six of nine strains isolated from patients with hereditary spherocytosis and
aplastic crisis were associated with skin rashes (Nunoue et al., 1987). An examination
of the B19 genome from human fetal organs and fluids, as well as sera from leukaemia
patients, showed that these genome types were similar to those from patients suffering
from aplastic crisis and from an asymptomatic individual (Umene and Nunoue, 1993).
However, the number of substitutions in the nucleotide sequence from the damaged
fetuses was higher (6 to 11 substitutions) than that found in patients with leukaemia,
aplastic crisis or in the asymptomatic person (none to 4 substitutions). Although these
findings do not indicate a link between a specific B19 variant and any particular clinical
outcome, they suggested a wider diversity of B19 virus in the fetus, perhaps due to the
persistence of the infection. Comparisons between different virus isolates at the DNA
and protein levels revealed that isolates from patients with persistent parvovirus B19
infection showed a tendency towards higher sequence variability (up to 4 and 8%) when
compared to isolates derived from individuals with acute B19 infection (Hemauer et al.,
1996). In addition, the genome type of three B19 isolates from patients with
encephalopathy revealed two strains assigned to a new genome type, namely group V
(Umene and Nunoue, 1995). A recent case study of children suffering from Henoch-
Schonlein purpura could not find any link between this condition and either B19 or V9
(Heegaard and Taaning, 2002). While all these observations can serve as clues
regarding connection between B19 genome types and clinical manifestations, further
studies are needed in this field.
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1.1.2. Infection and cell tropism
I.I.2.I. Life cycle
I.1.2.1.1, Receptor and viral entry
The receptor for human parvovirus B19 was first identified in 1993 as the blood group P 
antigen, or globoside (Brown et al., 1993). Target cells were indeed found to be 
protected from infection by preincubation with monoclonal antibodies to globoside. The 
very small proportion of the general population who does not bear the P antigen was 
shown to be naturally resistant to B19 infection (Brown et al., 1994).
Globoside is distributed on erythrocytes and erythroblasts, but also on endothelial cells, 
placenta, fetal liver and heart cells (Rouger et al., 1987), which is consistent with the 
clinical outcomes of B19 infection. However, other nonerythroid cells presenting the P 
antigen are nonpermissive for the productive infection by B19 (Heegaard and Brown, 
2002). Moreover, the high levels of globoside present on mature red blood cells (RBCs) 
would theoretically render them ideal targets for the virus, providing they had nuclei. 
Thanks to recombinant B19 vectors, the role of P antigen as the primary receptor for 
binding of B19 was confirmed (Weigel-Kelley et al., 2001). The level of P antigen 
expression did not correlate with the efficiency of viral binding, as seen in erythrocytes. 
Additionally, P antigen was shown to be necessary but not sufficient for parvovirus B19 
entry into cells, suggesting that a cell surface coreceptor might be needed for entry. 
Soon after, parvovirus B19 entry was shown to be mediated by a5pl integrins (Weigel- 
Kelley et al., 2003). This crucial role was demonstrated by inhibition of B19 entry into 
purified human erythroid progenitor cells following blocking of pi integrin function by 
antibodies. The model shown on figure 1.6 was proposed by Weigel-Kelley and 
coworkers (Weigel-Kelley et al., 2003). On panel A, mature RBCs, which express high 
levels of P antigen but no a5pi integrin coreceptor, are only able to bind parvovirus
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B19, without internalisation. On the other hand, panel B shows that erythroid progenitor
cells, which express both P antigen and a5(31 integrin coreceptor, are permissive for
parvovirus entry.
Figure 1.6: A model for parvovirus B19 binding and entry into primary human 
erythroid cells (Weigel-Kelley et al., 2003)
BFU-E/CFU-E
Moreover, Ku80 autoantigen was recently suggested to be a novel coreceptor for B19 
infection B19 (Munakata et al., 2005). This protein can be found on the surface of 
human bone marrow erythroid cells with glycophorin A or CD36, B cells with CD20, or 
T cells with CD3. When the Ku80 gene was transfected into HeLa cells, both binding of 
B19 and its entry into the cells were possible. Additionally, when the cell-surface 
expression of Ku80 was reduced in KU812Ep6 cells, a noticeable inhibition of B19 
binding was observed (Munakata et al., 2005).
1.1.2.1.2. Replication
After infection of the target cell, the viral DNA is liberated in the nucleus. The precise
mechanisms involved in nuclear delivery of the viral DNA still remain undefined. The
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phospholipase A2 activity, which has been associated with a domain of the viral capsid
protein, may play a role in decapsidation and liberation of the viral genomic DNA
(Zadori et al., 2001).
Studies on the replication of B19 in human erythroid bone marrow cells isolated from 
individuals with haemolytic anemias suggested that B19 replicated through high 
molecular weight intermediate forms, linked through a terminal hairpin structure 
(Ozawa et al., 1986; Ozawa et al., 1987a). These replicative forms (RFs), both 
monomeric and dimeric, were found in the nuclear DNA of infected bone marrow cells, 
indicating a nuclear replication site. In addition, replication of B19 was shown to occur 
from both positive and negative strands. The fact that viral single-stranded DNA was 
converted to double-stranded RFs by host DNA polymerases has also been suggested 
(Astell et al., 1997) (figure 1.7).
The monomer length molecules are converted to a double-stranded dimer intermediate, 
which is resolved into two monomer RF molecules by a mechanism still to be 
elucidated. These structures are used to synthesise single-stranded plus and minus 
strands, which are packaged into viral particles. The dotted line on the right side of 
figure 1.7 implies that dimeric molecules, although detected during B19 replication 
(Ozawa et al., 1987b), are not absolutely required to explain replication (Astell et al.,
1997). Since replication of the viral genome of animal parvoviruses such as AAV-2 and 
MVM was shown to require viral non-structural proteins (Bems, 1996), it is likely that 
these proteins are also required for replication of human parvovirus B19.
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Figure 1.7: General replication model for parvovirus genomes (proposed by Astell
et al., 1997)
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I.I.2.I.3. Transcription
I.I.2.I.3.I. RNA transcripts
One strand of parvovirus B19 DNA, by definition the plus strand, contains two large
ORFs extending throughout almost the entire genome (Cotmore et al., 1986; Ozawa et
al., 1988c). By comparison with the gene organisation of other members of the
Parvovirinae subfamily, the major right hand ORF encodes the VP1 protein (3.1 and
2.9 kb mRNAs) and the smaller VP2 protein (2.2 and 2.1 kb mRNAs) while only one
mRNA (2.3 kb mRNA) is derived from the left-hand side of the genome and encodes
the NS protein. The proposed transcript map is shown in figure 1.4 (Ozawa et al.,
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1987a). The splice junctions were predicted from careful mapping. In contrast to other
parvoviruses, B19 utilises a variant middle polyadenylation signal (ATTAAA at
nucleotide (nt) 2639 or AATAAC at nt 2645) and hence its transcripts can terminate at
either the middle or the extreme right side of the genome. However, it is likely that the
polyadenylation signal at nt 2639, in the middle of the genome, may be the major
processing signal (Liu et al., 1992). The main difference between B19 and other
parvoviruses is the production by B19 of abundant smaller size RNA species during
infection (Ozawa et al., 1987a; Beard et al., 1989). These small RNA transcripts can be
categorised in two classes: the first containing RNA transcripts ranging from 700 to 800
nt in length and terminating at the middle polyadenylation signal and the second class
containing RNA transcripts ranging from 500 to 600 nt in length and terminating at the
extreme right-side of the genome (Ozawa et al., 1987a). At least nine of these
polyadenylated RNAs have been identified and the proteins encoded by five of them
have been described. All but one of the nine transcripts are alternatively spliced and all
transcripts contained a 57 nt leader sequence. The only non-spliced mRNA encodes
NS1 and could be categorised in the first class described above since the sequence
corresponding to this transcript polyadenylation site is located in the middle of the
genome. In contrast, the polyadenylation site of the two mRNAs encoding for each of
the capsid proteins VP1 and VP2, is situated on the far right side of the genome (Ozawa
et al., 1987a).
Libraries of cDNA clones from B19 infected CML cells (obtained from a chronic 
myelogenous leukemia patient) and COS-7 cells transfected with hybrid B19/SV40 
plasmids were isolated and sequenced to establish unambiguously the splice junctions 
(St Amand and Astell, 1993). Two species of llkDa proteins were identified and 
showed to be encoded by an ORF contained within the 500 to 600 nt RNAs class. On
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the other hand, the 700 to 800 nt class was not detected in the COS-7 cell library,
suggesting that the middle polyadenylation signal was not recognised in these cells (St
Amand et al., 1991). However, later studies showed that the translation product of at
least one of these RNAs, a 7.5kDa protein, was made in transfected COS-7 cells (Luo
and Astell, 1993). It is therefore likely these mRNAs were present but of low
abundance. The biological functions of these small RNAs and 7.5 and 1 lkDa proteins in
the viral cycle remain undefined.
I.I.2.I.3.2. Identification of promoter elements
Studies of MVM and AAV-2 have shown that these viruses have separate promoters 
used to express the nonstructural and capsid proteins (Bems, 1996). In MVM, the RNAs 
are transcribed from two promoters, located at 4 (P4) and 39 (P39) map units (m.u.) on 
the viral genome (Pintel et al., 1983). Since the latter is 5,104 nt long, 1 m.u. 
corresponds to 51 nt. Transcripts overlap and all undergo 3’ end processing at the most 
distal polyadenylation signal at the far right side of the genome (Clemens and Pintel,
1987). Alternate splicing generates mRNAs that encode NS and VP proteins (Pintel et 
al, 1983; Cotmore et al., 1983; Morgan and Ward, 1986; Jongeneel et al., 1986). On 
the other hand, AAV-2 has three promoters at P5, P19 and P40 (Morinet et al., 2000). 
This virus also uses alternate splicing and a polyadenylation signal at the far right side 
of the genome. While the P5 and PI9 promoters trigger the expression of mRNAs that 
encode the NS proteins, the P40 promoter is used for VP expression.
In contrast, early studies of human parvovirus B19 transcription done by computer 
analysis of the virus sequence suggested that there could be a number of potential 
promoters able to express NS and VP proteins (Shade et al., 1986). However, a 
transcription assay using HeLa cell nuclear extracts allowed the identification of a
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region between nt 258 and 321 that was necessary for in vitro transcriptional activity
(Blundell et al., 1987). Moreover, RNA protection analysis of the 5’ ends of transcripts
indicated that all transcripts were initiated at a single strong left-hand promoter near
m.u. 6, thus named P6 (Ozawa et al., 1988a). In addition, primer extension studies
identified the start site of transcription at nt 350-351, 31-32 nt downstream of the
TATATATA sequence at position 319 (Blundell et al., 1987). Although the presence of
a second promoter at m.u. 44 (B19P44) was reported (Doerig et al., 1990), other
investigations failed to establish its function as a promoter (Blundell et al., 1987; Doerig
et al., 1987; Liu et al., 1991a). Nevertheless, both B19 P6 and P44 promoters may be
transactivated by the adenovirus type 2 El A protein in nonpermissive human cells,
although the extent of transactivation of the P44 promoter was significantly lower than
that of the P6 promoter (Ponnazhagan et al., 1995).
I.I.2.I.3.3. Regulation of RNA processing
Similar to other parvoviruses, B19 nonstructural protein NS1 plays the role of a trans- 
activator protein that can up-regulate the P6 promoter (Doerig et al., 1990). Further 
studies revealed that the region from nt 100 to 160 was essential for NS-l-mediated 
transcriptional activation (Gareus et al., 1998). The P6 promoter region has been studied 
to establish the cA-acting signals required for its activity and their possible roles in 
limiting replication of this virus to human erythroid progenitor cells. Footprinting 
experiments showed that B19 promoter P6 includes a complex regulatory region 
containing multiple sequences which affect promoter strength and that the GC-box 
motif (nt 292 to 301) is a major controlling sequence for in vitro, and likely in vivo, 
transcription (Blundell and Astell, 1989). Analysis of sequences upstream of known 
promoters in MVM (Astell et al., 1983), H-l virus (Rhode and Paradiso, 1983), AAV-2
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and B19 (Shade et al., 1986) indicated sequences closely related to high-affinity
transcription factor Spl sites. Blundell and Astell suggested that the HeLa cell nuclear
factor that binds to the B19 virus GC-box might be Spl (Blundell and Astell, 1989).
Additionally, transient reporter gene assays allowed the identification of a minimal
promoter extending to -96 upstream of the transcription start and containing two
tandem GC-boxes and TATA box (Liu et al., 1991b). The distal GC-box at -59 has the
consensus binding sequence for Spl, which would also suggest that this motif may be
an important element in the minimal promoter in vivo and might bind Spl. This minimal
promoter lies within the terminal hairpin (from -249 to -157) and contains an area of
tight protein binding with a 14 nt sequence that is protected by DNAasel footprinting.
This protein complex may be involved in the regulation of the promoter in vivo but it is
probably not Spl that binds to this site (Liu et al., 1991b). However, fixation of the Spl
factor to a GC-box placed just downstream of the transcription factor Ets binding site
was demonstrated, suggesting the Spl does play a role in the regulation of transcription
(Vassias et al., 1998). The palindromic terminal repeats of parvoviruses were also
shown to be required for viral DNA replication since they constitute the replication
origin and are almost completely protected from Dnase I digestion by proteins (Im and
Muzyczka, 1990).
Furthermore, NS-1-mediated transactivation was found to be dependent on the presence 
of two GC-rich elements arranged in tandem upstream of the TATA box (Gareus et al.,
1998). Gareus and colleagues thus proposed a model of NS1-mediated P6 
transactivation (figure 1.8) dependent on a multicomponent complex combining NS1 
with ATF, NF-icB/c-Rel, and GC-box (Spl) binding cellular factors.
In AAV, YY1, a multifunctional transcription factor, was found to act as a repressor of 
transcription from the AAV P5 promoter, which is relieved by El A protein (Shi et al.,
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1991). YY1 was also found to be prominently bound to three different motifs in the
terminal repeat region of parvovirus B19 (Momoeda et al., 1994b). However, in
contrast to AAV, YY1 was shown to be a positive regulator of viral transcription in
HeLa cells, although very weak (1.3-1.9-fold above basal transcription). When a
different cell type was used, namely Drosophila SL2 cells, YY1 had no effect on the P6
promoter, suggesting that this transcription factor might be dependent on the cells
transfected (Vassias et al., 1998). In the same study, the binding of the transcription
factor hGABP (also named E4TF1) to the Ets binding site resulted in the regulation of
the P6 promoter. A “3-fold sequence” containing YY1, Ets and Spl binding sites was
defined and Spl and hGHBP were shown to activate transcription synergistically
throughout this sequence (Vassias et al., 1998).
Figure 1.8: Model of the transactivating complex (proposed by Gareus et al., 1998)
GC-box binding proteins
ATF/CRGB site 
binding protein
NF-kappa B/c-Rei-site 
binding protein(s)
DNA-loop
Inr: transcription start site. The DNA segment in between could easily be lopped out.
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I.I.2.I.4. Translation regulation
Translational regulation may also be a way of controlling the expression of B19 genes. 
Immediately upstream from the VP1 translation initiation site is an unusual sequence 
containing multiple ATG triplets (Shade et al, 1986; Ozawa et al., 1987a). During 
RNA processing, this sequence, from nt 2,184 to nt 3,044/3,050, is spliced out of VP2 
RNA. It has also been noted that the upstream nontranslated region of both VP1 
mRNAs has multiple AUG codons. These codons are apparently bypassed by ribosomes 
to allow initiation of VP1 at the AUG at nt 2,444. Since capsid proteins are produced in 
strikingly different quantities (VP1<4%; VP2>96%), the role of this AUG-rich region in 
translational control was studied (Ozawa et al., 1988b). Its removal from VP1 RNA 
greatly increased the efficiency of translation while the addition of the same AUG-rich 
sequence upstream of the initiation site of VP2 decreased its translation. Therefore, it 
seems likely that this upstream AUG-rich region acts as a negative regulatory element 
in the translational control of B19 capsid protein production. In addition, a noticeable 
fact is that all of the B 19 mRNAs (except the unspliced NS1 messenger) exist as two 
related transcripts (Astell et al., 1997). Thus the selection of the splice acceptor site at nt 
1,910 versus nt 2,030 might plays some subtle, although currently not well understood, 
role in the regulation of expression of both structural proteins and 1 lkDa proteins.
I.1.2.2 Cell tropism
Early in vitro studies indicated that parvovirus B19 can cause clonal inhibition of 
erythroid progenitor cells in methylcellulose cultures (Mortimer et al., 1983) and can 
productively infect progenitor cells from bone marrow (Ozawa et al., 1986). Further 
reports detected infection of cells from peripheral blood (Kurtzman et al., 1988; 
Schwarz et al, 1992), fetal liver (Yaegashi et al., 1989; Brown KE et al., 1991),
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umbilical cord blood (Srivastava et al., 1992; Sosa et al., 1992), bone marrow cells from
M. fascicularis (Gallinella et al, 1995b), as well as in myocardial cells (Porter et al.,
1988) and megakaryocyte-enriched bone marrow fractions (Srivastava et al., 1990). 
However, most of these cells are very difficult to obtain due to ethics issues and/or 
availability. The suitability of apheresis cells for in vitro infection with B19 has also 
been shown (Hemauer et al, 1999). Apheresis is a technique that allows more of one 
particular part of the blood (platelets, granulocytes, etc.) to be collected than could be 
separated from a unit of whole blood. Using a special apheresis centrifuge, the blood 
can be fed into the system continually. As it spins, the components separate and the 
granulocytes (white blood cells) are drawn off. The plasma, erythrocytes and platelets 
are then recombined and returned to the donor. The whole procedure lasts about one 
hour. Apheresis may be therapeutically useful in cases of glomerulonephritides 
associated with antibody deposition, lupus erythematosus, antibody-mediated transplant 
rejection and in lowering the levels of preformed cytotoxic antibodies which may 
preclude transplantation (Smith et al., 2003; Kaplan, 2003).
Although the target cells for B19 virus are in the erythroid lineage from Burst-Forming 
Unit-Erythroid (BFU-E) to erythroblasts, with susceptibility to the virus increasing 
along with differentiation (Takahashi et al., 1990), some nonerythroid cells can also 
become infected. In addition, a number of human blast cell lines have also been infected 
with B19 virus, (either productively or non productively), namely TF-1 (Kitamura et al.,
1989), UT-7 (Komatsu et al., 1991; Shimomura et al., 1992; Nicolis et al, 1993; 
Shimomura et al., 1993), UT-7/EPO (Komatsu et al., 1992; Erickson-Miller et al., 
2000), KU812 (Nakazawa et a l, 1989), KU812Ep6 (Miyagawa et al., 1999), MB-02 
(Munchi et al., 1993), and JK-1 (Okuno et al., 1990; Takahashi et al., 1993). These cells 
have in common the fact that they all depend on the erythroid-specific hormone
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erythropoietin (EPO) for growth or differentiation. EPO is necessary for viral
replication, but it is not clear whether it represents a direct requirement. However, no
system has been established that could be suitable for the large-scale production of
infectious virus.
Studies of hypoxic culture conditions in France have suggested an enhancement of the 
B19 capsid protein synthesis, virus replication and virus production when human 
primary erythroid progenitor cells were exposed to severe hypoxia (1%) (Pillet et al., 
2004). Caillet-Fauquet and coworkers also suggested that B19 infection of the cell line 
KU812F cultured in mild hypoxia (6%) might result in higher yields of infectious B19 
progeny and to enhanced viral transcription compared to normal oxygen concentration 
(20%) (Caillet-Fauquet et al., 2004a). Severe hypoxia (1%) had previously been shown 
to have some positive effects on the maintenance and cloning efficiency of BFU-E, 
while inhibiting the terminal expansion and maturation of these clones (Cipolleschi et 
al., 1997). Moreover, the differentiation and amplification of the CFU-E pool observed 
in a mouse model during hypoxia might be due to an increase in EPO levels (Mide et 
al., 2001). These conditions might thus be sufficient for a more productive B19 
infection.
At the transcriptional level, when a lOObp fragment containing the B19 P6 promoter 
replaced the authentic AAV promoter at m.u. 5 (AAV P5) in an infectious clone of 
AAV-2, this recombinant virus was able to replicate autonomously in primary human 
hematopoietic progenitor cells (Wang et al., 1995). It was therefore proposed that the 
promoter P6 might play a role in erythroid specificity. In contrast, using plasmid- 
mediated transfection of established human cell lines, the B19 P6 promoter was shown 
to be very active in nonpermissive cells including Hela, K562, Raji and Jurkat, and
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highly active CEM cells, a T-lymphoblastoid cell line (Liu et al., 1991b). Because of
this indiscriminate activity from the P6 promoter, the latter seemed unlikely to play a
role in tropism of human parvovirus B19.
The different cellular permissiveness and regulation of B19 virus gene expression was 
assumed to lead to two different types of infection, according to a balance of production 
of NS or VP proteins, as shown on figure 1.9 (Liu et al., 1992). In the case of fully 
permissive cells such as erythroid precursor cells (Ozawa et al., 1987b), a full set of 
nonstructural and capsid proteins would be produced, leading to a productive infection. 
On the other hand, in the case of infection of nonpermissive cells, such as 
megakaryocytic precursor cells (Srivastava et al., 1990), the NS1 protein would be 
mainly produced, leading to an abortive infection and to cell death by reason of its 
cytotoxic and/or apoptosis-inducing characteristics (Moffatt et al., 1998; Ozawa et al., 
1988a). Furthermore, when the 3’ processing signals located in the middle of the viral 
genome were removed, expression of the VP gene transcripts increased in 
nonpermissive cells. Therefore, Liu and colleagues proposed that “differential transcript 
accumulation might be controlled not at the level of promoter initiation but by RNA 
processing events or by recognition of variant termination signals” (Liu et al., 1992).
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Figure 1.9: Schematic model of NS gene expression in nonpermissive cells (NSP:
NS protein) (proposed by Liu et al., 1992)
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An obstacle at the translational level was first proposed by Leruez and colleagues
(Leruez et al., 1994). In addition, in nonpermissive cells, it was suggested that the 3’
untranslated region (UTR) of the capsid protein mRNAs repressed capsid protein
synthesis by inhibiting ribosome loading (Pallier et al., 1997). Confirmation came from
further studies comparing the infection of bone marrow cells and of different human
blast cell lines with erythroblastoid (TF-1) and megakaryoblastoid (UT-7, M-07,
B1647) phenotypic characteristics (Gallinella et al., 2000; Avanzi et al., 1990; Komatsu
et al., 1993; Kitamura et al., 1989; Bonsi et al., 1997). Two patterns of restriction to
replication were observed in those cells (Gallinella et al., 2000). In the first instance
found in UT-7 cells, the ss viral DNA was converted into ds replicative intermediates
similar to those found in bone marrow cells. In addition, a full set of viral transcripts
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was produced. However, only a small proportion of cells supported replication and
transcription, with no production of capsid proteins. In the second restriction pattern,
which was observed in TF-1, M-07 and B1647, the ss viral DNA was not converted to
ds replicative intermediates. In another study using the megakarycytic cell line MB-02,
a novel splicing pattern was observed which lead to the fusion of the two first amino
acid of NS1 with those of the small 7.5 kDa protein (Brunstein et al., 2000). This novel
splicing pattern resulted in the functional inactivation of the viral structural genes and
effectively blocked production of progeny virions. According to Brunstein and
coworkers, this mechanism is “the crucial one in restricting viral tropism among bone-
marrow-derived cells” (Brunstein et al, 2000).
In conclusion, since the susceptibility to infection and the permissiveness for infection 
are not directly linked, the spectrum of target cells may be wider than expected. 
Therefore, the presence of viral receptors on the cell surface and of intracellular 
permissiveness factors should be fully determined in various cell types.
1.1.3. Epidemiology
I.I.3.I. Seroprevalence
The prevalence of anti-B19 immunoglobulin G (IgG) antibodies in the general 
population ranges from 2 to 15% in children aged 1 to 5 years old, 15 to 60% in 
children aged 5 to 19 years old and from 30 to 78% in adults (Torok, 1992; Kelly et al., 
2000; Abraham et al., 2002).
When comparing prevalence in England, Wales and Australia to that in Singapore and 
South Africa, a variation among countries was observed, with B19 being more prevalent 
in temperate countries rather than tropical ones (Kelly et al., 2000). Kelly and
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colleagues, who reported serology data in Australia from 1992 to 1998, also suggested
that parvovirus tended to occur in 4-year cycles, with 2 epidemic years followed by 2
endemic years. In addition, infection might be season-related since it was often found
associated with outbreaks of El in schools in the late winter and spring (Anderson and
Torok, 1989). However, it can also occur any time of the year in either the presence or
absence of an El outbreak.
I.I.3.2. Transmission
1.1.3.2.1. Route of transmission
In a B19 school outbreak, parvovirus DNA was detected in the throat swap of the 
teacher of several of the affected children, indicating that transmission of the virus 
might occur via the respiratory tract (Plummer et al., 1985). In the same year, the 
respiratory route of transmission was confirmed by intranasal infection of volunteers 
(Anderson LJ et al., 1985). Moreover, at the same time as viremia, parvovirus B19 was 
detected in nasal washes and gargle specimens from 3 of the 4 infected individuals, 
identifying the upper respiratory tract, and most probably the pharynx, as the site of 
viral shedding. Vertical transmission may also occur from mother to foetus in about one 
third of cases with serologically confirmed maternal infection (Torok, 1992).
1.1.3.2.2. Household infections
In a study of intrafamilial associations of B19 infection, no link was found between 
seropositivity of the parents and their children, neither between one spouse and the 
cospouse (Koch and Adler, 1989). However, when considering only the first and second 
siblings in the family, 50% of the younger siblings were infected if the older siblings 
were seropositive. Therefore, household infections represent a very high percentage of
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B19 infections among children but also were found to be significant in adults, especially
women. The transmission rate for susceptible household contacts of persons with El or
B19-associated aplastic crisis was found to be approximately 50%, regardless of age
(Plummer et al., 1985; Chorba et al., 1986). The infection rate amongst susceptible
pregnant housewives was 8.7%, (4 of 46) (Cartter et al., 1991). For pregnant women
whose serological status is unknown, the chance of suffering fetal loss after household
exposure is lower than 2.5% (Anderson et al., 1990).
I.I.3.2.3. Nosocomial and occupational infections
The risk associated with nosocomial infections that can involve both patients attending 
the hospital and hospital staff members themselves have been well documented (Bell et 
al., 1989, Dowell et al., 1995, Pillay et al., 1992, Koziol et al., 1992, Miyamoto et al., 
2000, Lui et al., 2001). The first report of a probable spread of B19 infection in hospital 
involved two paediatric patients with hereditary spherocytosis and sickle cell anemia, 
respectively (Evans et al., 1984). The spread of aplastic crisis to the patient with sickle 
cell disease occurred when she was exposed to the patient with hereditary spherocytosis, 
thereby emphasising the danger of contacts between patients with known haemolytic 
anemia.
Although a prospective survey reported no increase in annual seroconversion rates in 
childcare providers (1.5%) compared to the women of childbearing age control group 
(1.5%) (Koch and Alder, 1989), many other reports show an increase risk of B19 
infection in women working outside the home in school or day care settings (Cartter et 
al., 1991; Valeur-Jensen et al., 1999; Cordell, 2001; Schwarz et al., 1990).
Taken together, these studies indicated that the highest risk for B19 infection is found in 
households and selected occupational settings where workers can be exposed to infected
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patients or staff in hospital wards, or to infected children in schools and day care
centres.
I.I.3.2.5. Parenteral transmission
Although much less likely than the respiratory route, parenteral transmission may occur 
by transfusion of contaminated blood products and will be discussed in section II.
1.1.4. Immune response
In immunocompetent individuals, clearance of human parvovirus B19 from blood 
appears to be achieved almost entirely through the humoral immune response of the 
individual. Moreover, this response is mainly directed against the structural proteins 
VP1 and VP2. The important role of neutralising antibodies in clearing the virus is 
suggested by the fact that intravenous immunoglobulin can cure chronic B19 infections 
in immunosuppressed patients.
I.I.4.I. Antibody response in acute and past B19 infections
Experimental infection of healthy volunteers has shown that the predominant immune 
response is humoral (Anderson et al., 1985a; Kurtzman et al., 1989a). Figure 1.10 
summarises the time course of B19 serology, which will be detailed below (Heegaard 
and Brown, 2002).
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Figure 1.10: Time course of B19 viraemia and antibody response following B19
infection (Heegaard and Brown, 2002)
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I.I.4.I.I. IgM response
The IgM immune response was examined by Anderson and coworkers, who inoculated 
healthy adult volunteers intranasally with parvovirus B19 obtained from an 
asymptomatic blood donor (Anderson LJ et al., 1985). High-titre IgM antibodies to B19 
developed during the second week (9 to 10 days) after inoculation and represented the 
first detectable immune reaction indicating an acute B19 infection. IgM antibodies may 
be found in serum for 3 to 6 months, although in some cases the IgM antibodies may 
decline very rapidly resulting in negative values already after 2 to 3 weeks.
In order to study the immune response to B19 infection without having to inoculate 
volunteers, scientists had to overcome the shortage of B19 antigens by expressing 
recombinant B19 proteins in several systems, both prokaryotic and eukaryotic (Sisk and 
Berman, 1987; Brown et al., 1990a; Kajigaya et al., 1991; Soderlund et al., 1992; 
Saikawa et al., 1993; Palmer et al, 1996; Manaresi et al., 1999a).
Whether they are undenatured or denatured, recombinant VP1 and VP2 proteins can be 
used to detect immune response against conformational or linear epitopes respectively. 
Hence an Enzyme Linked Immunosorbent Assay (ELISA) with intact antigens can
- 7 7 -
 Chapter I
detect antibodies against conformational epitopes whereas a Western blot assay with
denatured antigens can be used to identify immunity against linear epitopes (Kerr et al.,
1999). However, data available on IgM reactivity against linear and conformational
epitopes of VP1 and VP2 is limited and rather controversial. While some studies
indicate that in patients with primary B19 infection, the IgM response to linear VP1
epitopes was more frequent, intense and persistent than the response to linear VP2
epitopes (Palmer et al., 1996, Manaresi et al., 2001; Manaresi et al., 2002a), other
studies found no difference in the IgM responses to VP1 and VP2 linear epitopes (Kerr
et al., 1999). It has also been reported that in the active phase of infection, IgM
antibodies against conformational epitopes of both VP1 and VP2 appeared at the same
time and with the same frequency but those against VP1 epitopes were longer lasting
than the other epitope specific IgM (Manaresi et al., 2001).
1.1.4.1.2. IgA response
A significant rise in specific IgG and IgA antibodies in 87% and 77%, respectively, of 
persons from whom acute and convalescent phase serum specimens were available has 
been reported (Erdman et al, 1991). Specific IgA antibodies were found in 93% of 
persons with EL However, these antibodies were also present in half of normal blood 
donors with prior B19 exposure, as indicated by specific IgG antibodies (Erdman et al.,
1991). This high prevalence of IgA antibodies among normal individuals indicates their 
long persistence. Moreover, breast milk has also been shown to contain IgA antibodies 
(Heegaard et al., 2000).
1.1.4.1.3. IgG response
Studies in infected volunteers have shown that IgG antibodies to B19 began to develop
at the end of the second week after inoculation and early in the third week,
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simultaneously with the decrease of IgM antibodies and the observation of the rash
typical for parvovirus B19 infection (Anderson et al., 1985a).
During the acute and early convalescent phases of B19 infection, the majority of IgG 
antibodies are thought to be directed against both conformational and linear epitopes 
present in the VP2 protein and against linear epitopes of the VP 1-unique region 
(Soderlund et al., 1995a). However, another report suggests that antibodies from some 
individuals do not react against linear epitopes on both denatured B19 VP1 and VP2 
antigens (Kerr et al., 1999). The discrepancy might be due to the fact that the two 
studies used different proteins (the unique region of VP1 or a VP 1/2 capsid combination 
compared with the whole proteins). In an attempt to further define the different phases 
in IgG response to B19 infection, it has been reported that in the active or very recent 
stage of infection, IgG against VP1 linear epitopes were detectable concomitantly, and 
with the same frequency, as IgG against VP2 conformational epitopes but in the 
convalescent phase, IgG against VP2 linear epitopes were detectable with the same 
frequency as IgG against VP2 conformational epitopes (Manaresi et al., 1999a). 
However, other reports suggest that antibodies against VP2 are detectable prior to IgG 
against VP1 (Schwartz et al, 1988; Kurtzman et al., 1989a) but this may reflect the 19- 
fold higher amount of VP2 antigen compared with VP1 antigen found in preparations 
using native virus as the antigen source (Manaresi et al., 1999a). Finally, the persistence 
of antibodies to conformational but not linear epitopes of VP2 during late 
convalescence is also unclear (Soderlund et al., 1995a; Manaresi et al. 1999a). The long 
term IgG antibody response is directed mainly against VP1, and in particular the 
aminoterminal half of the VP 1-unique region, which has been shown to be 
immunodominant (Musiani et al., 2000). A summary of IgG immune response in active 
and convalescent phases of B19 infection is shown in table 1.2.
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Table 1.2: Summary of IgG antibody response in active and convalescent phases of 
parvovirus B19 infection
Stage of infection
VP1 epitope VP2 epitope
Linear Conformational Linear Conformational
Active phase + - - +
Convalescent phase Unknown Unknown + +
The predominant subclass of IgG antibodies involved in the binding to VP1 and VP2 
capsid proteins is IgGl during the acute phase and early convalescence while subclass 
IgG3 peaks 2 weeks after infection but stabilises to low levels over 6 months (Franssila 
et al., 1996). Both IgGl and IgG3 decline to background levels during the recovery 
period. At the same time, a dramatic increase in VP 1-specific IgG4 activity is observed, 
although that subclass is barely detectable for the first three months after infection. This 
subclass of antibodies may also become prominent upon chronic antigenic stimulation 
(Aalberse et al., 1983; Iskander et al., 1981). This antigenic stimulation could arise 
from repeated subclinical exposure to the virus, which is highly probable in epidemic 
periods, persistence of the virus at low concentrations in immunocompetent individuals 
or repeated exposure to antigens as part of immune complexes (Franssila et al., 1996).
I.I.4.2. Characteristics of the linear and conformational epitopes of 
VP1/VP2 and the VP1-unique region
I.I.4.2.I. Major capsid protein VP2
Studies using monoclonal antibodies binding to synthetic peptides show that the 
neutralising epitopes are located at the carboxy terminal half of VP2 (amino acids 328- 
344 from the amino terminus), with recognisation sites at amino acids 253-272, 309-
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330, 325-346, 359-382, 449-468 and 491-515 (Sato et a l , 1991a; 1991b; Brown et a l ,
1992). A comparison with CPV suggests that this region is probably on the surface of 
the native virion. The viral surface of CPV is composed of a “spike” on each of the 
threefold axes, consisting of four loops (Tsao et al, 1991; Chapman and Rossmann,
1993). Superimposition of the largest loops (loops 3 and 4) of CPV on a map of the B19 
VP2 epitopes indicated that all the B19 epitopes lay between the projected surface loops 
of CPV, suggesting that the immunodominant domain on the VP2 capsids correlates 
with the surface spike of CPV (Brown et al, 1992; Sato et al, 1991b). Studies have 
shown that the CPV loops 1 and 3 are immunogenic and have surface exposed residues 
(Langeveld et a l, 1993). These loops might be possible sites for attachment of 
neutralising antibodies, which could interfere with binding between CPV virion and cell 
surface receptor. Similarly, in parvovirus B 19, the proximity of the antigenic epitopes to 
the receptor site, suggests that virus neutralisation may be caused by preventing 
attachment of viruses to the cells (Chipman et al, 1996).
Several studies have suggested that the VP1/VP2 junction and the VP2 capsid protein 
(amino acids 57-77) may be linear neutralising epitopes (Saikawa et a l, 1993; 
Yoshimoto et a l, 1991). It is clear that conformational epitopes are also present. In 
contrast, other studies have shown that recombinant VP2 capsids on their own do not 
elicit a neutralising antibody response in rabbits and require the presence of VP1 which 
may modulate the antigenicity of the native virus particles or, alternatively, may affect 
the conformational structure of the neutralising epitopes (Kajigaya et a l, 1991; 
Yoshimoto etal., 1991).
Additionally, when B cell memory was induced after B19 infection, B cell memory was 
strongly maintained against VP2 conformational epitopes and against VP1 linear
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epitopes, whereas it was not maintained against VP2 linear epitopes (Corcoran et al.,
2004).
I.I.4.2.2. VP1 and its unique region
Studies have shown that the most amino-terminal quarter of the unique region of VP1 is 
the most immunogenic region and that the immune recognition of the unique portion of 
VP1 is similar to reactivity against a soluble, conformationally free globular protein, 
while immune recognition of VP2 epitopes is much more conformationally fixed by the 
capsomere structure (Saikawa et al., 1993). This region contains numerous neutralising 
linear epitopes, clustered in particular at the amino-terminus (between amino acids 1 
and 80) and in the centre (amino acids 148-205) (Anderson et al, 1995; Gigler et al., 
1999; Zuffi et al., 2001). All these data indicate that the unique region of VP1 is located 
on the virion surface and thus accessible to antibody binding but its precise relationship 
to the rest of the capsid is still unknown (Kawase et al., 1995). An investigation of the 
genomic variability and the antigenic stability of the VP1 unique region confirmed that 
there was very little variation in amino acid sequence, between 0-3.2% or 8 amino acids 
(Dorsch et al., 2001; Hemauer et al., 1996; Erdman et al., 1996). These results 
confirmed that the amino-terminal part (amino acids 1 to 80) must be surface exposed 
and highly stable, and suggest that it could be folded in a loop-like structure.
1.1.4.3. Antibody response in persistent B19 infection and 
implication of immune response against the non-structural protein 
NS1
After the onset of neutralising antibody production, the virus is rapidly cleared from the 
circulation but in some cases of parovovirus B19 infection, persistence of the virus for
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up to a decade has been reported (Kurtzman et al., 1989a; Pont et al., 1992). Chronic
infection has been observed in four populations of patients: those with congenital
immunodeficiency, with HIV infection, those receiving immunosuppressive
chemotherapy for treatment of cancer, acute lymphocytic leukaemia and tissue
transplantation, and lastly in the developing fetus (Anderson and Young, 1997;
Kurtzman et al., 1989b).
Early studies indicated that sera from patients with acute or past infection without 
complications did not contain detectable levels of anti-NSl antibodies but NS1-specific 
antibodies were present in sera from patients suffering from severe B19-associated 
arthritis, perhaps reflecting persistent viral infection (von Poblotzki et al., 1995a; 
1995b). It is possible that these specific antibodies might indicate an elevated 
production of the non-structural protein in particular individuals or that prolonged viral 
presence might lead to the infection of non-erythroid cells bearing the B19 receptor, 
which would not normally be susceptible to the virus. Thus the expression pattern of the 
parvovirus B19 genome in these non-permissive cells may be shifted to the preferential 
production of NS1 protein (Liu et al., 1992). In addition, the elevated synthesis and 
release of NS1 protein after cell death might result in initiation of an NS1-specific 
humoral response (von Poblotzki et al., 1995b). In contrast, later studies indicated that 
anti-NSl antibodies were present in a proportion of patients with recent (12.5% to 45%) 
and past (36%) B19 infections (Searle et al., 1998; Jones et al., 1999). The discrepancy 
between these studies could be partly explained by three factors: the difference in the 
sizes of the patient groups investigated, the relative sensitivities of the assays used to 
detect the NS1 antibodies and the time of sampling after onset of infection as a number 
of studies have shown that NS1-specific IgG became detectable about four weeks after 
infection and about two weeks after VPl/VP2-specific immune response (Searle et al.,
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1998; von Poblotzki et al., 1995b; von Poblotzki et al., 1996; Hemauer et al., 2000).
Finally, as only low amounts of NS1 are synthesised during replication in the erythroid
progenitor cells, there may be insufficient antigen to prime a strong and long-lasting
immune response detectable in persons with past parvovirus infection (Ozawa and
Young, 1987; Tolfvenstam et al., 2000). Other studies have also shown the presence of
anti-NSl antibodies in 22 to 30% of B19 infected individuals, of which 13 to 27% had
recent infections and the remainder past infections (Venturoli et al., 1998; Hemauer et
al., 2000). These studies confirm that the development of anti-NS antibodies is not
limited to persistently infected patients or to those patients with B19 arthritis (Kerr and
Cunniffe, 2000). The percentage of persons with NS1-specific IgG has been found to
decline with increasing age, whereas IgG against capsid proteins are as prevalent in
younger as in elderly individuals (Hemauer et al., 1999; Searle et al., 1998).
Three NS 1-specific linear epitopes in the carboxy terminal region of NS1 (amino acids
191 to 206, 271 to 286 and 371 to 386) have been identified, with the highest
seroreactivity being against amino acids 271 to 286 (Tolfvenstam et al., 2000). These
antibodies are unlikely to be protective as persistence of the virus in the serum at
relatively high levels is possible despite the presence of NS1-specific immunoglobulins
(Von Poblotzki et al., 1995b). However, other reports have suggested a weak but
significant neutralising ability of anti-NSl antibodies (Gigler et al, 1999; Kurtzman et
al., 1989b), thus the role of NS1 in the persistence of B19 infection remains unclear and
controversial.
I.I.4.4. Cellular immunity
Despite early, unsuccessful attempts at demonstrating a proliferative cellular response to
B19 using peripheral blood mononuclear cells (PBMC) from individuals with serologic
evidence of exposure to virus (Kurtzman et al., 1989b), there is evidence now from
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several studies of a cellular response to B19 infection (von Poblotzki et al., 1996,
Franssila et al., 2001, Mitchell et al., 2001). A lymphoproliferative response against
B19 recombinant capsid proteins VP1 and VP2 was reported, although not in the form
of empty capsids (von Poblotzki et al., 1996). These groups demonstrated that CD4+ T
cells, also called T helper (Th) cells, make up the major population of reactive cells and
that viral determinants were presented to them by HLA class II molecules and observed
lymphocyte proliferation in response to stimulation with a recombinant B19 NS-1
protein in vitro.
It appears that the cellular response to B19 mainly involves differentiated CD4+ cells in 
late convalescence as an immunoglobulin class switch to IgG4, normally triggered by 
interleukin-4 (IL-4) and interleukin-13 (IL-13), which in turn are produced specifically 
by Th type 2 (Th2) (Franssila et al., 1996; Roitt et al., 1998). However, other reports 
suggest that the cellular immune response could be more TH1 oriented in the acute 
phase of infection as an increase in interferon gamma (IFN-y), which is produced by 
Th1 cells, as well as by natural killer (NK) cells (Roitt et al., 1998), was detected in 
these studies (Wagner et al., 1995). These authors also identified a rise in the production 
of IL-1 and IL-6 mRNA. The former is produced by many cells in response to infection 
and activates NK cells cytocidal activity, Th cell proliferation as well as B-cell 
proliferation (Roitt et al., 1998). Both IL-1 and IL-6 are released by some B-cells and 
enhance expression of IL-2 on T lymphocytes. In turn, IL-2 activates B-cells and NK 
cells and promotes division of T cells with release of IFN-y. Although there are signs 
that the immune response is TH1 oriented during the acute phase of infection, leading to 
macrophage activation, it is clear that the humoral response is also activated by a series 
of cytokines, which activate B-cell proliferation and subsequently antibody production.
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Other findings showing a significant T cell immunity elicited by B19, have been
reviewed (Klenerman et al., 2002). The first B19-derived CD8+ T-lymphocyte epitope
has been mapped and shown to be derived from the amino acids 391 to 399 of the non-
structural protein NS-1 (Tolfvenstam et al., 2001a). This peptide was able to stimulate
ex-vivo CD8+ T-lymphocyte responses in B19-seropositive donors. Moreover, using
ELISpot responses to peptides spanning the whole NS-1 sequence, multiple further
responses were identified in seropositive individuals, thus pointing to the presence of a
persistent memory population (Klenerman et al., 2002). In conclusion, the CD8+ T-
lymphocyte responses might indicate an ongoing stimulation by persistent antigen and
might involve a simultaneous maintenance role of CD4+ T cells (Wagner et al., 1995;
von Poblotzki et al., 1996; Franssila et al., 2001).
1.1.5. Diagnosis
The symptoms of parvovirus B19 infection are often non-specific and could 
theoretically be confused with various other infectious agents, such as rubella, 
cytomegalovirus (CMV), varicella zoster virus (VZV), mumps or rubeola. Therefore, 
differential laboratory diagnosis of B19 infection is essential, as a recent study showed, 
when 123 out of 344 samples (35.7%) collected during an epidemic of B19 from 
children with rashes presented neither B19 DNA, IgM nor IgG (Gallinella et al., 2003). 
Detection of B19 infection relies on a range of laboratory tests summarised in table 1.3. 
While serum samples are the most commonly tested specimens, bone marrow aspirates, 
cord blood samples, amniotic fluid samples and biopsy specimens of placenta and fetal 
tissues are also used to detect B19 infection (Zerbini et al., 2002).
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Table 1.3: Summary of diagnostic and detection assays for B19
Diagnosis by Diagnostic laboratory tests
Cellular factors
• Numeration of reticulocytes, neutrophils, 
lymphocytes and platelets
• Titration of haemoglobin
• Microscopic examination of bone marrow 
aspirates (giant pronormoblasts)
• Immunohistochemistry of skin lesions
Antibody detection 
IgM
IgG
• Immunoblot assay
• Enzyme immunoassay (EIA)
• Immunofluorescence assay (IFA)
• Immunoblot assay
• EIA
• IFA
B19 virus detection
• EM
• Immune electron microscopy (IEM)
B19 antigen 
detection
• Counter- immunoelectrophoresis (CIE)
• Radioimmuno-assays (RIA)
• EIA
• Blot immunoassays
• Receptor-mediated haemagglutination assay 
(RHA)
B19 DNA detection
• Dot blot hybridisation
• In situ hybridisation assay (ISH)
• Polymerase chain reaction (PCR)
I.I.5.I. Diagnosis by cellular and blood markers
When natural infection developed in volunteers infected by B19 virus, reticulocytes
were not detected from day 8 and 10 for a period of at least one week (Anderson et al.,
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1985a). This finding demonstrated that erythropoiesis is prone to interruption following
B19 infection in normal individuals. Moreover, a simultaneous significant decrease- as
low as 30% of baseline values- in levels of neutrophils, lymphocytes and platelets were
observed. In the normal host, the hemoglobin may fall by 2 to 3g/dL (Torok, 1992).
However, in patients who are already suffering from hematological disorders,
characterised by decreased red cell production or increased red cell destruction, B19
infection may result in a dramatic decrease in hemoglobin. All these cellular and blood
markers can sometimes prove useful in the diagnosis of recent B19 infection.
Furthermore, examination of bone marrow aspirates by light microscopy can reveal
histopathologic changes of erythoid precursor cells, suggestive of parvovirus B19, such
as abnormal giant pronormoblasts or “lantern” cells (Torok, 1992; Brown and Young,
1995). These cells have a markedly enlarged size and basophilic cytoplasm, fine nuclear
chromatin, prominent irregular nucleoli, or viral inclusions. Occasionally, vacuoles and
pseudopods can also be seen. In addition to pronormoblasts, in a paediatric patient with
acute anemia, some “lantern” cells, which contained a central clear area and reacted
strongly in the presence of a parvovirus-specific monoclonal antibody, have been
described (Jordan and Penchansky, 1995). Hence, a morphologic description of the
bone marrow aspirate could lead the pathologist to the diagnosis of B19 infection, and
thus is of major importance, especially when other tests, such as PCR, are not available.
Lastly, skin lesions can also be examined by light microscopy and using
immunohistochemistry with anti-human B19 monoclonal antibodies in order to locate
virus particles in the cytoplasm of endothelial cells (Takahashi et al., 1995). B19 should
be considered as part of a differential diagnosis in any patient presenting anaemia
associated with low or absent reticulocytes, especially for those immunosuppressed
individuals (Brown, 2000). The detection of morphologic changes may be
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complementary to a variety of methods which are used to detect anti-B19 antibodies,
B19 virus and viral antigens, as well as B19 genome.
I.I.5.2. Diagnosis by antibody detection
In immunocompetent hosts, B 19-specific IgM are the first antibodies to be produced, 
thus assays for IgM detection can be used to diagnose acute or recent infection. IgM can 
indeed be detected in more than 90% of cases by the third day of transient aplastic crisis 
(TAC), or at the time of rash in El, and can remain for up to 3 months (Anderson and 
Young, 1997). On the other hand, IgG antibodies become detectable several days after 
IgM and persist for years and are thus regarded as indicative of a past infection, either 
resolved or chronic. At present, only IgM and IgG directed against the capsid proteins 
VP1 and VP2 are used for diagnosis. In immunocompromised patients, B19 specific 
immune response may be normal, altered and even absent. Therefore, serological 
investigation is not the main tool to diagnose B19 in these subjects.
Antibodies to the non-structural protein NS1 may also be of interest as a supplementary 
assay in routine testing, since they may be related with persistent B19 infection or B19- 
associated arthritis (Von Poblotzki et al., 1995a; 1995b). As these antibodies usually 
become detectable at least 6 weeks after infection, their detection in pregnant women 
with borderline or weakly positive IgM results may be fairly common during pregnancy 
(Searle et al., 1998). However, only 30% of women in childbearing age were shown to 
produce anti-NS 1 antibodies, thus limiting the potential use of anti-NS 1 antibodies for 
diagnosis. IgA antibodies are too persistent to be a useful indicator of recent B19 
infection (Erdman et al., 1991) and the usual assays used are various assays for 
detection of IgM and IgG antibodies.
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1.1.5.2.1. Immunoblot assays
Immunoblot assays have been used extensively to measure both B19 IgM and IgG 
antibody responses and although these assays have problems with sensitivity and 
specificity and are labour-intensive, they allow the characterisation of antibody response 
to discrete B19 proteins (Schwarz et al., 1988; Anderson and Young, 1997). 
Immunoblots, also called Western blot assays, are now commercially available. The 
technique uses either recombinant or native B19 antigens, which are electrophoresed in 
denaturing gels and then transferred onto nitocellulose membranes. The immobilised 
antigens are exposed to patients’ sera, followed by enzyme-linked secondary antibody 
and, finally, a colorimetric substrate to visualise the immunoreactive bands (Palmer et 
al., 1996). The sensitivity of the assay may be improved by developing a 
chemiluminescent Western blot assay with a high-performance, video camera-based 
system (Manaresi et al., 1999b). While Western blot assays are able to detect immune 
response against B19 VP1 and VP2 linear epitopes, ELISA is used to determine the 
immune status against conformational epitopes (Kerr et al., 1999; Soderlund et al., 
1995a).
1.1.5.2.2. Enzyme immunoassays (EIA)
The early IgM immunoassay was based on an IgM antibody capture radioimmunoassay 
(MACRIA) and used to diagnose infection in children with sickle cell anaemia 
recovering from aplastic crisis (Anderson et al., 1982a). At the time, sources of antigen 
were sera or blood units obtained while in the phase of viraemia. In this assay, IgM 
from a dilution of patients’ serum is “captured” onto a solid phase coated with anti­
human IgM. B19 antigen is then added, followed by a detection system. This method is 
easier to perform and more sensitive than CIE testing of gradient separated IgM
fractions of serum (Kelleher et al., 1983). However, one of the disadvantages of
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MACRIA is that it uses large amounts of antigen. Development of an antibody-capture
assay, based on monoclonal antibodies to B19, for B 19-specific IgM and IgG resulted in
improved sensitivity (Cohen et al., 1983). Further improvements in sensitivity were
obtained by use of a detection system that included a mouse monoclonal antibody to
B19 and a 125I-labelled anti-mouse antibody (Cohen, 1997). This assay is used to detect
IgM antibodies and can thus be valuable for the diagnosis of recent acute B 19 infection.
Other groups have developed sensitive ELISA assays, one of which was shown to have
comparable sensitivity to DNA spot hybridisation using crude plasma (Anderson et al.,
1986, Schwarz et al., 1988). ELISA assays are easier to perform, can be used for mass
screening to detect B19 positive plasma and are good non-isotopic alternatives to RIA.
Due to the limited availability of B19 native antigens, several authors have reported
attempts to develop diagnostic tests based on renewable sources of B19 antigens using
synthetic peptides or recombinant antigens expressed in a baculovirus system (VP2
alone or VP1 and VP2) (Brown et al., 1990a; Schwartz et al., 1991a; Fridell et al.,
1991; Kajagaya et al., 1991; Salimans et al., 1992; Jordan, 2000). Compared with an
IgM assay using native B19 viral antigen, one of the peptide antigen assays was 92%
sensitive and 87% specific (Fridell et al., 1991). This assay showed good correlation
with a RIA which used native B19 virus, confirming the importance of recombinant
B19 antigens as a substitute for native virus. Lastly, a study showed that a Baculovirus-
expressed VP2 EIA produced fewer equivocal results and proved to be the most
accurate test to detect B19 antibodies in pregnant women compared with an E.coli-
based VP1 EIA for the detection of both IgM and IgG in sera (Jordan, 2000).
In EIA commercial kits for B19 diagnosis, IgM antibodies are mainly detected in
capture-EIA format, whereas IgG antibodies are usually revealed using indirect ELISA
format with antigen coated onto a solid phase (Zerbini et al., 2002). A comparison of
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four commercially available IgM EIA to indirect immunofluorescence and PCR assays
showed that the relative sensitivities and specificities of the ELISA assays ranged from
97 to 100% and from 81 to 99%, respectively (Sloots and Devine, 1996). Moreover,
rubella IgM cross-reactivity was found as particularly problematic in several
commercial assays. A similar study of a number of commercial assays showed
specificities for B19 IgM antibody detection between 88 and 96% and again a tendency
for cross-reactivity with IgM against rubella, as well as Epstein Barr virus (EBV) and
CMV was noted (Tolfvenstam et al., 1996). Other comparative studies of commercial
EIA assays for IgM found specificities ranging from 70.1% to 93.5% and sensitivities in
the range 97.4% to 97.5% (Bruu and Nordbp, 1995; Pickering et al., 1998). However, it
is likely that these comparative studies have little value in deciding which test format to
use for B19 diagnosis because of the lack of data on the absolute assay performance and
reproducibility (Doyle et al., 2000). In addition, external regulatory bodies rarely
control in-house assays, resulting in poor standardisation. The first parvovirus IgM EIA
to be cleared by the US Food and Drug Administration (FDA) was reported in 2000
(Doyle et al., 2000). There was no cross-reactivity with sera from patients with rubella,
CMV, VZV, mumps or rubeola, all of which could theoretically be confused with
parvovirus B 19 infection.
EIA have also been used to measure IgG avidity to discriminate primary and secondary 
infections. In the avidity assay, the patients’ antibodies are first allowed to bind to an 
immobilised antigen, then low-avidity antibodies, characteristic of primary infections, 
are eluted with a denaturing agent. The remaining antigen-bound IgG is quantified 
immunoenzymatically (Soderlund et al., 1995b; Manaresi et al., 2001). This assay can 
be used as a complement to IgM antibody assay.
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I.I.5.2.3. Immunofluorescence assay (IFA)
Indirect IFA for serum B 19-specific IgG and IgM antibodies can be used with 
recombinant baculovirus expressing either VP1 or VP2 antigen. Insect cells infected 
with this recombinant baculovirus expression system are then spotted and fixed onto 
glass slides. A series of incubations and washes are then carried out: first with dilutions 
of the serum to be tested, followed by goat-anti-human IgG or IgM conjugated with 
fluorescein isothiocyanate (FITC). Slides are mounted and examined under the 
fluorescence microscope and the IFA titres determined. A good correlation between IFA 
results and those obtained with solid-phase capture RIA have been reported although 
IFA has the advantage of being based on a renewable source of antigen (Brown et al., 
1990b; Cohen et al., 1983). Moreover, a later study showed comparable sensitivity of 
IgG detection by indirect enzyme immunoassay and IFA, with more than 95% acute 
infection confirmed by the latter (Pereira et al., 2001). In conclusion, although 
determination of antibody responses can be useful tools for the diagnosis of B19 
infection, these assays can also be inconvenient because of the requirement for two 
serum specimens, resulting in diagnostic delays.
I.I.5.3. Diagnosis by B19 virus and viral antigens detection
I.l.S.3.1. B19 virus
EM and IEM are sometimes used to confirm positive results obtained by other assays
and have also proven useful for antenatal diagnosis and in adult cases to examine
erythematous skin lesions and confirm B19 infection (Naides and Weiner, 1989;
Takahashi et al., 1995). In IEM, B 19-specific antibodies are added to the serum samples
in order to aggregate viral particles, if present. These aggregates are easier to see than
single particles would be by direct EM. Both EM and IEM require technical expertise
and costly specialised equipment and cannot be applied to the diagnosis of a large
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number of samples (Zerbini et al., 2002). Moreover, serum specimens have to be
collected during the early phase of infection when the virus titre is high.
I.I.5.3.2. B19 antigens 
1.1.5.3.2.1. Counter-immunoelectrophoresis (CIE)
In early B19 studies, CIE was widely used to detect B19 antigens in serum samples and 
thus determine acute infection. In this method, wells punched in agarose gel near the 
cathode are filled with test serum while the opposite wells, near the anode, are filled 
with B19 antibody positive serum. When the antigens and antibodies meet and form 
immunocomplexes, a visible line of precipitate appears on the gel (Zerbini et al., 2002). 
CIE can only detect B19 in blood samples containing 106 particles/ml or more and can 
thus diagnose primary B19 infection only when the virus titre is at a peak. Since CIE is 
quite insensitive, it has now been replaced by other techniques.
1.1.5.3.2.2. Radioimmunoassays (RIA) and enzyme 
immuno-assays (EIA)
The development and use of RIA and EIA for the detection of B19 antigens has 
improved sensitivities and specificities with respect to CIE and IEM. In these assays, a 
human reference immune serum is absorbed to a solid phase and captures B19 antigens 
present in serum sample. The immune complexes can then be detected by either I125 or 
enzyme labelled anti-mouse immunoglobulin for RIA and EIA, respectively (Anderson 
et al., 1986; Cohen et al., 1983). However, virus in immune complexes with early 
specific host antibodies may be masked from detection, as with CIE.
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1.1.5.3.2.3. Blot immunoassays
Blot immunoassays have been developed in two formats: Western blot and dot-blot. In 
Western blot, human serum is electrophoresed and transferred onto a nitrocellulose 
membrane, which is then treated with B 19-specific monoclonal antibodies. 
Immunocomplexes formed are visualised by addition of enzyme-conjugated anti-mouse 
antibody, followed by a colorimetric substrate. The dot-blot format can be used to test 
both serum samples and amniotic fluids, which are treated to expose the antigenic sites 
on the virions and to avoid the masking of the antigens by early specific host antibody. 
These samples are then directly placed onto a nylon membrane as a drop. This dot-blot 
immunoassay is performed in only four hours and is particularly suitable for large-scale 
screening of samples (Gentilomi et al., 1997). Moreover, the assay has a comparable, 
or slightly higher, sensitivity than that achieved by dot-blot hybridisation technique but 
less than that achieved by nested PCR.
1.1.5.3.2.4. Receptor-mediated haemagglutination 
assay (RHA)
RHA is a detection assay based on the agglutination of RBCs when mixed with serum 
containing parvovirus B19 (Sato et al., 1995). This reaction is pH-dependent and 
inhibited by purified globoside-B19 receptor, as well as by neutralising antibodies. The 
sensitivity of this method is between 105 and 106 genome copies/ml, which is almost as 
sensitive as RIA but much lower than PCR. However, it is simple and rapid to perform 
(the results are available in one day), can be suitable for large-scale screening and has 
the advantage of detecting only the virus particles that can bind to the receptor. A 
similar assay was developed in the UK (Cohen et al., 1995).
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I.I.5.4. Diagnosis by B19 DNA detection
The limitations of RIA assays can be avoided by an assay based on detection of the viral
genome, rather than the capsid antigen, by dot-blot hybridisation, microwell
hybridisation, in situ hybridisation and by amplification.
I.I.5.4.I. Dot-blot hybridisation assays 
A dot-blot hybridisation assay for detecting viral DNA uses serum specimens, which are 
filtered and spotted onto a nylon membrane. Different types of probes are then used, 
including single and double stranded DNA (Prato et a l, 1991; Clewley, 1985). A single 
stranded RNA probe that eliminates the risk of contaminating plasmid sequences has 
been described but extra caution is needed in handling such RNA probes (Cunningham 
et al., 1988; Zerbini et al., 1993). DNA probes have been reported to be about ten-fold 
more sensitive than RNA probes (Salimans et al., 1989a). Most hybridisation probes are 
obtained from cloned B19 DNA fragments (Clewley, 1985; Azzi et al., 1990; Prato et 
al., 1991; Zerbini et al., 1993), but can also be prepared by PCR amplification (Hicks et 
al., 1995; Zerbini et al., 2000; Zerbini et al., 2001) or synthetic oligonucleotides (Cubie 
et al., 1995). Initial detection methods used hybridisation to 32P-labelled probes 
(Anderson et al., 1985b; Clewley, 1985). These were replaced with biotin probes which 
eliminated the disadvantages associated with radioactivity (Cunningham et al., 1988). 
At present, digoxigenin is widely used since it is as sensitive as radioisotopes and more 
specific than biotin (Azzi et al., 1990; Prato et al., 1991; Hicks et al., 1995; Zerbini et 
al., 2001). Both digoxigenin-labelled probes and biotinylated probes can be stored at - 
20°C for months without loss of activity (Cunningham et al., 1988; Azzi et al., 1990). 
The detection system for hybridisation assays can be an immuno-enzymatic or a 
chemiluminescent reaction. In the former, antibodies against the probe are conjugated
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with alkaline phosphatase, which generates a colorimetric reaction. A variation of this
technique uses a tyramide signal amplification for biotinylated probes (Zerbini et al.,
2000). This method uses a horseradish peroxidase-streptavidin complex to catalyse the
deposition of biotinyl-tyramide conjugate and streptavidin coupled to alkaline
phosphatase to amplify the signal. A 10 to 50 times increase was observed when
compared to detection with alkaline phosphatase (~105 genome copies). Improved
sensitivities are obtained using a chemiluminescent substrate (Zerbini et al., 1993;
Zerbini et al., 2001). An initial study showed that the chemiluminescent reaction had a
sensitivity of 6x10 virus particles compared with an immuno-enzymatic reaction which
was able to detect 1.5xl04 virus particles (Zerbini et al., 1993). A second study in 2001
showed improved sensitivities for both methods of detection, although that of
chemiluminescence (~6xl 02 genome copies) was higher than that of immuno-enzymatic
reaction (-3x103 genome copies) (Zerbini et al., 2001). Chemiluminescence detection
offers the advantage of a permanent record of the reactions, whereas membranes stained
with a colorimetric substrate can lose colour over time. Moreover, the latter often
present a strong background, resulting in difficulty in interpreting results.
Unlike CIE and RIA, dot-blot hybridisation assay is not affected by the presence of
B 19-specific antibodies in host serum and allows testing of large numbers of specimens
since 1,000 blood donor plasma samples can be tested per day. Moreover, in terms of
virus particles detected, the dot-blot assay is more than 300 times more sensitive than
RIA, partly because the assay uses a much smaller volume (Anderson et al., 1985b). On
the other hand, the detection of DNA by dot-blot hybridisation has limited value for the
diagnosis of past B19 infections since the virus is detectable for only one week during
viraemia.
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1.1.5.4.2. In situ hybridisation assays (ISH)
ISH is an important tool for localisation of B19 DNA within individual cells and has 
been used in bone marrow cells, amniotic fluid cells, cord blood cells and fetal cells 
(Zerbini et al, 2002). The probes for in situ hybridisation have been made either from 
cloned DNA fragments or from synthetic oligonucleotides (Cubie et al., 1995). ISH 
with cloned probes can be labelled with radioisotopes, biotin (Porter et al., 1988), 
acetyl-aminofluorene (Salimans et al, 1989b) or digoxigenin (Morey et al, 1992). Non­
radiolabelled probes have been reported to be more sensitive than radiolabelled probes 
for in situ hybridisation on fixed tissues from a hydropic fetus (Salimans et a l, 1989b). 
However, while biotinylated probes offered advantages over radioactive probes, 
positive results should be confirmed by other methods (Cubie et a l, 1995). Since 
individual, infected cells can be examined, the apparent sensitivity of ISH is greater 
than with DNA amplification applied to a tissue sample consisting of many cells only a 
few of which are infected. Detection by ISH has the advantage of identifying the virus 
and relating its distribution to tissue morphology.
1.1.5.4.3. DNA amplification
The technique of DNA amplification, commonly known as PCR (Mullis et a l, 1986; 
Mullis and Faloona, 1987), has vastly improved the sensitivity of detection of B19 DNA 
compared with other methods. Studies have shown that B19 DNA is detectable longer 
by PCR than was earlier suggested by nucleic acid hybridisation studies (Anderson et 
al, 1985a; 1985b). It has been reported that the sensitivity can be improved by transfer 
of the DNA to a nylon membrane and hybridisation with a radioactive labelled probe 
(Salimans et al, 1989a; Salimans, 1990). Compared with conventional gel 
electrophoresis of the amplified DNA, hybridisation of the PCR products increased the
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sensitivity from 103-104 particles/ml to as few as 100 particles/ml. Various studies,
using modification such as nested PCR, PCR alone with subsequent hybridisation and
dot-blot hybridisation to detect B 19-specific products, have reported even greater
sensitivity of B19 DNA detection down to a single copy (Clewley, 1989; Koch and
Adler, 1990; Frickhofen and Young, 1990; Cassinotti et al., 1993a).
The most important drawback associated with this technique is the risk of
contamination due to carry-over between samples from the first to the second PCR
round, resulting in false positive results. In order to overcome these contamination
problems extensive and extremely strict precautions should be taken during the handling
of materials (Kwok and Higuchi, 1989). Additionally, only trained personnel should
perform the assays in three separate laboratories, ideally equipped with a laminar flow
cabinet and without cross-traffic of staff. Lastly, each sample should be tested in
duplicate and several negative controls should be included in each PCR reaction.
Another disadvantage of this technique is the high cost of screening a large number of
samples. On the other hand, this method is highly specific and the most sensitive assay
available at present. It can also be applied to a large variety of clinical materials, such as
blood, bone marrow, urine, ascites and leukocyte extracts, as well as synovial and
amniotic fluids, fetal and maternal blood (Koch and Adler, 1990; Cassinotti et al.,
1993a; Dieck et al., 1999). Parvovirus DNA was also amplified from a cutaneous
biopsy specimen during the acute phase of the disease in a case of popular purpuric
“gloves-and-socks” syndrome (Grilli et al., 1999). Lastly, results can be reported,
depending on laboratories, within 1.5 to 2 days, making PCR an important tool for the
early diagnosis of B19 infection.
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Studies have shown circulating vims may present with IgM but can only be detected by
PCR (Musiani et al., 1993). This is a very important aspect of B19 detection,
particularly in immunocompromised patients who often have a low-titre viraemia
undetectable by conventional nucleic acid hybridisation techniques. PCR is thus the
most suitable, and possibly the only, method of detection of B19 in such patients.
Sensitivity of detection being the major focus of any assay, further research has been
undertaken recently to develop very sensitive detection methods for B19 DNA,
especially useful for blood products testing. A PCR assay coupled with a hybridisation
protection assay, using acridinium ester-labelled DNA probes to detect the amplified
products claimed a sensitivity of a single copy in 10pl (100 copies/ml) (Sato et al.,
2000). In laboratory diagnostics, PCR assays are usually performed with qualitative
methods but several semi-quantitative or quantitative methods have also been reported.
These include competitive PCR assays and hybridisation of PCR products to probes in
microtitre plates, with either chromogenic or chemiluminescent reaction as a detection
system (Gallinella et al., 1997; Gruber et al., 1998; Fini et al., 1999). However, these
established methods are time-consuming, labour intensive and require post-PCR
handling steps, which may lead to contamination, and lack of standardisation. On the
contrary, the recently developed real-time PCR offers rapidity, monitoring of PCR
activity as it happens, the potential to eliminate carry-over contamination due to the
combination of amplification and detection in closed tube systems, and a quantitative
analysis. Two different instruments can be used for this fluorescence-based assay: the
ABI PRISM SD7700 system (PE Biosystems), otherwise known as TaqMan, and the
LightCycler system (Roche Molecular Biochemicals). The latter (figures 1.11 and 1.12)
has recently been used to detect PPV and to quantify the virus load in tested specimens
(Krumbholz et al., 2003). The ABI PRISM SD7700 system has been used for the
-  100 -
 Chapter I
development of a real-time PCR method that included duplex amplification, internal
standardisation and two-colour fluorescence detection (Gruber et al., 2001). It has also
been used to screen and identify blood donations containing high titres of B19, thereby
improving the safety margin of plasma and plasma products (Aberham et al., 2001)
while the LightCycler technology has been useful to evaluate large numbers of serum
specimens (Manaresi et al., 2002b). High levels of sensitivity and specificity were
found for the detection of B19 DNA. The LightCycler instrument was used in the
present study.
Figure 1.11: The LightCycler instrument
As shown in figure 1.12, the LightCycler instrument consists of an upper unit with the 
heating coil and a lower unit, which contains the thermal chamber, fluorimeter, drive
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units, electronic boards and power supply. During measurements, a stepper motor
rotates the sample carousel to position the capillary tip, which contains the sample,
precisely at the focal point of the fluorimeter optics.
Figure 1.12: Schematic of the LightCycler instrument (Source: operator’s manual)
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surface-to-volume ratio
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for rapid temperature 
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The kinetics of nucleic acid amplification by PCR has two phases: the exponential
phase and the plateau phase. The former reflects the generation of PCR product
molecules, which is directly proportional to input target molecules per PCR cycle.
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During the plateau phase, there is little or no net increase in PCR product yield.
Quantification of DNA is therefore possible during the exponential phase and can be
one of two kinds: relative or absolute. The relative quantification is the determination of
the target gene ratio in two samples. The advantage of this quantification is that no
absolute concentration of target or reference is necessary. On the other hand, absolute
quantification is the determination of the absolute amount of target molecules by using
an internal or external standard (copy number, mass, etc.).
A standard curve is usully generated by using a well established external reference 
reagent such as the WHO B19 International Standard (IS) which allows consistent 
quantitation of B19 DNA over 7 orders of magnitude (Saldanha et al., 2002). In order to 
quantify PCR product, the instrument has to acquire fluorescence once per cycle, 
thereby generating a fluorescence curve that increases in value with each cycle as the 
product accumulates. The most useful data can be found in the log-linear portion of the 
fluorescent curve and starts at the cycle number where fluorescence rises above 
background. The LightCycler software generates a best-fit line from this region of each 
curve called a crossing line. The crossing point ( C t )  is then determined as the 
intersection between the crossing line and the log-linear region of the fluorescent curve. 
The crossing point values for a set of standards can be plotted against known logio 
concentration to give a standard curve.
The PCR efficiency, which is a critical factor, can be calculated as shown in figure 1.13. 
An efficiency of 1.00 (100% doubling per cycle) is attained when the slope is -3.33 
whereas PCR efficiency of 0.78 (78% doubling per cycle), which is the cut-off level, is 
obtained when the slope is -4.0. Any slope that is less than -3.33 would represent more 
than 100% efficiency, which is impossible and should therefore be disregarded.
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Figure 1.13: Calculation of PCR efficiency
(Source: Qiagen seminar on strategies for quantification and lab results)
Efficiency =  10  V ^ - l
log amount of standard
By comparing the Cj of an unknown sample with the standard curve, the LightCycler 
instrument generates a quantitative estimate of the starting concentration of the target 
DNA in that sample (figure 1.14).
Figure 1.14: Calculation of target concentration using the standard curve
(Source: Qiagen seminar on strategies for quantification and laboratory results)
•  Standard
CT of unknown ••••
20
log amount of standardInitial concentration 
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Comparison of compiled PCR and serological results showed that single serologic
testing on a given clinical sample is highly inappropriate for the diagnosis of B19
infection (Cassinotti et al, 1993a). A recent study showed that, although IgM ELISA
was able to detect only 60% of infections, IgM antibodies were the unique diagnostic
markers in 20.8% of infections and are thus fundamental for the diagnosis of recent and
symptomatic infections where B19 DNA is no longer detectable (Gallinella et al.,
2003). PCR was able to detect 79.2% of documented infections and the presence of B19
DNA was the unique marker in as much as 32% of cases, making it fundamental for the
detection of B19 acute infections, especially before onset of immune response. Dot-blot
hybridisation was not sensitive enough to detect either all early acute infections or
persistent infections in which IgM was not detectable. Hence, the most appropriate
diagnosis should include determination of both B19 DNA by PCR and specific IgM by
ELISA (Gallinella et al, 2003).
1.1.6. Clinical features
I.I.6.I. Asymptomatic infection
Most individuals with B 19-specific antibodies have no recollection of previous 
symptoms and thus asymptomatic infection is considered common. Studies have shown 
that 26%-31% of adults exposed to the virus, in a school outbreak or via household 
contact, were asymptomatic (Woolf et al, 1989; Chorba et a l, 1986). In addition, 
differential rates of asymptomatic infection among black (68.8%) and white (20%) 
household members have been recorded but this is to be expected, as the characteristic 
rash of B19 infection is more difficult to detect on a dark skin (Chorba et a l, 1986). 
Although asymptomatic infection is common, a wide spectrum of clinical 
manifestations can result from B19 infection.
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I.I.6.2. Dermatologic manifestations
B19 infection as been shown to cause a wide spectrum of dermatologic manifestations,
including two specific B19-related dermatologic diseases: El and papular purpuric
“gloves-and-socks” syndrome (PPGSS), as well as other non-specific findings linked to
parvovirus infection (Seishima et al., 1999; Katta, 2002).
I.I.6.2.I. Erythema infectiosum (El)
El, also known as fifth disease, slapped cheek disease, academy rash or Sticker’s 
disease, is the major manifestation of B19 infection. However, the distinct clinical 
features of El were recognised long before the discovery of the aetiologic agent. The 
first description of this exanthematous rash illness of childhood was reported two 
centuries ago by a dermatologist, Robert Willan (Van Elsacker-Niele and Anderson, 
1987). The first picture of a child with El, called “rubeola sine catarrho” at the time, 
was shown in his dermatology book, written around 1800 (Figure 1.15). The rash was 
given the different names listed above, including fifth disease, as it was the fifth of the 
originally described childhood exanthematous diseases. It was thought that rubella virus 
could be associated with El, but a study of a school outbreak revealed that a history of 
rubella vaccination did not affect the risk of developing El (Lauer et al, 1976). 
Moreover, no rubella virus could be recovered from the children’s throat swabs.
The first reported El in association with human parvovirus B19 was in 1983, during an 
outbreak in a London school, UK (Anderson et al, 1983). Soon after, two studies from 
Japan confirmed the link between fifth disease and B19 infection (Nunoue et a l, 1985; 
Shiraishi et al, 1985). In the first study, anti-B19 IgM antibodies were detected in 33 of 
34 affected children (97%) but only in 21 of 141 healthy children (15%) while in the 
second study, B 19-specific IgM was detected in all 19 patients tested.
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Figure 1.15: First picture of a child with El (Van Elsacker-Niele and Anderson,
1987)
The course of El can be divided into three stages, the first occurring after an incubation 
period of four to fourteen days (Sabella and Goldfarb, 1999). This phase, often 
unrecognised, corresponds to a period of viraemia where the patient is contagious and 
can experience low fever, headache and gastrointestinal symptoms. The second stage of 
the illness, three to seven days later, is characterised by the distinctive “slapped cheek” 
appearance, a bright erythematous facial exanthem associated with surrounding relative 
pallor (figure 1.16). These clinical features vary depending on the age of the patient: in 
children, the classic rash described here is commonly present whereas in adults, it is 
more subtle and unusual.
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Figure 1.16: Slapped cheek rash (courtesy of Dr B. Cohen)
The highest rate of fifth disease was found to be in the five to nine years-old age group 
(Kelly et al, 1999). In adults, a higher incidence of associated arthralgia and arthritis 
was first recognised in 1966, and later confirmed in a second study (Ager et al., 1966; 
Joseph, 1986). The third stage of El occurs one to four days after the appearance of the 
facial rash and may last for one to three weeks, depending on exposure to sunlight, heat 
and stress (Anderson, 1987). This stage is characterised by a lacelike erythematous 
maculopapular exanthem on the trunk and/or the extremities. Patients presenting with 
such a rash are no longer contagious since it corresponds to the development of 619- 
specific IgM antibodies. Although the ex anthem may recur or persist for several 
months, there are no long-term sequelae (Woolf et al., 1989). In addition to the rash, 
generalised lymphadenopathy and splenomegaly was observed in a few patients 
(Plummer et al., 1985). Lastly, the prevalence of the symptoms associated with El can 
vary between outbreaks and individuals.
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I.I.6.2.2. Papular purpuric “gloves-and-socks” syndrome
(PPGSS)
PPGSS was first described in 1990 and associated with an acute infection by B19 in 
1991 (Harms et al., 1990; Bagot and Revuz, 1991). This distinctive painful rash takes 
its name from a symmetric erythema and oedema of the hands and feet, usually sharply 
demarcated at the wrists and ankles where the lesions progress gradually to purpura. 
The rash has mainly been described in young adults, although it has also been reported 
in children (Seabury Stone and Murph, 1993; Labbe et al., 1994). Other body parts can 
occasionally be affected, including cheeks, elbows, knees, inner thighs and buttocks 
(Harms et al., 1990; Nelson and Stone, 2000). Systemic symptoms in 
immunocompetent patients including fever, anorexia and arthralgias and 
lymphadenopathy have also been observed (Harms et al., 1990; Bagot and Revuz, 
1991). PPGSS usually resolves spontaneously within one to two weeks with no 
permanent sequelae whereas, in immunosuppressed patients, it may result in serious 
complications. For example, it has been reported that three HIV-positive patients who 
presented serological evidence of acute B19 and clinical signs of PPGSS, displayed 
persistent anaemia and prolonged skin lesions (Ghigliotti et al., 2000). It is important to 
note that, unlike patients with El, individuals suffering from PPGSS are considered 
contagious when the rash is present (Nelson and Stone, 2000).
I.1.6.2.3 Other dermatologic manifestations
Another clinical disease associated with B19 is a purpuric rash-like illness, often with 
other signs of vasculitis (Lefrere et al., 1985b; Mortimer, 1985; Li Loong et al., 1986). 
A case of a 27-year-old woman with a rash atypical for El because of the presence of a 
haemorrhagic exanthem and an area of near-confluent pustules and pseudo-pustules
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with a slightly purpuric base has been reported (Naides et a l, 1988). Various eruptions
such as erythema nodosum may also appear in the viraemic phase of B19 infection
(Borreda et al., 1992).
I.I.6.3. Haematologic manifestations
I.I.6.3.I. Transient red blood cell aplasia or aplastic crisis 
(TAC)
TAC, which is the abrupt onset of severe anaemia with absent reticulocytes, can occur 
as a unique event in the life of patients with a variety of underlying haematologic 
abnormalities. The first link between TAC and B19 was made in 1981 when parvovirus 
B19 was detected in a child with sickle cell anaemia hospitalised for aplastic crisis 
(Pattison et al., 1981). Further evidence, such as B19 viraemia, and a higher prevalence 
of B 19-specific antibodies in TAC patients with sickle cell disease than in controls, 
supported this link (Pattison et al., 1981; Serjeant et al., 1981). Other studies have 
demonstrated B19 viremia and/or the presence of specific IgM in all nine children with 
sickle cell disease suffering from aplastic crisis (Anderson et al., 1982b).
Since parvovirus B19 infects erythroid progenitor cells in the bone marrow and causes 
temporary cessation of red blood cell production, patients who have underlying 
haematologic abnormalities are prone to cessation of RBC production if they become 
infected. These patients consist of those suffering from decreased red cell production or 
increased destruction or loss. The former include a- and P-thalassemias (Chorba et al., 
1986; Lefrere et a l, 1986a; Lefrere et al., 1986b; Lefrere and Decazes, 1986) and 
patients with iron deficiency (Lefrere and Bourgeois, 1986; Graeve and Elliott, 1991). 
Infection can also cause TAC in individuals with increased red cell destruction or loss, 
such as in hereditary spherocytosis (Lefrere et al., 1986a; Lefrere et al., 1986c; Lefrere
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and Decazes, 1986; Saarinen et al., 1986; Baurmann et al., 1992), sickle cell disease 
(Anderson et al., 1982b; Chorba et al., 1986; Lefrere et al., 1986a; Lefrere and Decazes, 
1986; Saarinen et al., 1986), pyruvate kinase deficiency (Duncan et al., 1983) and 
autoimmune haemolytic anaemia (Lefrere et al., 1986a; Tomiyama et al., 1988). The 
result of all these studies suggests that, in predisposed individuals, 60 to 70% of TAC 
cases are caused by B19 infection (Heegaard and Brown, 2002). Laboratory findings 
reveal reticulocytopenia (0 to 1% reticulocytes) and anaemia with haemoglobin 
concentrations falling dramatically (5g/dL) (Sabella and Goldfarb, 1999). Although 
recovery often follows the appearance of specific antibodies, severe disease with heart 
failure can be life threatening.
When hospitalisation is required, patients can be monitored and treated with red blood 
cell transfusions and clinical symptoms usually resolve within 3 to 6 days (Anderson, 
1987). Unlike El, these patients are often viraemic and therefore still contagious and 
need to be kept in respiratory isolation to prevent nosocomial transmission. Such 
transmissions have been documented where two outbreaks of El among nursing staff 
were caused by two adolescent patients with sickle cell disease and aplastic crisis (Bell 
et al., 1989).
Parvovirus-induced red blood cell aplasia has also been reported in a child with no 
underlying haemolytic anaemia (Murray et al., 1993). In a study of volunteers, all four 
infected subjects had a reticulocytopenia, neutropenia, thrombocytopenia, lymphopenia 
and a gradual fall in haemoglobin, suggesting that reticulocytopenia can occur in any 
B19 infection, but usually disappears before development of a rash (Anderson et al., 
1985a). In a patient without shortened red cell survival time, the haemoglobin level is 
not low enough to be symptomatic or to be considered low. Thus anaemia, the other 
marker of TAC, often fails to be noticed (Anderson, 1987). However, there is no
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evidence to support the role of B19 infection in transient erythroblastopenia of
childhood (TEC) (Bhambhani et al., 1986, Skeppner et al., 2002).
Lastly, it is important to note that parvovirus-induced TAC has previously been
mistaken for myelodysplastic syndrome (MDS), which comprises a heterogeneous
group of clonal stem cell disorders characterised by blood cytopenia and dysplastic
traits in the bone marrow (Baurmann et al., 1992; Hasle et al., 1994). It was therefore
recommended that parvovirus B19 be considered in the differential diagnosis of MDS in
both children and adult patients.
I.I.6.3.2. Bone marrow failure
Due to a bone marrow insufficiency triggered by B19 infection, immunocompromised 
patients are unable to mount a neutralising antibody response. This results in persistent 
B19 infection that may cause pure red blood cell aplasia (PRCA) and chronic anaemia. 
PRCA can be characterised as anaemia with the almost complete absence of RBC 
precursors in the bone marrow, but essentially normal granulopoiesis and 
megakaryopoisis (Fisch et al., 2000).
Persistent B19 infection and resulting PRCA and chronic anaemia have been 
documented in five immunodeficient populations: congenital immunodeficiency, 
lymphoproliferative disorders, transplant patients, those with acquired 
immunodeficiency syndrome (AIDS) and those with haemophagocytic syndrome.
I.I.6.3.2.I. Congenital immunodeficiency
Several studies have reported the occurrence of PRCA in B19 infected individuals with
congenital immunodeficiency, including combined immunodeficiency with
immunoglobulins (Nezelof s syndrome) (Kurtzman et al., 1987; 1989a; Gahr et al.,
1991). In such cases, the B19 infection resulted in severe bone marrow failure, with
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erythroid hypoplasia and the presence of giant pronormoblasts. Studies on a patient with
a 10-year history of PRCA showed a variety of symptoms starting with intermittent 
fever, back and abdominal pain and fatigue at an early age and progressing to anaemia 
which was finally corrected by immunoglobulin therapy (Kurtzman et al., 1989a). 
Depressed serum antibody levels, low natural killer cell count and a high ratio of 
helper/suppressor T cells suggested underlying immunodeficiency. The notable feature 
of this case was that the patient’s older brother had developed PRCA simultaneously but 
died later of sepsis and hepatic cirrhosis due to transfusion haemosiderosis. The post­
mortem detection of B19 DNA in fixed spleen tissue confirmed chronic B19 infection 
in the sibling.
1.1.6.3.2.2. Lymphoproliferative disorders
Patients suffering lymphoproliferative disorders are mostly children with acute 
lymphoblastic leukaemia who are receiving chemotherapy. The latter is known to 
impair the immune system and thus persistent B 19 infections with bone marrow failure 
have been described. Several case reports have linked B19 infection in children with 
malignancies with severe chronic anemia, bone marrow failure and severe prolonged 
cytopenia (Kurtzman et al., 1988; Azzi et al., 1989; Yoto et al., 1993; Broliden et al., 
1998). Administration of immunoglobulin, as well as interruption of chemotherapy to 
reduce the level of immunosuppression may result in resolution of the B19-induced 
anaemia.
1.1.6.3.2.3. Transplant patients
Transplant recipients have to undergo immunosuppressive treatments, which make them 
susceptible to persistent B19 infection. B19 infection following kidney transplants can
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result in a range of diseases from PRAC (Corral et al., 1993; Uemura et al., 1995;
Holman et al., 1997; Mathias, 1997), severe symptomatic anemia characterised by
intranuclear inclusions in bone marrow and requiring transfusions (Pamidi et al., 2000),
and chronic anemia (Mathias, 1997). Such chronic B19 infection seems to be more
common and severe in recipients of transplants that require more intensive
immunosuppression, including liver and cardiac transplants (Thio and Janner, 1996;
Anderson and Young, 1997; Wicki et al., 1997). The presence of B19 DNA in a cardiac
transplant recipient who presented with severe anaemia was demonstrated by PCR on
the serum and a bone marrow aspirate revealed giant pronormoblasts, both findings
implying an acute B19 infection (Thio and Janner, 1996). B19 was shown to be the
causative agent for severe transfusion dependent anaemia in a lung transplant patient
(Kariyawasam et al., 2000) and severe anaemia with reticulocytopenia in two solid
organ transplant recipients (one heart and one lung) (Wicki et al., 1997).
Severe anaemia and PRCA have been reported in several cases following allogeneic 
bone marrow transplant (BMT) (Weiland et al., 1989; Niitsu et al., 1990). In the case of 
a patient who had suffered acute myeloid leukaemia and developed unexplained 
pancytopenia nine months after BMT, a bone marrow biopsy revealed a total absence of 
erythropoiesis and some enlarged cells with inclusions. A few weeks later, the patient 
developed a non-cardiogenic pulmonary oedema and died of an intracerebral 
haemorrhage. Post-mortem examination of the sera taken in the course of this illness 
revealed a prolonged B19 infection but the source of infection could not be determined 
(Weiland et al., 1989). Similarly, a patient who had suffered acute promyelocytic 
leukaemia and developed PRCA one month after BMT was thought to have contracted 
parvovirus B19 from the platelet transfusion (Niitsu et al., 1990).
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However, an investigation of serum samples from 201 allogeneic bone marrow
recipients, found 3 cases (-1.5%) of acute B19 infection during the second year
following BMT, suggesting that B19 is not a frequent cause of anaemia, leukopenia or
thrombocytopenia shortly after transplantation (Soderlund et al., 1997a). Interestingly,
the infections diagnosed during recovery may present either as primary or secondary
immune responses, depending on the immune history of the donor but regardless of the
serological status of the recipient before BMT. These findings have been confirmed by a
study of 51 BMT recipients who did not develop B19 infection, at least until hospital
discharge (Azzi et al., 1993; Soderlund et al., 1997a). It is possible that isolation
measures and intravenous immunoglobulin treatment of these patients may have helped
to prevent B19 infection.
I.I.6.3.2.4. AIDS
Due to the effect of the human immunodeficiency virus (HIV) on the cellular branch of 
the immune system, seropositive subjects have an impaired antibody production that 
can result in persistent infection. Persistent SPV infection and severe anaemia have been 
observed in monkeys with concurrent acute infection with simian immunodeficiency 
virus (SIV) (O’Sullivan et al., 1996). This can also be applied to human parvovirus 
B19, since it was shown to persist in some AIDS patients who have developed PRCA 
(Frickhofen et al., 1990) or chronic anaemia (Chemak et al., 1995). Giant 
pronormoblasts in bone marrow suggested the diagnosis and B19 DNA was amplified 
intermittently over several months. One study found an unusual pattern in B19 infection 
in AIDS patients: the bone marrow was hypercellular and erythroid precursors increased 
with abundant intranuclear inclusions (Crook et al., 2000). However, according to the 
authors, these findings are consistent with the hypothesis that failure to produce
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effective B 19-specific IgG neutralising antibodies may lead to persistent infection
through viral tolerance. Although PRCA can be improved by immunglobulin therapy,
some patients may develop El symptoms, consistent with their immune complexes
origin (Brown and Young, 1996). Moreover, a highly active antiretroviral therapy
(HAART) that includes the use of protease inhibitors was found to play an effective role
in clearing B19 virus leading to a complete remission of B19-associated PRCA,
possibly due to an increase in cellular immunity due to HAART (Mylonakis et al.,
1999; Taguchi et al., 2001). In a reported HIV positive case, HAART was shown to
have restored the humoral immunity since the clinical course of primary B19 infection
in this patient resembled that in an immunocompetent individual (Clarke and Lee,
2003). The prevalence of B19-associated anaemia has been investigated in two small-
scale studies (10 and 50 individuals, respectively) and neither acute nor persistent B19
viraemia in any HIV-1 patients was reported (Goedert et al., 1997; Anderson et al.
1985a). The rate of B19 infection in a larger cohort study of HIV-seropositive
homosexuals was similar to that in the general population (0.5%) (Abkowitz et al.,
1993). Nevertheless, 4 of 24 (17%) transfusion-dependent HIV patients presented with
B19 viraemia.
I.I.6.3.2.5. Virus-associated haemophagocytic
syndrome (VAHS)
VAHS is characterised by histiocytic hyperplasia, prominent haemophagocytosis and 
cytopenia, as well as a systemic viral illness (Risdall et al., 1979). Although VAHS is 
usually benign and self-limited, some patients present an underlying 
immunosuppression. Several studies have reported cases of malignant histiocytosis with 
PRCA as an unusual complication (Hanada et al., 1986; Reiner and Spivak, 1988).
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Parvovirus-associated VAHS have been observed in many cases in both adults and
children (Uike et al., 1993; Tsuda et al., 1994; Shirono and Tsuda, 1995; Hoang et al.,
1998; Sadahira et al., 1998). Although these studies suggest that B 19 is not a rare cause
of this condition, further research is needed to determine the role of B19.
I.I.6.3.3. Thrombocytopenia and neutropenia
A fall in white cell count was first noted in healthy volunteers infected with B19 
(Anderson et al., 1985a). Acute B19 infection and TAC are often associated with 
changes in the other blood lineages, resulting in neutropenia (Saunders et al., 1986; 
Doran and Teall, 1988) and thrombocytopenia (Saunders et al., 1986; Inoue et al., 
1991). The latter has shown to develop into idiopathic thrombocytopenic purpura (ITP) 
(Inoue et al., 1991). The involvement of parvovirus B19 has been suspected in ITP 
since B19 DNA and/or IgM antibodies against B19, both markers of an acute infection, 
were detected in this population of patients (Foreman et al., 1988; Lefrere et al., 1989; 
van Elsacker-Niele et al., 1996; Wehmeier et al., 2000). B19-associated ITP were found 
in only 5% (Lefrere et al., 1989), 1.7% (van Elsacker-Niele et al., 1996) and 12% 
(Wehmeier et al., 2000) of the investigated patients presenting ITP. The fact that the 
latter figure is higher than in the other two studies might be explained by the relatively 
small number of individuals included in the investigation. Parvovirus infection was 
suspected as the cause of chronic neutropenia of childhood in a study where B19 DNA 
by PCR was demonstrated in the bone marrow of 15 of 19 patients (79%), of whom 
only 6 had serological evidence of B19 infection (McClain et al., 1993). In contrast, a 
later study detected B19 DNA in the bone marrow of only 1 of 56 (-2%) children and 
young adults with chronic neutropenia, suggesting no evidence of the involvement of 
the human parvovirus (Hartman et al., 1994).
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I.I.6.3.4. Vasculitis syndromes
Human parvovirus B19 has been associated with several systemic and local necrotising
vasculitis syndromes, including polyarteritis nodosa (Corman and Dolson, 1992),
Wegener’s granulomatosis (Finkel et al., 1994), Henoch-Schonlein purpura (Lefrere et
al., 1986d) and severe digital arterial occlusive disease (Dingli et al., 2000). Although
serological data, DNA detection by PCR and in situ hybridisation have suggested a link
with B19, it may be that the virus is not directly responsible for the development of
these diseases, but rather can aggravate the underlying disease (Bultmann et al., 2003).
Moreover, circulating immune complexes may worsen any preexisting vascular
disorder. However, other studies have suggested B19 as the aetiologically responsible
agent as immunoglobulin therapy led to rapid improvement of the systemic vasculitis
manifestations in patients studied (Finkel et al., 1994). Vascular events have also been
reported in association with B19 infection and cerebral manifestations in sickle cell
disease patients (Wierenga et al., 2001).
I.I.6.4. Rheumatologic manifestations
Another common complication of B19 infection is joint involvement. However, 
compared with other infectious agents associated with arthritis, such as Campylobacter 
and Chlamydia, the prevalence of parvovirus B19 in adult patients with arthritis of less 
than 3 months’ duration is low (<3%) (Soderlin et al., 2003). Although rheumatologic 
manifestations only occur in 8% of infected children, they are more frequent in adults 
(60%) and especially in women (Torok, 1992; Freitas et al., 2002). While women 
usually develop an acute arthropathy with rash and flu-like illness, men rarely present 
joint symptoms (Woolf et al., 1989). The most common presentation in adults was acute 
symmetric polyarthritis, usually starting 1 to 6 days after the eruption of the rash
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(Scroggie et al., 2000). The symptoms affect mainly the small joints of the hand
followed by wrists, ankles, knees and elbows. Although the symptoms of arthropathy
resolve within a few weeks in most cases, some patients (-20%) have been reported
with chronic arthropathy for months to years (White et al., 1985; Reid et al., 1985;
Woolf et al., 1989). Parvovirus B19 arthropathy mainly affecting the wrists, elbows,
shoulders and neck has been described (Luzzi et al., 1985). Although the symptoms
persisted for 8 months, the joints became normal to examination 2 months after onset.
During this period, a rise in rheumatoid factor to high titre occurred and was noticed for
the first time, suggesting that B19 might be responsible for the presence of rheumatoid
factor.
B19 infections have also been linked to chronic arthropathy with an unusual 
involvement of some joints in the spine (Guillaume et al., 2002) and to the development 
of a rash, stiffness and swelling of hands and arms (Sasaki et al., 1995) in 
immunocompetent patients. The reappearance years later of fever, joint pain and a 
transient rash on hands and arms in some cases suggests that B19 may persist in bone 
marrow, where it may be reactivated. Several studies have reported viral arthritis and 
symptoms such as joint swelling, particularly of the hands, as well as pain and stiffness 
associated with lethargy and morning stiffness as common occurences in patients 
diagnosed with B19 infection (rash, El, IgM seroprevalence) (Woolf et al., 1989; 
Naides et al., 1990; Cassinotti et al., 1995). The presence of rheumatoid factor and B19 
infection in arthritis patients is unclear: some studies have indicated an association 
(Jobanputra et al., 1995, Luzzi et al., 1985; Sasaki et al., 1995) while others have failed 
to find a link between the presence of rheumatoid factor and B19 infection (Naides et 
al., 1990).
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Further studies have been reported on long-term follow-up of B19 infections with
reference to chronic arthritis. In a study of 54 patients with recent B19 infections who
had arthralgia, 72% presented with a skin rash, 64% with fever, 61% had arthritis
(Speyer et al., 1998). After a mean follow up of five years, arthralgia and malaise were
still present in 40% of individuals but none of the patients reported persistence of joint
swelling or restricted motion. In a survey involving patients with recent inflammatory
polyarthritis, there was serologic evidence of recent B19 infection in just 4 of 147
patients (2.7%), only one of whom did not satisfy criteria for rheumatoid arthritis (RA)
(Harrison et al., 1998). Although these various findings tend to suggest that B19 does
not typically cause chronic arthritis, other data are contradictory (Murai et a l, 1999).
This report followed 67 patients suffering from acute inflammatory polyarthritis for up
to six years. B 19-specific IgM and B19 DNA were detected in 12 of them (-18%). All
B19 cases but one were originally negative for the rheumatoid factor but, two to four
months after the onset of infection, four patients became positive. Although B19 DNA
could no longer be detected in serum samples of these four individuals, it was still
present in bone marrow and synovial tissue long after the initial infection. The
persistence of B19 in synovium of patients with chronic arthritis has been investigated
despite the fact that the findings do not always agree. B19 DNA was detected in
synovium of 15 of 90 patients (17%) with unexplained arthritis, whereas only 1 of 73
(1.37%) cases was positive when the synovial fluid was tested (Cassinotti et al., 1998).
Viral DNA has also been found in the synovial tissue of -42% (5 of 12) of patients with
undifferentiated monoarthriritis and in 75% (3 of 4) of those with oligoarthritis,
suggesting that these two conditions might eventually evolve to fulfil the criteria for RA
(Stahl et al, 2000a), and has been demonstrated in synovium of 75% of RA patients and
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in 17% of patients with osteoarthritis (OA) (Saal et al., 1992). These findings indicated
a highly disease-related persistence of parvovirus B19 in the RA synovium.
In contrast, an examination of serum and tissue from patients with RA and OA, found
B19 DNA in synovium of 10 of 26 patients (-38%) with RA and 9 of 26 (-35%) with
OA, but the data were not considered strong enough to support the involvement of B19
in RA pathogenesis (Kerr et al., 1995b). A similar conclusion was drawn from a study
including 37 children with juvenile chronic arthritis (JCA) and 27 young healthy adults
undergoing joint surgery for trauma as controls (Soderlund et al., 1997b). Although B 19
DNA could not be detected in any synovial fluid, bone marrow or serum samples, it was
found in the synovial membrane of 8 of 29 patients (28%) with JCA and in 13 of 27
controls (48%). Finally, the presence of B19 DNA was reported more frequently in the
synovial membrane of patients with haemophilic arthritis (31%) in comparison to
control individuals with athrosis or joint trauma (5%) (Zakrzewska et al., 2001).
All these studies confirmed that B19 DNA might persist in synovium of both healthy
immunocompetent individuals and patients with arthritis of unknown origin, whereas it
rarely does in synovial fluid. Moreover, tissue was confirmed to be better than synovial
fluid for detecting B19 persistence (Soderlund et al., 1997b; Cassinotti et al., 1998).
Parvovirus was also found to persist 4n the bone marrow of asymptomatic individuals
and patients with suspected B19 infection (Cassinotti et al., 1997).
The involvement of B19 infection in JCA or juvenile rheumatoid arthritis (JRA) has
also been studied by several groups (Nocton et al., 1993; Kishore et al., 1998) who have
reported a link between B19 infection and JCA/JRA in 40% to 100% of patients. In
contrast, in another study, B19 DNA was infrequently detected in patients with early
RA (2 in 61 i.e. 3.3%) but not detected at all in patients with advanced RA (Nikkari et
al., 1995). Therefore, although these findings suggest that B19 does not play a
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significant role in the aetiopathogenesis of RA, it may cause, in a few cases, a disease
that is indistinguishable from RA. The presence of B19 DNA in bone marrow aspirates
from four chronic arthropathy patients months to years following acute B19 infection,
and in three patients with acute, but nonchronic, joint symptoms suggest that B19
arthropathy is associated with persistence of B19 virus (Foto et al., 1993).
However, it can be argued that the presence of B19 DNA in bone marrow and/or 
synovium of a symptomatic patient does not prove that the disease is caused by B19 and 
that in order to demonstrate the role of parvovirus in the pathogenesis of RA, metabolic 
products such as viral mRNA and proteins, as well as a B 19-specific immune response 
or inflammation should be demonstrated (Ishii et al., 1999; Soderlund-Venermo et al., 
2002). One of the strongest indications of a link between B19 and RA was described by 
Takahashi and coworkers, who detected B19 DNA in the synovial tissues of 30 of 39 
patients with RA (77%), OA (15%) and traumatic joint disorders (16%) (Takahashi et 
al., 1998). Most importantly, a recent study of the link between B19 and RA 
demonstrated, by in vivo experiments, the presence of B19 as well as the expression of 
VP1 in follicular dendritic cells, macrophages, T cells and B cells in RA synovium from 
patients with RA. These findings suggested that the virus was replicating and infectious 
and that B19 might be involved in the initiation and perpetuation of RA synovitis 
leading to joint lesions.
The last aspect investigated was the role the HLA type in acute and persistent arthritis. 
Some studies have shown the association of HLA-DR4 with acute and persistent 
arthritis (Klouda et al., 1986; Gendi et al., 1996) but no link between HLA-DR1 and 
persistent arthropathy (Woolf et al., 1989).
-  122 -
 Chapter I
The conclusion from all these studies is that there is no significant evidence to conclude
that B19 persistence alone is enough to cause chronic arthritis, RA or OA (Ytterberg,
1999; Moore, 2000; Lefrere et al., 1985a; Stierle et al., 1987). Further research might
give an answer to this controversial question of the role of B19 in chronic arthritis and
in RA in particular. Historical records reveal that RA is a relatively new disease in
Europe, only appearing after the return of explorers from the new world at the end of
the 15 century (Altschuler, 1999). In contrast, the disease existed in North America for
many thousands of years. El, which is known to be caused by parvovirus B19, was also
first described in the old world in 18th century (Van Elsacker-Niele and Anderson,
1987). Thus, B19 may have been introduced into Europe around the 16th century about
the same time as the appearance of RA (Altschuler, 1999).
Parvovirus B19 has also been suspected of being involved in the autoimmune
connective tissue disease called systemic lupus erythematosus (SLE), which is
characterised by auto-reactive cells and autoantibodies that can potentially affect all
organ systems, including the heart, lungs, skin, kidneys and central nervous system
(Severin et al., 2003). Several infectious agents, such as retroviruses (Herrmann et al.,
1996), EBV (James et al., 1997), and CMV (Rider et al., 1997) have also been
suspected of triggering the onset of SLE. However, the similarities between B19
infection and SLE are striking, making it sometimes difficult to differentiate between
them (Negro et al., 2001; Trapani et al., 1999; Moore et al., 1999; Nesher et al., 1995).
Other reports have demonstrated a link between B19 infection and SLE (Fawaz-Estrup,
1996) and connective tissue disease (Crowson et al., 2000). Studies on SLE patients
demonstrated that B19 DNA was detected more commonly in sera from SLE patients
without specific-B19 antibodies than in those with antibodies, suggesting that B19
infection in SLE patients might be due to a lack of anti-B19 antibodies, either because
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of the immunocompromised state of the host, or the use of immunosuppressive drugs
(Hsu and Tsay, 2001). In contrast, a Swedish study concluded that while the possibility
that B19 might be a trigger of SLE in a minor proportion of SLE patients, in the general
population, B19 is unlikely to be the aetiologic agent in SLE (Bengtsson et al., 2000). In
conclusion, although these findings seem to indicate that parvovirus B19 may be
involved in pathogenesis or expression of SLE, there are no clear causative associations
to date (Severin et al., 2003). No link between B19 and another autoimmune disease,
dermatomyositis, which is characterised by inflammatory myopathy, has been
demonstrated, either by the detection of B19 DNA in muscle biopsies or the expression
of VP1 and VP2 capsid proteins by immunohistochemistry (Chevrel et al., 2003).
To conclude, it is important to consider the diagnosis of coincidental parvovirus B19 in 
patients with pre-existing rheumatic diseases where there are unusual features, e.g. 
Behqef s disease, which is characterised by arthralgia, mouth, nasal and genital ulcers, 
conjunctivitis and facial swelling (Longhurst et al., 2001).
I.I.6.5. B19 infection during pregnancy and hydrops fetalis
The classical definition of hydrops fetalis is “the presence of excessive fluid
accumulation in at least two fetal serous cavities” (Forouzan, 1997). An example of one
of these cavities is the amniotic sac. Hydrops fetalis is the final stage of a highly morbid
condition, caused by many different fetal, placental, and maternal diseases. Although
the condition was described more than 300 years ago, only recent advances have
allowed the differentiation of the various aetiologies involved. Hydrops fetalis can be
classified either as immune or nonimmune (White, 1999). The former results from a
rhesus incompatibility between the mother and fetus that result in maternal antibodies
against the fetal red blood cell antigens crossing through the placenta and causing
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severe fetal anaemia. On the other hand, nonimmune hydrops can have many different
causes. One of them can be haematological disorders causing fetal anaemia. A number
of infections including syphilis, toxoplasmosis, coxsackievirus, herpes simplex virus
(HSV), respiratory syncytial virus (RSV), rubella and CMV have also been associated
with this condition (Forouzan, 1997).
Numerous studies have demonstrated a convincing causal link between intrauterine fetal 
infection by parvovirus B19 and nonimmune hydrops fetalis. One of the first 
publications reported a case of intrauterine B19 infection associated with hydrops fetalis 
during an outbreak of El (Brown et al., 1984). Postmortem examination revealed 
generalised subcutaneous oedema with serous effusions in the pleural, pericardial and 
peritoneal cavities. Shortly after, a case of intrauterine fetal death (IUFD) at term with 
serological evidence of recent B19 infection was reported (Knott et al., 1984). A study 
in Germany looked at 2,279 pregnant women between 1985 and 1988 and found 54% 
with only anti-B19 IgG antibodies and 5% with both IgG and IgM antibodies, indicating 
an acute infection (Enders and Biber, 1990). Of these acute infections, 32% (36 of 114) 
were from women in the first, 54% (62 of 114) in the second and 14% (16 of 114) in the 
third trimester. The rate of hydrops fetalis was 8.7% while the rate of fetal death was 
7.8%. Seroprevalence of anti-B19 IgG antibodies amongst pregnant women was 30% in 
Singapore (Wong et al., 2000) whereas it was 64% in Melbourne, Australia 
(Karunajeewa et al., 2001). The seroprevalence of anti-B19 IgG and IgM antibodies 
was investigated in pregnant women in Kuwait and found to be 53.3% and 2.2%, 
respectively (Makhseed et al., 1999). Moreover, the rate of fetal loss was 15.4% in 
women with acute infection, all of which occurred in the first two trimesters. This rate 
was significantly higher than other studies (Enders and Biber, 1990; Miller et al., 1998) 
possibly because of the difference in the size of the cohorts studied. Studies have
-  125 -
 Chapter I
confirmed that fetal loss, with or without nonimmune hydrops, was confined to B19
infection in the first 20 weeks of gestation (Miller et al., 1998; Nunoue et al., 2002).
A prospective study of women experiencing third-trimester IUFD showed that 7.5% had 
detectable B19 DNA in freshly frozen placental tissue, suggesting that B 19 PCR should 
be included in the routine investigation of IUFD, like it is with hydrops fetalis 
(Skjoldebrand-Sparre et al., 2000). In a similar study during a nonepidemic period in 
Sweden, B19 was detected in 3% of placental tissues from first-trimester fetal losses but 
in 12% from second-trimester (Nyman et al., 2002). None of the placental tissues from 
full-term normal pregnancies were DNA positive. Another Swedish survey confirmed 
that the presence of B19 DNA in cases of late second-trimester fetal death is common 
(15%) and that most cases are non-hydropic (Tolfvenstam et al., 2001b). The authors 
reached the same conclusion for third-trimester fetal losses, which contradicts other 
findings (Nyman et al., 2002) which suggest that the reduced rate of fetal loss during 
the third trimester seems to be due to the ability of the fetus to mount an immune 
response to the virus (Brown, 1989).
There are conflicting reports on the link between B19 infection and late intrauterine
death in non-hydropic fetuses (Tolfvenstam et al., 2001b; Sebire, 2001; Crowley et al.,
2001). Overall, B19 is not considered as a notable cause of late intrauterine death in
non-hydropic fetuses as PCR detection of B19 DNA in placenta may be due to such
specimens containing maternal blood, which may still be viraemic, even after resolution
of B19 infection rather than fetal infection. Thus conventional techniques, including
serological testing of maternal serum and immunohistochemical staining of fetal tissues
are necessary to confirm diagnosis of B19 in IUFD. ISH and PCR of fetal tissues
(including heart, lung, brain and thymus) have been used to confirm B19 infection in
cases of IUFD (Salimans et al., 1989b; Lowen and Weinstein, 1997). Studies on
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hydropic fetuses have described numerous features including viral intranuclear
inclusions in bone marrow and blood cells (Burton, 1986), erythroid precursor cells
from most fetal tissues tested, including lung, liver, heart, kidney, thymus, spleen,
pancreas, intestine, diaphragm, brain and rib and bone marrow (Morey et al., 1992),
lesions in the central nervous system and in the liver (Garcia et al., 1998),
multinucleated giant cells of macrophage/microglia lineage as well as many small
calcifications around the vessels, especially in the cerebral white matter (Isumi et al.,
1999). Finally, histologic examination of hydropic fetal tissues sometimes have shown
changes in all organs, particularly the liver, where many hepatocyte nuclei showed
degeneration, and signs of apoptosis with peripheral condensation of chromatin in many
erythroid cells, despite the absence of intranuclear inclusions (Anand et al., 1987).
Thus, it is important to screen and identify all pregnant women who may have been
exposed to B19 infection (Kelly et al., 1999). In Great Britain, recent guidelines on
management of parvovirus B19 and other rash illnesses in pregnancy have been
compiled by the former Public Health Laboratory Services (PHLS), now known as the
Health Protection Agency (HP A) (Morgan-Capner et al., 2002). These
recommendations include screening all pregnant women with a non-vesicular rash
illness simultaneously for rubella and parvovirus B19 infection and all pregnant women
who have had significant contact with a person suffering from a non-vesicular illness
for asymptomatic parvovirus B19 infection, a significant contact being defined as
“being in the same room for over 15 minutes, or face-to-face contact” (Morgan-Capner
et al., 2002). As for women with proven parvovirus B19 infection in the first 20 weeks
of pregnancy, they “should be followed by regular ultrasound scanning, and referred to
regional units of fetal medicine if hydrops fetalis is detected” (Morgan-Capner et al.,
2002). Different management of B19 infection in pregnancy can lead to different
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outcomes in cases of hydropsis. Two options are available: either diagnostic
cordocentesis and intrauterine transfusion or management of the case expectantly,
although the latter option presents the highest risk of fetal death (Xu et al., 2003). In
some cases, spontaneous resolution of hydropsis occurs without the need of transfusion
(Petrikovsky et al., 1996). A useful marker in B19 infections is maternal serum alpha-
fetoprotein (MsAFP) levels which have been shown to be elevated in several women
who subsequently aborted B19-infected fetuses (Anderson and Hurwitz, 1988;
Carrington et al., 1987). Monitoring of this marker can also be useful for detecting
abnormalities at least four weeks before detection by ultrasound. Such abnormalities
include placentomegaly, myocarditis, and generalised subcutaneous oedema greater
than 5mm and ascites, pleural and pericardia effusion (Suchet et al., 2000). For those
fetuses that make a spontaneous recovery, as well as for those, less fortunate, who
develop hydrops fetalis, no signs of any structural fetal anomaly have been observed,
either antenatally, at birth or post-mortem nor any serological evidence of persistent
infection after matemofetal B19 infection (Suchet et al., 2000; Miller et al., 1998;
Dembinski et al., 2003).
In addition to the risks for the fetus, B19 infection can also affect the pregnant woman, 
who might experience complications. The first factor that comes to mind is 
psychological, since the irregular fetal heart rate pattern and the condition of the fetus in 
general can often lead to stress for the mother-to-be. Other complications include 
maternal anaemia, pregnancy-induced hypertension, antepartum hemorrhage but also 
malpresentation of the fetus at the time of birth, difficult vaginal delivery, leading to a 
higher caesarean delivery rate in those women and prematurity (Forouzan, 1997). 
However, no link has been demonstrated between B19 infection of the fetus (with no 
signs of maternal B19 infection and hydropsis fetalis) and premature birth (Koga et al.,
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2001), but this conclusion is only based on a small scale study and further investigations
are necessary using an appropriate control cohort.
I.I.6.6. Involvement of other organs
I.I.6.6.I. Liver
When there is no evidence of the involvement of the five major hepatitis viruses (A, B, 
C, D and E), the nature of the agent that causes acute fulminant liver failure (AFLF) has 
been unclear and controversial. Cases of hepatitis of unknown aetiology are often 
associated with aplasia (Pol et al., 1993; Oriol et al., 1994; Cattral et al., 1994), which is 
itself commonly caused by parvovirus B19 infection. Studies have shown that aplastic 
anaemia is a common complication among children undergoing transplantation for 
AFLF (Cattral et al., 1994) and have identified B19 DNA in native livers of several 
patients with cryptogenic FLF and undergoing such transplantation who did not have 
associated aplastic anaemia (Langnas et al. 1995; Sokal et al., 1998). In addition, 
several groups have reported acute viral hepatitis of unknown origin associated with 
B19 infection, suggesting that testing for B19 infection in non-A, non-B, non-C 
hepatitis is as relevant as testing for EBV and CMV (Yoto et al., 1996a; Naides et al., 
1996; Hillingsp et al., 1998). However, detecting viral DNA in the liver tissue of 
patients with fulminant hepatitis is not sufficient to demonstrate active viral infection. 
Using a specific and sensitive immune adherence PCR (IA-PCR) assay in which B19 
viral particles were captured by monoclonal antibodies on solid phase before PCR 
amplification, the presence of full virions was thus demonstrated in 83% of livers from 
patients with non-A to E AFLF associated with aplasia and in 75% without aplasia, 
compared to 17% from patients with AFLF of known aetiology and 18% of controls 
with chronic or neoplastic liver disease (Karetnyi et al., 1999). Moreover, mRNA for
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B19 structural proteins was detected in the tissues of IA-PCR positive livers, suggesting
replication of the virus and providing evidence for B19 involvement in liver damage.
B19 DNA has also been detected frequently in adults with severe liver damage.
However, B19 DNA has also been detected in livers from anti-B19 IgG positive
patients without hepatic disease suggesting that B19 DNA might persist in the liver but
further research is needed to confirm this hypothesis (Eis-Hubinger et al., 2001).
Other studies have reported hepatitis in a patient with B19 infection who also developed
myositis and life-threatening interstitial lung disease (ILD) (Bousvaros et al., 1998) and
a renal transplant recipient who developed fibrosing cholestatic hepatitis (FCH),
possibly related to a persistent B19 infection (Shan et al., 2001). Following
immunosuppressive therapy, a persistent and increased viral replication would indeed
further aggravate an aplastic anaemia and a hepatic failure secondary to FCH.
Parvovirus B19 DNA was detected in liver tissue and B19 particles accumulated in the
cytoplasm of enlarged hepatocytes. In contrast, no evidence has been reported to link
B19 to “cryptogenic” chronic hepatitis (Arista et al., 2003).
I.I.6.6.2. Lungs
Reports of lung disease associated with B19 infection in humans are few. B 19-specific 
IgM antibodies have been detected in 21 young children with prolonged obstructive 
respiratory diseases, including bronchitis, bronchiolitis, laryngitis and acute asthmatic 
attacks in those known to be suffering from bronchial asthma (Wiesrbitzky et al., 1991), 
while a possible association with B19 in an immunodepressed patient with pneumonia 
has been described (Zerbini et al., 1992). ILD was reported in a patient who showed a 
prolonged and severe illness but no clinical or laboratory evidence of underlying 
immunodeficiency but with confirmed serological and PCR data on B19 infection at the
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time of onset of illness (Bousvaros et al., 1998). In this case, the systemic persistence of
B19 in the blood and lungs and the simultaneous development of ILD are unlikely to be
coincidental. It is thus possible that the lung damage was indirectly caused by B19
infection, perhaps through the host immune response. In addition to ILD, it has been
proposed that B19 is associated with acute chest syndrome (ACS), a major source of
mortality among sickle cell disease (Lowenthal et al., 1996; Wierenga et al., 2001).
This condition is characterised by the presence of pleuritic chest pain, fever, rales on
lung auscultation and pulmonary infiltrates on chest X-ray. However, further research is
necessary to establish an etiologic role of B19 in ACS.
1.1.6.6.3. Heart
Among the numerous complications following B19 infection are acute myocarditis and 
congenital heart disease (Saint-Martin et al, 1990; Borreda et al., 1992; Tsuda et al., 
1994; Heegaard et al., 1998; Enders et al., 1998). In these cases, B19 structural proteins 
were detected by immunocytochemistry on myocardial tissue sections, or B19 DNA 
was detected in the myocardial cells, or specific IgM antibodies were present, indicating 
an acute B19 infection. These cases include the first, and as yet only, case of 
myopericarditis due to parvovirus 6 months after acute B19 infection (Chia and 
Jackson, 1996). Studies have shown that B19 might be another cause of heart failure 
and should thus be considered in similar cases (Malm et al., 1993) and may also be 
involved in congenital heart disease (Wang et al., 2000).
1.1.6.6.4. Kidneys
Very little is known about the renal involvement caused by B19 infection. Several
studies have investigated the link between B19 and focal and segmental
glomerulosclerosis (FSGS) (Markenson et al., 1978; Tanawattanacharoen et al., 2000)
- 131 -
 Chapter I
and glomerulonephritis with proteinuria following aplastic crisis caused by parvovirus
B19 in patients with homozygous sickle cell disease (Wierenga et al., 1995). However,
in one of the studies on FSGS patients, although B19 DNA could be detected in these
patients, ISH studies failed to detect B19 DNA in any of the kidney tissue samples,
implying the lack of ongoing, high-level viral replication. These findings indicated that
kidneys might be a frequent reservoir of latent parvovirus B19 DNA but did not
establish a definitive role for that DNA. However, certain individuals with FSGS might
have active, perhaps transient, infection. B19 infection has also been associated with El
and/or arthropathy with transient urinary abnormalities and (Takeda et al., 2001), El
associated with nephritic syndrome (Ohtomo et al., 2003) and nephritic syndrome with
renal impairment and (one with transient acute renal failure) in patients with sickle cell
disease (Wierenga et al., 2001). Finally, persistent infection linked to renal involvement
resulting in glomerulopathy was demonstrated in immunosuppressed patients, including
renal transplant recipients (Moudgil et al., 1997). Although the acute or persistent B19
infection preceding renal involvement tends to point to a possible causal link, the
precise mechanism of pathogenesis is still unclear because of the failure to demonstrate
viral antigen in the kidney using immunohistochemical techniques.
I.I.6.6.5. Central nervous system
Encephalitis meningitis and acute cerebellar ataxia are rare complications of El in 
children (Balfour et al., 1970; Okumura and Ichikawa, 1993; Shimizu et al., 1999). 
There have been reports of direct invasion of B19 into the central nervous system 
(CNS) in a case of aseptic meningitis, in which B19 DNA, IgM and IgG antibodies 
were detectable in cerebrospinal fluid (CSF) (Okumura and Ichikawa, 1993). Moreover, 
B19 DNA was detected in the CSF of 7 of 162 patients (4.3%) with
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meningoencephalitis, suggesting that B19 infection should be included in the
differential diagnosis of this condition during the neonatal period, childhood and
adolescence (Barah et al., 2001) and in a paediatric case presenting with unexplained
neurological illness (Yoto et al., 1994). In contrast, B19 DNA could only be detected in
the serum and not in the CSF of a 2-year-old boy with acute cerebellar ataxia (Shimizu
et al., 1999) suggesting that the mechanism for acute cerebellar ataxia might not involve
direct viral invasion but could be caused by a transient vascular reaction in the
cerebellum during B19 infection.
Parvovirus B19 infection of the fetus has already been shown to be associated with 
lesions in the central nervous system (Garcia et al., 1998). In a retrospective study of 
aplastic crises in Jamaican patients with sickle cell disease, ten patients had 
cerebrovascular complications in temporal association with B19 infection and presented 
with haemiplegia, seizures and encephalitis, which might be related to B 19-specific 
immune complexes (Wierenga et al., 2001). Adult cases of B19-associated CNS 
infections are also few. There have been reports of B19 infection (persisting for up to 
nine months) in the blood and in CSF of an immunocompetent patient following an 
acute infection with meningitis (Cassinotti et al., 1993b), in the CSF of a patient with 
malignant lymphoma who developed encephalitis and later died (Heegaard et al., 1995) 
and in an immunocompetent patient who developed encephalitis complicated by 
prolonged status epilepticus (Skaff and Labiner, 2001). The possibility that a different 
B19 genotype may be associated with encephalopathy requires further confirmation 
(Umene and Nunoue, 1995).
B19 has also been shown to be the causative agent in a patient with neuralgic 
amyotrophy (Pellas et al., 1993) and to result in a more severe meningoencephalitis in a 
patient with a cocomitant mumps infection (Yazawa et al., 2002). Finally, a study of
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autistic children did not support a link between infantile autism and B19 (Anlar et al.,
1994). Tables 1.4, 1.5 and 1.6 show a summary of the clinical manifestations following
B19 infection, those thought to be linked to B19 infection and those unlikely to be
caused by B19.
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1.1.6.7. Pathogenesis
The clinical outcome of human parvovirus B19 infection involves three major 
pathogenic components: the cytopathic effect of the virus on susceptible and dividing 
cells, the humoral immune response and the result of antibody deficiency (Cherry,
1999). Although each potential pathogenic system will be discussed separately, the 
pathogenesis of B19 virus is complex and often involves a combination of these 
mechanisms.
The onset of viraemia occurs six days after infection and is associated with infection of 
erythrocytes in the bone marrow after attachment to these cells through the receptor 
(Brown et al., 1993). The local replication is one of the first pathogenic mechanisms in 
several conditions, including El, TAC, bone marrow failure, congenital red cell aplasia, 
vasculitis and hepatitis (Kerr, 2000). The reticulocytopenia observed in most patients is 
caused by the cytopathogenic effect of the virus on erythroid progenitors. Although this 
temporary phenomenon goes unnoticed in otherwise healthy children and adults, it can 
lead to TAC in those with underlying haemolytic disorders, or to PRCA in those unable 
to mount an immune response to the virus. Additionally, the massive destruction of the 
erythroid lineage cells through apoptosis leads to severe anaemia and results in heart 
failure of the infected fetus, and eventually to hydrops fetalis (Cherry, 1999; Yaegashi,
2000). However, in order to understand the potential risks involved in transplacental 
infection, it is important to establish which cell types in the developing fetus are 
susceptible to viral attack. Reports have shown the presence of viral non-structural gene 
products in the liver, lung and, to a smaller extent, other tissues (e.g. spleen) in the 
infected fetus (Cotmore et al., 1986). These findings are suggestive of an active viral 
replication in at least one cell type in these tissues. Fetal liver contains islands of 
haematopoitic tissue, which are likely to contain susceptible cells. B19 can thus
- 138 -
 Chapter I
presumably bind to the cell surface and penetrate liver cells not only in the fetus but
also in the adult.
Similarly, replication in the lung tissue is not unexpected, since it is highly probable that 
B19 is transmitted as an infection of the respiratory tract (Anderson et al., 1985a) and 
that it therefore replicates in at least one cell type present therein. It is likely that B19 
can bind to other glycosphingolipids located in liver, kidney and bowel tissues, but not 
in lung (Cooling et al., 1995). In comparison with the adult tissue, many more cell types 
are undergoing cell division in the fetus. Therefore, although B19 is mainly 
haematotropic in adults, it might have a more extensive tissue tropism in the fetus, 
thereby causing more damage to the fetal tissues and organs (Cotmore et al., 1986). The 
destruction of erythrocytes can also lead to excess production of red blood cells by the 
fetus which tries to compensate for the loss, leading to hepato-splenomegaly (Garcia et 
al., 1998). The direct infection of hepatocytes has been implicated in cases with severe 
liver disease (Morey et al., 1992). Such severe necrosis may lead to decreased 
production of albumin with lowered plasma oncotic pressure (Suchet et al., 2000). This, 
associated with severe anaemia, can produce oedema and thereby contribute to high 
cardiac output failure. In third-trimester fetuses, it seems that cardiac decompensation is 
the main determining factor affecting the survival of the fetus. However, the majority of 
reported fetal deaths appears to be in the second trimester, as the fetus is at greatest risk 
of hydrops because of the rapid increase in fetal red cell mass at that time of gestation. 
Since in situ hybridisation located B19 gene in the nucleus of cardiac cells of CHD 
sufferers, it might influence gene expression and thereby affect the development of the 
heart, which could result in CHD (Wang et al., 2000). The cytopathic effect might 
involve the cytotoxicity of NS-1 protein (Ozawa et al., 1988a) as well as its ability to 
upregulate cytokine production. Using a transgenic mouse model for nonimmune
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hydrops fetalis induced by the NS-1 gene of B19, it has been demonstrated that the
nonstructural protein plays a crucial role in the cytotoxocity and the outcome of
intrauterine B19 infection (Chisaka et a l, 2002).
Previously, the involvement of NS-1 protein in apoptosis had been controversial. The 
initiation of cell death was observed to occur 24 hours after the induction of NS-1, 
suggesting that the nonstructural protein might mediate the apoptosis of the erythroid 
cell lines used in this study (Yaegashi, 2000). Apoptosis was characterised by cell 
rounding, chromatin condensation and DNA fragmentation. However, other studies 
could not find any correlation between the presence of anti-NS-1 antibodies in pregnant 
women and the occurrence of fetal complications (Searle et al., 1998). As for 
upregulation of cytokine production, NS-1 protein has been shown to induce activation 
of IL-6 gene expression, which supports the possible relationship between B19 infection 
and polyclonal activation of B-cells in RA (Moffatt et al., 1996). In addition, in vitro 
infectivity experiments, have shown that susceptible cell lines (tonsillar cells and 
macrophages) became infected when cocultured with RA synovial cells, but not OA 
synovium (Takahashi et al., 1998). Coculture generated not only the expression of VP1, 
but also an enhanced production of IL-6 and TNF-a that was significantly inhibited by 
the induction of neutralising antibodies for B19. Therefore, it appears that B 19-positive 
T cells and macrophages might infiltrate into the synovium and recruit circulating 
immunocytes. Synovial T cells and macrophages, continuously activated by B19, 
secrete inflammatory cytokines, such as TNF-a and IL-6, to stimulate a variety of 
synovial cells via the autocrine and paracrine network of cytokines. This leads to an 
excessive production of cytokines and proteolytic enzymes resulting in persistent 
inflammation and tissue destruction, including cartilage, joints and bone erosion (Ishii et 
al., 1999).
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Additionally, both TNF-a and NS1 have been involved in apoptosis of erythroid cells
leading to reticulocytopenia (Moffatt et al., 1998; Sol et al., 1999). An increase in TNF-
a  has been described in an adult patient presenting with VAHS and myocarditis, as well
as an increase in macrophage-colony stimulating factor (M-CSF) and granulocyte-
colony stimulating factor (G-CSF) (Tsuda et al., 1994). This patient had neutrophilia
rather than the expected neutropenia and it was proposed that B19 might induce the
production of M-CSF, which could in turn activate monocytes and macrophages to
proliferate into abnormal haemophagocytes and to produce G-CSF and TNF-a (Tsuda
et al., 1994). Due to the disrupted release of G-CSF, mobilisation of neutrophils might
have overcome the cell destruction.
Several mechanisms have been proposed regarding the implication of B19 in the 
pathogenesis of liver damage and hepatitis. Mutations identified in the NS1 gene might 
generate variant B19 virus with hepatotoxic NS1 that would result in apoptosis of 
hepatocytes (Naides et al., 1996). Alternatively, B19 might have a direct effect on 
hepatocytes and the action of various cytokines (including IFN-y) might result in liver 
dysfunction via immunological mediation (Yoto et al., 1996a; Yoto et al., 1996b).
The usual manifestations of primary B19 infection are El in children and arthralgia in 
adults, both starting about 17 days after infection when the viraemia has cleared 
(Anderson et al., 1985b). In patients with B19-associated arthritis, low serum 
complement levels and circulating immune complexes are found (White et al., 1985). 
Moreover, a study in Spain, involving 43 patients diagnosed with B19 infection 
resulting in various clinical outcomes, revealed that 81.6% of cases had detectable 
circulating immune complexes (Garcfa-Tapia et al., 1995). Taken together, these 
findings tend to confirm that immune-mediated pathogenesis, in the form of deposition
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of immune complexes, is involved. Such a mechanism was also found in mink affected
with Aleutian disease as anti-B19 IgA-B19 antigen complexes deposited in renal
glomeruli (Portis and Coe, 1979). In humans, the occasional renal involvement in B19
infection was discussed previously. Although it has been suggested that B19 could bind
to and penetrate some kidney cells, it is more plausible that the renal lesions observed in
some studies might be caused by an immune complex-mediated phenomenon which is
closely related to B19 infection in the host (Cooling et al., 1995; Takeda et al., 2001).
Such immune complex deposits were indeed recently found in the renal biopsy of an 8-
year-old child who developed nephritic syndrome during the course of El due to
parvovirus B19 (Ohtomo et al., 2003).
Serum antinuclear antibodies (ANA) have been described in several patients with acute
polyarthritis caused by B19 (Cobeta-Garcfa and Rodilla, 2000). Three months later, the
clinical symptoms had completely resolved, anti-B19 IgG antibodies were positive and
IgM antibodies and ANA were undetectable. Whether these ANA play a role in the
pathogenesis is still unclear. Several patients infected with B19 and suffering from
chronic symmetric polyarthritis resembling RA have also been shown to produce
autoantibodies (Lunardi et al., 1998). Patients had symptoms and IgM antibodies to B19
for 4 months to 2 years. Cross-reactivity of these anti-B19 antibodies with a variety of
antigens including keratin, collagen type II, single-stranded DNA and cardiolipin have
been demonstrated. These findings were later confirmed by a study showing the
production of anti-cardiolipin as well as anti-neutrophil cytoplasmic antibodies in
patients with El and polyarthralgia, polyarthritis and mild fever (Chou et al., 2000)
suggestive of molecular mimicry or epitope spreading, and a link of B19 to the
induction of an autoimmune response that could perhaps lead to the development of
some SLE cases. However, it is still not clear why antibodies would cross-react with
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such a wide range of autoantigens (Ytterberg, 1999). Other studies have confirmed that
a number of mechanisms might be involved in the induction of autoimmune disease by
B19, including the molecular mimicry mentioned above and the induction of enhanced
cytokine production via the NS1 protein (Lehmann et al., 2002).
One of the mechanisms that could trigger the production of anti-phospholipid (aPL) 
antibodies, found in paediatric and adult patients with rheumatic disease, might be the 
phospholipase A2-like activity associated with the carboxy-terminal domain of the VP1 
unique region (Zadori et al., 2001; Lehmann et al., 2002; Dorsch et al., 2002). The 
latter mechanism has been supported by the fact that aPL antibodies are frequently 
found in serum of children with juvenile idiopathic arthritis previously infected by B19 
and presenting a persistent infection (von Landenberg et al., 2003). Moreover, adult 
patients with aPL antibodies also appear to have a high incidence of persistent B19 
infection, indicating that parvovirus might be directly implicated in the development of 
autoimmune responses via aPL.
The implication of NS 1 in cytotoxicity was recently proposed in the case of a patient
with mixed connective tissue disease and arthralgia (Kerr and Behan, 2002). Although
the patient was weakly positive for ANA, she did not develop any other autoantibodies
and parvovirus B19 DNA was detected in the skeletal muscle. The NS1 gene had a high
mutation rate (3.52%) compared to the wild type (<1%). All ten mutations were silent
except one immediately downstream of the NTP binding site. Such a mutation might
facilitate persistence of the virus by modifying cytotoxicity (Kerr and Behan, 2002). In
contrast, the viral coding regions of B19 DNA found in the synovial tissue of both
persistently and recently infected patients were in an apparently continuous, intact DNA
molecule (Hokynar et al., 2000). Thus, these findings suggest that persistence of B19
virus does not seem to be due to exceptional mutations or particular variants. Although
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NS1 protein might be involved in cytotoxicity, no correlation was found between the
presence of NS1-specific antibodies and the development of acute or chronic
arthropathy (Mitchell et al., 2001).
An altered immune function, such as the B-cell defects observed in 
immunocompromised patients, can also play a role in the pathogenesis of B19 virus. 
Such patients are indeed unable to produce effective neutralising antibodies, resulting in 
persistence of B19 in the host (Frickhofen and Young, 1989; Broliden et al., 1998).
As far as the vascular events are concerned, strokes are known to occur in sickle cell 
disease patients (Wierenga et al., 2001). They are commonly associated with blockage 
of major vessels, which is unexpected in such a condition characterised by occlusion of 
small vessels. A simultaneous B19-induced aplastic crisis would result in lowered 
haemoglobin levels, thereby reducing oxygen delivery to areas already rendered 
vulnerable by pre-existing vascular disease. However, this is only hypothetical and the 
pathogenesis of B19 in such vascular complications is still unclear.
In conclusion, the importance of each mechanism of pathogenesis in the clinical 
outcome varies depending on the virus/host interaction and thus on the host’s immune 
status. More research is still needed to characterise further the role of B19 in this wide 
clinical outcome.
1.1.7. Treatment, vaccine and animal models
I.I.7.I. Treatment
The two main ways used to treat symptomatic B19 infection are RBCs transfusions and 
intravenous immunglobulin (IVIG).
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I.I.7.I.I. Transfusions
Regular transfusions of erythrocytes were reported for a 12-month-old girl with severe
combined immunodeficiency (Gahr et al., 1991). These transfusions were usually
necessary every 2 months and resulted in short periods with normal reticulocyte counts.
However, a full and stable recovery of erythropoiesis was never achieved in this case
and she died at the age of 4 before bone marrow transplantation could be done.
Successful intrauterine treatment of two cases of fetal hydrops caused by B19 has been
reported (Gloning et al., 1990). Signs of hydrops disappeared after intrauterine
transfusions and the infants were bom healthy and developed normally. It is first
recommended to perform fetal blood sampling to test for blood grouping, anaemia, viral
infections, toxoplasmosis, bleeding disorders, severe combined immunodeficiencies and
also for a rapid karyotyping in some conditions. In case of fetal anaemia, intrauterine
intravascular transfusion can be used as therapy. The role of intrauterine transfusion for
fetal hydrops arising from maternal parvovirus B19 infection has been investigated by
following the progress of 38 hydropic fetuses in England and Wales between 1992 and
1994 (Fairley et al., 1995). At the first abnormal scan, 12 of 38 received intrauterine
transfusions and 3 (25%) died, whereas the other 26 fetuses did not receive any
transfusion and 13 (50%) died. Even when taking into account the severity of the
hydrops and gestational age, there was a significantly higher risk of fetal loss for those
who had not received intrauterine transfusion, thereby emphasising the benefits of such
treatment for some fetuses. Intrauterine transfusion can be performed at the first signs of
hydrops fetalis. This therapeutic intervention, however, should be restricted only to
specialised centres and only be considered in intact pregnancies. An informed consent
of the parents should be mandatory. Moreover, it seems that an active treatment
consisting of a combination of pre- and postnatal transfusions and IVIG can be
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beneficial to correct severe hydrops fetalis and subsequent congenital anaemia
(Heegaard et al., 2000).
Ll.7.1.2. Intravenous immunoglobulins (IVIG)
Although functional T lymphocytes are required for recognition and final clearance of
parvovirus, the very dramatic correction of anaemia with IVIG therapy is itself
convincing evidence that antibody is the principal defence in human parvovirus disease
(Kurtzman et al., 1989b). A course of commercial Ig preparations is indicated in
patients with anemia and parvoviraemia and also for those with documented persistent
B19 infection. A drastic decline in viral concentrations in the blood within hours of
administration is observed, followed by prompt reticulocytosis and return to normal or
near-normal levels (Frickhofen et al., 1990). Intravenous treatment with Ig, at a dose of
0.4g/kg body weight over 5 days, resulted in marked improvement in several patients
suffering from chronic undifferentiated non- and oligoarthritis (Stahl et al., 2000b).
Currently, HIV-positive patients are treated with the same dose as previously mentioned
(Frickhofen et al., 1990). Patients should be monitored for evidence of relapse, by
observation of the reticulocyte counts, and assays for B19 viraemia when indicated
(Brown, 2000). This applies especially if zidovudine treatment complicates the
interpretation of reticulocyte counts (Frickhofen et al., 1990). Relapses may occur early
in patients with more advanced disease. Most patients with CD4 counts lower or equal
to 80 cells/mm3 suffer from relapse within 6 months, necessitating retreatment with
IVIG, whereas patients with CD4 counts greater than 300 cells/mm3 do not require
routine maintenance therapy (Koduri et al., 1999). If a relapse occurs less than 6 months
after the initial treatment, an empiric maintenance treatment with a single-day infusion
of 0.94 g/kg IgG every 4 weeks should be applied (Frickhofen et al., 1990). Persistent
erythroid aplasia caused by B19 in patients with other forms of immunodeficiency, such
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as common variable immunodeficiency, can be treated with low-dose (50mg/kg for 6
days) Ig (Chuhjo et al., 1999). Transplant recipients presenting PRC A or severe
anaemia usually respond well to a high-dose treatment (Holman et al., 1997; Moudgil et
al., 1997; Mathias, 1997; Marchand et al., 1999; Pamidi et al., 2000). In addition,
reduction in immunosuppression may also be helpful as an approach to treat this
infection in such patients (Pamidi et al., 2000). A course of IVIG, along with isolation
measures, also seems to contribute in preventing B19 infection in bone marrow
transplant recipients (Azzi et al., 1993). Additionally, high-dose IVIG has been used to
treat patients with acute or chronic ITP, autoimmune neutropenia and autoimmune
haemolytic anaemia (Berkman et al., 1988).
However, the mechanism of action of high-dose Ig therapy is unclear and has been the 
subject of speculation. Many effects of IVIG on the function of the immune system 
have been proposed, including blockade of Fc receptors (Fehr et al., 1982), decreased 
Fc-receptor-mediated phagocytosis (Kimberly et al., 1984), enhancement of suppressor 
T-cell function (Delfraissy et al., 1985), depression of natural killer cells activity 
(Engelhard et al., 1986) and lowering of autoantibody titres through idiotypic/anti- 
idiotypic interactions (Sultan et al., 1984). McGuire and colleagues have supported the 
latter therapeutic mechanism since they found that both the F(ab’)2 fragment of IgG and 
the whole intravenous gamma globulin preparation, but not an Fc fragment of IgG, were 
capable of neutralising the cytotoxic action of the patient’s IgG fraction (McGuire et al., 
1987).
I.I.7.2. Vaccine
Treatment by blood transfusion, Ig or intrauterine transfusion is efficient in controlling 
human parvovirus B19 infection. However, prevention being better than treatment,
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research has been undertaken to develop a safe and effective vaccine. Vaccines against a
number of animal parvoviruses, such as PPV (Mengeling et al., 1979; Pye et al., 1990),
CPV (Eugster, 1980) and FPV (Davis et al., 1970; King and Gutekunst, 1970) have
already been developed using live attenuated or killed viruses. As far as parvovirus B19
is concerned, development of a vaccine for B19 has been hampered by the limited
availability of viral antigen. Firstly, it is complicated to identify a viraemic patient,
since viraemia usually resolves before clinical symptoms of B19 virus infection appear.
Secondly, when a viraemic individual has been identified, it is difficult to obtain
sufficient quantities of virus. Cell culture production of B19 virus would be an
alternative but has not yet been possible with the currently available cell lines.
However, even if sufficient quantities of live virus could be obtained, there are safety
issues associated to its use in a vaccine, such as the possibility of contamination with
other viruses.
Finally, extensive investment in research is needed to either attenuate or inactivate such 
live viruses (Collett and Young, 1994). These limitations, however, have been 
overcome with the development of genetically engineered expression systems for the 
production of B19 parvovirus antigens. These expression systems allow for the efficient 
production of unlimited quantities of safe, non-infectious B19 virus antigen and thus 
offer an opportunity for the development of a B19 parvovirus vaccine. Bacterial 
expression was used by various groups, who inserted into Escherichia coli some 
plasmids with portions of the viral capsid protein sequences fused to other proteins such 
as (3-galactosidase or protein A (Sisk and Berman, 1987; Rayment et al., 1990; Morinet 
et al., 1989; Rosenfeld et al., 1992). Although large amounts of recombinant protein 
were produced in bacteria, they lacked the native conformation of B19 virion.
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The first eukaryotic expression system to produce complete native B19 capsids was a
mammalian cell line engineered from Chinese hamster ovary cells and designated 3-11-
5 (Kajigaya et al., 1989). The particles produced were composed of both VP1 and VP2
capsid proteins in a ratio similar to that observed in genuine virions (-4% and -96%,
respectively). The other eukaryotic system used as a source of native B19 capsid
proteins (either VP2 alone or both VP1 and VP2) was the baculovirus/insect cell
expression system (Brown CS et al., 1991; Kajigaya et al., 1991). It has been shown
that in order to elicit a neutralising antibody response in rabbits, recombinant empty
capsids had to contain VP1 since recombinant capsids consisting of VP2 only fail to
elicit a neutralising immune response in animals (Kajigaya et al., 1991). Moreover, an
evaluation of the immune response elicited by recombinant B19 parvovirus capsids of
various structural protein compositions (4%, 25%, 35% or 41% VP1 protein) found that
recombinant capsids of a protein composition similar to that of naturally occurring B19
virions (4% VP1 capsids) were a relatively poor vaccine immunogen for the elicitation
of virus neutralisating antibodies (Bansal et al., 1993). However, given that human
convalescent sera usually have strong virus neutralising activity, there might be slight
differences of a structural and conformational nature between the natural and
recombinant capsids that may be immunologically important. Additionally, there may
be differences in the presentation to the immune system of a replicating virus and a
nonreplicating particle. Another conclusion from this study was that the effective
immune response was proportional to the quantity of VP1 contained in the empty capsid
immunogen, although only up to a certain point (Bansal et al., 1993). Capsids consisting
of more than 25% VP1 did not appear to have a significantly improved ability to elicit
neutralising antibody production. All formulations in Freud’s adjuvant trigged
significant levels of anti-B19 antibodies 4 weeks post inoculation in guinea pigs. Empty
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capsids containing various VP1 concentrations were then tested with or without
aluminium hydroxide. Vigorous neutralising response was induced at low doses when
formulated with the latter adjuvant whereas a similar activity in the absence of adjuvant
was elicited by 100 fold higher doses. These data suggest that recombinant VP1-
enriched empty capsids could be a good candidate for a B19 vaccine. Furtherore,
recombinant empty capsids were also able to stimulate human T helper lymphocytes,
which are essential for B-cell maturation and antibody class switching (Franssila et al.,
2001). The immunogenicity of a more recent candidate recombinant B19 vaccine
(MEDI-491; Medlmmune), composed of -25% VP1 and -75% VP2 capsid proteins,
was successfully evaluated in a randomized, double-blind, phase I clinical trial (Ballou
et al., 2003). All volunteers (n=24) developed neutralising antibody titres that peaked
after the third immunisation and was sustained for one year.
The last approach to vaccine development has been via synthetic peptide immunogens 
containing neutralising epitopes. Protective immunity has already been observed in 
BALB/c mice after vaccination with a synthetic peptide derived from CPV capsid 
proteins (Rimmelzwaan et al., 1990). As for parvovirus B19, this method is realistic 
providing a number of linear epitopes on the capsid proteins have been defined and 
showed involvement in virus neutralisation. The use of NS1 as a vaccine target is not 
recommended as no epitope was universally recognised by the different groups 
reviewed previously (Tolfvenstam et al., 2000). Additionally, and as discussed 
previously, anti-NS antibodies are unlikely to induce a neutralising response (Von 
Poblotzki et al., 1995b).
The first and so far only report of the use of synthetic peptides demonstrated that several 
of them, containing about 20 amino acids of the unique region of VP1, elicited 
neutralising antisera in rabbits (Saikawa et al., 1993). Although those results are
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encouraging, a lot more research will be required for the development of a useful
synthetic peptide vaccine candidate containing a mixture of several neutralising
epitopes. Major concerns about such a peptide are its presentation to the B-cell epitope
and its capability to induce T helper cell activity (Collett and Young, 1994). Moreover,
synthetic peptide-based vaccines are usually poor immunogens and consequently
provide incomplete protection. The prospects for the development of a human
parvovirus B19 vaccine are fairly good and a hopeful candidate appears to be based on
recombinant empty capsids.
While it has proven difficult to develop vaccines against parvoviruses, it was ironical to
discover that parvoviruses could be used as vectors for the presentation of foreign
epitopes to the immune system (Miyamura et al., 1994). Similarly, hepatitis B virus
(HBV) core antigen has already proven to be a good presentation system for peptides of
the foot-and-mouth disease virus (Clarke et al., 1987), epitopes from the envelope
protein of HIV-1 (Stahl and Murray, 1989) and for rhino virus peptides (Francis et al.,
1990). Synthesis of virus-like particles (VLPs) mimicking authentic virions but lacking
the genetic material has been used with autonomous parvoviruses to generate a
collection of VLPs (Casal, 1999). Sedlik and coworkers have constructed a PPV VP2
chimera containing the poliovirus C3:T epitope that was able to induce a strong peptide-
specific proliferative response in vivo (Sedlik et al., 1995). The very good T CD4+
response obtained against the inserted T-cell epitope was later characterised as being of
Thl phenotype (Lo-Man et al., 1998). Hybrid VLPs prepared by self-assembly of the
modified PPV VP2 capsid protein carrying a CD8+ T cell epitope from lymphocytic
choriomeningitis virus, was shown to induce vigorous CD8+ and CD4+ cell responses
without adjuvant (Sedlik et al., 1997). These VLPs were nonreplicative and the
protective responses elicited were long-lived. Further research showed that these vectors
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could initiate both humoral and cellular responses when delivered intranasally, whereas
no immune response was observed when mice were orally immunised (Sedlik et al.,
1999). Interestingly, three sites suitable for the insertion of B- and T-cell epitopes were
defined on the VP2 capsid protein: epitopes placed at the N-terminus of VP2 induce
cellular immune response, both through TH cells and cytotoxic cells, epitopes on loop 2
of VP2, located on the surface of the capsid, can elicit strong humoral immune response
against the inserted epitope and some sites around the 5-fold axis, the region situated
on the “neck” of the caspid, can present epitopes able to trigger a humoral response
(Rueda et al., 2000). Therefore, the possibility of combining different types of epitopes
on different positions of a single particle to stimulate different branches of the immune
system could pave the way to the production of more potent vaccines in a simple and
cheap way. In addition, the heat resistance of human parvovirus B19 could become an
advantage for vaccination programs in the warmer countries of the developing world
(Miyamura et al., 1994).
I.I.7.3. Animal models for B19 infection
Animal models for human parvovirus B19 can be used for two types of studies: 
pathogenesis of infection and virus inactivation.
Despite the fact that human parvovirus B19 is still the only officially accepted member
of the Erythrovirus genus, several candidate viruses have been proposed for inclusion in
this relatively new genus. Remarkable similarities have indeed been noticed between the
simian and B19 parvoviruses, such as their predilection to infect bone marrow cells in
vitro (Gallinella et al., 1995b) and their capacity to cause severe anaemia in infected
subjects, respectively cynomolgus monkeys and humans (O’Sullivan et al., 1994;
1997). Two other outbreaks of anaemia were later reported to be caused by two distinct
but similar SPV, namely pig-tailed macaque and rhesus parvoviruses, in the
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corresponding hosts (Green et al., 2000). All three SPV, which are highly tropic for
erythroid progenitor cells, are currently being studied as animal models for the
pathogenesis of B19 infection (Brown and Young, 1997). Another candidate
erythrovirus was isolated from Korean Manchurian chipmunks (Yoo et al., 1999). Its
nucleotide and amino acid sequences showed significant homology to B19 and SPV,
suggesting it might also be a potentially useful animal model for B19 infection.
Additionally, a recent investigation aiming at understanding the role of B19 NS1 protein
in non-immune hydrops fetalis led to the establishment of NS1-transgenic mice lines
that can provide an animal model for the study of this condition (Chisaka et al., 2002).
Due to the lack of a suitable infectivity assay for human parvovirus B19 to date, animal
models have been widely used in virus inactivation studies, including MVM (House et
al., 1990), CPV (Hart et al., 1994; Borovec et al., 1998; Roberts and Hart, 2000), BPV
(Brauniger et al., 2000; Roberts and Hart, 2000) and PPV (Blumel et al., 2002a).
However, as will be discussed further in chapter V, the relevance of these models is
debatable. A recent study by Blumel and colleagues has indeed showed that thermal
resistance of B19 markedly differs from that of animal parvoviruses (Blumel et al.,
2002b).
1.2. Contamination of blood and blood products 
1.2.1. Prevalence of human parvovirus B19
1.2.1.1. Blood donations and plasma pools
Two factors can influence the incidence of B19 in blood donations: the sensitivity of the 
detection method used and the epidemiology of the virus (Siegl and Cassinotti, 1998). 
The latter refers to the particularity of B19 infections to occur in late winter and spring 
(Anderson and Torok, 1989) and in 4-year cycles, with 2 epidemic years followed by 2
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endemic years (Kelly et al., 2000). Therefore, taking into account both factors, the
incidence of B19 virus in blood donations can vary greatly.
The first reported incidence of B19 in British donations in a non-epidemic situation was 
11 instances being found in approximately 500,000 blood donations by CIE, which 
corresponds to about 1 in 45,000 (Mortimer et al., 1983). Subsequently, although the 
primary aim of their study was to identify a B19 positive donation that could be used as 
a source of antigen for diagnostic purposes, Cohen and colleagues estimated the 
incidence of B19 viraemia in blood donors as 1 in 24,000 donations (Cohen et al., 
1990). The single donation showed a positive reaction for B19 antigen by CIE and was 
later confirmed by JEM. Although the positive donation was reported immediately to 
the North London Blood Transfusion Centre, where the sample was donated, it had 
already been incorporated in a plasma pool of 28 donations. This pool was then made 
available for further research. Neither CIE nor radio-immuno assay (RIA) could detect 
B19 antigen whereas the dot-blot hybridisation assay was positive for B19 DNA. Since 
the dilution effect would not explain those results, the presence of B19 antibodies from 
other donations of the pool might have blocked the antigen reactivity. Direct EM 
confirmed the presence of aggregates of B19 particles coated by antibodies, while direct 
EM on the single donation had not shown any antibody coating of the virus particles nor 
aggregation. Therefore, it seemed that the presence of antibodies did not interfere with 
DNA detection (Cohen et al., 1990).
The importance of the sensitivity of the detection method used and B19 infection 
epidemiology was shown in a number of studies detailed below. While Japanese 
samples tested by ID and in a non-epidemic period showed an incidence of 1 in 35,000, 
that figure increased to 1:4,000 under an epidemic situation, when measured with the 
same method (Tsujimura et al., 1995). Moreover, when using the more sensitive PCR
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detection method during a minor epidemic of El, the incidence of B19 viraemia in
healthy blood donors was 1:167 (0.6%), which was considerably higher than in previous
surveys (Yoto et al., 1995). Still in Japan, Sato and coworkers first used double
immunodiffusion (DID) to find 1 in about 14,000 donations positive for B19 in 1992,
which was a prevalent year for El (Sato et al., 1995). The following year, which was not
epidemic for El, 1 in 90,000 donations was contaminated with B19. Nevertheless, when
both DID and RHA were used for screening from April to July 1995 -again not
prevalent for El in Japan-, no positive donation was detected by DID, whereas RHA
identified 27 positives among 45,735 tested (~1 in 1,700). However, only 7 of those
were confirmed positive by PCR, thereby bringing the figure to 1 in 6,500 and
underlining the weak specificity of the RHA screening method. Another study using
PCR to detect B19 DNA in blood units in a non-epidemic year found approximately 1
positive in 3,300 (McOmish et al., 1993). The most recent study reported the results of
the implementation of PCR screening of plasma pool samples for B19 DNA at the
“laboratoire francais du fractionement et des biotechnologies” in France (Aubin et al.,
2000). This was the most extensive of such studies reported to date since it was done
over a 2-year period. During this time, the frequency of parvovirus B19 viraemic
donations was 1 in 5,950, which correlated with previously published data. Moreover,
the previously described seasonal and annual B19 epidemics were observed in this
report as during the peak of the French epidemic in April 1997, B19 incidence in blood
donors was as high as 1 in 1,420. B19 DNA levels in positive pools ranged from 102 to
1011 copies/ml. Table 1.7 summarises the data available to date.
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Table 1.7: Incidence of parvovirus B19 viraemic sera
Situation Incidence Method of detection Country Reference
Non-epidemic 1:45,000 CIE UK Mortimer et al., 1983
Non-epidemic 1:24,000 CIE UK Cohen et al., 1990
Non-epidemic
Epidemic
1:35,000 
1: 4,000
ID Japan Tsujimura et al., 1995
Epidemic 1:167 PCR Japan Yoto et al., 1995
Epidemic 1:14,000 DID
Non-epidemic 1:90,000 DID Japan Sato et al., 1995
Non-epidemic 1:6,500 PCR
Non-epidemic 1:3,300 PCR UK McOmish et al., 1993
Non-epidemic
Epidemic
1:5,950
1:1,420
PCR France Aubin et al., 2000
These PCR-based data have raised the concern that B19 might frequently contaminate 
blood products, which are generated from pools of 3,000 to 10,000 plasma units. It 
appeared essential to screen blood products for B19 DNA and to investigate the effect 
of the virus removal/inactivation used.
I.2.I.2. Plasma products
I.2.I.2.I. Coagulation factors
The first group to test the hypothesis that parvovirus B19 was spread by blood products 
was Mortimer and colleagues as early as 1983 (Mortimer et al., 1983). He demonstrated 
that young American haemophiliacs receiving factor VIII and IX concentrates showed a
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higher prevalence of anti-B19 (97%) than in either blood donors or age-matched
controls (20%). However, as far as individual blood donations were concerned,
Mortimer did not show any significant increase in anti-B19 antibodies prevalence (36%)
in a group of multiply transfused patients, compared to the untransfused control group.
A few years later, the prevalence of anti-B19 IgG in non-heat-treated factor VIII
concentrates was found to be 89% (47 of 53), compared with 39% (53 of 135) of their
age-matched controls (Williams et al., 1990). On the other hand, treatment with single
donor units of plasma or plasma fraction (cryoprecipitate) was not associated with an
increase in the prevalence of anti-B19 IgG. Moreover, two of 12 boys (17%) who had
received the NHS 8Y factor VIII concentrate were positive for IgG, compared to 11 of
36 (31%) of controls. Williams and colleagues emphasised the fact that those promising
results were preliminary, and rightly so, since Yee and his team showed transmission of
B19 by this product a few years later (Williams et al., 1990; Yee et al., 1995; Yee et al.,
1996).
B19 DNA was detected in clotting factor concentrates by dot-blot hybridisation, 
Southern blot hybridisation and by nested PCR (Zakrzewska et al., 1992). Once again, 
the different sensitivities of these detection methods influenced the prevalence of the 
virus in the batches tested. Only two concentrates were shown to contain B19 DNA by 
either dot blot or Southern blot hybridisation, whereas seven samples out of 25 tested 
were reported to contain viral DNA after nested PCR amplification. Similarly, only one 
of these concentrates (steam-heated) contained sufficient B19 DNA to be detectable by 
all the assays used. Overall, B19 DNA was detected in 2 of 3 untreated concentrates and 
in 4 of 20 treated concentrates.
A Norwegian study investigated the prevalence of B19 antibodies among haemophiliacs 
with different types and severities of coagulation factor defects (Rollag et al., 1991).
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The results showed that the prevalence in the different groups varied from 52% to 88%,
depending on type and severity of the defect, whereas 49% of household contacts had
B19 antibodies. The highest prevalence was found among persons with severe
haemophilia A and B, but with an even higher prevalence among individuals with
haemophilia B than A. The latter finding could be explained by the fact that factor IX
concentrates, used to treat haemophilia B, were extracted from a larger plasma pool
(250 donors) than that used for production of factor VIII concentrates (6 donors), which
is given to patients suffering from haemophilia A. The fact that the prevalence of B19
antibodies is higher among those with severe haemophilia reflects the increased factor
concentrate requirement and therefore the increased risk of receiving a B19 infected
concentrate. Although the factor concentrates themselves were not tested for B19 DNA,
an indirect correlation was made between the use of coagulation factor concentrates to
treat haemophilia and the high prevalence of B19 antibodies among the patients
receiving those blood products, as was already suggested by Mortimer and colleagues
(Rollag et al., 1991; Mortimer et al., 1983). This correlation was also proposed in
another study, although there was no significant difference between Dutch patients with
haemophilia A, B or von Willebrand’s disease (Mauser-Bunschoten et al., 1998). This
report showed that, in children of 0-10 years, 42 of 55 (76%) of the haemophilia
patients and 11 of 48 (23%) of the controls were positive for anti-B19 IgG, as well as a
striking 100% of children with severe haemophilia A who were treated on a
prophylactic basis with clotting factor concentrates. These data emphasized once more
the high risk of B19 transmission through plasma-derived clotting products.
In addition, while 20% of clotting factor batches tested in France (both factor VIII and
IX concentrates) contained B19 DNA (Lefrere et al., 1994), as much as 100% (7 of 7)
of factor Vm batches tested in Great Britain were also positive (Saldanha and Minor,
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1996). Two German groups also tested batches of factor VIQ and reported 47 of 70 
(67%) (Eis-Hiibinger et al, 1996) and 15 of 19 (79%) positive for B19 DNA by PCR 
(Willkommen et al., 1999).
I.2.I.2.2. Albumin
The first study to investigate contamination of albumin with human parvovirus B19 
tested 29 commercial batches, of either 4% or 20% albumin solution, produced from 
European plasma by two different manufacturers (Lefrere et al., 1995). No B19 DNA 
was found in albumin concentrates, which are routinely heated by pasteurisation at 60°C 
for 10 hours to inactivate blood-borne viruses. Although B19 is thermostable and non­
enveloped, it was suggested that the ethanol fractionation process might have 
inactivated or eliminated B19. Saldanha and Minor, on the other hand, detected B19 
DNA in 3 of 12 albumin batches (25%) (Saldanha and Minor, 1996). The limit of 
detection of B19 DNA had been improved from 400-4000 genome equivalents/ml 
(Lefrere et al., 1995) to 115 genome equivalents/ml (Saldanha and Minor, 1996), which 
might explain in part the disparity of the results in those two studies.
Furthermore, while Willkommen and coworkers detected 3 of 44 albumin batches (7%) 
positive for B19 DNA (Willkommen et al., 1999), they found it remarkable that some of 
their German colleagues reported the presence of B19 DNA in 5 of 30 (17%) lots of 
recombinant factor VIII from two manufacturers, to which human albumin was added 
as a stabiliser during the preparation and purification procedures (Eis-Hiibinger et al., 
1996). Although albumin was also subjected to pasteurisation at 60°C for 10 hours, Eis- 
Hiibinger et al. suggested that the differences in the manufacturing process for albumin, 
such as ethanol fractionation, purification by chromatography or filtration, could
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contribute to the divergence seen between their results and Lefrere and colleagues’ (Eis-
Hiibinger et al., 1996; Lefrere et al., 1995).
I.2.I.2.3. Immunoglobulins
Besides albumin and factor VIII batches, Saldanha and Minor investigated both 
intravenous (IV) and intramuscular (IM) immunoglobulin (IG) batches, finding B19 
DNA in 3 of 15 IVIG samples and 3 of 4 IMIG samples (Saldanha and Minor, 1996). 
Those IMIG samples found positive for B19 DNA were from two different 
manufacturers who did not use any specific viral inactivation technique and one batch 
even presented with a B19 DNA titre that was the same as in the start pool. Regarding 
the start pools tested in the same study, the majority (65 of 75: -87%) was found to 
contain B19 DNA.
In conclusion, the contamination risk depends on several factors that could facilitate the 
presence of human parvovirus B19 in blood and blood derivatives. Firstly, the number 
of potentially infected blood donors is significant as, by the age of 60 years old, 60% of 
the general population would have been infected by the parvovirus. Secondly, the vast 
majority of infected adults are clinically asymptomatic, making diagnosis at the time of 
donation difficult. The rash, when present, develops after the viraemic phase. Thirdly, 
the incubation period during primary infection usually results in very high viraemia of 
10n -1013 virus particles/ml (Frickhofen and Young, 1989). Fourthly, although the virus 
is normally cleared in 5 to 10 days, some infected individuals present a long-lasting but 
low level viraemia (102 to 104 virus particles/ml), although they have developed an IgG 
response and are thus immunocompetent (Faden et al., 1992; Cassinotti et al., 1993; 
Kerr et al., 1995; Sasaki et al., 1995). Additionally, human parvovirus B19 might stay
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latent in the bone marrow (Sasaki et al., 1995; Cassinotti et al., 1997). Last but not
least, it is still unclear whether the presence of anti-B19 IgG in other donations within a
pool is sufficient to neutralise infectious virus particles and to prevent susceptible
recipients of blood and blood products from developing viraemia and possibly B19
infection. However, despite the incidence of parvovirus B19 in blood and blood
products detailed previously, the actual transmission of clinical infection is rare in the
recipients because the viruses might not be infectious or could have been destroyed by
viral inactivation steps during the manufacturing process. Moreover, anti-B19
antibodies from other blood donations in large plasma pools might be sufficient to
neutralize B19 virus particles present in a single donation and prevent the infection. The
few cases of infectious virus transmission by blood and blood products over the years
are detailed in the following paragraph.
1.2.2. Evidences of infectious virus transmission by blood and blood
products
I.2.2.I. Blood donations
The first report of transmission of infectious B19 by a single-donor transfusion was in a 
young woman suffering from p-thalassemia (Zanella et al., 1995). This patient 
developed a symptomatic B19 infection involving transitory heart failure as well as 
transient red cell aplasia. B19 DNA was detected in blood samples taken from both the 
patient and one of the donors of the blood transfused, whose child had El one week 
before donation. Additionally, the presence of anti-B19 IgM in the patient’s serum 
indicated an acute infection and could also implicate the RBC transfusion in B19 
transmission. Such an unusual case of transfusion-related B19 infection, as well as B19 
incidence mentioned previously illustrate the fact that its transmission through blood
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donations is a rare event in a non-epidemic situation, whereas it can become a
significant risk during an epidemic period. As Aubin et al. emphasised, “during peak
epidemic periods, manufacturing pools of several thousands of donations could contain
as many as ten viraemic donations” (Aubin et al., 2000). Moreover, since a blood
13donation from an individual at the peak of viraemia can contain up to 10 virus 
particles/ml, even this single positive donation will contaminate a large plasma pool. 
Even contamination to a smaller plasma pool can occur and was reported in a pool 
containing 28 donations (Cohen et al., 1990). The contaminated plasma pool had not 
been given to patients nor used for fractionation and was withheld from processing on 
time. Unfortunately, this is not always the case and the health of blood products 
recipients can sometimes be put at risk, as demonstrated by the following cases of 
infectious B19 transmission.
I.2.2.2. Plasma products
I.2.2.2.I. Clotting factors
B19 infection was reported following a first dose of factor VIII into a previously 
untreated patient who developed viraemia and a B 19-specific IgM response ten days 
after receiving the concentrate, without any other possible source of infection such as a 
proceeding or concurrent illness in a close contact (Mortimer et al., 1983). This was the 
first direct evidence that factor concentrates can transmit B19 infection. Subsequently, 
evidence for B19 transmission by unheated commercial factor VIII was given in two 
patients who had been infrequently exposed to concentrates (Williams et al., 1990). The 
presence of anti-B19 IgM demonstrated an acute infection, even though asymptomatic. 
Although both boys had received the same batch of factor VIII 3 to 4 weeks before 
testing, evidence of B19 contamination in this batch could not be found since all tests
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performed were negative (RIA, EM and dot blot hybridisation). On one hand, the
techniques used at the time might not have been sensitive enough to detect the virus as
PCR would nowadays, while on the other hand, it seems more likely that the patients
were infected through their treatment rather than by the natural route.
The introduction of a solvent/detergent (S/D) treatment was confirmed not to be
efficient on human parvovirus B19 as was indicated by the first case of hypoplastic
anaemia in a young haemophiliac who had been transfused for the first time with a S/D
treated factor VIII concentrate (Morfini et al., 1992). The patient showed all the signs of
a B19 primary infection, with high level of IgM detected just after the treatment, as well
as anaemia and extreme fatigue after 10 days. IgG were found in the second serum
sample drawn 3 weeks after anaemia and the patient recovered well within a week. The
second case of S/D treated clotting factor involved in B19 transmission was that of a
female haemophilia B carrier, who acquired a symptomatic B19 infection via S/D-
treated factor IX concentrates (Yee et al., 1996). Blood samples from the patient were
positive for B19 DNA by primary and nested PCR (>107 genomes/ml). These cases
emphasise the vulnerability of such patients and might become a significant problem if
parvovirus infection following treatment was to occur during pregnancy.
In Britain, although heat-treated factor VIII concentrate 8Y was previously thought to
be comparatively safe (Williams et al., 1990), B19 infection of an immunocompetent
adult who had received this product was suggested (Yee et al., 1995). Despite the fact
that the patient’s serum sample was negative for anti-B19 antibodies immediately
before the first treatment, both IgM and IgG became detectable by RIA at the time of
admission for sepsis, myelosuppression and hepatic dysfunction. Moreover, the batch of
factor VEH concentrate received by the patient was found to be positive for B 19 DNA
by nested PCR. It is important to note that even infrequent users of clotting factor
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concentrates are still at high risk of contracting a transfusion-associated B19 infection.
As for factor IX concentrates, there had been a previous report of three patients
presumed to have contracted symptomatic B19 infection via such products (Lyon et al,
1989). The patients had only limited exposure to blood products and two had received
only the National Health Service heat-treated factor IX concentrate. Despite the fact that
none of these patients gave a history of contact with a person with a rash before the
development of their own rash and that anti-B19 antibodies were negative in an earlier
stored serum, both anti-B19 IgM and IgG were detected after the onset of the rash. B19
DNA was amplified by PCR in one particular batch of factor IX concentrate used to
treat these patients, which suggested that parvovirus B19 might be transmitted by heat-
treated factor VIII and IX.
Although recombinant factor VIII concentrates had been regarded as safe concerning 
blood borne viruses, seroconversion for B19 in 5 of 16 susceptible patients receiving 
this product was reported (Aygoren-Pursiin et al., 1997). Despite the fact that the results 
were ambiguous in 3 of the cases, concerns remained for the other two patients 
regarding the possible transmission of the virus via recombinant factor VIII. 
Additionally, and as mentioned previously, parvovirus B19 DNA had already been 
amplified by nested PCR in recombinant factor VIII preparations where human albumin 
was used as a stabiliser during the manufacturing process (Eis-Hubinger et al., 1996). In 
Aygoren-Piirsiin and colleagues’ study, albumin was also present as excipient in the 
recombinant product and could thus be suspected to be the cause of seroconversion 
(Aygoren-Piirsun et al., 1997). Nevertheless, the natural infection of the patients within 
the community cannot be ruled out.
 Chapter I
I.2.2.2.2. Immunoglobulin
While evaluating the possible genetic changes related to chronic parvovirus B19
infection, Erdman and coworkers found an abrupt change in B19 sequences in samples
collected in a 5-year-old patient after administration of different lots of IVIG (Erdman
et al., 1997). Possible explanations for this sequence change included a specimen cross-
contamination in the laboratory, the genetic evolution or immune selection of B19
variants and a reinfection by natural exposure or from B19 contaminated IVIG. After
investigation, given the timing of the appearance of this new B19 strain just after
administration of IVIG and the fact that IVIG had been shown to frequently contain
B19 DNA (Saldanha and Minor, 1996), transmission of infectious parvovirus B19 by
contaminated IVIG seemed to be the most likely event to have occurred. Although B19
antibodies present in IVIG would normally neutralize both the patient’s virus and any
virus potentially present in the preparation, it is possible that the immune complexes
formed by specific antibodies and the virus particles enable infection of cells bearing
the Fc receptor, such as monocytes and macrophages (Erdman et al., 1997; Morey et al.,
1992). Infection of those cells would be non-productive, short-term and clinically
asymptomatic, which was the case for the young patient studied by Erdman and
colleagues. However, some reservations about the possibility of B19 transmission from
IVIG in this particular case were raised a few years later (Hayakawa et al., 2002) as no
correlation was indeed shown between the B19 genotype in the patient’s serum sample
and the IVIG administered to the patient in Saldanha and Minor’s paper (Saldanha and
Minor, 1996). Therefore, Hayakawa and coworkers claimed to have presented “the first
report to clearly show parvovirus B19 transmission from IVIG” (Hayakawa et al.,
2002). Only a few days after administration of IVIG later, found to be contaminated by
B19, a patient’s serum sample had become positive for B19 IgM antibody and for B 19
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DNA by PCR. In this case, the patient suffered from fulminant hepatitis likely to have
been caused by B19 infection following pre-existing coxsackie B4 infection. However,
the implication of IVIG in transmitting B19 infection had not been clearly established
and further evidence would be needed to establish the cause of infection in this
particular case.
I.2.2.2.3. Fibrin sealant
Another blood derivative implicated in infectious B19 transmission is fibrin sealant, 
which consists of fibrinogen and thrombin mixed with factor XIII and calcium. It is 
used as a haemostatic agent. Despite dry-heat viral inactivation on both fibrinogen and 
thrombin components, three cases of symptomatic B19 infection due to the use of the 
same batch of fibrin sealant during surgery were reported (Hino et al., 2000). The batch 
in question was found positive for B19 DNA by PCR. In addition, the possibility of 
transmission by medical staff members was excluded after they were all confirmed 
negative for B19 IgM. Following these cases, a careful follow-up of patients treated 
with fibrin sealant was advised and the need for recombinant products was emphasised. 
The frequency of B19 infection transmission by fibrin sealant during surgery was 
estimated in a group of 85 patients who underwent thoracic surgery and needed fibrin 
sealant to stop air leak or haemorrhage (Kawamura et al., 2002). In 6 of 29 patients 
(20.7%) whose blood samples were negative for anti-B19 IgG before surgery, samples 
obtained 12 to 48 weeks after surgery were positive for both anti-B19 IgG and B19 
DNA by PCR. Batches of fibrin sealant used in 2 of those 6 patients also tested positive 
for B19 DNA. It was therefore suggested that these post-chest surgery infections were 
transmitted by B19 contaminated fibrin sealant.
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The various reports of significantly elevated prevalence of anti-B19 antibodies in
haemophiliacs, as well as in other patients receiving frequent treatment with plasma
products derived from such pools, gave further evidence that the virus is very robust. It
is able to withstand the treatment and purification steps of these plasma products and
still be present -and sometimes infectious- in the final product.
1.2.3. “Inefficiency” of viral inactivation methods used in current
processes
According to Bumouf, who reviewed virus inactivation treatments, “one problem in 
establishing these techniques is to ensure a high level of virus inactivation while 
preserving the biological activity of the coagulation factors” (Bumouf, 1992). It is 
essential to design effective inactivation methods that will avoid the alteration of the 
three-dimensional structure of therapeutic proteins. Moreover, it seems that plasma 
protein purification technologies, based on high-resolution chromatographic extractions, 
already play a role in viral safety. The manufacture of coagulation factor concentrates 
involves a combination of centrifugation, precipitation, chromatography, ultrafiltration 
and freeze-drying steps. All of these steps could, in theory, contribute to inactivate or 
remove viruses. In practice, at least one, but often two, validated viral inactivation/ 
removal techniques have to be included in blood products preparation.
PCR was used to detect B19 DNA in seven of seven factor VH[ samples tested, which 
had been treated with either S/D plus monoclonal antibody purification, dry heat (80°C 
for 72 hours) or solvent-detergent followed by ion-exchange chromatography (Saldanha 
and Minor, 1996). Although Saldanha and Minor emphasised that further work on many 
more samples is required, Their results suggest that none of these viral inactivation 
methods are sufficient to destroy B19 viral DNA. As mentioned previously, the same
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study showed that some IVIG batches were positive for B19 DNA. IVIG usually
undergoes various viral inactivation steps. For instance, the manufacturers can use S/D
treatment, pasteurisation (60°C for 10 hours), low pH step (pH 4.25) or treatment with
protease at pH 6.5. All fifteen pools from one of the manufacturers who used pH 4.25
presented high levels of B19 DNA but the six IVIG batches derived from those were
negative for B19 DNA, suggesting that such low pH could destroy the virus (Saldanha
and Minor, 1996). However, B19 DNA was found in IVIG from the manufacturer who
used a S/D step. The possible transmission of B19 virus by S/D treated factor VIII
concentrate had been suggested in a young haemophiliac who developed hypoplastic
anaemia after first infusion with the former product (Morfini et al., 1992). It is well
known that this inactivation technique destroys only lipid-enveloped viruses and that
B19 virus can thus withstand such a virucidal method. Subsequently, Koenigbauer and
coworkers published the case report of a patient who was infused with several units of
solvent (tri(n-butyl)phosphate)-detergent (Triton X-100) treated plasma later found to
have high levels of parvovirus B19 DNA (Koenigbauer et al., 2000). The patient was
positive for both IgG and IgM, which reflected an acute B19 infection. This particular
case shows once more the inefficiency of S/D treatment to inactivate B19 virus.
In order to supplement S/D treatment with a technique that might be more effective on
non-lipid-enveloped viruses, heating treatments, including dry-heating and
pasteurisation, were investigated. Four of 20 treated clotting concentrates tested for B19
DNA were positive (Zakrzewska et al., 1992). Only a small number of chloroform
treated and dry-heated products were included in the study and, although none was
found to contain B19 DNA, the number tested was too small to be representative of the
effectiveness of these treatments. Similarly, B19 DNA was not detectable in the seven
pasteurised concentrates tested in this study. Although the pasteurisation technique is
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suggested to reduce the risk of B19 infection, it doesn’t eliminate it (Lyon et al., 1989;
Azzi et al., 1992). Even if the study by Mauser-Bunschoten et al. did not detect B19
virus particles directly, it showed a significant difference in prevalence of B19 IgG
between haemophiliacs and healthy individuals but, interestingly, did not observe any
change between the patients treated with S/D or with pasteurised products (Mauser-
Bunschoten et ah, 1998). Furthermore, despite the fact that factor VHl 8Y was treated
for 72 hours at 80°C (final product), this clotting factor concentrate still transmitted
parvovirus B19 infection to an immunocompetent adult (Yee et al., 1995). This product
was previously thought to be associated with a lower incidence of B19 transmission
(Lyon et al., 1989). More recent data showed that blood products either vapour-treated
(60°C for 10 hours followed by 80°C for 1 hour) or dry-heat treated (80°C for 72 hours),
transmitted B19 infection, although asymptomatic, in two young recipients (Blumel et
al., 2002a). The use of dry heating at sterilising temperature (100°C for 10 to 30
minutes) was also recommended with minimal loss for factor VIII and IX concentrates
(Rubinstein and Rubinstein, 1989; Rubinstein, 1990). Following this suggestion, an
Italian manufacturer chose to add a terminal inactivation step based on heating at 100°C
for 30 minutes in lyophilised clotting factor concentrates (Santagostino et al., 1994).
Nevertheless, an acute B19 infection developed in four patients out of the ten who were
anti-B19 IgG negative before receiving the treated factor VIII or IX concentrates. This
report was criticised by Prowse, who thought that the data should have been interpreted
with regard to an age-matched healthy control group or an untransfused haemophilic
group (Prowse, 1994). Most previously untreated haemophiliacs would be under the age
of ten, which is an age group that would be expected to show a higher rate of B19
viraemia. The other comment on the study by Santagostino and colleagues came from
Guillaume, who proposed to extend the terminal viral inactivation step at 100°C to 45 or
-  169 -
 Chapter I
even 60 minutes in blood products in order to eliminate parvovirus B19 (Guillaume,
1994). However, it was argued that this final inactivation step might increase the risk of
a reduced yield and the possibility of a higher frequency of inhibitors (Thomas, 1994).
To this reservation, Lusher and coworkers replied that the same arguments were given
in the early 1980s when the introduction of dry heat and pasteurisation treatments to
clotting factors production was discussed, but neither of these events took place and a
large number of infections by HIV and HCV were spared thanks to these inactivation
techniques (Lusher et al., 1994). To end this argument, Thomas seemed resilient to
“acknowledge that absolute safety is a mirage”, statement to which both Lusher et al.
and Colvin reacted strongly as “no one should abandon the goal of achieving absolute
safety” (Thomas, 1994; Colvin, 1994; Lusher et al., 1994).
Other processes used to supplement S/D treatment included purification by anion 
exchange chromatography, as well as nanofiltration (pore size 0.2pm). The reduction of 
B19 DNA in factor VHl manufactured in such a way was investigated by spot 
hybridisation and Southern blotting (Schwarz et al., 1991). It was thought that physic- 
chemical interaction occurred between B19 virus and the anion exchange material of the 
column since there was a reduction of at least logio 2 of the total amount of B19 virus 
used to spike the start product. Additionally, DNA hybridisation could not detect any 
viral DNA after the filtration step, which showed that residual virus particles, seen as 
aggregates by EM, were cleared in this final step. Although these results were 
interesting, they were not obtained with the most sensitive nucleic acid detection 
method (PCR) and they still do not indicate whether B19 virus found after anion 
exchange chromatography represents infectious or inactivated virus.
Nanofiltration of factors IX and XI concentrates also showed promising results on the 
elimination of bovine parvovirus (BPV; 20-25nm) (Bumouf-Radosevich et al., 1994).
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The 15N filter (pore size 0.15pm) used was able to remove more than logio 6.3 of BPV
while virus aggregates were also eliminated by more than logio 5.8 when passed through
a 35N filter (pore size 0.35pm). Although BPV is a small non-enveloped virus resistant
to S/D treatment and has been used as a model for parvovirus B19, further studies using
human parvovirus B19 virus itself are still required to evaluate the efficiency of
nanofiltration. Furthermore, this method cannot be applied to higher molecular weight
plasma proteins, such as factor VIII molecule or von Willebrand factor concentrates.
Tables 1.8 and 1.9 summarise the characteristics of established viral removal and
inactivation procedures regarding protein integrity and efficacy to inactivate parvovirus
B19.
Table 1.8: Characteristics of well-recognized viral removal procedures
Treatment Properties Points to Consider
Precipitation
Purifies protein
Can be effective against both 
enveloped and non-enveloped 
viruses including parvovirus 
B19
• Usually modest virus removal
• Difficult to model
Chromatography
Purifies protein
Can be effective against both 
enveloped and non-enveloped 
viruses including parvovirus 
B19
• Virus removal highly 
dependent of choice of resin, 
protein solution, and buffers
• May be highly variable from 
one virus to another
• Resin must be sanitized 
between lots
Nanofiltration
Effective against enveloped 
viruses
Can be effective against non- 
enveloped viruses including 
parvovirus B19
Non-denaturing to proteins
High recovery of “smaller” 
proteins such as coagulation 
factor IX
• Degree of virus removal 
depends on the pore size of 
filter used
• Elimination of small viruses 
may not be total
• Some filter defects may not be 
detected by integrity testing
-  171 -
 Chapter I
Table 1.9: Characteristics of well-recognized viral inactivation procedures
Treatment Properties Points to Consider
Pasteurisation
Inactivates enveloped and some 
non-enveloped viruses including 
HAV
Relatively simple equipment
• Protein stabilizers may also 
protect viruses
• Does not inactivate parvovirus 
B19
Terminal Dry 
Heat
Inactivates enveloped and some 
non-enveloped viruses including 
HAV
Treatment applied on the final 
product
• Does not inactivate Parvovirus 
B19
• Requires strict control of 
moisture content
Steam or 
vapour Heat
Inactivates enveloped and some 
non-enveloped viruses
• Does not inactivate Parvovirus 
B19
• Relatively complex to put in 
place
S/D
Very efficient against 
enveloped viruses
Non-denaturing to proteins
High process recovery
Relatively simple equipment
• Non-enveloped viruses 
unaffected
• Not generally affected by buffers 
used
• S/D reagents must be removed
Acid pH
Effective against enveloped 
viruses
Relatively simple equipment
• Limited efficacy against non- 
enveloped viruses
• Use largely restricted to IgG
• At pH 4, effective virus kill 
requires elevated 
temperatures
Methylene
blue
Efficiency depends on nucleic 
acid content (greater for double 
stranded than single stranded)
Good efficiency for enveloped 
viruses but variable efficiency 
for non-enveloped viruses
• Loss of functional activity of 
coagulation proteins (more 
severely affected are factor 
Vni and fibrinogen)
• Can be applied to single unit 
system
The main conclusion that can be drawn from such data is the difficulty to evaluate the 
efficiency of established viral removal/inactivation methods to reduce the risk 
associated with infectious parvovirus B19. The first reason for this is that the actual
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infectivity of the virus is not reflected by the B19 DNA titre, which highlights the lack
of a reproducible and sensitive infectivity assay. Although the cell line KU812Ep6 has
been used to detect infection by mRNA amplification (reverse-transcriptase-PCR: RT-
PCR) or immunofluorescence staining (Blumel et al., 2002b; Boschetti et al., 2004), the
UT-7/Epo-Sl cell line was found to be more susceptible to parvovirus B19 infection
(Chaput and Saldanha, unpublished data). The second reason resides in the fact that the
animal models available, including BPV, PPV, CPV and MMV are not representative of
the behaviour of human parvovirus B19. For instance, recent studies have clearly shown
that animal models have different susceptibility to pasteurisation and low pH treatment
(Blumel et al., 2002b; Boschetti et al., 2004). Human parvovirus was shown to be
inactivated by more than logio 4 after 10 minutes at 60°C in albumin solutions, whereas
PPV was resistant to pasteurisation treatment (Blumel et al., 2002b). Similarly, when
exposed to pH 4.0 for 2 hours, parvovirus was inactivated by more than logio 5 whereas
MMV was resistant for over 9 hours. These new data revealed not only that animal
parvoviruses should not be used as models for B19, but also that human parvovirus B19
might be much more susceptible to inactivation treatments than previously suspected.
1.2.4. What solutions for safer, B19-free plasma?
A number of solutions can be applied to improve the safety of plasma pools regarding 
parvovirus B19 at the time of donation, during the manufacturing process or with the 
increasing use of recombinant clotting factor concentrates.
I.2.4.I. At the first stage of blood donation
Donors could be selected on the basis of being anti-B19 IgG positive, since they are 
likely to represent a resolved infection. However, reinfection can occur in those who
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have a low level of anti-B19 IgG, resulting in a second IgM response (Anderson and
Young, 1997).
One of the key solutions, which is already applied routinely by some manufacturers, is 
the screening of blood donors by nucleic acid testing (NAT) for B19 DNA to limit the 
number of B19 transmissions (McOmish et al., 1993). The potential benefit of NAT for 
parvovirus B19 was discussed at a workshop on the implementation of NAT to screen 
donors of blood and plasma (Tabor et al., 2000). At the time, it was considered to be an 
“in-process control” rather that a donor screening test. As of June 2000 in the United 
States, NAT screening for HCV RNA and HIV RNA in minipools was implemented 
efficiently, without compromising the availability of the blood supply (Busch and Dodd,
2000). However, in the context of the debate over minipool versus individual-donation 
NAT, the main concern was that the shorter window-period and yield of individual- 
donation NAT compared to minipool NAT for HIV and HCV would be very small and 
very expensive. The political and regulatory bodies in developed countries decided to 
apply minipool NAT but might introduce further safety, including individual-donation 
NAT and NAT for additional agents, such as West Nile virus in Canada and parvovirus 
B19 in Europe. However, such a decision should be an international consensus since 
“blood policies, like the viruses we are trying to avoid, ramify globally” (Busch and 
Dodd, 2000) although realistically, there is a huge gap between rich countries and 
developing countries, where both the high viral prevalence and the minimal, sometimes 
the absence of screening leads to hundreds of thousands of infections a year being 
transmitted through blood.
One disadvantage of donor-screening procedures is the lack of specificity in the deferral 
criteria, leading to a large number of safe donors being deferred (Kleinman, 2001). 
Additionally, the main limitation of NAT remains the fact that the presence of B19 in
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concentrates does not necessarily indicate that the product is infectious (Luban, 1994).
Therefore, in vitro infectivity studies are still needed, as well as a clear correlation
between viral sequences as detected by PCR and infectivity of the virus.
I.2.4.2. During the manufacturing process
Another way to improve safety is the introduction in the manufacturing procedure of a 
new virucidal method effective on non-lipid enveloped viruses, such as psoralen 
treatment, iodine, UVC light irradiation, gamma-irradiation and SuperFluids™.
In the absence of ultraviolet (UV) light, psoralens reversibly intercalate into helical 
regions of DNA and RNA. When illumination with UVA occurs, they react with 
pyrimidine bases to form covalent mono-adducts and cross-links with the nucleic acids 
(Corash, 2003). Consequently, both nucleated cells (T cells, leukocytes) and pathogens 
are unable to replicate. Psoralen S-59 (Cerus Corporation, Concord, CA, USA) for use 
on platelet concentrates is now being introduced into clinical practice in Europe since it 
has received final CE Mark approval. However, when RBCs are processed through the 
system, they constitute a difficult environment for pathogen inactivation because of the 
light absorbance by haemoglobin and the viscosity of packed RBCs (Corash, 2003). A 
compound that does not require light activation, called S-303 (Cerus Corporation, 
Concord, CA, USA), is thus utilised and is activated by a pH shift created by the 
introduction of erythrocytes into the system. Phase III clinical trials on S-303-treated 
RBC are underway to evaluate their safety and efficacy in the treatment of acute and 
chronic anaemia. Another compound used for pathogen reduction in RBC concentrates 
is PEN 110 (INACTINE™; VI Technologies, Watertown, MA, USA). It is a highly 
water-soluble cation capable of diffusing through cell membranes and covalently 
interacts with nucleophilic centres of nucleic acids, essentially with N7 of guanine
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residues (Lazo et al., 2002). N7 guanine alkylation can cause opening of the imidazole
ring, base loss and strand breakage, resulting in disruption of transcription and
replication of the pathogen genome (Lazo et al, 2002; Purmal et al, 2002). The
removal of PEN 110 to a non-toxic level is then performed using an automated cell-
washing process.
A different chemical treatment is that of iodine, a strong oxidizing agent with powerful 
microbicidal properties. When it is bound to polymers or dextran chromatographic 
medium such as Sephadex®, there is a slow, controlled release of iodine into the protein 
solution, with virus inactivation occurring over a longer time course (hours) (Miekka et 
al, 1998). In the case of the chromatographic medium, protein is passed through a bed 
of iodine-Sephadex® followed immediately by a bed of Sephadex® used to trap and 
remove free iodine. The factors that might affect the iodine inactivation system are 
iodine concentration, age of iodine-Sephadex®, temperature, contact and incubation 
times and composition of protein solution being treated. All these factors need to be 
defined and controlled. Liquid iodine has also been found to inactivate several 
enveloped and non-enveloped viruses in an antithrombin IE concentrate (Highsmith et 
al, 1995).
Several physical treatments can also be applied, such as UVC light (254nm), which 
targets nucleic acid, thereby inactivating a wide range of viruses, irrespectively to the 
presence of a lipid envelope. Both albumin and IVIG solutions had to be treated with
o  #
5,000 Joules/m UVC before non-enveloped and heat and/or acid resistant viruses (polio 
2, vaccinia and T4 phage) were effectively inactivated (Hart et al, 1993). A recent 
study also showed that UVC can be used at doses that preserve protein activity but still 
inactivate MVM, parvovirus B19, the encephalomyocarditis virus, which is a model for
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HAV, and bovine herpes virus type 1, a model for enveloped viruses such as HBV
(Caillet-Fauquet et al., 2004).
Gamma irradiation has been used extensively for the treatment of a variety of materials 
ranging from sterilizing medical devices (Doue, 2001) to reducing bacterial and viral 
contamination in animal sera (House et al., 1990). Such irradiation readily penetrates 
protein solutions and has the potential to inactivate pathogens during the manufacture of 
bulk intermediates and in final products (Miekka et al., 2003). It can act either by direct 
rupture of covalent bonds in target molecules including proteins and nucleic acids, or 
indirectly by producing reactive free radicals and other active, radiolytic products, 
which in turn can react with proteins and nucleic acids.
Lastly, the novel system of SuperFluids™ (Aphios Corporation, Woburn, MA, USA) 
has the ability to reduce the viral load of both enveloped and non-enveloped viruses. 
They are normally gases which, when compressed to a particular pressure and heated to 
a specific temperature, enter the supercritical fluid region and show enhanced solvation, 
penetration and expansion properties (Dr T Castor, personal communication). Treatment 
of viruses with these fluids results in inflation of the particles due to penetration of the 
SuperFluids™. Subsequent decompression causes their expansion within the virus 
particles resulting in rupturing of the particles at their weakest point. This technology 
does not damage proteins and enzymes since it is purely physical and does not involve 
the use of chemicals, heat or irradiation. The other advantages are the fact that they are 
readily separated, with no toxic residues and that the system can be easily scaled up to 
production levels with continuous flow operations. However, this technique cannot be 
used on blood donations that still contain red blood cells because these fluids would 
damage them.
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I.2.4.3. Replacement therapy
The last point to consider is an alternative choice of replacement therapy, namely
recombinant clotting factor concentrates. The first-generation recombinant factor VIII,
formulated in albumin, was licensed in the early 1990s (Mannucci, 2002). Although
they showed excellent efficiency and triggered no more inhibitors than plasma-derived
factors do, the safety of the albumin used as a stabiliser was questioned, as discussed
previously (Eis-Hiibinger et al., 1996; Aygoren-Piirsiin et al., 1997). Second-generation
recombinant factor VIII, in which no human albumin is added but includes a S/D step,
is licensed in both the US and Europe (Mannucci, 2002). Additionally, clinical trials are
underway for third-generation recombinant factor VIII, which are manufactured with no
human or animal protein. Such formulated and manufactured recombinant factor IX is
already available. However, those products cost 2 to 3 times more than blood products
and few haemophiliacs can be prescribed this safer alternative. Moreover, the
production capacity for recombinant factors is still limited, leading to a risk of shortage.
1.3 Aims of the thesis
In the present study, several continuous cell lines were evaluated for susceptibility to 
B19 infection with a view to developing a sensitive in vitro infectivity assay. As B19 
does not produce any cytopathic effect in susceptible cell cultures, replication can be 
demonstrated by IFA detection of viral proteins, (particularly NS1, which is not present 
in the B19 inoculum), an increase in viral DNA or in the detection of B19 mRNA. 
Quantification by IFA is difficult due to the poor susceptibility of the cell lines used for 
B19 replication and the sensitivity of the technique. Similarly, accurate quantification 
by DNA amplification is complicated by the fact that it is difficult to ensure that all 
input viruses are thoroughly removed before analysis of progeny virus, especially at the
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lower dilutions. The best method is thus detection of mRNA. In B19 replication, spliced
mRNAs are transcribed off the B19 template and these are easily amplified by reverse
transcriptase PCR (RT-PCR). They have a distinct size compared with amplicons that
may possibly be amplified from the DNA template.
In addition to using B 19-specific primers for RT-PCR, primers specific for the 
housekeeping gene (3-actin were included in the amplification reaction. Housekeeping 
genes are expressed at a constant level in different tissues, stages of development and 
experimental treatment. The level of actin in samples for a particular assay was used to 
normalise the B19 mRNA results.
The initial work on the evaluation of cell lines for B19 infectivity assays was done with 
the KU812 and UT-7/EPO cell lines, which were easily available. Later in this study, 
the KU812Ep6 cell line, which was reported to be a better line for B19 infection, was 
obtained and some preliminary work was done with this cell line. However, due to 
restrictions on the use of the KU812Ep6 cell line, the clonally selected cell line, UT- 
7/EPO-S1, was obtained and evaluated.
Several parameters, such as the optimal time to infect the cell lines, the passage number, 
the conditions for culture and inoculation were investigated. In addition, the effects of 
cell synchronisation on susceptibility to B19 infection were studied. Cell 
synchronisation has been reported to enhance the susceptibility of the human 
megakaryocytoblastoid cell line UT-7 to B19 infection (Shimomura et a l, 1993). This 
was possibly due to the requirement of a product of the S phase of cell division for B 19 
replication. It has also been reported that B19 requires rapidly dividing cells for 
propagation (Anderson, 1987b). Finally, the effects of hypoxia on the susceptibility of 
the cell lines to B19 infection were studied. In contrast to standard cell culture 
conditions, characterized by 20% oxygen concentration, cells in the human body are
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exposed to much lower oxygen concentrations, ranging from 16% in the pulmonary
alveoli to less than 6% in most other organs of the body (Semenza, 2001). Moreover,
oxygen concentration may even drop to extremely low concentrations, close to anoxia,
in the presence of altered vascularization as observed at pathological sites such as
tumors. Several studies have shown that severe hypoxia (1% oxygen) increased the
number of erythroid BFU-E generated from CD34+ cells, as well as their maintenance
in a liquid culture system (Cipolleschi et al., 1997; Sun et al., 2000). On the other hand,
hypoxia inhibited the expression of CD36, a marker of erythroid CFU-E and maturing
erythroid precursors (Cipolleschi et al., 1997). The role of EPO levels in the
differentiation and amplification of the CFU-E pool under hypoxia was found to be
crucial in mouse model (Mide et al., 2001). EPO, which is a hypoxia-inducible
cytokine, might indeed act as a “survival factor” at the CFU-E level and/or increase the
flow of cells from BFU-E to CFU-E. The enhancement of B19 replication in cells
grown in low oxygen conditions could thus be due to the proliferation and maintenance
of the virus target cells. In addition, this phenomenon could be explained by an increase
in the expression of viral receptors on cells grown in hypoxia. Such conditions have
recently been found to induce high expression of CXC-chemokine receptor 4 (CXCR4),
one of the primary HIV-1 co-receptors in vivo, in different cell types: monocytes,
monocyte-derived macrophages, tumor-associated macrophages, endothelial cells and
cancer cells (Schioppa et al., 2003).
In addition to quantification of B19 DNA, the present study describes optimization of a 
procedure to semi-quantitate B19 mRNA in B19-infected cell cultures.
The second part of the present study used the optimised B19 infectivity and quantitative 
B19 DNA assays to evaluate the efficacy of five methods for the inactivation or removal
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of pathogens from blood products. Two chemical methods (psoralin and Inactin
treatments) and two physical methods (pressure cycling and dry heating) for pathogen
inactivation were studied. In addition, a pathogen removal method, nanofiltration, was
included in this study.
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II.l. Materials
II.l.l. Agarose gel electrophoresis
• 50 x Tris-acetate-ethylenediamine tetraacetic acid (EDTA) (TAE) stock. Made 
at NIBSC: 2M Tris-acetate, 50mM EDTA. Working solution is 1 x TAE.
• Ethidium bromide tablets (EtBr) (BIO-RAD, 161-0430).
• Ethidium bromide-agarose gel: a 2% agarose gel was prepared by adding 100ml
of lx TAE buffer to 2g of agarose powder (Agargel H/M, CLP, #5410.500), 
which was then heated in a microwave oven for a couple of minutes to dissolve 
the agarose. The gel solution was stirred, left to cool down to just above body 
temperature. EtBr was then added at a final concentration of lpg/ml (lOOjil of 
1 mg/ml stock). The agarose solution was poured into the gel apparatus and the 
combs were put in place.
• 6x blue/orange loading dye (Promega, G190A)
• The PCR markers (Promega, G3161A) contained lambda phage
EcoRlfragmements 1000, 750, 500, 300, 150 and 50 base pairs in length. For 
gel analysis, the DNA ladder was prepared by adding 5jxl of PCR markers to 2j l l 1 
of blue/orange dye.
• The gel was placed into the gel tank of the electrophoresis apparatus (Horizon™ 
11.14, BRL) and the combs removed carefully to avoid tearing the wells. The 
power was supplied through GenePower Supply GPS 200/400 (Pharmacia) and 
the gel was run for approximately 1 hour at 90V (110mA).
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n.1.2. Nucleic acid extraction
All buffers for extraction, RT-PCR and PCR were prepared in a dedicated “clean”
room. All sample dilutions and extraction of nucleic acids were done in a level 2+
laboratory in a class II cabinet.
• DNA extraction: QIAamp DNA blood mini kit (50 extractions) (Qiagen, 51304) 
Buffer OL1 from QIAamp DNA mini kit: 30pl of p-mercaptoethanol (P-ME; Sigma- 
Aldrich, M6250) was added per 1ml of lysis buffer OL1, supplied in the Qiagen kit. 
Due to its toxicity, p-ME must be dispensed in a fume cabinet and appropriate 
protective clothing must be worn. OL1 buffer is then stable for 1 month at room 
temperature.
• mRNA extraction: Oligotex direct mRNA micro kit (Qiagen, 72012)
■ Buffer OCL (lysis buffer) made in-house for mRNA extraction:
lOmM Tris.Cl pH 7.5 (made up from Trizma®Hydrocloride (Sigma, T-9285) 1M and 
Trizma®Base (Sigma, T-8524))
140mM NaCl (5M solution, Sigma, S5150)
5mM KC1 (sigma, P5405)
1% IGEPAL CA-630 (Sigma, 13021)
Buffer OCL was stored at 4°C for one month and kept on ice during the extraction.
■ Buffer OCD (dilution buffer) was made fresh before each extraction:
1M lithium chloride (LiCl) (8M solution, Sigma, L7026)
20mM Tris.Cl pH 7.5
2mM Ethylenediamine-tetracetic acid (EDTA) (Sigma, E7889)
1% Sodium dodecyl sulfate solution (SDS; Sigma-Aldrich, L4522)
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II. 1.3. Nucleic acid amplification 
11.1.3.1. DNA amplification
The kit used for DNA amplification was the LightCycler Faststart DNA Master S YBER 
Green kit (Roche, 3003230). The LightCycler glass capillaries were also supplied by 
Roche (1909339).
The primers (desalted) were first obtained from GIBCO BRL Life Technologies (UK), 
renamed (from October 2001) Invitrogen Life Technologies (UK). They were 
reconstituted in RNAase-free water to obtain a working solution at 25pmol/pl 
However, the absorbance at 260nm of all the primers was also measured and the 
concentrations calculated using the following equation:
Concentration (nmole/ml) = A260 x weight per OD (given by the manufacturer on the
data sheet) x dilution factor
The sequence of the forward primer, B19F, was:
5’ GGC AGC ATG TGT TAA AGT GGA 3’. The annealing temperature of this primer 
in 50mM Na+ was 55.8°C and it was located at positions 1538-1558 on the B19 
genome. The sequence of the reverse primer, B19R, was:
5’ CTC CAG GCA CAG CTA CAC TTC 3’. The annealing temperature of the reverse 
primer in 50mM Na+ was 57.7°C and it was located at positions 1840-1820 on the B19 
genome. This primer pair amplified a 302 base pair region of the NS1 gene.
11.1.3.2. mRNA amplification
The kit used for RNA amplification was the one step RT-PCR kit (100 reactions) 
(Qiagen, 210212).
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The primers (desalted) used for mRNA amplification were first obtained from GIBCO
BRL Life Technologies (UK), renamed (from October 2001) Invitrogen Life
Technologies (UK). The relative positions of the primers on the B19 genome are shown
on figure 2.1 and the primers sequences and the sizes of the specific amplification
products are listed in table 2.1. The splicing donor and acceptor sites indicated on figure
2.1 were first described by Ozawa and coworkers, and then revised by St Amand and
colleagues (Ozawa et al., 1987; St Amand et al., 1991). Map location of the primers was
calculated from B19-Au accession number M 13178 (Shade et al., 1986). Details of the
actin primer pair are showed in table 2.2. The primer concentration was calculated after
measurement of their absorbance at 260nm.
Figure 2.1: Location of B19 primers on the genomic and transcription maps of B19
Genomic
DNA
AGGT
mRNA
B19-6
B19-9 XPP2
GT: splicing donor site (406)
AG: splicing acceptor site (1910; 1925; 1952; 2030)
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II.1.4. Purification of amplified products from agarose gels for sequencing
Tris-EDTA (TE) buffer: lOmM tris, pH 8 , ImM EDTA. It was used to wash the spin
column.
n.1.5. FACS analysis
• The wash buffer contained PBS (made at NIBSC) with 2% foetal calf serum 
(FCS) (GIBCO Invitrogen cell culture, 16000) and 0.05% w/v sodium azide 
(Sigma, S8032)
• The fixative buffer was 2% saline formaldehyde solution (formaldehyde solution 
from VWRIntemational, 284216N)
• Mouse IgG negative control RPE (Serotec, MCA928PE)
• Mouse anti-human CD34 Class II-RPE (Serotec, MCA1578PE)
II. 1.6. Primary cells
II.1.6.1. CD34+ cells
Cells expressing CD34 are normally present at a frequency of 0.05-0.2% in peripheral 
blood whereas the peripheral blood from patients whose stem cells have been mobilised 
contains up to 1% of CD34+ cells (Dr M. Watts, personal communication; Watts and 
Linch, 1997). Thus, Dr M. Watts (Department of Haematology, University College 
Hospital, London, UK) kindly provided mobilised peripheral blood (on a weekly basis), 
from which CD34+ cells were selected.
II. 1.6.2. Aperesis cells
Samples of apheresis cells, or mobilised PBMC, were kindly given weekly by Dr M. 
Watts (Department of Haematology, University College Hospital, London, UK).
n.1.7. Continuous human erythroid cell lines
The human cell lines used in this study are shown in table 2.3.
Chapter II
Table 2.3: Human cell lines used in this study
Cell line Origin Reference Growth medium Source
KU812
Patient with 
chronic myeloid 
leukemia
Nakazawa 
etal., 1989
RPMI1640 +10% 
FCS + 1% glutamine 
+ 1% pen/ strep
Dr Nakazawa, 
Niigata 
University, 
Japan
KU812Ep
6
Erythropoeitin- 
dependent 
subline of 
KU812
Miyagawa 
etal., 1999
RPMI 1640 +10% 
FCS + 6  IU/ml EPO + 
1% glutamine + 1% 
pen/ strep + 1% 
fungizone
Ube Research 
laboratory, 
Fujirebo, 
Japan
UT-
7/EPO
Erythropoeitin- 
dependent 
subline of UT-7, 
a human 
leukaemia cell 
line
Komatsu 
etal., 1993
IMDM +10% FCS + 
2 IU/ml EPO + 1% 
pen/ strep + 1% 
fungizone
Dr.Komatsu, 
Jichi Medical 
School, 
Tochigi, Japan
UT-
7/EPO-S1
Erythropoeitin- 
dependent 
subline of UT- 
7/EPO
Morita et 
al., 2 0 0 1
Iscoves modified 
DMEM + Glutamax- 
1 +10% FCS + 2 
IU/ml EPO + 1% 
gentamycin + 1% 
fungizone
Dr Morita, 
Tohoku 
University, 
Japan
All the cell lines grew as suspension cultures, either as single cells or in aggregates. All 
cell lines were grown at 37°C in a 5% CO2 atmosphere, either in 75mm3 flasks (Falcon) 
or in 24-well or 96-well plates (Falcon). The stock cell cultures were split every 3-5 
days at a split ratio of 1:3 to 1:5. The cell suspension was centrifuged at 715g for 10
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minutes to pellet the cells. The pellet was then resuspended in a small volume of growth
medium (usually l-5ml), diluted 1:10 in trypan blue solution and the live cells
(unstained) counted in a haemacytometer (Sigma).
UT-7/EPO-S1 cell aggregates, which can be seen on figures 2.2 and 2.3, had already 
been shown to be more susceptible to B19 infection than single cells (Dr Morita, 
personal communication). Thus before splitting, the cells were left for 30 minutes to 
settle at the bottom of the flask and most of the medium was carefully removed, leaving 
behind the cell aggregates. The latter were then resuspended in a small volume of 
growth medium, and the cell aggregates dispersed by pipetting before further 
processing.
Hypoxia studies on UT-7/EPO-S1 cells were performed in the laboratories of the 
Canadian Blood Services (Ottawa, Canada), which had a dedicated incubator required 
for tissue culture in a controlled low oxygen atmosphere, using regulated oxygen and 
nitrogen supplies.
Figure 2.2: UT-7/EPO-S1 cell aggregates under the light microscope (x20)
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Figure 2.3: UT-7/EPO-S1 cell aggregate under the light microscope (x40)
II. 1.8. Cell culture reagents
• RPMI 1640 with L-glutamine and sodium biocarbonate (Sigma, R8758-500ml)
• Iscove’s Modified Dulbecco’s Medium (IMDM) (GIBCO BRL (Life 
Technologies Ltd, 21980-024)
• IDMEM with Glutamax-I (GIBCO BRL Life Technologies Ltd, 31980-022)
• TCI00 insect culture medium (for SF9 cells) with L-glutamine and sodium 
biocarbonate (Sigma, T3160)
• GIBCO Invitrogen cell culture, 16000
• Erythropoeitin (EPREX, 1000IU/0.5ml) (Janssen-Cilag Ltd, 140165)
• Penicillin and streptomycin (Pen/strep) (Sigma, P0781)
• Fungizone (250|ig/ml; 20ml) (VWR International, 700/0030/08)
• Trypan blue 0.4% solution (Sigma, T8154)
• Inverted light microscope (Olympus Tokyo)
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• Fluorescence microscope (Zeiss, Axiovert 10)
• Collagen I from rat-tail (Sigma, C7661-5MG), at a working solution of 50pg/ml 
made in a solution of 0.02N acetic acid (0.57ml of glacial acetic acid (Fisons, 
A10400/PB17) in 500ml sterile glass distilled water).
• Fibronectin-like protein polymer genetically engineered (Sigma, F5022). The 
stock solution (lmg/ml) was diluted 1:10 in PBS-A (prepared in-house) to 
obtain a working solution at lOOjug/ml.
• The stock solution of hydroxyurea was prepared as follows:
A 1M solution of hydroxyurea was prepared by adding 0.7605g of hydroxyurea (Sigma, 
H8627) into 10ml of sterile water. The solution was then filtered with a 25mm diameter 
filter, 0.2jim pore size (Whatman). The working solution of hydroxyurea was made by 
1:100 dilution (lOmM) of ImM hydroxyurea in sterile, distilled water
• Culture of CD34+ cells: IMDM, 20% FCS, 20ng/ml human stem cell factor 
(SCF) (Sigma, S7901), 2u/ml EPO, lng/ml human IL-3 (Sigma, 11646), 1% 
fungizone and 1% penicillin/streptomycin
• Culture of BFU-E: 80ml FOX’s complete medium (StemCell Technologies, 
Methocult™ H4230), 20ml IMDM, 30ng/ml IL-3, 2U/ml EPO, 25ng/ml G-CSF, 
lOng/ml SCF and 25ng/ml GM-CSF.
• 5M NaCl: 290.2g NaCl (BDH AnalaR®, 102414J) were dissolved in 1 litre 
double-distilled water and dispensed into 1 0 0ml aliquots.
• Preparation of phosphate buffers:
■ 0.2M phosphate buffers: a stock solution of 0.2M NaH2P0 4  was
prepared by dissolving 24g of sodium phosphate monobasic (NaKfePC )^ (Sigma, S5011) 
in 1 litre double distilled water. The stock solution was aliquoted in 100ml volumes and 
autoclaved.
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■ A stock solution of 0.2M of Na2HPC>4 was prepared by dissolving
28.4g of sodium phosphate diphasic (Na2HP0 4 ) in 1 litre double distilled water, 
aliquoted in 1 0 0 ml volumes and autoclaved.
■ The required pH was obtained by mixing the two buffer components 
as in the following proportions:
Table 2.4: Phosphate buffers composition
Phophate buffer (0.2M) pH 5.7 pH 6.0 pH 6.5 pH 6.7
Volume of Na^PCL (ml) 93.5 87.7 68.5 56.5
Volume of Na2HPC>4 (ml) 6.5 12.3 31.5 43.5
■ Physiological phosphate buffers
In order to obtain lOmM physiological phosphate buffers (to keep the cells viable), 5 ml 
of 0.2M buffers shown above were mixed to 2.9ml of 5M NaCl (Sigma, S5150) and 
92.1ml of sterile water to give a buffer containing 0.85% NaCl. The pH of the buffers 
was checked with a pH meter (3520 pHMeter, Jenway).
• Preparation of acetate buffers:
■ 0.2M acetate buffers: a stock solution of 0.2M sodium acetate was
prepared by dissolving 16.4g sodium acetate (C2H3 0 2Na) (Sigma, S2889) in 1 litre 
double distilled water. The stock solution was aliquoted in 100ml volumes and 
autoclaved.
■ The required pH was obtained by mixing the stock buffer solution 
with glacial acetic acid (Fisons, A10400/PB17) as in the following proportions:
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Chapter II
Acetate buffer (0.2M) pH 5.6 pH 5.2 pH 4.8 pH 4.4 pH 4.0
Volume of glacial acetic acid (ml) 4.8 10.5 2 0 30.5 41
Volume of Na acetate (ml) 45.2 39.5 30 19.5 9
■ Physiological acetate buffers:
In order to obtain alOmM physiological acetate buffers, (to keep the cells viable), 5 ml 
of 0.2M buffers shown above were mixed to 2.9ml of 5M NaCl and 92.1ml of sterile 
water to give a buffer containing 0.85% NaCl. The pH of the buffers was checked with 
a pH meter (3520 pHMeter, Jenway).
• Sterilization of stock and working cell culture reagents by autoclaving. All 
buffers and solutions were autoclaved (121°C for 15 minutes) before use.
11.1.9. Immunofluorescent reagents
PBS/0.05% Tween 20 (Sigma, P1379)
Evans blue/ PBS/Tween: 1 drop of Evans blue in 5ml of PBS/Tween 
Polyvinyl alcohol mounting medium with DABCO (Sigma, 10981)
11.1.10. Antibodies
• Mouse monoclonal antibody against VP1 and VP2 proteins (Novocastra 
Laboratories Ltd, UK, R92F6)
• Mouse monoclonal antibody against VP1 and VP2 proteins (kindly given by Dr 
Miyagawa, Fujirebo, Japan)
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• Mouse monoclonal antibody against VP1 and VP2 proteins (kindly supplied by
Dr. J. Blumel, Paul Erhlich Institut, Germany)
• Rabbit polyclonal antibody against NS1 protein (kindly supplied by Dr. S. 
Doyle, National University of Ireland, Republic of Ireland)
• Anti-mouse IgG (whole molecule)-FITC antibody produced in goat (affinity 
isolated antibody buffered aqueous solution; Sigma, F2012)
• Monoclonal anti-rabbit immunoglobulins-FITC antibody produced in mouse 
(clone RG-16 purified immunoglobulin buffered aqueous solution; Sigma, 
F4890)
• Alexa Fluor® 488 signal amplification kit for mouse antibodies was obtained 
from Cambridge BioScience (catalogue number A-l 1054)
11.1.11. MACS
• MACS direct CD34 progenitor cell isolation kit (Miltenyi Biotech, 467-02)
• 50 Pre-Separation Filters (Miltenyi Biotech, 130-041-407)
• MiniMACS Starting Kit (Miltenyi Biotech, 130-090-312)
• Wash buffer: PBS-4salts/ 2mM EDTA/ 0.5% BSA. Keep cold.
11.1.12. Sequencing
GenElute™ Minus EtBr spin column (56501; Sigma-Aldrich, UK) was used to 
eliminate ethidium bromide from stained DNA. The PCR reaction to amplified the 
extracted DNA was run on the robocycler PCR machine called RoboCycler® gradient 
96 (Stratagene). Sequencing itself was done using the ABI kit and the ABI310 
sequence analyzer (ABI, UK).
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II.1.13. Human parvovirus B19 removal/inactivation studies
II. 1.13.1. Virus removal by nanofiltration using Planova® filters: 
Asahi Kasei Pharma
Planova® filters are available as single-use, self-contained modules in four mean pore 
sizes of 15 nm, 19 nm, 35 nm, and 72 nm, which correspond to Planova® 15N, 20N, 
35N, and 75N, respectively (figure 2.4).
Figure 2.4: Photograph of 15N and 35N Planova® filters
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In the present study, the first three types of filters were used. A range of surface areas 
for each mean pore size allows simple scale-up from validation studies to process scale. 
Planova® filters were subject to two separate integrity tests by the manufacturer to 
confirm pore size distribution (Planova® New Pressure Hold Test) and the absence of 
membrane defects (leakage test).
Planova® filters utilise a hollow-fibre microporous membrane constructed of naturally
hydrophilic cellulose with a narrow pore distribution. The Planova® membrane is
actually a tortuous, three-dimensional structure of interconnected "voids" and
"capillaries" (figure 2.5). Higher protein recoveries are possible due to the hydrophilic
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properties of the membrane which lower the probability that product protein will be
adsorbed to the surface of the membrane.
Figure 2.5: Capillary-void structure in a Planova® 15N (x 50,000)
Positive image Negative image
C a p i l l a r y
Human albumin was chosen as a model protein of plasma-derived product to test this 
virus removal technique. Reconstituted 25% albumin was obtained from department of 
Immunobiology at NIBSC.
II.1.13.2. Virus inactivation by SuperFluids™: Aphios Inc., USA
Aphios Corporation (Woburn, MA, USA) was granted a US Patent (No: 5,877,005) in 
March 1999, “Viral inactivation method using near-critical, supercritical or critical 
fluids” for pathogen inactivation. As shown on figure 2.6, SuperFluids™ are normally 
gases which, when compressed to a particular pressure (critical pressure Pc) and heated 
to a specific temperature (critical temperature Tc), enter the supercritical fluid region 
and show enhanced solvation, penetration and expansion properties.
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Temperature
Three supercritical fluids were used in the present study, namely Freon-22, Freon-23 
and N20 /C 0 2.
The laminar flow SuperFluids™ inactivation unit is composed of an isobaric chamber, 
SuperFluid5™ and sample inputs, a decompression chamber and a collection system. 
Additionally, several isobaric chambers can be used in the system when a multistage 
laminar flow SuperFluids™ inactivation is set up that can further increase the reduction 
in viral load. The inactivation protocol consists of four steps: addition of SuperFluids™ 
to the product to be treated, adjustment of the operating pressure and temperature, 
mixing in order to reach a specific contact time between the SuperFluids™ and the 
virion, typically from 10 seconds to 1 minute. This step results in inflation of the 
particles due to penetration of the SuperFluids™. Finally, decompression of the system 
causes expansion of the SuperFluids™ within the virus particles resulting in rupturing 
of the particles at their weakest point.
SUPERCRITICAL 
FLUID REGION
LIQUID
SOLID
NEAR CRITICAL 
REGION
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11.1.13.3. Virus inactivation by the INACTINE™ system: Vitex, USA
The INACTINE™ System, which was developed by VI technologies or Vitex, features 
small molecules that, due to their size and stability in blood, are able to penetrate 
through the protective walls of resistant pathogens. These molecules, which can be 
synthesized in abundant quantities, are activated only when they bind to their target, the 
DNA or RNA of the pathogen. The loss of DNA or RNA replication is a fatal event for 
viruses or bacteria whereas the red blood cells do not need DNA or RNA to function. 
By purifying the red cells during the automated washing process to remove the 
INACTINE™ PEN110 (the Psoralen treatment compound) to trace levels, the 
INACTINE™-treated RBCs concentrates appear very safe.
11.1.13.4. Virus inactivation by S-59: the Helinx® technology; Cerus 
Corporation, USA
Cerus Corporation (CA, USA), has developed a family of novel small molecules which 
target and crosslink nucleic acids. These Helinx® compounds penetrate cellular and 
nuclear membranes and intercalate into the helical regions of DNA and RNA. The 
Cerus technology, the INTERCEPT Blood System, includes the INTERCEPT platelet 
system, the INTERCEPT plasma system and the INTERCEPT red blood cell system. 
They were developed in collaboration with Baxter Healthcare, for use in blood centres, 
and include a sterile disposable set pre-filled with Helinx® inactivation compounds. 
When plasma and platelet concentrates are treated, the psoralen compound amotosalen 
hydrochloride (HC1) S-59 is used. Crosslinking of nucleic acids can be achieved in four 
steps, the first one being targeting, which involves the penetration of the psoralen 
compound amotosalen into cells, viruses, bacteria and other pathogens. The second step 
is the docking of the psoralen compound between the paired A, C, G and T bases of the
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DNA ladder. The third step starts when, under illumination with 3.0 J/cm2 ultraviolet A
(UVA) light (a first photon), amotosalen reacts with the pyrimidine bases C or T,
resulting in the formation of a link with the DNA. Finally, additional illumination can
form a crosslink with both strands of DNA. This reaction can occur with the genomic
material of DNA- and RNA-based viruses, in genomes that are either single or double
stranded. Pathogens, as well as potentially harmful white blood cells with crosslinked
DNA, can no longer replicate and cause infection or destructive transfusion reactions.
Nevertheless, platelets, plasma and red cells do not contain nuclear DNA or RNA that
can be targeted by this molecule and therefore retain their biological utility after
Helinx® inactivation treatment (Wollowitz, 2001).
II.2. Methods
II.2.1.Virus quantification
Three B19 virus isolates were used for this study: two from Germany, isolates JS and 
JB, and one from the USA, named isolate LP. These isolates were quantitated using the 
established LightCycler quantitative assay. Dilutions of the WHO B19 International 
Standard (IS) were run in parallel in order to construct a standard curve for the 
quantitation.
Isolate JS (titre lxlO12 IU/ml) was used throughout this study for the establishment of
all the assays and will be referred to as “B19 stock virus”. In addition, this isolate was
used to spike the samples that were treated for viral inactivation and removal. The DNA
and infectivity titres of the three isolates were compared using the optimised mRNA
1 ^assay. Isolate LP (titre 5x10 IU/ml) was used as a positive control in infectivity assays 
to evaluate the efficacy of the viral inactivation studies (chapter IV).
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EM and IEM by negative staining were done on B19 stock virus by Mr B. Megson and
Ms H. Appleton (HPA). IEM used 50pl of JS isolate and 50pl of antibody, contained in
serum Pickem (Cossart et a l, 1975). Normal EM was done with the isolate only (50pl).
II.2.2. Detection of virus infectivity by indirect immnunofluorescent assay
(IFA)
II.2.2.1. Preparation of microscope slides
The Shandon Cytospin® 2 (Life Sciences International) was used to spin cell 
suspensions and simultaneously sediment the cells onto a microscope slide. The result 
was a monolayer of cells concentrated in a small-defined zone (6 mm circle). The cell 
suspension was placed into a disposable cytofunnel, which had been attached to a 
cytoblock, with the slide and blotter. Up to 12 samples could be run during one spin, 
which lasted for 5 minutes at 45g. The disadvantage of this method was that only one 
sample could be spun on one microscope slide, which meant that many slides had to be 
processed. The slides used in this method were Apes slides which were made in-house 
by the histology laboratory at NIBSC by coating glass slides with 3-amino 
propyltriethoxysilane (Sigma). When the monolayer was dry, the cells were fixed in 
cold acetone for 10  minutes.
Alternatively, cells were spun for 5 minutes at 145g and the supernatant discarded. The 
pellets were resuspended in 50pl of PBS-A and lOpl of cell suspension was first place 
on the slide and left to air dry. The slides used were multispot microscope slides 
polytetrafluoroethylene (PTFE) coated from Hendley-Essex. The slide was observed 
under light microscope to ensure that an even layer of cells was obtained and the cell 
density adjusted accordingly. Once dry, the cells were fixed in cold acetone for 10 
minutes.
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11.2.2.2. Protocol
If the slide used did not already contain defined spots, as in the coated multispot 
microscope slides (Hendley-Essex), a circle was drawn around the fixed cells with a 
PAP pen (Cambridge BioScience) in order to define the area where the antibodies 
would be placed and to retain the reagents on the glass slide.
The slides were washed in PBS/Tween 20 (0.05%) and air dried in a class 1 cabinet. A 
mouse monoclonal anti-VPl/VP2 antibody (R92F6; Novocastra Laboratories Ltd, UK) 
was diluted 1:80 and a negative serum diluted 1:100 in PBS/Tween. 100 to 150jil of 
antibody or negative serum was added to the cells, which were then incubated for 30 
minutes at 37°C (5% CO2).
The slides were washed twice in PBS/Tween for 10 minutes each time. In the meantime, 
a goat anti-mouse FITC conjugate was diluted 1:100 in Evans blue/ PBS/Tween. Evans 
blue was used to avoid high background staining. The edges of the slides were carefully 
dried after the washes and IOOjliI of the conjugate was added to the cells, which were 
incubated for 30 minutes at 37°C (5% CO2).
The slides were then washed twice again in PBS/Tween for 10 minutes each time, and 
once with distilled water. They were air dried inside the cabinet and mounted with 
Dabco using a cover slip. The slides were then ready to be viewed under the 
fluorescence microscope (oil immersion objective) or could be stored at -20°C for a few 
months.
11.2.2.3. Positive controls: baculovirus expressing B19 capsid antigens
Since baculovirus is an insect virus, either SF9 or SF21 insect cell lines could be used 
for culturing the recombinant viruses. Both cell lines were cultured at 28°C in TC100 
medium with 10% fetal calf serum (FCS) and 1% fungizone in 75cm3 flasks as a cell
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monolayer. When the cells were confluent, the medium was discarded and the cells
scraped off with a sterile cell scraper. The cells were resuspended into 60ml of fresh
medium and 5ml of this cell suspension was dispensed into six 25cm3 flasks, labeled
VP1, VP2 and negative control. The cells were left undisturbed for 6  hours at 28°C to
allow the cells to attach to the flask and form a monolayer. Two types of inoculi were
available: baculovirus expressing parvovirus VP1 or VP2 proteins (kindly provided by
Dr J.Clewley and Dr B.Cohen, HPA; Hicks et al., 1996). lOOjiil of each neat inoculum
was added to the corresponding flask whereas nothing was added into the negative
control flask. The flasks were incubated at 28°C for 3 days. The cells were then scraped
off, harvested and centrifuged at 168g for 5 minutes. The cell pellets were resuspended
in 1ml of TCI00 medium. Microscope slides were prepared in one of the two ways
described previously and the cells fixed in cold acetone for 10 minutes. Once dry, the
slides were either treated immediately for immunofluorescence or stored at -20°C for
later use.
II.2.3. Primary cells
II.2.3.1. CD34+ cells
n.2.3.1.1. Isolation of CD34+ cells from PBMC
The positive selection of CD34+ cells was performed using a direct CD34 progenitor 
cell isolation kit, using the MiniMACS (MAgnetic Cell Sorting) kit from Miltenyi 
Biotech GmbH (Germany). This technology is based on the use of MACS MicroBeads, 
MACS Columns and MACS Separators. The MicroBeads are superparamagnetic 
particles that are coupled to highly specific monoclonal antibodies, anti-CD34 in the 
present experiment. They are used to magnetically label the target cell population: 
CD34+ haematopoietic progenitor cells. As the MicroBeads are extremely small (50nm),
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the use of a high-gradient magnetic field is required to retain the labeled cells. By using
a MACS Column with a coated matrix placed in a permanent magnet, the MACS
Separator, the magnetic force is sufficient to retain the target cells labeled with a
minimum of MicroBeads. All the unlabeled cells are washed out thoroughly by rinsing
the column with buffer, without affecting the labeled or unlabeled cell fractions. The
labeled fraction can be collected by removing the column from the magnet. The entire
procedure can be done in less than 30 minutes.
Approximately 4 to 5 ml of peripheral blood were kindly provided weekly by Dr M. 
Watts (Department of Haematology at University College Hospital, London, UK). The 
patients whose blood samples and apheresis cells were tested by BFU-E assay were 
assigned a number in order to respect their anonymity.
The first step consisted of harvesting mononuclear cells from PBMC by density gradient 
centrifugation over Ficoll Paque® (Pharmacia Biotech). The latter was added to the 
blood sample (1 0 % of blood volume), mixed gently and centrifuged for 1 0  minutes at 
168g. The supernatant, which was the platelet-rich plasma (PRP), was removed and 
stored at -20°C for later antibody testing. The peripheral blood was diluted a first time 
1:1 (volume: volume) with RPMI and 10% FCS and the collection tube rinsed with this 
buffer. A second 1:1 (volume: volume) dilution of blood into Ficoll-Paque® was done at 
an angle so that the blood remained on top of the Ficoll-Paque®. The sample was 
centrifuged for 20 minutes at 543g. In the meantime, the MACS Column was prepared 
by placing a 30pm pre-separation filter on top of the reservoir, situated on the upper part 
of the column in order to remove cell clumps.
Three collection tubes (labeled ’Wash’, ‘Waste’ and ‘CD34+’) were prepared and the 
wash tube was placed under the column. The azide in the MACS column was washed 
off with 1ml of cold wash buffer, through the pre-separation filter, which had to be lifted
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to release the buffer. When the centrifugation of peripheral blood and Ficoll-Paque®
was complete, the different cell types had migrated, leading to the formation of layers.
The bottom layer contained erythrocytes, which had been aggregated by the Ficoll and,
therefore, sedimented completely through the Ficoll-Paque®. The layer immediately
above the red blood cells contained mostly granulocytes whereas the lymphocytes,
platelets and monocytes, because of their lower density, were found in the interface
between the remaining plasma and the Ficoll-Paque®. The lymphocytes were collected
with care, transferred to a new tube and the cell clumps were broken by gentle pipetting.
The cells were washed with wash buffer to remove any remaining Ficoll-Paque® and
spun at 1050g for 5 to 7 minutes. Most of the supernatant was discarded and the cell
pellet resuspended by gently flicking the tube. To these cells was added lOOpl of
magnetic beads to which CD34 specific antibodies were directly coupled. These beads
were provided with the direct CD34 progenitor cell isolation kit (Miltenyi Biotech
GmbH). The cells and the magnetic particles were left at 4°C for 30 minutes, with a
gentle mix after 15 minutes.
The cells were then washed with wash buffer and centrifuged at 905g for 5 minutes. The 
supernatant was discarded and the cell pellet resuspended in 0.5ml of wash buffer. The 
waste tube was placed under the MACS column and the cell suspension added in the 
filter. Additional wash buffer was used to wash potential remaining cells from the tube 
and was added to the filter. The MACS column was rinsed with 3 to 4 volumes of wash 
buffer, thereby allowing all the unlabeled cells to be washed out thoroughly, without 
affecting the labeled or unlabeled cell fractions. The MACS column was then removed 
from the magnet and placed onto the CD34+ collection tube. Between 0.5ml and 1ml of 
wash buffer was added to the column and the CD34+ cells were forced out of the 
column by using a plunger. The expected cell count of the isolated CD34+ cells was
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between 105 and 106 cells/ml. The cells were cultured at 37°C (5% CO2) in CD34+ cell
culture medium.
U.2.3.1.2. FACS analysis of isolated CD34+ cells
The cells were labeled with Phycoerythrin-(PE) conjugated anti-CD4 antibody, acquired 
using the FACS (Fluorescence Activated Cell Sorter) machine and the data were 
analysed using the Cellquest program.
CD34+ cells isolated from peripheral blood and apheresis cells were centrifuged for 5 
minutes at 580g. The cell pellet was resuspended in 1 ml of buffer, which was kept at 
4°C. The cells were spun again and most of the supernatant discarded, keeping -lOOpl 
of liquid in the tube. To the cells was added 20|il (2mg/ml stock solution) of mouse 
anti-human CD34 IgGl antibody PE-conjugated. In addition, a negative control was 
used with matching mouse IgGl-PE to assess for non-specific staining. Both samples 
were mixed and left for 1 hour at 4°C. A first wash was done using 1ml of wash buffer 
and the cells were centrifuged for 2 to 3 minutes at 6110g. The supernatant was 
discarded and the wash step repeated. Finally, 1ml of FACS fixative buffer was added 
to the apheresis cells.
The FACS machine (Becton Dickinson) was operated by Dr R. Stebbings (Department 
of Immunobiology, NIBSC).
n.2.3.1.3. Infection of CD34+ cells
Approximately four days after isolation from peripheral blood, CD34+ cells in culture 
(CD34+ cell culture medium supplemented with lng/ml of IL-3) were harvested and 
placed in a 1.5ml sterile Eppendorf tube. The cells were centrifuged for 5 minutes at 
580g and the supernatant was removed.
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For infection, cell pellets containing approximately 105 cells/ml, were resuspended in
30pi of neat B19 stock virus (lxlO12 IU/ml) or 1:10 dilution (lxlO12 IU/ml) whereas
30pl of IMDM was used for the negative control. The cell suspensions were mixed
thoroughly by vortexing and placed at +4°C for 2 hours, with occasional mixing. At the
end of the incubation period, 3ml of freshly prepared IMDM was added to each sample.
Each sample was plated out in a 6 -well plate (0.5ml cell suspension/well). After 3 to 4
days incubation at 37°C (5% CO2), the cells were harvested and slides were prepared
for indirect IFA in one of the two ways described previously (see section II.2.2.1).
II.2.3.2. Apheresis cells
II.2.3.2.1. Determination of anti-B19 IgG status of apheresis 
cell donors by EIA
The anti-B19 IgG status of some of the apheresis cells donors were kindly tested by Dr 
B. Cohen (HPA, London, UK), using serum samples from the donors where available. 
The kit used was the parvovirus B19 IgG sandwich enzyme immunoassay (3rd 
generation) by Biotrin (Dublin, Ireland). In this protocol, lOOjil of diluted patient serum 
(1:10 dilution in sample diluent provided with the kit), lOOpl of negative control (ready- 
to-use) and lOOpl of positive control (ready-to-use) were added to the wells of a coated 
microwell plate. The plate was incubated for 1 hour at room temperature. During this 
step, specific parvovirus B19 IgG antibodies present in serum bound to the microtitre 
wells coated with a purified parvovirus B19 recombinant VP2 protein. Following a 
wash step with wash solution, peroxidase-labelled rabbit anti-human IgG was added 
(lOOpl), which bound to the human parvovirus B19 IgG if present. The samples were 
incubated for 30 minutes at room temperature. After a wash step, the whole complex 
was then detected by addition of substrate (lOOpl), which turned blue in the presence of
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peroxidase. The plates were left at room temperature for a further 10 minutes and stop
solution was added to the samples, leading to a stable yellow end product. Absorbance
at 450nm was read for the controls and each sample tested.
11.2.3.2.2. Determination of anti-B19 IgG status of apheresis 
cells donors by IFA
This test was performed with the help of Dr B. Cohen (HPA, London, UK). Positive and 
negative controls, as well as serum samples from patients who had donated apheresis 
cells, were applied onto the slides and incubated. Following washes, a rabbit anti-human 
FITC conjugate antibody (1:40 dilution) was added onto the slides. Two washes with 
PBS/Tween were followed by one wash with distilled water. Once dried, the slides were 
mounted and observed using the water immersion objective of a fluorescent microscope.
11.2.3.2.3. BFU-E reduction assay
After a cell count, the hospital staff advised on the volume of sample containing 103 
cells. Twice this volume (2 x 10 cells) was transferred into eight sterile 1.5ml 
Eppendorf tube and spun at 2,300g for 30 seconds at room temperature. Seven of these 
tubes were used for infection with parvovirus B19 while the eighth one was the 
uninfected negative control. The pellet in the latter was resuspended by vortexing. In the 
other samples, the supernatant (medium) was removed but saved. The pellet was 
resuspended in 30jxl of B19 stock virus (lxlO12 IU/ml), which had been serially diluted 
1:3 and vortexed. Both infected samples and negative control were left for minimum 2 
hours at +4°C. The medium previously saved was then added to the corresponding 
infected sample and vortexed. Each sample (infected and control) was added to a 2.5ml 
aliquot of Fox’s medium, mixed thoroughly by vortexing and plated out in a 24-well
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plate (0.5ml in each well). The plate was incubated for 10 to 11 days at 37°C in a 5%
CO2 incubator without moving it. The red colonies formed in the negative control were
counted with the naked eye (between 50 and 100 red colonies/well on average) and a
cell count was also done in the infected wells if red colonies were visible.
The percentage BFU-E reduction was calculated using the formulae:
Percentage reduction = (A-B)/A x 100
A being the total number of red colonies in the five control wells and B being the total 
number of red colonies in the five wells inoculated with virus.
II.2.4. Nucleic acid extractions
II.2.4.1. Nucleic acid extraction using QIAamp DNA blood mini kit 
(Qiagen)
The QIAamp DNA blood mini kit (Qiagen) is designed to purify genomic, 
mitochondrial, bacterial and viral nucleic acids from blood and related body fluids. 
Nucleic acids bind specifically to the QIAamp silica-gel membrane while contaminants 
pass through the spin columns. Wash buffers are then used to remove impurities, such 
as PCR inhibitors, and pure, ready-to-use nucleic acids are eluted in water.
Before starting the extraction procedure, and according to the manufacturer’s 
recommendations, the carrier was redissolved in water to obtain a l|JLg/|xl solution, l|il 
of which was added to 200jil the lysis buffer, labelled AL, resulting in a concentration 
of carrier of 1 |ig/reaction. Two hundred micorlitres of sample was gently mixed with 
20|l i 1 of proteinase K (20mg/ml) in a 1.5ml Eppendorf tube. Two hundred and one 
microlitres of AL+carrier was then added to the tubes, which were mixed, spun briefly
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and incubated at 56°C for 10 minutes. A brief spin preceded the addition of 250|il of
ethanol (99% purity). The tubes were once more mixed, spun briefly and left at room
temperature for 10 minutes. The samples were then loaded onto the columns provided
and spun at ll,450g for 1 minute. The collection tubes were changed and the columns
washed once with 500jll1 of AW1 and spun at ll,450g for 1 minute. The collection tubes
were changed and the columns washed with 500jil of AW2 and spun at ll,450g for 1
minute. Once more, the collection tubes were replaced and the columns were spun at
17,530g for a further 3 minutes. The silica columns were then transferred to siliconised
tubes (whose lids had been cut off) and left to stand for a couple of minutes to allow any
residual ethanol to evaporate. To elute the nucleic acids, 60pl of water was added to the
centre of the columns, which were left at room temperature for 1 minute then
centrifuged at ll,450g for 3 minutes. The eluted nucleic acids were transferred to
0.5mL siliconised tubes for immediate amplification and quantification by the
LightCycler system (Roche Molecular Biochemicals). Alternatively, nucleic acids were
stored at -70°C.
II.2.4.2. Oligotex direct mRNA kit (Qiagen) for extraction of poly A+
RNA from whole cells
The Oligotex direct mRNA kit (Qiagen) allows isolation of pure poly A+ mRNA 
directly from cultured cells. Rigorous denaturing lysis conditions applied to the 
homogenised cells can generate an immediate RNAse-free environment for the 
extraction of intact mRNA. Moreover, the Oligotex resin used is composed of 
polystyrene-latex particles of uniform size (1.1pm diameter) and spherical shape. These 
particles form a stable suspension, thereby providing a large surface area for fast and 
efficient hybridisation with polyadenylic acids. After washing, mRNA is eluted in a
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small volume of elution buffer (OEB) and can be used immediately for RT-PCR
amplification.
Prior to extraction, the Oligotex suspension was heated for 10 to 15 minutes at 37°C, 
mixed by vortexing and then left at room temperature while buffer OEB was placed in a 
water bath at 70°C. Approximately 2xl07 cells (grown in suspension) were initially 
pelleted by centrifugation at 402g for 5 minutes in 1.5 ml RNAase-free Eppendorf 
tubes. The cells were disrupted by addition of lysis buffer OL1 (with P-ME) at room 
temperature. To achieve this, the cell pellet was loosened by flicking the tube and
z ' n
adding 600jll1 of OL1 (for 1x10 to 1x10 cells). The sample was vortexed for a few 
seconds or pipetted up and down. In order to homogenise the sample, the lysate was 
passed 5 to 10 times through a 20-gauge needle (0.9mm diameter) fitted to an RNAase- 
free syringe. At this stage, the lysate was either stored at -70°C (for several months) for 
later use or used immediately. To process frozen cell lysates, samples were thawed for 
10 minutes (<2xl07 cells) in a 37°C water bath to redissolve the salts. Dilution buffer 
(ODB), supplied in the kit, was then added to the homogenised cells (1.2ml) and the 
samples were mixed thoroughly by pipetting. The samples were spun for 3 minutes at 
15,115g and the supernatant transferred to a new RNAase-free tube. Thirty-five 
microlitres of Oligotex suspension was added to each sample, mixed by vortexing and 
left at room temperature for 10 minutes. The Oligotex-mRNA complex was pelleted at 
15,115g for 5 minutes. The supernatants were carefully removed and discarded. The 
pellets were resuspended by adding lOOjxl of lysis buffer (OL1), followed by vortexing. 
Four hundred microlitres of ODB was added to the samples which were then incubated 
at 70°C for 3 minutes followed by incubation at room temperature for a further 10 
minutes. This step slightly enriched for poly A+ mRNA by decreasing the amount of 
rRNA. The samples were spun at 15,115g for 5 minutes and the supernatant removed
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carefully. The pellets were resuspended with 350j.ll of wash buffer 1 (OW1) by
vortexing. The samples were then transferred to spin columns provided in the kit and
centrifuged for 1 minute at 15,115g. The collection tubes containing the flow-through
were discarded and replaced. The columns were washed twice with 350jLil of wash
buffer 2 (OW2) as described above. The spin columns were then transferred to 1.5ml
RNAase-free tubes and 30pl of preheated (at 70°C) elution buffer OEB added to the
columns. The buffer was pipetted up and down three to four times to resuspend the resin
and the columns spun for 1 minute at 15,115g. The eluted mRNA was carefully
transferred to new RNAase-free centrifuge tubes, and either placed on ice for immediate
use or stored at -70°C for later amplification.
II.2.4.3. Oligotex direct mRNA kit (Qiagen) for extraction of poly A+
RNA from cell cytoplasm
The same Oligotex direct mRNA kit (Qiagen) was used to extract mRNA from cell 
cytoplasm. However, the lysis buffer (OCL) and dilution buffer (OCD) were prepared 
in-house according to the manufacturer’s instructions (section 1.1.2). Prior to extraction, 
the Oligotex suspension was heated in a 37°C water bath for 10 to 15 minutes, mixed by 
vortexing and then left at room temperature while buffer OEB was incubated in a 
second water bath heated to 70°C. The cells grown in suspension were harvested two 
days post-infection, placed in RNAase-free centrifuge tubes and spun for 5 minutes at 
402g. The cell pellets were loosened by flicking the tubes and 0.2ml of chilled OCL 
buffer was added, followed by incubation on ice for 7 minutes. The tubes were then 
spun for 2 minutes at 755g at 4°C in a pre-chilled centrifuge to pellet the nuclei (the 
nuclear pellets were white and much smaller than the cell pellets). The supernatants, 
containing the cytoplasmic fraction, were transferred to an RNAase-free centrifuge tube.
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Two hundred microlitres of OCD and 20|Lil of Oligotex suspension were added to the
supernatant and mixed thoroughly. After 3 minutes incubation at 70°C, the samples
were placed at room temperature for a further 10 minutes. The samples were spun for 5
minutes at 15,115g at room temperature. The supernatants were carefully removed and
discarded. The pellets were then resuspended in 350pl of wash buffer OW1 by gently
pipetting. Both spin column, supplied in the Oligotex kit, and batch format protocols
were tested.
In the batch format, instead of collecting the Oligotex resin in a spin column, the 
polysyrene-latex particles were pelleted by centrifugation for 2 minutes at 15,115g. The 
supernatants were removed and the pellets resuspended in 350pi of OW2. The samples 
were spun again for 2 minutes at 15,115g and the OW2 wash and centrifugation 
repeated using a new tube. The pellet was then resuspended in 30pl of OEB prewarmed 
at 70°C. All samples were incubated in a water bath at 70°C while adding the buffer. 
Samples were left at this temperature for a couple of minutes, followed by 
centrifugation at 15,115g for 2 minutes. The supernatants containing the eluted mRNA 
were carefully transferred to new RNAase-free tubes, which were then either placed on 
ice for immediate use or stored at -70°C for later use.
In the spin column format, the cytoplasmic fraction was transferred to a spin column 
(supplied with the kit) and processed as above except that the wash buffers and 
supernatants flowed through the column into collection tubes. The collection tubes were 
changed at the end of each centrifugation step.
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II.2.4.4. Nuclisens™ (Organon Teknika) extraction of total nucleic
acids
The Nuclisens™ kit (Organon Teknika) allowed extraction of total (viral and cellular) 
nucleic acids. The silica supplied in the kit was resuspended by vortexing. Fifty 
microlitres of silica were added to 0.9ml of kit lysis buffer which itself lysed samples, 
stabilised nucleic acids and enhanced selective nucleic acid adsorption to the silica 
particles. Two hundred microlitres of sample were added to a tube containing lysis 
buffer and silica, and was mixed thoroughly. The samples were then left at room 
temperature for 10 minutes and vortexed every minute to ensure the nucleic acids bound 
to the silica. The samples were spun for 30 seconds at 15,115g. After removal of the 
supernatant, 1ml of wash buffer was added to each sample, followed by vortexing. The 
samples were spun for 30 seconds at 15,115g, the supernatants removed and the 
washing step repeated once. The silica pellets were resuspended in 1ml of 70% ethanol, 
the suspensions were transferred to clean 1.5ml Eppendorf tubes and spun for 30 
seconds at 15,115g. After removing the supernatants, 1ml of ethanol was added as 
before and the samples vortexed and spun. The supernatants were discarded. The 
samples were washed with 1ml of acetone, vortexed, spun and the acetone discarded. 
The silica pellets were dried at 56°C for 30 minutes and 50pl of pre-warmed elution 
buffer was added to each sample. The samples were vortexed until resuspended and 
incubated for 30 minutes at 70°C in order to completely redissolve the nucleic acids. 
During this incubation step, samples were vortexed every 10 minutes to resuspend the 
silica. The samples were finally spun for 5 minutes at 15,115g and the supernatant 
containing total nucleic acids (~35pl) was carefully removed and transferred to clean 
RNAase-free tubes (0.5ml) which were either stored at -70°C for later use or placed on 
ice for immediate use.
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II.2.4.5. QIAamp DNA mini kit (Qiagen) for extraction of total
nucleic acids
QIAamp DNA mini kits (Qiagen) contained Proteinase K, which had been shown to be 
the optimal enzyme for use with the lysis buffer. Two hundred microlitres of samples 
were added to 1.5 ml microcentrifuge tubes which already contained 20pl of Proteinase 
K. Then 200pl of lysis buffer (AL) were added to each sample, mixed thoroughly by 
vortexing and incubated for 10 minutes at room temperature, followed by 10 minutes at 
56°C. The centrifuge tubes were briefly centrifuged to remove drops from the inside of 
the lids. Two hundred microlitres of absolute ethanol were added to the samples, which 
were mixed by vortexing and briefly centrifuged. The mixture was carefully applied 
onto the QIAamp Spin Columns provided in the kit (in 2ml collection tubes) without 
wetting the rim. The caps were closed and the spin columns were centrifuged at 6000g 
for 1 minute. The spin columns were placed in clean 2ml collection tubes and the tubes 
containing the filtrate were discarded. Five hundred microlitres of wash buffer 1 (AW1) 
were added onto the spin columns, which were centrifuged at 6000g for 1 minute. The 
spin columns were again placed in clean 2ml collection tubes and the tubes containing 
the filtrate were discarded. The spin columns were washed twice with 500pl of wash 
buffer 2 (AW2) and centrifuged at 6000g for 1 minute. The spin columns were placed in 
clean 2ml collection tubes and the tubes containing the filtrate were discarded. An 
additional centrifugation at full speed (20,000g) was done after the second wash for 3 
minutes. The spin columns were placed in clean 2ml collection tubes and the tubes 
containing the filtrate were discarded. Two hundred microlitres of elution buffer (AE) 
were added to each spin column. After incubation at room temperature for 5 minutes, 
the spin columns were centrifuged at 6000g for 1 minute. The eluted total nucleic acids 
were stored at -20°C for later use.
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II.2.5. DNA quantification by LightCycler system (Roche Molecular
Biochemicals)
The DNA FastStart Master SYBR Green I kit (Roche Applied Science) includes MgCL 
stock solution (25mM, vial 2) to adjust the MgCL concentration, sterile PCR grade 
water to adjust the final volume and the LightCycler FastStart enzyme (vial la), which 
is mixed with the LightCycler FastStart reaction mix SYBR Green I (vial lb). This 
mixture contains FastStart Taq DNA polymerase, reaction buffer, dNTP mix, SYBR 
Green I dye and lOmM MgCL. FastStart Taq DNA polymerase is a modified form of 
thermostable recombinant Taq DNA polymerase. The heat-labile blocking groups on 
some of the amino acid residues of the enzyme allow it to stay inactive at room 
temperature. Therefore, there is no elongation during the period where primers can bind 
non-specifically. The pre-incubation step at 95°C, for a maximum of 10 minutes 
removes the blocking groups and activates the modified enzyme.
During each phase of DNA synthesis, the SYBR Green I dye binds to the amplified 
nucleic acids and produces a fluorescent signal. As SYBR Green I dye binds non- 
specifically to the minor grooves of double-stranded DNA, both specific amplicons and 
primer dimers will contribute to the overall fluorescent signal. However, since the 
melting curve of primer dimers is usually lower than that of specifically amplified PCR 
product, an analysis of the melting curve enables collection of fluorescence data at a 
temperature at which the primer dimers are denatured and do not contribute to the 
fluorescent signal. Previous studies in the laboratory had shown that the melting 
temperature of the primer dimers was below 80°C while that of the amplified product 
was above this temperature. Therefore, in the B19 assay, fluorescence data were 
collected at 80°C to exclude signals from primer dimers. The ideal target length would 
be 100 to 150bp and the use of SYBR Green allows a flexible detection of different
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targets and is less expensive than fluorogenic probes (i.e. dual-labelled probes, FRET
probes and molecular beacons).
In addition to the DNA quantification provided by the LightCycler instrument (Roche 
Diagnostics), the PCR products from the optimisation experiments were analysed on a 
2% agarose gel containing ethidium bromide. The DNA samples were prepared by 
adding 2 to 3.5pl of 6x loading dye to a 1.5ml Eppendorf tube without a lid. The glass 
capillaries were gently removed from the LightCycler carousel, uncapped and placed 
inverted in the prepared tubes. The capillaries were then spun twice in a microcentrifuge 
at 700g for a few seconds to remove the amplicons. The samples were analysed on a 2% 
agarose gel run at 100 volts for 40-50 minutes. The bands were visualised under the UV 
light and photographed either using a Polaroid camera or by the Autochemi™ 
photographic system (UVP).
II.2.6. mRNA amplification by OneStep RT-PCR
The OneStep RT-PCR kit (Qiagen) contains lOx OneStep RT-PCR buffer, 
deoxynucleotides mix (dNTPs), 5x Q buffer solution, RT-PCR enzyme mix and 
RNAase-free water. OneStep RT-PCR buffer is designed to enable both reverse 
transcription and specific amplification. The buffer contains a balanced combination of 
KC1 and (NH4)2S0 4  which allows specific primer annealing over a wide range of 
annealing temperatures and Mg2+ concentrations. The Q solution, supplied with the kit, 
was used to improve suboptimal RT-PCR amplification caused by RNA and DNA 
templates that have a high degree of secondary structure or that are GC-rich. Q buffer 
has also been shown to prevent the amplification of non-specific RT-PCR products. The 
OneStep RT-PCR enzyme mix contains enzymes for both reverse transcription 
(Omniscript™ and Sensiscript™ reverse transcriptases) and PCR amplification
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(HotStarTaq™ DNA polymerase). Omniscript™ reverse transcriptase is directed at
RNA amounts greater than 50ng whereas Sensiscript™ reverse transcriptase is
optimised for use with very small amounts of RNA (less than 50ng), thereby providing
sensitive RT of any amount of RNA from lpg to 2pg. During the RT-step,
HotStarTaq™ DNA polymerase is completely inactive and does not interfere with the
RT reaction. Once the latter is completed, reactions are heated to 95°C for 15 minutes to
activate HotStarTaq™ DNA polymerase while inactivating the reverse transcriptases.
This procedure eliminates extension from non-specifically annealed primers and primer-
dimers in the first cycle, allowing specific PCR amplification.
II.2.7. Statistical Analysis
All statistical analyses were kindly done by Mr Alan Heath (Informatics Division, 
NIBSC, UK).
II.2.7.2. LightCycler Standard curve
In the first validation study investigating the limit of detection of the LightCycler PCR 
assay, no statistical analysis was performed. It was sufficient to look at the melting 
temperatures to determine the limit of detection.
The second validation study looked at the linearity and precision of the LightCycler 
standard curve. Results were available from 7 separate assays. For each assay the 
estimated concentration (logio IU/ml) for the four samples tested were obtained by 
reading off the standard curve using the LightCycler software. The overall means of the 
estimates of logio IU/ml were calculated, along with the standard deviation across the 7 
estimates in each case. To interpret the standard deviation, assuming a normal 
distribution of repeat estimates, 95% of estimates would fall within the range mean +/- 2
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x standard deviation. Therefore, from the results shown on table 3.6, at logio 6 IU/ml,
the expected range would be +/- logio 0.066 representing very good precision and
repeatability. At logio 3 IU/ml the expected range would be +/- logio 0.6.
11.2.7.2. DNA extraction and amplification
As for the study above, analysis was based on the overall mean and standard deviation 
of the estimates of logio IU/ml. Interpretation is again based on the expected range of 
+/- 2 x standard deviation.
11.2.7.3. Determination of 95% and 50% detection limits of the 
optimised infectivity assay
The methods used for determining the detection limits use a statistical model based on 
the Poisson distribution. This assumes that the number of “detectable units” (copies or 
genome equivalents) in an individual samples follows the Poisson distribution with 
mean given by the average number of “detectable units” at that dilution. Under this 
model, the dilution equivalent to a mean of one copy per sample tested would result in 
63% of tests being positive. The dilution equivalent to three copies per sample would 
result in 95% of tests being positive. This is defined as the 95% detection limit. The 
Poisson model can be fitted to the data in table 3.12, represented as a number of positive 
out of number tested at each dilution, using the commercial statistical software package 
SAS.
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II.2.8. Sequencing of PCR products
11.2.8.1. Purification of amplified products from agarose gels for 
sequencing
Amplified products obtained with the primer combination B19-9 and XPP-2 were 
separated on 2% agarose gels and the bands visualised on a UV transilluminator. A gel 
slice containing the specific band was cut out using a sterile blade and placed in a 
siliconised 1.5ml Eppendorf tube. The gel slice was snap frozen in a mixture of ethanol 
and dry ice for 30 minutes. The material used to eliminate ethidium bromide from this 
stained DNA was the GenElute™ Minus EtBr spin column (56501; Sigma-Aldrich, 
UK). Before starting the DNA recovery, the spin column was washed by adding lOOpl 
of TE buffer (made in-house), placed in a 1.5ml Eppendorf tube and centrifuged at 
17,005g for 5 seconds. The microcentrifuge tube containing TE buffer was discarded 
and replaced by a new one. Since the spin column should not be left to dry, the frozen 
gel slice was transferred onto it quickly. The column was centrifuged at 17,005g for 10 
minutes to extract the DNA (in buffer) from the gel slice. The eluted DNA was 
precipitated by the addition of 2 volumes of ethanol and 0.1 volume of 5M ammonium 
acetate (pH 5.3), followed by incubation at -20°C for 10 minutes. The DNA precipitate 
was collected by centrifuging at 17,005g for 5 minutes. The supernatant was discarded 
and DNA was then redissolved in lOpl of TE buffer.
11.2.8.2. Sequencing protocol
Gel purified RT-PCR products were run on a 2% agarose gel with 5 pi DNA markers 
and the concentration of DNA in the amplified products estimated by a comparison of 
the fluorescence of the product and one of the marker bands in the appropriate size 
range.
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Sequencing was done using the ABI kit (ABI, UK). Approximately lOng amplified
DNA was further amplified in a reaction containing 4pl of terminator mixture, 1.6pmol
of primers B19-6 and B19-9 and RNAase-free water to make the final volume lOpl. The
PCR reaction was run with the following conditions: 1 cycle at 96°C for 1 minute,
followed by 25 cycles of 96°C for 30 seconds, 55°C for 20 seconds and 60°C for 20
seconds and lastly 1 cycle at 60°C for 3 minutes. The PCR products were then purified
from unincorporated primers by ethanol precipitation. In a 0.5ml Eppendorf tube were
placed lpl of 3M NaOAc, pH 4.6 and lOpl of the sequencing reaction. After mixing
thoroughly, 25pi of absolute ethanol (EtOH) was added to the tube, then mixed again
and left at room temperature for 15 minutes. The reaction was centrifuged at 28,215g
for 15 minutes to pellet the DNA. The supernatant was carefully removed and 300pl of
70% EtOH was used to resuspend the pellet by flicking the tube. After centrifugation at
28,215g for 5 minutes, the supernatant was removed and another 300pl of 70% EtOH
was added to the DNA pellet. The latter was resuspended by flicking again and spun at
the same speed for 5 minutes. The supernatant was removed very carefully and the
sample centrifuged again to collect any residual EtOH, which was then discarded. The
tube was left opened (covered with tissue paper) to dry at room temperature for 30 to 40
minutes. Some template suspension buffer (TE buffer, 15pi) was used to re-dissolve the
DNA pellet. The sample was transferred to a thin wall PCR tube and heated to 95°C for
2 minutes and immediately placed onto ice. The sample was transferred to a labelled
sequencing tube and loaded onto the ABI 310 sequence analyzer.
II.2.9. Human parvovirus B19 removal/inactivation studies
The optimised tissue culture assay using UT-7/EPO-S1 cells and RT-PCR assay 
described previously were used to test one method of virus removal by nanofiltration
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(Asahi Kasei Pharma) and four virus inactivation techniques: dry heat treatment (BPL),
super critical fluids (Aphios Inc.), INACTINE™ system (Vitex) and Helinx®
technology (Cerus Corporation). Each of these companies was provided with a sample
of B19 virus stock (isolate JS; lxlO12 IU/ml). This inoculum was used to spike the
products before inactivation or removal. Samples from different stages of these methods
were then sent back to NIBSC for infectivity and B19 DNA assays.
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III.l. Characterisation of the virus isolates used in this study
III.l.l. Electron microscopy on the virus stock (JS isolate)
Three B19 virus isolates were used for this study: two from Germany, isolates JS and 
JB, and one from the USA, isolate LP. These three isolates were identified before the 
discovery of the B19 genotypes 2 and 3. They are therefore very likely to be genotype 1 
isolates, which is that found most commonly in North America and Western Europe. 
The isolates were quantitated using the established LightCycler quantitative assay. 
Figure 3.1 below shows EM and IEM photos of the virus stock (isolate JS).
Figure 3.1: IEM and EM of Human Parvovirus B19
(A, B and C: IEM; D: EM)
Chapter III
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III. 1.2. DNA Quantification of B19 samples
The DNA titres of the three isolates mentioned above were obtained by quantitative 
real-time LightCycler PCR as lxlO12 IU/ml, 3xl012 IU/ml and 5x l013 IU/ml for JS, JB 
and LP, respectively.
III.2. Detection of virus infectivity by IFA: controls
Insect cells SF9 were infected with baculovirus expressing either VP1 or VP2 
recombinant protein as positive controls (figures 3.3 and 3.4) whereas some cells were 
mock infected to serve as negative control (figure 3.2). The mouse monoclonal anti-B19 
VP1/VP2 antibody (Novocastra Laboratories Ltd) was used at a 1:80 dilution.
Figure 3.2: IFA in mock infected SF9 cells
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Figure 3.3: IFA in SF9 cells infected by baculovirus expressing VP1 recombinant
protein
Figure 3.4: IFA in SF9 cells infected by baculovirus expressing VP2 recombinant
protein
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Infected SF9 cells were easily identified by the presence of green dots where the
recombinant proteins were produced. Another type of fluorescence was seen, which was
brighter and more diffuse in the cell.
III.3. Primary cells
III.3.1. CD34+ cells
DI.3.1.1. FACS results
The aim of this experiment was to access the proportion of haematopoietic stem cells 
present in the CD34+ isolated samples. In addition to the negative control, three test 
runs were performed; CD34 test.001, CD34 test.002 and CD34 test.003. CD34 test.001 
and test.003 were looking at isolated CD34+ cells from two different patients while 
CD34 test.002 was investigating apheresis cells from a patient who had not been 
included in the BFU-E studies. Two graphs were obtained with the Cellquest program 
after measurements by the cytometer. The first graph was a plot of cell granulosity 
(SSC-H) versus size (FSC-H) (figures 3.5, 3.8 and 3.11) while the second was a plot of 
CD34+ versus size (figures 3.6, 3.9 and 3.12). Additionally, and in order to visualise the 
fluorescence associated with CD34+ cells, a histogram of events versus CD34 
fluorescence was plotted (figures 3.7, 3.10, 3.13).
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• CD34 test.001 (isolated CD34+ cells)
Figure 3.5: Dot plot of the cell granulosity (SSC-H) versus cell size (FSC-H) for
CD34
SSC-H versus FSC-H
E m p ty
Figure 3.6: Dot plot of CD34+ versus cell size (FSC-H) for CD34 test.001
o CD34 versus FSC-H
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Figure 3.7: Histogram of events versus CD34 fluorescence for CD34 test.001
C D 3 4
• CD34 test.003
Figure 3.8: Dot plot of the cell granulosity (SSC-H) versus cell size (FSC-H) for
CD34 test.003
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Figure 3.9: Dot plot of CD34+ versus cell size (FSC-H) for CD34 test.003
CD34 versus FSC-Ho
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Figure 3.10: Histogram of events versus CD34 fluorescence for CD34 test.003
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• CD34 test.002 (apheresis cells)
Figure 3.11: Dot plot of the cell granulosity (SSC-H) versus cell size (FSC-H) for
CD34 test.002
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Figure 3.12: Dot plot of CD34+ versus cell size (FSC-H) for CD34 test.002
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Figure 3.13: Histogram of events versus CD34 fluorescence for CD34 test.002
C D 3 4
In figures 3.5 and 3.8 (experiments CD34 test-001 and CD34 test.003), CD34+ cells 
could be seen in the lower right-hand quadrant: 17.5% and 17.2%, respectively. On 
figures 3.6 and 3.9, these cells were in majority in the upper right-hand quadrant: 73.6% 
and 72.4%, respectively. However, it was clear that CD34+ cells were not the only cell 
population in the samples where the CD34+ cells had been isolated from mobilized 
peripheral blood. Figures 3.11, 3.12 and 3.13 (experiment CD34 test.002), which 
represented the cell populations in the apheresis sample, showed, as expected, that the 
CD34+ cell density was not as high as that of the CD34+ isolated sample. The 
proportion of CD34+ labelled cells was indeed only 37% (figure 3.13).
-2 3 3  -
....................................................................................................................................................................... Chapter III
ni.3.1.2. Detection of infectious parvovirus B19 particles in CD34+ 
cells by IFA
B19 infected CD34+ isolated cells were stained by IFA to investigate the presence of 
B 19-specific fluorescence. The initial experiments using cells from patients 9, 13, 15 
and 19 failed due to poor cell growth or bacterial contamination prior to IFA. Therefore, 
in subsequent experiments, 1% penicillin/streptomycin and 1% fungizone were added to 
the medium before and after B19 infection CD34+ cells. Those CD34+ cells isolated 
from the peripheral blood of a patient whose cells were not tested in the BFU-E 
reduction assay were inoculated with 1:10 dilution of B19 stock virus (lxlO11 IU/ml) 5 
days after CD34+ isolation. Microscope slides were prepared (using the method of the 
drops on slide) on day 3 and 4 post-infection and IFA was performed using a mouse 
monoclonal anti-VPl/VP2 antibody (R92F6; Novocastra Laboratories Ltd, UK) 
followed by a goat anti-mouse FITC conjugate (Sigma). Observation under the 
fluorescence microscope revealed no evidence of positive staining. This suggested either 
the absence of infected CD34+ cells or the absence of viral replication in those cells or 
again a poor sensitivity of the IFA.
The final experiment attempted to detect infectious parvovirus B19 particles in CD34+ 
cells by IFA using cells isolated from two further patients who were not included in the 
BFU-E study. The volume of cell suspension used for culture after isolation was 
reduced to 200jxl of 2xl05 cells/ml suspension in each well of a 96-well plate (flat 
bottom with low evaporation lid, Falcon). After 4 days at 37°C, the cells were settled at 
the bottom of the wells and the medium was removed carefully and discarded. Only 
20jil of 1:10 dilution of B19 stock virus (lxlO11 IU/ml) were added to two wells while 
20|il of negative serum were added to two negative control wells. Then the infection 
proceeded as detailed previously and slides were made 4 days post-infection. Three
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types of antibodies were used in this IFA: human monoclonal antibody anti-NSl, 1:50
and 1:100 dilutions (kindly provided by Dr S. Modrow, Germany), mouse monoclonal
antibody anti-VPl/VP2, 1:80 dilution (R92F6, from Novocastra, UK) and rabbit
polyclonal antibody anti-NSl, 1:100 dilution (kindly provided by Dr S. Doyle, Ireland).
No fluorescence was detected with any of the antibodies tested.
Slides of infected SF9 cells were also tested with the above corresponding monoclonal 
antibodies, with the exception of the rabbit polyclonal antibody anti-NS-1. The presence 
of contaminating anti-insect cell antibodies in the latter prevented it from being used in 
our insect expression systems such as baculovirus expressing recombinant VP1, VP2 
and NS1 proteins. When stained with anti-VPl/VP2 antibodies, SF9 cells infected with 
baculovirus expressing VP1 protein presented bright fluorescence whereas those cells 
infected with baculovirus expressing VP2 protein showed a weaker signal. As far as 
SF9 cells inoculated with baculovirus expressing NS1 protein were concerned, no 
positive staining could be observed. This could have been due to a lack of sensitivity 
and/or specificity of the anti-NS-1 antibodies.
These experiments suggested that infectious virus particles could not be detected in 
CD34+ cells isolated from different patients using indirect IFA with different B19 
antibodies.
III.3.1.3. Detection of infectious parvovirus B19 particles in CD34+ 
cells by detection of mRNA transcripts
Attempts were made to demonstrate the replication of B19 in inoculated CD34+ cells by 
detection of B19 specific transcripts. Cells expressing CD34 were isolated from the 
peripheral blood of patients 31 and 32 (not tested by BFU-E reduction assay), with final 
concentrations of 8.6xl05 cells/ml and 9xl05 cells/ml, respectively. After 4 days at 37°C
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(5% CO2) in CD34+ medium, the cell count was lxlO7 cells/ml and 1.5x10s cells/ml for
patients 31 and 32, respectively. CD34+ cells were then harvested and inoculated with
lOOjil of either negative serum or a 1:10 dilution of B19 stock virus (lxlO11 IU/ml). The
cells were plated out in 4 wells of a 96-well plate using 200jil of medium/well for
patient 31 and 2 wells of a 96-well plate for patient 32. Cells from patient 31 were
harvested on days 1, 2, 3 and 4 post-infection while cells from patient 32 were harvested
on days 5 and 6 post-infection. Total nucleic acids were isolated using the Nuclisens™
extraction method that will be described later (see section II.2.4.4).
Two reverse transcription (RT)-PCR reactions were prepared with either actin-specific
primers (actin-3 and actin-4) or B 19-specific primers (B19-6 and B19-9) (see section
II. 1.3.2). The total volume for each RT-PCR reaction was 50pl, including 5pl mRNA
template added last. Each reaction contained lOjil of RT-PCR buffer, 2|il of lOmM
dNTP mix, 1.2jil of 25pmol/pl forward and reverse primers, 2pl of RT-PCR enzyme
mix and finally 28.6jil of RNAase-free water to make up the reaction volume to 50jiil.
The RT-PCR conditions were as follows: 1 cycle at 50°C for 30 minutes, 1 cycle at
94°C for 15 minutes, 43 cycles of 94°C for 45 seconds, 55°C for 45 seconds and 72°C
for 2 minutes and finally 1 cycle at 72°C for 5 minutes. A 2% agarose gel was run with
the RT-PCR products and visualised under UV light.
The results are shown in figures 3.14 and 3.15. The internal control, actin (~635bp), was
present in all samples tested (figure 3.14), confirming that the cellular nucleic acids had
been extracted from all samples. Considering the brightness of the actin bands, 2jil of
template would have been sufficient for the amplification of mRNA transcripts. The
expected sizes for B 19-specific mRNA transcripts amplified with B19-6 and B19-9
primers were 155bp, 275bp and 1779bp. All three bands could be detected in all CD34+
samples inoculated with the virus from day 1 to day 6 post-infection (figure 3.15). The
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smear seen in these samples could be due to the absence of Q buffer in the RT-PCR
reaction, which would have prevented unspecific amplification. The large product seen
in lane 11 (figure 3.15; day 6, negative serum) might have been due to a contamination
from the neighbouring wells during loading of the samples. As far as CD34+ cells from
patient 31 were concerned, the intensity of the amplification seemed to be greatest on
days 1 and 2 post-infection. These time points were not tested for cells from patient 32,
which showed the greatest intensity of amplification on day 6 post-infection.
By detecting B 19-specific mRNA transcripts, this experiment demonstrated that CD34+
cells isolated from mobilised peripheral blood were able to support the replication of
human parvovirus B 19, from day 1 to at least day 6 post-infection.
Figure 3.14: Agarose gel with RT-PCR products amplified with actin-specific 
primers
M l  2 3 4 5 6 7  8 9  10 11 12
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635 bp
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1. Day 1, negative serum (patient 31)
2. Day 1, 2x10" IU/ml (patient 31)
3. Day 2, negative serum (patient 31)
4. Day 2, 2x10" IU/ml (patient 31)
6. Day 3, 2 x l0 n IU/ml (patient 31)
7. Day 4, negative serum (patient 31)
Lane Sample
8. Day 4, 2x 1 ()'1 IU/ml (patient 31)
9. Day 5, negative serum (patient 32)
10. Day 5, 2x 10 11 IU/ml (patient 32)
11. Day 6, negative serum (patient 32)
12. Day 6, 2xl()" IU/ml (patient 32)
13. RNAase-free water
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Figure 3.15: Agarose gel with RT-PCR products amplified with B 19-specific 
primers
M l  2 3 4 5 6 7 8 9 10 11 12 13
1,000 bp 
750 bp
500 bp
300 bp
150 bp
50 bp
*4
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M. PCR markers
1. Day 1, negative serum (patient 31)
2. Day 1, 2x10" IU/ml (patient 31)
3. Day 2, negative serum (patient 31)
4. Day 2, 2x 10 11 IU/ml (patient 31)
6. Day 3, 2xlOn IU/ml (patient 31)
7. Day 4, negative serum (patient 31)
Lane Sample
8. Day 4, 2xlOn IU/ml (patient 31)
9. Day 5, negative serum (patient 32)
10. Day 5, 2x10" IU/ml (patient 32)
1 1. Day 6, negative serum (patient 32)
12. Day 6, 2x10" IU/ml (patient 32)
13. RNAase-free water
III.3.2. BFU-E reduction assay
III.3.2.1. Anti-B19 IgG status of apheresis cells donors
SF9 insect cells were used in this IFA and were infected with baculovirus expressing 
either VP1 or VP2 recombinant proteins and fixed on microscope slides as positive 
controls. Some uninfected SF9 cells were also included in the test as negative controls. 
The IgG status of some of the apheresis donors was tested using IEA and IFA and the 
results are shown in table 3.1 below.
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Table 3.1: Anti-B19 IgG status of some apheresis cells donors
Patient nb Anti-B19 IgG (T/CO) IFA VP1 IFAYP2
1 + (7.8) + +
9 -(0.1) - -
13 + (2.2) - -
14 + (4.4) + (low) -
15 - (0.0) - -
16 + (5.2) + (low) -
17 + (9.3) + (strong) +
18 + (1.7) - -
19 -(0.1) - -
20 -(0.1) - -
24 + N/A N/A
25 + N/A N/A
26 + N/A N/A
27 + N/A N/A
29 - N/A N/A
Ten of fifteen patients tested for anti-B19 IgG antibodies were found positive using 
IEA. Of these ten, six were also tested by IFA and only the one with the highest cutoff 
value of 9.3 showed strong fluorescence with VP2 protein and some fluorescence with 
VP1 protein. Patient 1 had a cutoff value of 7.8 and the IFA was positive for both 
capsid proteins. On the other hand, the two patients with the lowest cutoff values of 2.2 
and 1.7 (patients 13 and 18, respectively) didn’t show any fluorescence with either VP1
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or VP2 proteins. The last two patients with intermediate cutoff values of 4.4 and 5.2
(patients 14 and 16, respectively) displayed weak fluorescence with the VP1 protein
only and none with VP2 in the IFA.
III.3.2.2. BFU-E reduction assay results
An example of the red colonies formed from BFU-E after plating the cells on Fox’s 
medium is shown in figure 3.16.
Figure 3.16: Red colonies in a negative control of BFU-E reduction assay
The red colonies were counted in each well and the percentage BFU-E reduction 
calculated for each dilution. The raw data of the BFU-E reduction assay of all the 
patients who donated apheresis cells are shown in appendix 1. The results indicated a 
significant discrepancy between the different patients who donated apheresis cells. To 
confirm this observation, the virus dilution containing 2xl07 IU/ml was looked at more
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closely. When this virus dilution was added to apheresis cells collected from donors 15
and 30, no reduction in the formation of red colonies was noted (0% reduction). There
were two hypotheses for this result: the first one was that there were not enough B19
infectious particles in the sample to interfere with the differentiation of haemapoitic
progenitors into erythrocytes, and the second one was that the apheresis cells from these
patients were not fully permissive to B19 infection.
When inoculated onto apheresis cells of patients 1, 18, 27 and 29, the same virus 
dilution (2xl07 IU/ml) induced a percentage BFU-E reduction lower than 10% i.e. 7.14, 
9.35, 3.57 and 5.74%, respectively. This observation ruled out the first hypothesis 
proposed above since the same virus dilution resulted in reduction of red colony 
formation in different patients. Therefore, cells collected from patients 1, 18, 27 and 29 
seemed to be more permissive than those from patients 15 and 30. Even more 
permissive to B19 infection were all the cell samples in which 2xl07 IU/ml gave rise to 
a red colony formation reduction from 11.46% (patient 24) to 63.49% (patient 21). 
These apheresis cells were collected from patients 14 (19.16%), 23 (23.51%), 25 
(25.46%), 19 (31.01%), 20 (31.87%), 26 (32.42%), 28 (39.29%), 17 (54.88%), 22 
(57.75%) and 13 (57.8%). The major discrepancies noted between patients seemed to be 
due to a difference in cell susceptibility to B19 infection.
III.3.2.3. Detection of infectious parvovirus B19 in cells from BFU-E 
colonies by indirect IFA
The aim of the experiments in this section was to assess the susceptibility to B19 
infection of apheresis cells differentiated into erythrocytes.
In the first experiment, patient 7 was specifically chosen because of the apparent lack of
susceptibility to B19 infection suggested by the BFU-E reduction assay results
(Appendix 1). When inoculated with lxlO10 IU/ml of B19 stock virus, the apheresis
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cells from patient 7 only showed 3.4% BFU-E reduction, whereas the same virus
dilution tested in 18 other samples induced on average 79% BFU-E reduction. Results
from patient 8 at that virus dilution was slightly lower than average at 66.83%
(Appendix 1). The red colonies formed in the negative control of BFU-E assays of
patients 7 and 8 were thus picked by aspiration using a sterile glass Pasteur pipette and
placed in 1ml of fresh IMDM medium (Appendix 1). The cell counts were 2.1xl06
cell/ml and 2.3xl06 cells/ml, for patients 7 and 8, respectively. The cells were
centrifuged for 10 minutes at 145g and the supernatant discarded. The differentiated
cells were inoculated with either lOOpl of medium or lOOpl neat B19 stock virus
(lxlO12 IU/ml) and incubated at 4°C for 2 hours with occasional mixing. Fresh medium
was then added to the samples to obtain a final concentration of 5x10s cells/ml and this
cell suspension was plated out in a 96-well plate using lxlO5 cells/well (i.e. 200pl/well).
The plate was placed at 37°C (5% CO2) and the cells harvested on the day of infection,
as well as on days 1, 2, 3, 4 and 7 post-infection. Microscope slides were prepared and
IFA was performed using mouse monoclonal antibody anti-VPl/VP2, 1:80 dilution
(R92F6, Novocastra).
As expected, neither of the samples (patients 7 and 8) inoculated with B19 stock virus 
(lxlO12 IU/ml) presented fluorescence on the day of infection since the virus had not 
had time to replicate. Cells from patient 7 harvested on day 3 post-infection presented 
only a few positive cells (-5%; not shown) whereas on day 4, the proportion of infected 
cells was slightly greater (-10%; figure 3.17). The fluorescence was brighter than on the 
previous day and mainly diffuse, although fluorescent spots could be seen on a few 
cells, as shown on figure 3.17. On day 7 post-infection, the type of fluorescence 
remained the same but it was detected in a higher proportion of the cells (-20%), as can 
be seen on figure 3.18.
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Figure 3.17: IFA in differentiated cells from patient 7 infected with parvovirus
B19, day 4 post-infection
Figure 3.18: IFA in differentiated cells from patient 7 infected with parvovirus
B19, day 7 post-infection
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As for patient 8, very few cells presented positive staining on days 3 and 4 post­
infection (not shown). Of those infected, the majority showed diffuse fluorescence in 
the whole cells rather than spots. On day 7 post-infection, a larger proportion of cells 
were infected (-25%) and showed fluorescence for VP1/VP2 proteins (not shown). 
When compared to each other on day 7 post-infection, cells from patient 8 seemed to be 
slightly more susceptible to B19 infection than cells from patient 7 since there were 
more positive cells in the former. The type of fluorescence seemed to be overall more 
diffuse in cells from patient 8 compared to those from patient 7 where some infected 
cells showed fluorescent spots. This phenomenon might have been explained by the fact 
that infection in cells from patient 8 was more significant, with possibly a higher viral 
replication rate than in cells from patient 7. Results from a previous BFU-E reduction 
assay (Appendix 1) had indeed suggested that cells from patient 7 were less susceptible 
to B19 infection than those from patient 8 when inoculated with lxlO10 IU/ml. 
However, when inoculated with lxlO12 IU/ml, 100% reduction had been induced in 
both these patients. Therefore, if more cells had been available, this IFA experiment 
would have been repeated using a lower virus titre for inoculation in order to assess 
better the susceptibility to B19 infection of erythrocytes differentiated from those 
apheresis cells.
In order to compare these results with those of another patient, a second time-course 
experiment was performed using cells from patient 6. The cell count was 3.3xl06 
cells/ml and cell harvest was done every day from day 2 to day 10 post-infection. In this 
experiment, the microscope slides were prepared using the cytospin method. The IFA 
results of this experiment showed that no positive staining could be detected in cells 
until day 3 post-infection. Figure 3.19 shows the negative control on that day. In the
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sample inoculated with B19 stock virus, only a few cells (-1%) showed fluorescent dots
representing VP1/VP2 proteins, as shown on figure 3.20.
Figure 3.19: IFA in uninfected differentiated cells from patient 6, day 3 post-
Figure 3.20: IFA in infected differentiated cells from patient 6, day 3 post-infection
■«r-
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Lastly, a third time-course experiment investigated the cells from two more patients: 3
and 4. The protocol above was followed and the cell counts of picked red colonies were
2.5xl06cell/ml and 9.5x10s cells/ml for patients 3 and 4, respectively. The IFA results
showed that few cells were actually fixed on the microscope slides and that no positive
staining was present in the differentiated cells from either patient on any day (not
shown). The absence of fluorescence might have been due to either the lack of
susceptibility of those particular primary cells or to the fact that the cells might have
been dying of a different cause before they were harvested. This second hypothesis
might explain why there were so few cells on the slides.
III.4. Continuous human erythroid cell lines
III.4.1. Growth curves
As human parvovirus B19 is known to infect cells in S phase (Kishore and Kapoor, 
2000), it was crucial to determine the growth pattern of the cells and thereby decide on 
the optimum time for viral inoculation.
m.4.1.1. KU8I2Ep6 cell line
For the KU812Ep6 cell line, the growth curves of cells at both early (n+19) and late 
passage (n+81) were compared. For each cell passage, cell suspension concentrations 
(prepared using fresh medium) of lxlO5, 5xl04 and lxlO4 cells/ml were tested. In 
addition to providing an indication on the best time to infect the cells, this experiment 
allowed the determination of the best starting concentration when splitting the cells. 
Each cell suspensions was seeded into two 24-well plates using 1ml of cell suspension 
per well. The plates were incubated at 37°C (5% CO2). Every day and for 8 days, lOOpl
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of trypan blue was added to 4 wells of each cell suspension dilution and the live cells
(unstained) counted using a haemacytometer.
The cell counts and growth curves for KU812Ep6 cells are shown in appendix 2, tables 
A2.1 to A2.6 and in figures 3.21 and 3.22.
Figure 3.21: KU812Ep6 growth curves (n+19)
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Figure 3.22: KU812Ep6 growth curves (n+81)
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The results suggested that these cells should be used at a starting concentration of lxlO5 
cells/ml and should be harvested 5 days after passaging them to optimise the yield of 
dividing cells, which have been reported to be the most permissible for parvovirus B19. 
The study showed that an earlier passage (n+19) led to higher cell concentrations than a 
later cell passage (n+81) suggesting that the former might be more suitable regarding a 
higher cell yield.
III.4.1.2. UT-7/EPO cell line
The protocol described above for KU812Ep6 cells was followed for UT-7/EPO cells at 
passages n+19 and n+80 and for UT-7/EPO-S1 cells at passage n+14, using cell 
suspensions at starting concentrations of 1x10s, 5xl04and lxlO4cells/ml.
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The cell count results are displayed in appendix 2, tables A2.7 to A2.12 and the growth
curves are shown in figures 3.23 and 3.24.
When UT-7/EPO cells were used at passage n+80 (tables A2.10 to A2.12, figure 3.24), 
they showed an earlier exponential phase than that of the lower passage n+19 (tables 
A2.7 to A2.9, figure 3.23). Additionally, the growth of ealier passage cells (n+19) 
showed a plateau phase (figure 3.23) whereas the growth curves of cells at a later 
passage (n+80) were decreasing quickly after reaching the peak, revealing rapid cell 
death (figure 3.24). The use of such late passage (n+80) was therefore not 
recommended. These data suggested that UT-7/EPO cells should be passaged at the 
starting concentration of lxlO5 cells/ml and virus inoculation should be done 3 days 
after splitting them.
Figure 3.23: UT-7/EPO growth curves (n+19)
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Figure 3.24: UT-7/EPO growth curves (n+80)
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III.4.1.3. UT-7/EPO-S1 cell line
The same protocol as described for KU812Ep6 cells (see section III.4.1.1) was followed 
but the results of the cell counts for UT-7/EPO-S1 cell line with a starting cell 
concentration of 1x10 cells/ml were too low to be significant and thus the results are 
not shown. Tables A2.13 and A2.14 in appendix 2 and figure 3.25 show the cell counts 
for the starting cell concentrations of lxlO5 and lxlO4 cells/ml. The growth curve using 
lx l0 4cells/ml (green) did not show the typical shape, i.e. exponential growth, plateau 
and decrease. The cells were still multiplying 9 days after seeding. It was therefore 
decided that UT-7/EPO-S1 cells would be split to obtain the starting concentration of 
1x10' cells/ml in all experiments using this cell line, and that the cells should be used 
for virus inoculation 5 days after passaging them.
4 5
Days after seeding
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Figure 3.25: UT-7/EPO-S1 growth curves (n+14)
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III.4.2. Cell attachment study
The aim of this experiment was to evaluate whether any of the suspension cell lines 
could form a monolayer on suitably treated plates in order to establish a plaque assay 
for B19, which would be more user friendly. Accordingly, the bottom of a 96-well plate 
was treated with either collagen or fibronectin, known to promote cell attachment, in 
order to determine whether KU812, KU812Ep6 and UT-7/EPO cells would adhere to 
the wells.
To coat each well of a 96-well plate (0.32 cm2) with 2.5jiig of Collagen I, 50pl of a 
working solution of Collagen I (rat-tail, Becton-Dickinson), containing 50pg/ml was 
added (5|ig/cm2). The plate was left at room temperature for 1 hour, the Collagen I
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solution discarded from the wells and replaced with 200|il of PBS-A. The plate was left
to stand for 30 seconds and the buffer discarded. The plate was air-dried and used 
immediately. Alternatively, the coated plate could be stored at 4°C for up to a week.
A second plate was coated with fibronectin-like engineered protein polymer (Sigma). In 
order to coat each well of a 96-well plate (0.32cm2) with 3.2jig of fibronectin-like 
engineered protein polymer, 32jil of the working solution (lOOpg/ml) was added to each 
well (10p,g/cm2). The plate was left for 5 minutes at room temperature, fibronectin-like 
engineered protein polymer was discarded and the coated plate was immediately rinsed 
twice with PBS-A and air-dried. The coated plate could either be used immediately or 
stored at room temperature for up to 4 months. An example of part of the 96-well plate 
is shown below in table 3.2. Columns 1, 3 and 5 of the plate were coated (+ sign) with 
either Collagen I or fibronectin-like engineered protein polymer as described above, 
whereas columns 2, 4 and 6 were not coated (- sign). The latter served as negative 
controls.
Table 3.2: Plate for cell attachment experiment
1 2 3 4 5 6
A + - + - + -
B + - + - + -
C + - + - + -
D + - + - + -
E + - + - + -
F + - + - + -
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Rows A and B were used for UT-7/EPO cell line (duplicate), rows C and D for KU812
cell line (duplicate), and rows E and F for KU812Ep6 cell line (duplicate). A cell
concentration of lxlO5 cells/ml was used in columns 1 and 2, 5xl05 cells/ml in columns
3 and 4 and lxlO6 cells/ml in columns 5 and 6. 200pl of cell suspension in fresh
medium was added to the corresponding well in the two coated plates, which were then
placed in an incubator (37°C, 5% CO2).
After 4 hours, the cells were disturbed by shaking gently and observed under a light 
microscope for any sign of adherence to the coated plate. Only a few cells in each well, 
coated or non-coated, seemed attached to the plate. All three cell lines tested presented 
the same results. The plates were replaced in the incubator. After 24 hours, the medium 
was removed by inverting the plates and the cells observed under the light microscope. 
When the cell concentration was high i.e. lxlO6 cells/ml, some cells situated at the 
periphery of the wells stayed attached whereas the rest of the cells in suspension were 
removed when the medium was removed. This observation was made in both coated 
and non-coated wells, suggesting that neither treatment with Collagen I nor with 
fibronectin-like engineered protein polymer was responsible for this phenomenon. As 
far as lower cell concentrations were concerned, the cells were removed with the 
medium, thereby confirming that no attachment took place. Once more, all cell lines 
tested showed the same results.
In conclusion, this experiment suggested that KU812, KU812Ep6 and UT-7/EPO 
suspension cells could adhere to neither Collagen I nor fibronectin-like engineered 
protein polymer-coated plates. The development of a plaque assay for human parvovirus 
B19 using one of the above suspension cell lines was therefore ruled out, and an 
infectivity assay detecting viral mRNA transcripts was developed using those cells.
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III.4.3. Detection of B19 proteins by indirect IF A in continuous cell lines
III.4.3.1. Comparison of KU812, KU812Ep6 and UT-7/EPO cell lines
Three cell lines: KU812, KU812Ep6 and UT-7/EPO (2xl05 cells), were inoculated with 
either 30|LLl of neat B19 stock virus (lxlO12 IU/ml) or 30pl of negative serum. The cells 
were incubated at 4°C for 2 hours, with occasional mixing by flicking the tubes in order 
to keep the cells in suspension. Fresh medium (1ml) was added to each sample, which 
was then seeded into a 24-well plate (0.5ml per well). The plate was incubated at 37°C 
(5% CO2) and the cells were harvested 5 days post-infection. Microscope slides were 
prepared using the cytospin method (200jil of cell suspension).
Two different primary antibodies were tested in this indirect IFA: mouse monoclonal 
anti-VPl and VP2 proteins (1:80 dilution; Novocastra), mouse monoclonal anti-VPl 
and VP2 proteins (1:50, 1:80, 1:100, 1:500, 1:1,000 dilutions; kindly provided by Ube 
Research laboratory, Fujirebo, Japan). A negative serum (1:100 dilution) was also 
included as a control.
As expected, no fluorescence was seen in any cell line when the negative serum was 
used as primary antibody with B19 inoculated cells. Similarly, no staining was detected 
in cells inoculated with negative serum (negative controls). With the Novocastra 
monoclonal antibody, positive staining was observed equally in cell lines KU812 and 
KU812Ep6 (-10%) whereas less fluorescence was seen in cell line UT-7/EPO (-5%). 
However, the proportion of positive cells was much higher when the monoclonal 
antibody from Ube Research laboratory, Fujirebo (Japan) was used as the primary 
antibody (>30%). Overall, the cell line UT-7/EPO also presented slightly less 
fluorescence than the other two cell lines. Although all three cell lines showed positive 
staining when the highest dilution (1:1,000 dilution) of the antibody from Ube Research 
laboratory, Fujirebo (Japan) was used, the highest proportion of infected cells and the
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brightest fluorescence were displayed in the KU812Ep6 cell line. Photos of each cell
line stained with the Japanese antibody (1:80 dilution) are shown on figures 3.26 to
3.28.
Figure 3.26: IFA in UT-7/EPO cells inoculated with human parvovirus B19, 5 days
post-infection n
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Figure 3.27: IFA in KU812 cells inoculated with human parvovirus B19,5 days
post-infection
Figure 3.28: IFA in KU812Ep6 cells inoculated with human parvovirus B19,5 days
post-infection
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III.4.3.2. KU812Ep6 cell line
Comparison of UT-7/EPO, KU812, KU812Ep6 cell lines in the previous experiment
suggested that the KU812Ep6 cell line might be the most permissive one for human
parvovirus B19 infection. This cell line was therefore investigated further. Infection of
KU812Ep6 cells (passage n+72; 2xl06 cells) was done with either 300|il of a 1:10
dilution of the B19 stock virus (lxlO11 IU/ml) or 300pl of negative serum. Cells were
left at 4°C for 2 hours, with occasional mixing to resuspend the cells, and washed twice
with PBS-A. Fresh medium (1ml) was added to both positive and negative samples,
which were then seeded into a 24-well plate. The plate was incubated at 37°C (5% CO2)
and the cells were harvested 5 days post-infection. Microscope slides were prepared
using the cytospin method (200jll1 of cell suspension).
IFA was performed using either rabbit polyclonal anti-NSl protein (1:100 dilution; 
from Dr S. Doyle, National University of Ireland, Republic of Ireland) or a commercial 
mouse monoclonal antibody anti-VPl/VP2 (1:50, 1:100, 1:1,000, 1:10,000 dilutions; 
Novocastra) with the Alexa Fluor® 488 signal amplification kit (Cambridge 
BioScience, UK). The latter system includes the Alexa Fluor 488 rabbit anti-mouse IgG 
(1:100 dilution), followed by enhancement with the Alexa Fluor goat anti-rabbit IgG 
(1:100 dilution). These conjugates are claimed to be significantly brighter and more 
photostable than fluorescein-labelled probes. Alexa Fluor goat anti-rabbit IgG conjugate 
only was used as the secondary antibody for cells stained with rabbit polyclonal anti- 
NSl protein.
As expected, the cells which had been inoculated with negative serum did not show 
evidence of positive staining with either antibody used. KU812Ep6 cells inoculated 
with B19 and stained using mouse monoclonal anti-VPl/VP2 proteins presented
-257-
............................................................................................................ Chapter III
positive staining in only a couple of cells in each slide in the form of fluorescent spots,
as seen on figure 3.29.
Figure 3.29: IFA in KU812Ep6 cells inoculated with human parvovirus B19,5 days 
post-infection (stained with mouse monoclonal anti-VPl/VP2)
¥
When the cells inoculated with the virus were stained with rabbit polyclonal anti-NSl 
protein, some fluorescence was detected in a small proportion of the cells (-1%; not 
shown).
III.4.3.3. UT-7/EPO-S1 cell line
The IFA method kindly provided by Dr. J. Bltimel (Paul Erhlich Institut, Germany) was 
tested on the UT-7/EPO-S1 cells. This protocol differed slightly from the one described 
previously in the method of infection, as well as in the use of a different mouse 
monoclonal antibody anti-VPl/VP2.
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Cell aggregates were harvested, pelleted by centrifugation at 580g for 1 minute, and 7
samples were prepared with 2xl05 cells/sample. The cell pellet was resuspended in
200pl of medium without FCS (IMDM with 2U/ml EPO, 1% penicillin/streptomycin
and 1% fungizone). Serial dilutions of the B19 stock virus were also prepared in
medium without FCS, with concentrations ranging from lxlO11 to lxlO6 IU/ml. lOOpl
of either a virus dilution or medium without FCS (negative control) was added to the
corresponding cell sample. The cells were then placed in a 37°C water bath for 2 hours.
One millilitre of complete medium (IMDM with 10% FCS, 2U/ml EPO, 1%
penicillin/streptomycin and 1% fungizone) was added to each sample, without washing.
The cell suspensions were seeded in a 24-well plate and incubated at 37°C (5% CO2).
The cells were harvested 4 days post-infection and centrifuged at 715g for 1 minute.
The medium was discarded (poured out rather than pipetted out) and the cell pellet
washed with 1ml of PBS-A. The samples were centrifuged again (715g for 1 minute)
and most of the supernatant discarded, leaving about 50pi. A volume of 8jil of this cell
suspension was placed onto each spot of a multi spot slide (12 spots; Dunn, UK), air
dried and fixed in cold acetone/methanol (1:1, volume:volume) for 10 minutes.
One slide was stained with the commercial mouse monoclonal antibody anti-VPl/VP2
(Novocastra, 1:100 dilution) while the other was incubated with a mouse monoclonal
antibody (kindly provided by Dr J. Bliimel) directed the VP1/VP2 proteins (1:100
dilution), followed by the goat anti-mouse FITC-conjugated secondary antibody
(F0257, Sigma).
As expected, all cells inoculated with negative serum (negative controls) did not show 
any fluorescence. When the commercial mouse monoclonal (Novocastra) was used to 
stain UT-7/EPO-S1 cells, specific fluorescence, although very faint, was detected in a 
small proportion (-1%) of cells inoculated with dilutions of the B19 stock virus
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containing 2x10*1 and 2xl010 IU/ml. On the other hand, when the antibody provided by
Dr Bliimel was used, positive staining was bright and a few infected cells (~2-5%)
could still be seen in cells inoculated with 2xl09 IU/ml of B19 virus. The differences in
staining between the two antibodies can be seen in figures 3.30 and 3.31.
Figure 3.30: IFA in UT-7/EPO-S1 cells inoculated with human parvovirus B19
(2xl010 IU/ml), 4 days post-infection
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Figure 3.31: IFA in UT-7/EPO-S1 cells inoculated with human parvovirus B19
(2xl010 IU/ml), 4 days post-infection
The major difference between the infection method used in the present research project 
and Dr Blumel’s protocol was the use of a larger inoculum volume in the latter method, 
thereby increasing the multiplicity of infection. This experiment suggested that the 
mouse monoclonal antibody provided by Dr Blumel was logio 1 more sensitive at 
detecting fluorescence in infected UT-7/EPO-S1 cells than the commercially available 
antibody (Novocastra). However, the virus titre at which the cells had to be inoculated 
with was still very high (2xl09 IU/ml).
Consequently, an infectivity assay using nucleic acid amplification (RT-PCR) to detect 
viral mRNA transcripts seemed a much more sensitive and specific alternative to IFA.
-261 -
....................................................................................................................................................................... Chapter III
III.4.4. B19 infectivity assay for the detection of B 19-specific mRNAs in
continuous cell lines
In the B19 infectivity assay developed in the present study, the number of infectious 
units/ml can be calculated by taking the product of the reciprocal of the highest dilution 
giving a positive signal in the mRNA assay and a factor to allow for the volume of 
inoculum. Since the volume of virus used to infect the cells was 30pl, the factor was 
x33.3 or logio 1-5.
III.4.4.1. KU812 cell line
This experiment was aimed at determining whether KU812 cells were able to support 
parvovirus B19 replication and thereby to assess its possible use in the B19 infectivity 
assay. This was done by detecting viral mRNA transcripts using nucleic acid 
amplification (RT-PCR). As it was the first attempt at infecting these cells with B19, a 
high titre of virus was used and a time-course experiment was done for the isolation of 
mRNA from KU812 cells.
Two samples, each containing 106 cells, were prepared and centrifuged at 580g for 5 
minutes. One sample (negative control) was inoculated with lOOpl of negative serum 
while the other sample was resuspended in lOOjul of B19 stock virus diluted 1:10 in 
PBS-A (lxlO11 IU/ml). The cells were left at 4°C for 2 hours and washed twice with 
200pl of PBS-A. The cell pellets were then resuspended in 5ml of fresh medium and 
seeded into 5 wells of a 24-well plate. The plate was incubated at 37°C. One negative 
control and one sample inoculated with the virus were harvested on day 1, 2, 3, 4 and 5 
post-infection. The isolation of total nucleic acids was carried out following 
Nuclisens™ extraction protocol.
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Two different amplification assays were done, one with actin-specific primers (actin-3
and actin-4; 25pmol/jil) and the second with B 19-specific primers (B19-6 and B19-9;
25pmol/pl). The RT-PCR conditions were 1 cycle at 50°C for 30 minutes, 1 cycle at
94°C for 15 minutes, 43 cycles of 94°C for 45 seconds, 55°C for 45 seconds and 72°C
for 2 minutes and finally 1 cycle at 72°C for 5 minutes.
Figures 3.32 shows a photo of the agarose gel run with mRNA products amplified using 
actin- (A) and B 19-specific (B) primers.
Although actin transcripts (figure 3.32, panel A) were present in all samples, the 
concentration of actin (as judged by the brightness of the band) progressively decreased 
from day 4 post-infection. When B 19-specific primers were used (figure 3.32, panel B), 
all samples that had been inoculated with B19 virus (samples 2, 4, 6, 8 and 10) showed 
both B 19-specific bands. The very faint bands seen in the negative samples 1 and 3 
were due to a contamination from the neighbouring well when loading sample 2. The 
other negative samples did not show any amplification (samples 5, 7 and 9). This 
experiment showed that, when inoculated with high titre parvovirus B19, KU812 cells 
did allow the replication of the virus, at least from days 1 to 5 post-infection.
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Figure 3.32: Analysis of mRNA products in KU812 cells
(A) A m plified with actin-specific prim ers
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
(B) A m plified with B19-6 and B19-9 prim ers
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bp
Lane Samples
M PCR markers
1. day 1 post-infection, negative serum
2. day 1 post-infection, 2xlOn IU/ml inoculum
3. day 2 post-infection, negative serum
4. day 2 post-infection, 2xlOn IU/ml inoculum
5. day 3 post-infection, negative serum
6. day 3 post-infection, 2x10" IU/ml inoculum
7. day 4 post-infection, negative serum
8. day 4 post-infection, 2xlOn IU/ml inoculum
9. day 5 post-infection, negative serum
10. day 5 post-infection, 2x10" IU/ml inoculum
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III.4.4.2. KU812Ep6 cell line
A number of parameters regarding infection of cell cultures with parvovirus B19 were 
investigated in order to determine the optimum conditions for the use of KU812Ep6 
cells in an infectivity assay. These parameters were concentration of erythropoietin 
(EPO) in the culture medium, passage number of cells for infection, pH of phosphate 
buffer used as the virus diluent and temperature of incubation of the infected cells.
III.4.4.2.1. Concentration of erythropoietin (EPO)
The aim of this study was to grow KU812Ep6 cells in medium containing increasing 
concentrations of EPO in order to determine the optimum culture conditions for this cell 
line with respect to susceptibility to B19 infection.
The cells were passaged and placed at 37°C in 5 tissue culture flasks (25mm3; Falcon) 
containing medium supplemented with 2, 4, 6, 8 and lOU/ml of EPO. Four days later, 
the cells were harvested and counted. Six samples with 106 cells were prepared and 
centrifuged at 580g for 5 minutes. Serial 1:3 dilutions of the B19 stock virus were made 
in PBS-A to contain lxlO8'5, lxlO8, lxlO7'5, lxlO7 and lxlO6'5 IU/ml. Five cell samples 
were resuspended in these virus dilutions (30pl) whereas the negative control was 
resuspended in negative serum (30jil).
After 2 hours at 4°C, the cells were washed twice with 200ql PBS-A and the 
supernatant discarded. Each sample was resuspended in 5ml fresh medium containing 
the corresponding EPO concentration of 2, 4, 6, 8 or lOU/ml and was seeded in 5 wells 
of a 24-well plate. The latter was then incubated at 37°C (5% CO2).
The cells were harvested two days post-infection and mRNA was isolated from whole 
cells using the Oligotex direct mRNA kit (Qiagen). Extracted mRNA was used as 
template in a multiplex RT-PCR assay using actin-specific primers (actin-3 and actin-4;
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2.5pmol/jil) and B 19-specific primers (B19-6 and B19-9; 25pmol/pl). The amplification
conditions were 1 cycle at 50°C for 30 minutes, 1 cycle at 94°C for 15 minutes, 43
cycles of 94°C for 45 seconds, 55°C for 45 seconds and 72°C for 2 minutes and finally
1 cycle at 72°C for 5 minutes.
The results are shown in figure 3.33. As expected, none of the negative controls 
(samples 6, 12, 19, 25 and 31) showed amplification of B 19-specific transcripts while 
all samples from which mRNA had been isolated showed amplification of the actin- 
specific transcript.
When KU812Ep6 cells were cultured with EPO concentrations of 2, 4, 8 and lOU/ml, 
the last sample in which B19-mRNA transcripts could be amplified was that inoculated 
with a dilution of the B19 stock virus containing lxlO8 IU/ml. When the cells were 
grown with 6U/ml of EPO, the last sample in which B19-mRNA transcripts could be 
amplified was that inoculated with a dilution of the stock virus containing lxlO7 IU/ml 
(sample 17). Therefore, this experiment showed that the sensitivity of the infectivity 
assay was optimum when KU812Ep6 cells were cultured in medium containing 6U/ml 
of EPO (which was also the concentration used by the laboratory which originally 
described this cell line).
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Figure 3.33: Analysis of mRNA products in KU812Ep6 cells with increasing EPO
concentrations
M 1 2 3 4 5 6 7 8 9 10 11 12 13 M 14 15 16 17 18 19 20 21 22 23 24 25 26 27 2 8 29 30 31
1,000 bp 
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500 bp 
300 bp
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Lane M. PCR markers
Lanes 1 to 6: 2U/ml EPO
l . l x l 0 8 5 IU/ml inoculum
2. lx l0 8 IU/ml inoculum
3. I xlO75 IU/ml inoculum
4. lxlO7 IU/ml inoculum
5. lxlO 65 IU/ml inoculum
6. Negative serum
20 to 25: 8U/ml EPO
20. lxlO 85 IU/ml inoculum
21. 1 x 108 IU/ml inoculum
22. lx l 07  ^ IU/ml inoculum
23. lxlO7 IU/ml inoculum
24. lx l 06 5 IU/ml inoculum
25. Negative serum
7 to 12: 4U/ml EPO
7. lxlO85 IU/ml inoculum
8. 1 x 10s IU/ml inoculum
9. 1 x 107 5 IU/ml inoculum
10. lxlO 7 IU/ml inoculum
11. lxlO 7 IU/ml inoculum
12. Negative serum
13. RNAase-free water 
26 to 31: lOU/ml EPO
26. 1 x 108 5 IU/ml inoculum
27. 1 x 10s IU/ml inoculum
28. lx l0 75IU/ml inoculum
29. lxlO 7 IU/ml inoculum
30. 1 x 106 5 IU/ml inoculum
31. Negative serum
14 to 19: 6U/ml EPO
14. lxlO 85 IU/ml inoculum
15. lxlO8 IU/ml inoculum
16. 1 x 107  ^ IU/ml inoculum
17. lxlO7 IU/ml inoculum
18. 1 x 106  ^ IU/ml inoculum
19. Negative serum
III.4.4.2.2. Cell passage number
Since previous experiments (not shown) had suggested that KU812Ep6 cells at a higher 
passage number might be more susceptible to B19 infection than cells at a lower 
passage, it was considered important to compare different passage number in terms of 
infectivity assay results.
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KU812Ep6 cells at passages n+8, n+29, n+81 and n+93 were counted and 5 samples
containing 4xl05 cells each were pelleted by centrifugation (715g for 5 minutes) for
each passage tested. The cells were washed once with 500jil of phosphate buffer pH5.7
and centrifuged at 715g for 5 minutes. The cell pellets were resuspended in 30|Lil of
dilutions of the B19 stock virus (made in phosphate buffer pH5.7) containing lxlO8,
H f \  c   _1x10 , 1x10 and 1x10 IU/ml. The negative control was resuspended in buffer only. All 
samples were left at 4°C for 2 hours and washed twice with PBS-A. To each sample, 
lml of fresh medium was added and the cells seeded in a 24-well plate. After two days 
in a 37°C (5% CO2) incubator, the cells were harvested and the mRNA isolated from 
cell cytoplasm using the Oligotex direct mRNA kit.
Extracted mRNA was used as template in a multiplex RT-PCR assay using actin- 
specific primers (actin-3 and actin-4; 2.5pmol/jxl) and B 19-specific primers (B19-6 and 
B19-9; 25pmol/jil). The amplification conditions were: 1 cycle at 50°C for 30 minutes, 
1 cycle at 95°C for 15 minutes, 43 cycles of 94°C for 45 seconds, 54°C for 40 seconds 
and 72°C for 50 seconds and finally 1 cycle at 72°C for 5 minutes.
The results are shown on figure 3.34.
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Figure 3.34: Analysis of mRNA products in KU812Ep6 cells at various passages
M 1 2 3 4 5 6 7
1,000 bp 
750 bp 
500 bp
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150 bp 
50 bp
9 10 11 12 13 14 15 M M 16 17 18 19 20 21
Lane M. PCR markers 
Lanes 1 to 5: passage n+8
1. lxlO8 IU/ml inoculum
2. lxlO7 IU/ml inoculum
3. lxlO6 IU/ml inoculum
4. lx l0 5 IU/ml inoculum
5. Negative serum
Lanes 11 to 15: passage n+81
11. lxlO8 IU/ml inoculum
12. lxlO7 IU/ml inoculum
13. lxlO6 IU/ml inoculum
14. 1x10s IU/ml inoculum
15. Negative serum
Lanes 6 to 10: passage n+29
6. lxlO8 IU/ml inoculum
7. lxlO7 IU/ml inoculum
8. lxlO6 IU/ml inoculum
9. 1 x 105 IU/ml inoculum
10. Negative serum
Lanes 16 to 20: passage n+93
16. lxlO 8 IU/ml inoculum
17. lxlO7 IU/ml inoculum
18. lxlO6 IU/ml inoculum
19. lxlO 5 IU/ml inoculum
20. Negative serum
21. RNAase-free water
In KU812Ep6 cells at passage n+29, the only sample in which B19-mRNA transcripts
could be amplified was that inoculated with a dilution of the stock virus containing
1x10s IU/ml (sample 6). When cells at passages n+8 and n+81 were used, the last
sample in which B19-mRNA transcripts were detected was that inoculated with 1x10
IU/ml of virus stock (samples 2 and 12). In the case of cells at passage n+93, the 275bp
band specific for B19 was very faint and the only one detected in samples 17 and 18,
inoculated with dilutions of the stock virus containing lxlO7 and lxlO6 IU/ml
respectively. In conclusion, this study suggested that KU812Ep6 cells from a higher the
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passage number were more susceptible to B19 infection than cells from a lower passage
number.
III.4.4.2.3. pH of diluent buffer
Since it has been reported that a low pH is preferable in a B19 haemagglutination assay 
(Sato et al., 1995) to allow better adsorption of the virus onto the cells, low pH 
phosphate buffers were investigated for use as a diluent for the virus serial dilutions 
used in the infectivity assay. Phosphate buffers (lOmM) at pH 5.7, 6.0, 6.5 and 6.7, 
containing 0.85% NaCl, were investigated.
Sixteen samples (three inoculated with B19 and one negative control for each of the 
four pHs) were prepared with 106 KU812Ep6 cells (passage n+42) per sample. The cells 
were washed once with 0.5ml of phosphate buffer and centrifuged (580g for 5 minutes). 
The cell pellets were resuspended in 3 0 jll1 of the respective phosphate buffer containing 
lxlO9, lxlO8 and lxlO7 IU/ml of B19 virus stock. The negative control was 
resuspended in the corresponding buffer only. The samples were incubated at 4°C for 2 
hours and washed twice with 200jil of PBS-A to restore the pH to 7.2. The cell pellets 
were resuspended in 5ml of fresh medium and seeded into 5 wells of a 24-well plate and 
incubated at 37°C for 2 days, after which the cells were harvested. Isolation of mRNA 
from whole cells was done using the Oligotex direct mRNA kit (Qiagen). Extracted 
mRNA was used as template in multiplex RT-PCR using actin-specific primers (actin-3 
and actin-4; 2.5pmol/|il) and B 19-specific primers (B19-6 and B19-9; 25pmol/|iil). The 
amplification conditions were 1 cycle at 50°C for 30 minutes, 1 cycle at 94°C for 15 
minutes, 43 cycles of 94°C for 45 seconds, 55°C for 45 seconds and 72°C for 2 minutes 
and finally 1 cycle at 72°C for 5 minutes.
The results are shown on figure 3.35.
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Figure 3.35: Analysis of mRNA products in KU812Ep6 cells with various pHs of
diluent buffer
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 4: Phosphate buffer pH 5.7
1. lxlO9 IU/ml inoculum
2. 1 x 108 IU/ml inoculum
3. lxlO 7 IU/ml inoculum
4. Negative serum
9 to 12: Phosphate buffer pH 6.5
9. lxlO9 IU/ml inoculum
10. Ix l0 x IU/ml inoculum
11. lxlO7 IU/ml inoculum
12. Negative serum
5 to 8: Phosphate buffer pH 6.0
5. lxlO9 IU/ml inoculum
6. 1 x 108 IU/ml inoculum
7. lxlO 7 IU/ml inoculum
8. Negative serum
13 to 16: Phosphate buffer pH 6.7
13. lxlO9 IU/ml inoculum
14. 1 x 108 IU/ml inoculum
15. lxlO7 IU/ml inoculum
16. Negative serum
17. RNAase-free water
The bright actin band in all samples suggested that the cells did not loss significant 
viability as the pH decreased. The results showed that all pHs tested allowed detection 
of lxlO65 B19 infectious units/ml. Moreover, at pH 5.7, the B 19-specific bands were 
the brightest. Therefore it appeared that phosphate buffer pH 5.7 could be used as 
diluent in the B 19 infectivity assay.
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In addition to phosphate buffer pH 5.7, lOmM acetate buffer (with 0.85% NaCl) at 
lower pHs (pH 5.6, 5.2, 4.8, 4.4 and 4.0) were tested the second study for comparison 
purposes. Twenty-five samples (three inoculated with B19 and one negative control for 
each of the five pHs) were prepared with 106 KU812Ep6 cells (n+47) per sample. The 
protocol described in the previous experiment was followed using dilutions of the B19 
stock virus, made in the appropriate buffer, containing lxlO8, lxlO7 and lxlO6 IU/ml. 
Isolation and amplification of mRNA were performed in the same way as in the first 
study. The results are shown in figure 3.36.
There was a clear decrease in the brightness of the actin band as the pH decreased, 
suggesting that the cells were not viable at a very low pH. When acetate buffer at pH 
5.6 and 5.2 were used as diluent of B19 stock virus, the last sample in which B 19- 
specific mRNA transcripts were detected was that inoculated with a dilution of the B19 
stock virus containing lxlO7 IU/ml (samples 3 and 7). When acetate buffers at pH 4.8 
and 4.4 were used, the infectivity assay was able to detect logio 1 less infectious virus 
particles per ml than at pH 5.6 and 5.2. There was no amplification of B 19-specific 
transcripts when acetate buffer pH 4.0 was used However, the use of phosphate buffer at
n c
pH 5.7 led the detection of 1x10 ‘ infectious units/ml, suggesting that it was the most 
efficient buffer to use for optimum B19 infection of KU812Ep6 cells. This buffer was 
therefore chosen as the virus diluent in the infectivity assay with KU812Ep6 cells.
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Figure 3.36: Analysis of mRNA products in KU812Ep6 cells with various pHs of
diluent buffer
(A)
M 1 2  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
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Lane M PCR markers
(A) Lanes 1 to 5: acetate buffer pH 5.6
1. 1x10s IU/ml inoculum
2. 1 x 10s IU/ml inoculum (duplicate)
3. lxlO7 IU/ml inoculum
4. lxlO 6 IU/ml inoculum
5. Negative serum
Lanes 10 to 13: acetate buffer pH 4.8
10. 1x10s IU/ml inoculum
11. lxlO7 IU/ml inoculum
12. lxlO6 IU/ml inoculum
13. Negative serum
(B) Lanes 18 to 21: acetate buffer pH 4.0
18. lxlO8 IU/ml inoculum
19. lxlO7 IU/ml inoculum
20. lxlO 6 IU/ml inoculum
21. Negative serum
Lanes 6 to 9: acetate buffer pH 5.2
6. 1x10s IU/ml inoculum
7. lxlO 7 IU/ml inoculum
8. lxlO 6 IU/ml inoculum
9. Negative serum
Lanes 14 to 17: acetate buffer pH 4.4
14. 1x10s IU/ml inoculum
15. lxlO7 IU/ml inoculum
16. lxlO 6 IU/ml inoculum
17. Negative serum
Lanes 22 to 25: phosphate buffer pH 5.7
22. 1 x 108 IU/ml inoculum
23. lx 107 IU/ml inoculum
24. lxlO6 IU/ml inoculum
25. Negative serum
26. RNAase-free water
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III.4.4.2.4. Incubation temperature
The incubation period, during which cells and viruses were in contact, lasted for 2 hours
and was done at 4°C. However, in order to ensure that this incubation temperature was
optimal for B19 infection of KU812Ep6 cells, the results of the infectivity assay were
compared to incubation at 37°C and room temperature. Eighteen samples of KU812Ep6
cells (passage n+39; 8xl05 cells/sample) were prepared and inoculated in triplicate with
either negative serum or dilutions of the B19 stock virus containing lxlO10, lxlO9,
lxlO8, lxlO7 and lxlO6 IU/ml, prepared in PBS-A. One set of samples was placed in a
37°C water bath, another at 4°C and the last set left at room temperature for 2 hours.
The cells were washed twice with PBS-A and 4ml of fresh medium added to each
sample. The cells were seeded in a 24-well plate (1ml per well), incubated at 37°C for 2
days, after which they were harvested. Isolation of mRNA from whole cells was done
using the Oligotex direct mRNA kit. Extracted mRNA was used as template in
multiplex RT-PCR using actin-specific primers (actin-3 and actin-4; 2.5pmol/pl) and
B 19-specific primers (B19-6 and B19-9; 25pmol/jxl). The amplification conditions were
1 cycle at 50°C for 30 minutes, 1 cycle at 94°C for 15 minutes, 43 cycles of 94°C for 45
seconds, 55°C for 45 seconds and 72°C for 2 minutes and finally 1 cycle at 72°C for 5
minutes. The RT-PCR products were run on agarose gels, which are shown on figure
3.37.
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Figure 3.37: Analysis of mRNA products in KU812Ep6 cells using various
incubation temperatures
M I 2 3 4 5 6 7 8 9 10 11 12 M 13 14 15 16 17 18 19
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bv
Lane M. PCR markers
Lanes 1 to 6: incubation at 37°C
1. lx l0 10IU/ml inoculum
2. lxlO9 IU/ml inoculum
3. 1x10s IU/ml inoculum
4. 1 x 107 IU/ml inoculum
5. lxlO6 IU/ml inoculum
6. Negative serum
Lanes 13 to 18: incubation at 4°C
13. 1 x 1010 IU/ml inoculum
14. lxlO 9 IU/ml inoculum
15. 1x10s IU/ml inoculum
16. lxlO 7 IU/ml inoculum
Lanes 7 to 12: incubation at room temperature
7. lx lO 10 IU/ml inoculum
8. lxlO9 IU/ml inoculum
9. lx l0 8 IU/ml inoculum
10. lxlO 7 IU/ml inoculum
11. lx l 06 IU/ml inoculum
12. Negative serum
17.1x10 IU/ml inoculum
18. Negative serum
19. RNAase-free water
As expected, a bright actin band was present in all samples where mRNA was extracted. 
When the cells and virus were incubated at 37°C, the last sample in which B 19-specific 
mRNA transcripts were detected was the one inoculated with a dilution of the stock 
vims containing lxlO9 IU/ml (sample 2). Although very faint bands of the size of the 
B 19-specific mRNA transcripts were seen in sample 5 inoculated with a dilution of the 
stock vims containing lxlO6 IU/ml, no specific bands were detected in samples 3 and 4, 
inoculated with lxlO8 and lxlO7 IU/ml, respectively. Therefore, this result might have
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been due to the Poisson distribution and might not have been significant. The same
infectivity assay results were obtained when the incubation period was done at 37°C,
room temperature and 4°C. At these temperatures, the assay could detect lxlO9 IU/ml.
The conclusion of this experiment was that the incubation temperature did not seem to
be a significant parameter that could influence the susceptibility of KU812Ep6 cells to
B19 infection. Therefore, 4°C was used as the incubation temperature for the optimised
infectivity assay.
Overall, the experiments described in this section suggested that KU812Ep6 cells of a 
higher rather than lower passage number grown in medium supplemented with 6U/ml of 
EPO were optimum for the B19 infectivity assay. In addition, phosphate buffer, pH 5.7, 
was shown to be a good diluent for B19 virus in the infectivity assay and the study 
indicated that the incubation temperature of cells with virus was not a significant 
parameter in the inoculation step of the assay.
III.4.4.3. UT-7/EPO cell line
The optimal conditions for B19 infection of the UT-7/EPO cell line were also 
investigated. Three different virus diluents, namely phosphate buffer pH 5.7, acetate 
buffer pH 5.6 and PBS-A, were compared in this infectivity assay using UT-7/EPO 
cells. Twelve samples, including three inoculated with three dilutions of B19 stock virus 
and one negative control for each of the three buffers tested, were prepared with UT- 
7/EPO cells (passage n+46; 4xl05 cells/sample). The cells were washed once with 
phosphate buffer pH 5.7, acetate buffer pH 5.6 or PBS-A. Three different virus dilution 
series were prepared using each of the three buffers as diluent, and the cell pellets were 
resuspended in 30pl of virus dilution, containing lxlO8, lxlO6 or lxlO4 IU/ml, or with
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the corresponding buffer alone. The samples were incubated at 37°C for 2 hours, after
which UT-7/EPO cells were washed twice with 0.5ml of PBS-A. The cell pellets were
resuspended in 2ml of freshly made medium and seeded in 2 wells of a 24-well plate.
After 2 days incubation at 37°C (5% CO2), the cells were harvested and the mRNA
extracted from cell cytoplasm using the Oligotex direct mRNA kit (Qiagen). As the RT-
PCR step could not be done immediately following mRNA isolation, the extracted
mRNA samples were stored at -70°C. Two different pairs of primers were used for the
amplification step: multiplex RT-PCR using B19-6 and B19-9 (25pmol/|Lil) with actin-3
and actin-4 primers (2.5pmol/|il), and single RT-PCR using the B19 primer pair XPP2
and B19-9 (25pmol/pl). The amplification conditions were 1 cycle at 50°C for 30
minutes, 1 cycle at 95°C for 15 minutes, 43 cycles of 95°C for 45 seconds, 57°C for 40
seconds and 72°C for 40 seconds and finally 1 cycle at 72°C for 10 minutes.
Figure 3.38 and 3.39 show the results of RT-PCR amplification using B19-6 and B19-9
(multiplex) and XPP2 and B19-9, respectively.
It is important to note, on figure 3.38, that most actin bands were very faint, except for 
samples 10, 11 and 12. The cell loss observed was probably not due to low pH since the 
actin bands were also faint when PBS-A was used. Moreover, previous experiments 
with KU812Ep6 cells suggested that cell loss only occurred at and below pH 4.4. This 
low level of isolated mRNA could have explained the lack of amplification of the B 19- 
specific transcripts when B19-6 and B19-9 primers were used. Only sample 10, which 
had been inoculated with a dilution of the stock virus containing lxlO6 IU/ml (diluted in 
phosphate buffer pH 5.7), showed amplification of B 19-specific transcripts.
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Figure 3.38: Analysis of mRNA products in UT-7/EPO cells amplified with B19-6
and B19-9 primers
M 1 2 3 4 5 6 7 8 9 10 11 12 13
1,000 bp 
750 bp
500 bp
300 bp
150 bp
50 bp
Lane M. PCR markers 
Lanes 1 to 4: PBS-A
1. 1 x 10s IU/ml inoculum
2. lx l0 6 IU/ml inoculum
3. 1 x 104 IU/ml inoculum
4. PBS-A
Lanes 9 to 12: phosphate buffer pH 5.7
9. lxlO 8 IU/ml inoculum
10. lxlO 6 IU/ml inoculum
11. 1 x 104 IU/ml inoculum
12. Phosphate buffer pH 5.7
13. RNAase-free water
Lanes 5 to 8: acetate buffer pH 5.6
5. 1x10s IU/ml inoculum
6. 1 x 106 IU/ml inoculum
7. lxlO4 IU/ml inoculum
8. Acetate buffer pH 5.6
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Figure 3.39: Analysis of mRNA products in UT-7/EPO cells amplified with XPP2
and B19-9 prim ers
M l  2 3 4 5 6 7 8 9 10 11 12 13
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bp
Lane M. PCR markers 
Lanes 1 to 4: PBS-A
1. lxlO8 IU/ml inoculum
2. Ix 106 IU/ml inoculum
3. 1 x 104 IU/ml inoculum
4. PBS-A
Lanes 9 to 12: phosphate buffer pH 5.7
9. 1x10s IU/ml inoculum
10. lxlO 6 IU/ml inoculum
11. lx l0 4 IU/ml inoculum
12. Phosphate buffer pH 5.7
13. RNAase-free water
Lanes 5 to 8: acetate buffer pH 5.6
5. 1 x 10s IU/ml inoculum
6. lxlO6 IU/ml inoculum
7. lxlO4 IU/ml inoculum
8. Acetate buffer pH 5.6
Amplification with primers XPP2 and B19-9 primers gave faint bands specific to B19 
(figure 3.39). Amplification was seen in samples 1 and 5, which had been inoculated 
with a dilution of the stock virus containing lxlO8 IU/ml diluted in PBS-A and acetate 
buffer pH 5.6, respectively. When phosphate buffer pH 5.7 was used as diluent, 
amplification of B 19-specific transcripts occurred in all three samples inoculated with 
the virus (samples 9, 10 and 11). In these conditions, the infectivity assay was able to 
detect lxlO4 IU/ml of B19. The difference in results between the different buffers tested
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might have been due to the fact that more mRNA was present in samples 10, 11 and 12
than in the other samples. However, phosphate buffer pH 5.7 was still confirmed to be
the most suitable buffer to use as virus diluent in infectivity assays using UT-7/EPO
cells.
III.4.4.4. Comparison of the susceptibility of the KU812, KU812Ep6 
and UT-7/EPO cell lines to infection with B19
III.4.4.4.1. B19 infectivity assays using the KU812Ep6, KU812 
and UT-7/EPO cell lines
Since all three cell lines had been shown to support B19 replication, this experiment 
was aimed at determining which one was the most suitable for establishing a sensitive, 
B19 infectivity assay by inoculating the cells with serial, half-logio dilutions (1:3 
dilutions) of the B19 stock virus. Seven samples, containing 2xl05 cells per sample, 
were prepared for each of the cell line, KU812Ep6 (passage n+54), KU812 (passage 
n+68) and UT-7/EPO (passage n+53), and centrifuged at 580g for 5 minutes. Serial 
dilutions of virus in phosphate buffer pH 5.7, containing lxlO8, lxlO7'5, lxlO7, lxlO6'5, 
lxlO6 and lxlO5'5 IU/ml were prepared. For each cell line, six of the cell pellets were 
resuspended in 30|il of the corresponding virus dilution while the remaining cell pellet 
was inoculated with phosphate buffer pH 5.7 only. After 2 hours incubation at 4°C, the 
cells were washed twice with PBS-A and seeded in lml of the corresponding medium. 
The 24-well plate was placed at 37°C. Two days later, isolation of mRNA from whole 
cells was done using the Oligotex direct mRNA kit (Qiagen). Extracted mRNAs were 
used as templates in a multiplex RT-PCR assay with actin primers and the B 19-specific 
primer pair B19-6 and B19-9. The amplification conditions werel cycle at 50°C for 30
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minutes, 1 cycle at 94°C for 15 minutes, 43 cycles of 94°C for 45 seconds, 55°C for 45 
seconds and 72°C for 2 minutes and finally 1 cycle at 72°C for 5 minutes.
Figure 3.40 shows that B 19-specific mRNA transcripts were present in all samples 
inoculated with the virus. All three cell lines displayed similar results, although KU812 
cell line seemed slightly better than the other two cell lines because both bands of 155bp 
and 275bp were present in all samples inoculated with parvovirus B19.
Since KU812Ep6 cells were derived from KU812 cell line, these two cell lines were 
compared in the following experiment using higher virus dilutions.
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Figure 3.40: Analysis of mRNA products in various cell lines amplified with B19-6
and B19-9
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 M 15 16 17 18 19 20 21 22
1,000 bp 
750 bp
500 bp 
300 bp
150 bp
50 bp
Lane M. PCR markers 
Lanes 1 to 7: KU812Ep6 cells
1. Ix 10s IU/ml inoculum
2. 1 x 107 5 IU/ml inoculum
3. 1 x 107 IU/ml inoculum
4. lxlO 65 IU/ml inoculum
5. lxlO6 IU/ml inoculum
6. lxlO 5 5 IU/ml inoculum
7. Phosphate buffer pH 5.7 
Lanes 15 to 21: UT-7/EPO cell
15. 1x10s IU/ml inoculum
16. lxlO 75 IU/ml inoculum
17. lxlO7 IU/ml inoculum
18. lx l0 65 IU/ml inoculum
19. lxlO 6 IU/ml inoculum
20. lxlO55 IU/ml inoculum
21. Phosphate buffer pH 5.7
22. RNAase-free water
Lanes 8 to 14: KU812 cells
8. 1x10s IU/ml inoculum
9. lx l0 75IU/ml inoculum
10. 1 x 107 IU/ml inoculum
11. lx l0 6 IU/ml inoculum
12. lxlO6 IU/ml inoculum
13. lxlO 5 5 IU/ml inoculum
14. Phosphate buffer pH 5.7
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III.4.4.4.2. B19 infectivity assay using KU812 and KU812Ep6
cell lines
This experiment was done in order to investigate the relative sensitivities of the KU812 
(passage n+70) and KU812Ep6 (passage n+56) cell lines to infection with B19. The 
protocol described above was followed using lower virus dilutions (in phosphate buffer 
pH 5.7) for inoculation of the cells. Cells were thus inoculated with dilutions of the B19 
stock virus containing lxlO7, lxlO6, lxlO5, lxlO4, lxlO3, lxlO2, lxlO1 and 1x10° 
IU/ml. A negative control with buffer only was also included for both cell lines. 
Isolation of mRNA from whole cells was done using the Oligotex direct mRNA kit 
(Qiagen). Extracted mRNAs were used as templates in a multiplex RT-PCR assay with 
actin primers and the B19 primer pair B19-6 and B19-9. The amplification conditions 
were the same as in the previous experiment (section III.4.4.4.1).
The results of nucleic acids amplification are shown on figure 3.41.
The housekeeping gene actin was present in samples 1 to 18, suggesting that mRNA 
had been extracted in all samples tested. Although there seemed to have been some non­
specific bands in some samples using KU812Ep6 cells (samples 2, 3 and 4), the last 
sample that showed amplification of B 19-specific transcripts was sample 5, which had 
been inoculated with a dilution of the stock virus containing 1x10 IU/ml. However, 
only the 275bp band was detected in samples 1, 3 and 5, while no B19 transcripts were 
amplified in sample 4 (inoculated with lxlO4 IU/ml). This could have been due to the 
Poisson distribution. In comparison, when cells KU812 were used in the infectivity 
assay, the last sample that showed amplification of B 19-specific transcripts was sample 
11, inoculated with lxlO6 IU/ml. Therefore, in this particular study, B19 infectivity 
assay was able to detect logio 3 more infectious virus units per ml with KU812Ep6 cells 
than with the parent cell line KU812. This was in contrast to the previous experiment,
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which had found KU812 to be more permissive for B19 infection than KU812Ep6 or
UT-7/EPO cell lines. However, since lower virus titres were used to infect the cells in
the present experiment, the variation in sensitivity between the cell lines might have
been due to the Poisson distribution of virus at limiting dilutions.
Figure 3.41: Analysis of mRNA products in KU812 and KU812Ep6 cell lines 
amplified with B19-6 and B19-9
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 M 16 17 18 19
i
Lane M. PCR markers 
Lanes 1 to 9: KU812Ep6 cells
1. lxlO7 IU/ml inoculum
2. lxlO 6 IU/ml inoculum
3. lxlO5 IU/ml inoculum
4. lxlO4 IU/ml inoculum
5. lxlO 3 IU/ml inoculum
6. lxlO2 IU/ml inoculum
7. lxlO 1 IU/ml inoculum
8. 1x10° IU/ml inoculum
9. Phosphate buffer pH 5.7
Lanes 10 to 18: KU812 cell
10. lx l0 7 IU/ml inoculum
11. 1 x 106 IU/ml inoculum
12. lxlO 5 IU/ml inoculum
13. lx l0 4 IU/ml inoculum
14. lxlO3 IU/ml inoculum
15. lxlO2 IU/ml inoculum
16. lxlO 1 IU/ml inoculum
17. 1x10° IU/ml inoculum
18. Phosphate buffer pH 5.7
19. RNAase-free water
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III.4.4.4.3. Cell synchronisation
The aim of this experiment was to determine whether cells synchronised in S phase
were more susceptible to B19 infection. Three cell lines: KU812 (passage n+73),
KU812Ep6 (passage n+59) and UT-7/EPO (passage n+58) were treated with
hydroxyurea, which is a drug that inhibits ribonucleotide reductase and arrests the cell
cycle at the Gl/S boundary or in the S phase, depending upon the hydroxyurea
concentration, the time of exposure and the type of cells.
For each cell line, 106 cells were counted and pelleted by centrifugation at 580g for 5 
minutes. The cells were resuspended in 10ml of the appropriate cell culture medium 
containing ImM hydroxyurea (without antibiotics or fungizone), placed in a 25mm 
flask and incubated at 37°C (5% CO2) for 36 to 40 hours. The cell suspensions were 
centrifuged for 5 minutes at 670g and washed twice in 5ml of the appropriate cell 
culture medium without FCS, prewarmed at 37°C. A cell count was performed after the 
second wash in order to establish the volume of cell suspension to be used for infection 
(2xl05 cells/sample). Six samples, including five inoculated with serial dilutions of the 
B19 stock virus and one inoculated with phosphate buffer at pH 5.7, were prepared for 
each cell line. Serial dilutions of the virus stock containing lxlO7, lxlO6, lxlO5, lxlO4 
and lxlO3 IU/ml were prepared in phosphate buffer pH 5.7. The cell pellets were 
resuspended in 30pl of the appropriate virus dilution or 30|il of buffer only (negative 
control). After 2 hours incubation at 4°C, the cells were washed twice with 200pl of 
PBS-A, resuspended in 1ml of the appropriate fresh cell culture medium and seeded into 
a 24-well plate. The latter was incubated at 37°C for 2 days (5% CO2). The cells were 
harvested two days post-infection and poly A+ RNA was extracted from whole cells 
using the Oligotex direct mRNA kit (Qiagen). Isolated mRNA was used as template in a 
multiplex RT-PCR assay using actin-specific primers (actin-3 and actin-4; 2.5pmol/|il)
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and B 19-specific primers (B19-9 and B19-6; 25pmol/|xl). The amplification conditions
were 1 cycle at 50°C for 30 minutes, 1 cycle at 94°C for 15 minutes, 43 cycles of 94°C
for 45 seconds, 55°C for 45 seconds and 72°C for 2 minutes and finally 1 cycle at 72°C
for 10 minutes.
The results are shown on figure 3.42. Actin-specific transcripts were present in all 
samples except sample 14, which had been lost during mRNA extraction. As expected, 
all three negative controls (samples 6, 12 and 19) did not show any B 19-specific bands. 
Both B 19-specific transcripts were still detected in KU812Ep6 cells inoculated with 
lxlO4 IU/ml (sample 4). However, no amplification of B 19-specific transcripts was 
detected in sample 3, which could be due to the Poisson distribution at limiting 
dilutions.
In KU812 cells, although no amplification was detected in sample 7, faint B 19-specific 
bands could be seen in sample 8, where cells had been inoculated with lxlO6 IU/ml.
In UT-7/EPO cells, the total lack of amplification of B 19-specific mRNA transcripts 
suggested that the cells did not support B19 replication. However, B 19-specific 
transcripts had previously been detected in those cells using the same infectivity assay. 
The second hypothesis was that the treatment with hydroxyurea might not have had the 
expected effect on the cells and possibly have interfered with cell growth of 
susceptibility to B19 infection. However, the parent cell line UT-7 had previously been 
reported to support the replication of B19 following treatment with hydroxyurea 
(Shimomura et al., 1993). Lastly, the fact that the actin-specific band was faint in all 
UT-7/EPO samples suggested that less mRNA was isolated from these cells compared 
with other cell lines. Thus, this experiment suggested that the best infectivity results 
after cell synchronisation were obtained with KU812Ep6 cell line.
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Figure 3.42: Analysis of mRNA products in various cell lines treated with
hydroxyurea and amplified with B19-6 and B19-9
M 1 2 3 4 5 6 M 7 8 9 10 11 12 M 13 14 15 16 17 18 19
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
Lane M. PCR markers 
Lanes 1 to 6: KU812Ep6 cells
1. lxlO7 IU/ml inoculum
2. lxlO6 IU/ml inoculum
3. lx l0 5 IU/ml inoculum
4. lxlO 4 IU/ml inoculum
5. lxlO 3 IU/ml inoculum
6. Phosphate buffer pH 5.7
Lanes 7 to 12: KU812 cells
7. lxlO7 IU/ml inoculum
8. lxlO6 IU/ml inoculum
9. 1x10s IU/ml inoculum
10. lxlO4 IU/ml inoculum
11. 1 x 103 IU/ml inoculum
12. Phosphate buffer pH 5.7
Lanes 13 to 19: UT-7/EPO cell
13. lxlO 7 IU/ml inoculum
14. lxlO 6 IU/ml inoculum (sample lost during extraction)
15. lxlO5 IU/ml inoculum
16. lxlO4 IU/ml inoculum
17. lxlO 3 IU/ml inoculum
18. Phosphate buffer pH 5.7
19. RNAase-free water
When compared to non-synchronised cells, the results of the infectivity assay were 
similar for the KU812 cell line whereas the detection of B19 transcripts was logio 1 
higher with non-synchronised KU812Ep6 cells than with synchronised cells. As far as 
the UT-7/EPO cell line was concerned, the highest dilution detected was lxlO5'5 IU/ml
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of the B19 stock virus when the cells were not synchronised whereas no amplification
was detected after cell synchronisation.
Overall, it seemed that cell synchronisation did not significantly improve the 
permissibility of the cells to parvovirus B19 infection. In conclusion, the data obtained 
in this study comparing the three cell lines suggested that non synchronised KU812Ep6 
cells were the best candidate for use in a B19 infectivity assay, in terms of 
permissiveness to B19 infection as well as in being able to support virus replication. 
However, due to confidentiality issues with the group from which the cells had been 
obtained, work was discontinued on this cell line. A new cell line, UT-7/EPO-S1, which 
had been reported to be more susceptible to B19 replication than the parental cell line, 
UT-7/EPO (Morita et al., 2001), was obtained for evaluation in the B19 infectivity 
assay.
III.4.5. Optimisation of B19 infectivity assay using UT-7/EPO-S1 cells
The newly obtained cell line UT-7/EPO-S1 was investigated to determine whether it 
was able to support B19 replication and to assess its susceptibility to the virus compared 
to other cell lines previously studied. UT-7/EPO-S1 cells (passage n+4) were pelleted 
and washed once with phosphate buffer pH 5.7. Approximately 2xl05 cells were 
inoculated with either 30pl of buffer (negative control) or serial dilutions of the stock 
B19 virus, diluted in phosphate buffer pH 5.7, containing lxlO9, lxlO8, lxlO7, lxlO6, 
lxlO5, lxlO4 and lxlO3 IU/ml. After 2 hours incubation at 4°C, the cells were washed 
twice with 500pl of PBS-A. The cells were resuspended in 1ml of fresh medium and 
seeded in a 24-well plate placed at 37°C (5% CO2). Two days post-infection, the cells 
were harvested and the mRNA isolated from the cell cytoplasm using the Oligotex 
direct mRNA kit (Qiagen). Nucleic acids amplification was done using the B 19-specific
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primers XPP2 and B19-9. The amplification conditions, which were used for all 
experiments using UT-7/EPO-S1 cells, were 1 cycle at 50°C for 30 minutes, 1 cycle at 
95°C for 15 minutes, 43 cycles of 95°C for 45 seconds, 50°C for 40 seconds and 72°C 
for 40 seconds and finally 1 cycle at 72°C for 10 minutes.
Amplification of the housekeeping gene actin (not shown) confirmed successful 
isolation of mRNA from all cell samples. Figure 3.43 shows the amplified RT-PCR 
products on the agarose gel.
Figure 3.43: Analysis of mRNA products in UT-7/EPO-S1 cells amplified with 
XPP2 and B19-9
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
M 1 2  3 4  5 6  7 8 9  M
M PCR markers
1.1x10 IU/ml inoculum 6. 1x10 IU/ml inoculum
2. 1x10 IU/ml inoculum 7. 1x10 IU/ml inoculum
8. Phosphate buffer pH 5.7
9. RNAase-free water
3. 1x10 IU/ml inoculum
4. 1x10 IU/ml inoculum
5. 1x10 IU/ml inoculum
The results indicated that the infectivity assay using UT-7/EPO-S1 cells was able to 
detect B 19-specific mRNA transcripts in cells inoculated with lxlO4 IU/ml (sample 6). 
The absence of B19 transcripts amplification in sample 5, which had been inoculated
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with lxlO5 IU/ml of vims, might have been due to the Poisson distribution. Therefore,
this preliminary study indicated that this new cell line was able to support B19
replication and also appeared to be slightly more susceptible to B19 infection, i.e. more
permissive, than the parent cell line, UT-7/EPO. A comparison of the infectivity results
with the UT-7/EPO-S1 cells with results previously obtained with KU812Ep6 cells
suggested that the UT-7/EPO-S1 cell line would be a very good candidate cell line for
the B19 infectivity assay. The following sections describe the optimisation of the assay
using this new cell line.
III.4.5.1. Virus diluent buffer
In order to establish that phosphate buffer pH 5.7 was the optimum buffer for 
inoculation of the UT-7/EPO-S1 cell line as it was for the other cell lines studied, a 
further experiment was done to compare the sensitivity of this cell line to vims diluted 
in phosphate buffer pH 5.7 and cell culture medium without FCS. Cells (passage n+5) 
were prepared as above and inoculated with serial dilutions of the stock B19 vims, 
prepared in either phosphate buffer pH 5.7, or cell culture medium without FCS, 
containing lxlO7, lxlO6 and lxlO5 IU/ml. mRNA isolated from the cell cytoplasm 
using the Oligotex direct mRNA kit. Nucleic acids amplification was done using the 
B 19-specific primers XPP2 and B19-9 and the conditions were as previously described 
(section ffl.4.5).
Figure 3.44 shows amplification of the nucleic acid extracted from UT-7/EPO-S1 cells.
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Figure 3.44: Analysis of mRNA products in UT-7/EPO-S1 cells amplified with
XPP2 and B19-9
M l  2 3 4 5 6 7 9 10 M
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 4: phosphate buffer pH 5.7
1. lxlO7 IU/ml inoculum
2. lxlO6 IU/ml inoculum
3. lx l0 5 IU/ml inoculum
4. Phosphate buffer pH 5.7 
Lanes 9 and 10: controls
9. RNAase-free water
Lanes 5 to 8: medium without FCS
5. lxlO7 IU/ml inoculum
6. lxlO 6 IU/ml inoculum
7. 1 x 105 IU/ml inoculum
8. Medium without FCS
10. RT-PCR positive control: 2x10 IU/ml inoculum
Amplification of the housekeeping gene actin (non-shown) confirmed successful 
isolation of mRNA from all cell samples. The results shown on figure 3.44 indicated 
that, when phosphate buffer pH 5.7, was used as the virus diluent, the assay was able to 
detect at least lxlO5 IU/ml of virus (sample 3). The RT-PCR B 19-specific bands were 
still very bright in the sample from cell inoculated with the highest dilution of virus, 
suggesting that an even higher dilution might be detected. In contrast, only a very faint 
band was seen in sample 5, which had been inoculated with a dilution of the stock virus 
containing lxlO7 IU/ml diluted in medium without FCS. This study clearly confirmed 
that B19 infection at low pH increased the cells susceptibility to the virus and phosphate
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buffer pH 5.7 was therefore chosen as the virus diluent buffer for the B19 infectivity
assay with UT-7/EPO-S1 cells.
III.4.5.2. Cell passage number
The two experiments in this section investigated the influence of the cell passage 
number on the susceptibility of UT-7/EPO-S1 cells to infection with B19. The first 
experiment studied cells, at passage n+5 and n+45, inoculated with serial dilutions of 
the B19 stock virus, diluted in phosphate buffer pH 5.7, containing lxlO6'5, lxlO6, 
lxlO5,5, lxlO5, lxlO4'5 and lxlO4 IU/ml. mRNA was isolated from the cell cytoplasm 
using the Oligotex direct mRNA kit (Qiagen) and amplified in a multiplex assay with 
actin-specific primers (actin-3 and actin-4; 5pmol/pl) and B 19-specific primers (XPP2 
and B19-9; 25pmol/pl). The amplification conditions were as previously described 
(section III.4.5).
The results comparing passage number n+5 and n+45 are shown on figure 3.45. The 
presence of a bright actin band in all samples confirmed that mRNA had been extracted 
successfully. The results showed that there was a logio 1 difference between the results 
obtained with UT-7/EPO-S1 n+5 and n+45. The assay was able to detect lxlO6 IU/ml 
when passage n+5 was used (sample 2) whereas lxlO5 IU/ml were detected with 
passage n+45 (sample 11). This first experiment thus suggested that a late, rather than 
early, cell passage might improve the results of the B19 infectivity assay.
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Figure 3.45: Analysis of mRNA products in UT-7/EPO-S1 cells (passages n+5 and
n+45) amplified with XPP2 and B19-9
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
Lane M. PCR markers 
Lanes 1 to 7: cell passage n+5
1. lxlO 65 IU/ml inoculum
2. lxlO6 IU/ml inoculum
3. lxlO 55 IU/ml inoculum
4. 1 x 10s IU/ml inoculum
5. lx l0 4 5 IU/ml inoculum
Lanes 8 to 14: passage number n+45
8. 1 x 106 5 IU/ml inoculum
9. lxlO6 IU/ml inoculum
10. lxlO 55 IU/ml inoculum
11. 1x10' IU/ml inoculum
12. Ix l0 4:i IU/ml inoculum
13. 1x10 IU/ml inoculum
14. Phosphate buffer pH 5.7
6. 1x10 IU/ml inoculum
7. Phosphate buffer pH 5.7 
Lanes 15 and 16: controls
15. RNAase-free water
16. RT-PCR positive control: lxlO7 IU/ml inoculum
The above experiment was repeated using cells at passage number n+14 and n+53. The 
cells were inoculated with dilutions of the B19 stock virus, diluted in phosphate buffer 
pH 5.7, containing lxlO7, lxlO65, lxlO6, lxlO55, lxlO5, lx l0 45and lxlO4 IU/ml. The 
results are shown on figure 3.46.
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Figure 3.46: Analysis of mRNA products in UT-7/EPO-S1 cells (passages n+14 and
n+53) amplified with XPP2 and B19-9
M 1 2 3 5 6 7 10 11 12 13 14 15 16 17
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
Lane M. PCR markers 
Lanes 1 to 8: cell passage n+14
1. 1 x 107 IU/ml inoculum
2. lxlO65 IU/ml inoculum
3. lxlO6 IU/ml inoculum
4. 1 x 105 5 IU/ml inoculum
5. 1x10s IU/ml inoculum
6. lxlO45 IU/ml inoculum
7. lxlO4IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 9 to 16: passage number n+53
9. lxlO7 IU/ml inoculum
10. Ix l0 6s IU/ml inoculum
11. 1 x 106 IU/ml inoculum
12. 1x10s 5 IU/ml inoculum
13. 1x10s IU/ml inoculum
14. Ix l0 4s IU/ml inoculum
15. lxlO4IU/ml inoculum
16. Phosphate buffer pH 5.7
17. RNAase-free water
The amplification of the housekeeping gene, actin, suggested that the extraction of 
mRNA had been successful. Figure 3.46 also showed that the use of both cell passages 
n+14 and n+53 allowed the detection of lxlO6 IU/ml of virus (samples 3 and 11). When 
compared to the first experiment in this series, the data were similar to those obtained 
with cell passage n+5.
Therefore, the logio 1 difference between passages n+5, n+14, n+53 and n+45 might 
have been insignificant and was probably due to detection variation from one 
experiment to another. It appeared that UT-7/EPO-S1 passage number did not have a 
significant impact on the outcome of the B19 infectivity assay.
- 2 9 4 -
........................................................................................................................................................................Chapter III
III.4.5.3. Hypoxia studies
III.4.5.3.1. Growth curves
The cell line UT-7/EPO-S1 at passage n+16 was used at a starting concentration of 
lxlO3 cells/ml. Two 24-well plates were incubated at 37°C, one in a normal 20% 
oxygen atmosphere while the second was in an incubator with 3% oxygen. Every day 
and for 7 days, lOOpl of trypan blue was added to 4 wells of each cell suspension 
dilution. The live cells (unstained) were counted using a haemacytometer in order to 
construct a growth curve. Table A2.15 in appendix 2 shows the cell concentrations 
calculated from the cell counts done everyday for 10 days and figure 3.47 is a plot of 
these values.
Figure 3.47: Growth curves of UT-7/EPO-S1 cell line (n+17) in a 20% and 3%
oxygen atmosphere
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As expected, the cells grown in 3% oxygen showed a slower growth than those cultured 
in normal atmospheric conditions. However, the optimum time for cell harvest to 
provide the highest number of dividing cells for the B19 infectivity assay was 5 days 
after cell passage for both set of conditions.
III.4.5.3.2. Hypoxia conditions
The effect of hypoxia on the susceptibility of UT-7/EPO-S1 cells to B19 infection was 
investigated. Table 3.3 below shows the oxygen concentration at which the cells were 
incubated before infection with B19, as well as after B19 infection. Samples marked 
“A” were incubated in 20% oxygen both before and after inoculation with parvovirus 
while samples “B” were grown in 20% oxygen before infection and in 3% oxygen post­
infection. Finally, samples labelled “C” were grown in a 3% oxygen atmosphere and 
were incubated in the same hypoxic conditions post-infection.
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Table 3.3: Conditions and samples names for hypoxia study
Pre-infection
oxygen
Post-infection
oxygen
Time of 
harvesting
Name of 
samples
20% 20% 24 hours A24-1 to 10
20% 20% 48 hours A48-1 to 10
20% 20% 72 hours A72-1 to 10
20% 3% 24 hours B24-1 to 10
20% 3% 48 hours B48-1 to 10
20% 3% 72 hours B72-1 to 10
3% 3% 24 hours C24-1 to 10
3% 3% 48 hours C48-1 to 10
3% 3% 72 hours C72-1 to 10
Ten samples for each harvest time i.e. 24, 48 and 72 hours (30 samples for A, 30 
samples for B and 30 samples for C) were prepared with UT-7/EPO-S1 cells (2xl05 
cells per sample; passage n+17). Thirty microlitres of serial dilution of the B19 stock
8 7 5  7virus, prepared in phosphate buffer pH 5.7 and containing 1x10 , 1x10 ‘ , 1x10 , 
lxlO6'5, lxlO6, lxlO5'5, 1x10s, lxlO4’5 and lxlO4IU/ml were used to inoculate the cells. 
One negative sample for A, B and C was inoculated with 30pl of buffer only. All 
samples were incubated at 4°C for 2 hours, washed twice with PBS-A and resuspended 
in 1ml of fresh medium. The cell suspensions were seeded in 24-well plates and 
cultured for 24 hours, 48 hours or 72 hours at 37°C (5% CO2) with either 20% or 3% 
oxygen (table 2.3). Once harvested, the mRNA was extracted from cell cytoplasm using 
the Oligotex direct mRNA kit (Qiagen). Multiplex RT-PCR was performed using
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primers specific for the housekeeping gene (actin-3 and actin-4; 5pmol/pl) and for
parvovirus B19 (XPP2 and B19-9; 25pmol/pl). The amplification conditions were as
previously described (section m.4.5).
The results of the hypoxia experiment are shown in table 3.4.
Table 3.4: Hypoxia experiment results
Pre- infection 
oxygen
Post- infection 
oxygen
Time of harvesting 
(hours)
Logio infectious 
particles/ ml
20% 20% 24 climit of detection
20% 20% 48 7
20% 20% 72 7
20% 3% 24 climit of detection
20% 3% 48 7
20% 3% 72 7
3% 3% 24 climit of detection
3% 3% 48 8
3% 3% 72 8
III.4.6. Quantification of B19 DNA by LightCycler system
III.4.6.1. MgCh titration
The effects of MgCl2 concentration on the efficiency of the PCR assay was investigated 
by testing increasing amounts of MgCl2 from 1 to 5mM. The total reaction volume was 
20pl, including 2|il of SYBR Green master mix, B19F and B19R primers at a final 
concentration of 0.5|liM, MgCl2 at a concentration optimum for the amplification of B19
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DNA and nuclease-free water to give a final volume of 20|il. The PCR mix was loaded
into glass capillaries, followed by the addition of 5pl of DNA template. The DNA
samples used for this study were the B19 IS (99/800) and 1:10 and 1:100 of this
standard. The B19 IS has an established concentration of 106 IU/ml. From the
collaborative study used to establish this standard, 1IU is approximately equivalent to
0.6-0.8 genome equivalents (Saldanha et al., 2002). The four steps of PCR
amplification were 1 cycle at 95°C for 10 minutes (pre-incubation), 40 cycles of 20
seconds at 95°C, 30 seconds at 65°C (amplification) and 5 seconds at 80°C (fluorescent
data collection), 1 cycle at 65°C for 15 seconds (melting), and a final cycle at 40°C for
30 seconds (cooling). The MgCl2 concentration was titrated by testing increasing
concentrations of 1, 2, 3, 4 and 5mM (0, 0.8, 1.6, 2.4 and 3.2p,l, respectively) in order to
optimise the DNA amplification reaction.
The results are shown on figure 3.48 and the concentrations of ImM and 2mM MgCl2 
proved inadequate for an efficient DNA amplification. MgCl2 concentrations from 3 to 
5mM seemed to be optimum for this assay since the bands on the agarose gel were 
much neater and brighter than the lower concentrations.
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Figure 3.48: Analysis of DNA products amplified by LightCycler for MgCh
titration
M 1 2  3 4 5 6 7 8 9 10 11 12 13 14 15 16 M 17 18 19 20
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp
Lane M. PCR markers 
Lanes 1 to 4: ImM MgCl2
1. B 19IS 106 IU/ml
2. B 19IS 105 IU/ml
3. B 19 IS 104 IU/ml
4. Carrier tRNA (control) 
Lanes 9 to 12: 3mM MgCl2
9. B 19 IS l()6 IU/ml
10. B 19 IS 105 IU/ml
11. B19IS 104 IU/ml
12. Carrier tRNA (control) 
Lanes 17 to 20: 5mM MgCl2
17. B19IS 106 IU/ml
18. B19IS 105 IU/ml
19. B 19IS 104 IU/ml
20. Carrier tRNA (control)
III.4.6.2. Validation studies
The validation studies used the optimised conditions of nucleic acid extraction and 
DNA quantification. Therefore, QIAamp DNA blood mini kit (Qiagen) was used to 
extract total nucleic acid, which was in turn quantified by real-time PCR on the 
LightCycler instrument (Roche). The PCR kit used for this amplification was FastStart 
DNA Master SYBR Green I kit (Roche). The total reaction volume was 20pl, including
- 3 0 0 -
Lanes 5 to 8: 2mM MgCl2
5. B 19IS 106 IU/ml
6. B 19IS 105 IU/ml
7. B 19 IS 104 IU/ml
8. Carrier tRNA (control) 
Lanes 13 to 16: 4mM MgCl2
13. B 19 IS 106 IU/ml
14. B 19 IS 105 IU/ml
15. B 19 IS 104 IU/ml
16. Carrier tRNA (control)
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2 jll1 of SYBR Green master mix, 0.5pl of each primers (B19F and B19R) at the working 
concentration of 20pmol/jil (lOpmol per reaction), MgCL at the optimum concentration 
of 5mM (3.2pl), 8 .8 jll1 of nuclease-free water and 5pi of template. The conditions for 
amplification were 1 cycle at 95°C for 10 minutes, 40 cycles of 20 seconds at 95°C, 30 
seconds at 65°C and 5 seconds at 80°C, 1 cycle at 65°C for 15 seconds, and a final cycle 
at 40°C for 30 seconds.
in.4.6.2.1. B19 DNA Standard curve
Two studies were performed to establish the validity of the B19 standard curve. Firstly, 
in order to determine the limit of quantitation of the assay, serial dilutions of the B19 IS 
DNA were prepared as follows: neat (106 IU/ml), 1:10 dilution (105 IU/ml), 1:102 
dilution (104 IU/ml), 1:103 dilution (103 IU/ml), 1:104 dilution (102 IU/ml), 1:105 
dilution (10 IU/ml) and 1:106 dilution (1 IU/ml). Two negative controls were added to 
each of the four runs, namely RNAase-free water and B19 negative plasma. The B19 IS 
DNA samples and the B19 negative plasma samples used in this first study had been 
extracted on different days. The PCR kit used was the FastStart DNA Master SYBR 
Green I (Roche Diagnostics) and the primers were B19F and B19R. A standard curve 
was then constructed using the LightCycler software. All PCR products were visualised 
on a 2% agarose gel.
In all four runs, although the LightCycler computer program calculated a value for the 
“B19 DNA concentration” below 1x10s IU/ml, this value corresponded to a 
fluorescence generated by the formation of primer dimers and was therefore not specific 
for B19. In order to confirm this, both melting peaks (figures 3.49, 3.50 and 3.51) and 
agarose gels (figure 3.52) were examined. Taking into account all four runs, the melting 
temperature of the IS DNA samples ranging from 106 to 103 IU/ml was between 84.4
-301 -
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and 85°C (figure 3.49, from run 2). As shown on figure 3.50, the 1:104 dilution of the IS 
(lxlO2 IU/ml) in run 2 presented two melting peaks: a large one at a melting 
temperature of 79.94°C and a smaller one at a melting temperature of 84.57°C. 
Although the latter temperature was within the range specific for B19 DNA, the 
fluorescence measured was mainly generated by primer dimers. The latter have a 
melting temperature between 79.9 and 80.5°C. Primer dimers could also be seen on the 
agarose gels for this particular sample (50bp band), while a faint band specific for B19 
was still visible in 3 of 4 runs. This sample was therefore considered below the limit of 
quantitation. Even higher dilutions of the standard (10 and 1 IU/ml), as well as the 
negative controls (water and negative plasma), also showed two melting peaks but the 
smaller one was not specific for B19 DNA since the melting temperature was lower 
than 84°C. In conclusion, all calculated values lower than lxlO3 IU/ml were considered 
negative for B19 DNA.
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Figure 3.52: Analysis of PCR products for the 1st validation study
(A)
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
Run 1 Run 2
M l  2 3 4 5  6 7 8 9 M 1  2 3 4 5 6  7 8 9
Hi ■«*£ it*
(B)
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bp
Run 3 Run 4
M 1 2 3 4 5 6 7 9 M 1 2  3 4 5  6 7  8 9
Lane M. PCR markers 
Lanes 1 to 7: B19 IS DNA
1. B19 IS neat (106 IU/ml)
2. B 19 IS 10 1 (105 IU/ml)
3. B 19 IS 102 (104 IU/ml)
4. B 19 IS 103 (103 IU/ml)
5. B 19 IS 10 4 (102 IU/ml)
6. B 19 IS 10'5 (10 IU/ml)
Lanes 8 and 9: Controls
8. PCR negative control: RNAase-free water
9. B 19 negative plasma
7 .B 1 9 IS  10b (l IU/ml)
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In a second validation study, standard curves set up in 7 different amplification runs
were statistically analysed in order to evaluate the linearity of the standard curve. The
virus concentrations ranged was from 106 to 103 IU/ml. The results of the expected
values and the calculated values obtained for 7 standard curves from 7 different assays
are shown in table 3.5 (logio values). Statistical analysis was kindly done by A. Heath
(Department of Informatics, NIBSC; see section n.2.7.1) and the results are shown in
table 3.6.
Table 3.5: Validation results for B19 standard curve
Study
number
Std 1 (logio 6) 
logio DNA 
concentration 
(IU/ml)
Std 2 (logio 5) 
logio DNA 
concentration 
(IU/ml)
Std 3 (logio 4) 
logio DNA 
concentration 
(IU/ml)
Std 4 (logio 3) 
logio DNA 
concentration 
(IU/ml)
1 6.029 5.073 3.764 3.132
2 6.029 5.073 3.764 3.132
3 6.059 4.929 3.962 3.048
4 6.016 4.966 4.016 2.726
5 6.029 4.941 4.029 2.307
6 6.024 4.951 4.024 2.709
7 5.951 5.022 4.100 2.925
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Table 3.6: B19 standard curve statistics
.Chapter III
Logio DNA concentration (IU/ml) Mean estimate Standard deviation
6 6.020 0.033
5 4.994 0.062
4 3.951 0.134
3 2.854 0.298
This study examined the linearity of the standard curve over the range logio 6 to logio 3 
IU/ml and the reproducibility of the curve. The mean estimates were very close to the 
expected concentrations at logio 6- logio 4, but were poor at logio 3 (Std 4), indicating a 
good linearity over most of the range. The standard deviations also showed excellent
reproducibility at logio 6, but the reproducibility decreased as the concentrations got
0 • •lower. Although the limit of detection might be 10 IU/ml, the first validation study
suggested to chose logio 3 IU/ml as the lower limit of quantitation for this assay.
Overall, it was decided that the standard curve should include the following dilutions of 
the B19 IS DNA: neat (106 IU/ml), 1:10 dilution (105 IU/ml), 1:102 dilution (104 IU/ml), 
1:103 dilution (103 IU/ml), as well as a negative sample (RNAase-free water). An 
example of such a curve is shown on figure 3.53, with the calculated efficiency and 
slope. According to the manufacturers’ instructions, curves with a slope less than -3.33 
were considered satisfactory.
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III.4.6.2.2. Study 1: validation of DNA extraction and
amplification on the LightCycler
In order to study the reproducibility of the quantitative PCR assay, the first validation 
study included six DNA extractions done in 6 separate runs. The samples included one 
positive control (B19 IS neat), three negative controls (one anti-B19 antibody negative 
plasma, one anti-B19 antibody negative serum, one water control) and a test sample, 
which was a 1:10 dilution of the IS in water (105 IU/ml). The positive and negative 
controls for each run were first amplified by LightCycler PCR in order to check that 
there were no false positive/negative results. The test samples from each extraction run 
were amplified by LightCycler PCR in two separate LightCycler PCR runs on different 
days (days 1 and 2) with an expected B19 DNA titre of 105 IU/ml. B19 DNA titres were 
calculated using a standard curve obtained from serial dilutions of one B19 IS extracted 
in the first run and the results are shown in table 3.7.
Table 3.7: Results of validation study 1
DNA extraction run 
number
Logio DNA concentration 
(IU/ml) day 1
Logio DNA concentration 
(IU/ml) day 2
1 4.770 4.841
2 4.231 4.504
3 4.934 4.985
4 4.397 4.244
5 5.695 5.542
6 4.710 4.784
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Statistical analysis, kindly performed by Alan Heath (Informatics Department, NIBSC)
was based on the logio titres. It was noted that the titres for extraction run 5 were
considerably higher than for the other samples (about logio 1). The overall mean of the
logio titres was logio 4.804 IU/ml, again slightly lower than the anticipated logio 5
IU/ml. This represents a geometric mean of 6.368x104 IU/ml.
The variability between extractions was assessed by calculating the mean logio titre 
from the two repeat runs for each sample, and then calculating the standard deviation of 
the means across samples, which was 0.472. Therefore 95% of results from repeated 
extractions should fall approximately within +/- logio 0.94 IU/ml. This figure was 
relatively high, and had been influenced by the high results for sample 5 noted above. 
However, it is possible that there may have been a dilution error with run 5. A 1:10 
dilution is a required step. If this had been omitted, it may have accounted for the results 
for run 5, being 10-fold higher than for the other samples. The analysis was thus 
repeated omitting run 5. The overall mean of the logio titre was logio 4.641 IU/ml. This 
represented a geometric mean of 4.37xl04 IU/ml. The standard deviation across samples 
was 0.282. Therefore 95% of results from repeated extractions should fall 
approximately within +/- logio 0.56 IU/ml. This figure represents the overall expected 
variability in the test, including the extraction step, based on two replicate LightCycler 
runs.
III.4.6.2.3. Study 2: Validation of B19 LightCycler PCR
The second study included six repeat nucleic acid amplifications on different days of a 
sample from a single extraction in order to study the variability in the amplification step 
of the assay. B19 DNA was extracted from the IS (sample 1) and diluted in RNAase- 
free water 1:10 to make a stock B19 DNA solution containing 105 IU/ml for testing.
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This test sample for the validation study was amplified by LightCycler PCR on 6
different days and the B19 DNA titre of the test sample (expected concentration 105
IU/ml) was calculated against a standard curve obtained from serial dilutions of the B19
IS, which was extracted in parallel with the test sample.
The overall mean of the six logio titres was logio 4.915 IU/ml, slightly lower than the 
anticipated logio 5.0 IU/ml. This represents a geometric mean of 8.214xl04 IU/ml. The 
standard deviation of the logio titres was 0.092 i.e. 95% of individual results from repeat 
testing of this sample would be expected to fall within approximately two standard 
deviations of the mean i.e. +/- logio 0.18 IU/ml. This gives a measure of the expected 
variability from the LightCycler PCR, independent of the extraction process.
III.4.6.3. Quantification of B19 samples used in this study
Three high titre B19 samples were used in this study; samples JS (B19 stock virus) and 
JB, which were obtained from Germany and sample LP, which was from the USA. B19 
DNA was extracted from these samples in parallel with the B19 IS (106 IU/ml). Ten­
fold serial dilutions from 10'1 to 10"8 of the samples were prepared in DNAse-free 
water. Ten-fold serial dilutions from 10'1 to 10'5 of the IS were also prepared. All 
samples were amplified in duplicate by real-time PCR on the LightCycler instrument. A 
standard curve was constructed from the dilutions of the IS and B19 DNA was 
quantified in the B19 samples by reading the results off this curve.
III.4.7. Optimisation of mRNA isolation
III.4.7.1. Time course experiments
The studies described in the following section were all aimed at finding the optimum 
time to harvest infected cells for maximum yield of B19 mRNA. The cell line used in
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the first experiment was KU812Ep6 and infection was done using lOOpl of either
negative serum as the negative control or a 1:10 dilution of the B19 stock virus (lxlO11
IU/ml). Each well of a 24-well plate was seeded with 1.8xl05 cells. One well of both
infected and uninfected cells was harvested on day 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14,
15, 16 and 21 post infection (15 samples). Fresh medium (1ml) was added to all
remaining wells on day 14 since considerable evaporation of medium had occurred by
this time. A cell count was done after each harvest in order to note any major difference
in the cell number, which might have influenced the outcome of the mRNA extraction
step. The harvested cells were centrifuged and frozen at -70°C until extracted all
together. The mRNA isolation method used was the Nuclisens™ extraction of total
nucleic acids. The RT-PCR step was performed separately for B19 (primers B19-6 and
B19-9; 25pmol/(il) and actin genes (primers actin-3 and actin-4; 25pmol/pl). The RT-
PCR conditions were similar for amplification using B19- and actin-specific primers: 1
cycle at 50°C for 30 minutes, 1 cycle at 94°C for 15 min, 43 cycles at 94°C for 45
seconds, 55°C for 45 seconds and at 72°C for 2 minutes and lastly, 1 cycle at 72°C for 5
minutes. The products were analysed on 2% agarose gels.
Table 3.8 shows the cell count performed after each harvest for both KU812Ep6 cells 
infected with a 1:10 dilution of the B19 stock virus (lxlO11 IU/ml) and uninfected cells. 
The cell counts suggested that there was no major difference over time for infected cells 
and negative controls. The number of surviving cells was lower after 21 and 16 days in 
culture for infected and uninfected cells, respectively. This phenomenon was expected 
because of natural cell death, even after addition of fresh medium on day 14 post­
infection. When infected and uninfected cells were compared, there seemed to be fewer 
cells in the infected samples compared with the negative controls. This was also to be
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expected since B19 vims would lyse and thus kill a proportion of the cells in the
infected samples.
Table 3.8: Cell counts of infected and uninfected KU812Ep6 cells over time post­
infection
Day post infection Infected sample (cells/ml) Negative sample (cells/ml)
0 1.8 x 103 1.8 x 103
3 3.4 x 103 5.3 x 103
4 5.2 x 103 6.7 x 103
5 7.3 x 103 7.8 x 103
6 6.6 x 10" 7.5 x 103
7 4.1 x 103 7.6 x 103
8 4.3 x 103 8.4 x 103
9 2.4 x 103 7.3 x 103
10 2.8 x 103 8.5 x 103
12 2.7 x 105 3.9 x 103
13 4.7 x 103 5.2 x 103
14 4.3 x 103 6.3 x 103
15 4.4 x 103 7.9 x 103
16 4.5 x 103 4.7 x 103
21 1.8 x 103 4.8 x 103
mRNA was extracted from infected and uninfected cells and amplified, in separate 
assays, with actin primers and with B 19-specific primers (primers B19-6 and B19-9), as 
shown on figure 3.54 (panels A and B, respectively).
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Figure 3.54: Analysis of mRNA products extracted from KU812Ep6 cells
(A) Amplified with actin-specific primers
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp
(B) Amplified with B 19-specific primers
M l  2 3 4 5 6 7 8 9 10 11 12 13 14 15 6 17 18 M 19 20 21 2223 2425 26 2728 2930
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp
Lane M. PCR markers
1. Day 2, negative serum
2. Day 2, lx lO 11 IU/ml inoculum
3. Day 3, negative serum
4. Day 3, lx lO 11 IU/ml
5. Day 4, negative serum
6. Day 4, lx lO 11 IU/ml inoculum
7. Day 5, negative serum
8. Day 5, lx lO 11 IU/ml inoculum
9. Day 6, negative serum
10. Day 6, 1x10" IU/ml inoculum
11. Day 7, negative serum
12. Day 7, lx lO 11 IU/ml inoculum
13. Day 8, negative serum
14. Day 8, lx lO 11 IU/ml inoculum
15. Day 9, negative serum
16. Day 9, lx lO 11 IU/ml inoculum
17. Day 10, negative serum
18. Day 10, lx lO 11 IU/ml inoculum
19. Day 12, negative serum
20. Day 12, lx lO 11 IU/ml inoculum
21. Day 13, negative serum
22. Day 13, lx lO 11 IU/ml inoculum
23. Day 14, negative serum
24. Day 14, 1 x 10 11 IU/ml inoculum
25. Day 15, negative serum
26. Day 15, lx lO 11 IU/ml inoculum
27. Day 16, negative serum
28. Day 16, 1 x 10 11 IU/ml inoculum
29. Day 21, negative serum
30. Day 21, 1 x 10 11 IU/ml inoculum
M l  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 M 19 20 2 1 2 2  23 24 25 26 27 28 29 30
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From the agarose gel analysis, the internal control was amplified and the band was
bright in all extracted samples. This suggests that the mRNA isolation was successful 
and that the products amplified with B 19-specific primers could be compared. The two 
RT-PCR products of 155bp and 275bp, which are characteristic of B19 mRNA 
transcripts with this primer pair, were present in all samples infected with parvovirus 
B19. These two bands were very bright over time, except on days 5, 6 and 7, when 
fainter bands were detected. The largest RT-PCR product (l,779bp), which could not 
always be detected, was also present in most infected samples up to day 10 post­
infection. The negative control on day 12 post-infection (lane 19) showed specific B19 
bands, which are most probably due to a contamination from the neighbouring well 
(infected sample, day 12, lane 20). In conclusion, this experiment indicated that cell 
harvesting could be done as early as 2 days post-infection and that B19 mRNA 
transcripts were still produced 21 days post-infection.
In order to investigate the time course of B19 infection in other cell lines, the second 
and third experiments used UT-7/EPO and KU812 cells, respectively. Since the first 
experiment showed that the cells begin to die after about 2 weeks in culture, studies 2 
and 3 only investigated the presence of mRNA transcripts until 10 days post-infection. 
Moreover, unlike experiment 1, the cells were harvested from day 1 post-infection. The 
protocols for infection (inoculation with a 1:10 dilution of the B19 stock virus (lxlO11 
IU/ml) or mock-infected with negative serum), harvest, cell count, mRNA extraction, 
RT-PCR and analysis on agarose gels were similar to those described for the first 
experiment. Tables 3.9 and 3.10 show the cell counts after each harvest of UT-7/EPO 
and KU812 cells, respectively cells. Extracted mRNA was amplified in separate assays,
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with actin primers and B 19-specific primers (B19-6 and B19-9), as displayed on figures
3.55 and 3.56, panels A and B, for UT-7/EPO and KU812 cells, respectively.
Table 3.9: Cell counts of infected and uninfected UT-7/EPO cells over time post­
infection
Day post infection Infected sample (cells/ml) Negative sample (cells/ml)
0 2 x10s 2 x10s
1 1.8 x10s 2.8 x10s
2 3.5 xlOs 4.9 x10s
3 3.1 xlO5 4.7 xlO5
4 3.5 xlO3 5.5 xlOs
5 4.6 x10s 7 x10s
6 4.4 x10s 8.7 xlO5
7 4.2 xlO5 1.2 x10s
8 6 x10s 1.4 x10s
9 5.1 xlO5 3.7 x10s
10 6.8 xl0s 1.9 xlO6
No major difference in the cell count was noted either between infected and uninfected 
samples or over time. The RT-PCR step with actin primers showed that all samples 
were extracted successfully since a bright band on the agarose gel was seen in all 
samples.
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Figure 3.55: Analysis of mRNA products extracted from UT-7/EPO cells
(A) Amplified with actin-specific primers
M l  2 3 4 5 6 7 8 9 10 M 11 12 13 14 15 16 17 18 19 20
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bp
(B) Amplified with B19-specific primers
M 1 2 3 4 5 6 7 8 9 10 M 11 12 13 14 15 16 17 18 19 20 21
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bp
Lane M. PCR markers
1. Day 1, negative serum
2. Day 1, lx lO 11 IU/ml inoculum
3. Day 2, negative serum
4. Day 2, lxlO 11 IU/ml inoculum
5. Day 3, negative serum
6. Day 3, lx lO 11 IU/ml inoculum
7. Day 4, negative serum
8. Day 4, lx l 0 11 IU/ml inoculum
9. Day 5, negative serum
10. Day 5, lx lO 11 IU/ml inoculum
11. Day 6, negative serum
12. Day 6, lx lO 11 IU/ml inoculum
13. Day 7, negative serum
14. Day 7, lx lO 11 IU/ml inoculum
15. Day 8, negative serum
16. Day 8, lx lO 11 IU/ml inoculum
17. Day 9, negative serum
18. Day 9, lxlO 11 IU/ml inoculum
19. Day 10, negative serum
20. Day 10, lx lO 11 IU/ml inoculum
21. RNAase-free water
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As far as amplification with B 19-specific primers was concerned, two negative samples
(day 1, lane 1 and day 6, lane 11) showed two faint bands characteristic of RT-PCR
products. This was due to overloading from the neighbouring wells. These B 19-specific
bands were present in all infected samples from days 1 to 10, with the brightest bands
on days 1 and 2 post-infection. When compared with the results obtained with the
KU812Ep6 cell line in the first experiment, the largest RT-PCR product (l,779bp) was
not present on the gel. The fainter bands observed 7 days post-infection with
KU812Ep6 cells were not seen with UT-7/EPO cells. There was no other variation
between the two cell lines.
Table 3.10: Cell counts of infected and uninfected KU812 cells over time post­
infection
Day post infection Infected sample (cells/ml) Negative sample (cells/ml)
0 2 xlO3 2 xlO3
1 2.9 xlO5 2.5 xlO3
2 2.9 xlO3 4.2 xlO3
3 3.2 xlO3 2.7 xlO3
4 1.9 xlO3 3.5 xlO3
5 2.3 xlO3 3.2 xlO3
6 2.2 xlO3 3.8 xlO3
7 2.7 xlO3 3.3 xlO3
8 2.6 xlO3 4.3 xlO3
9 2 xlO3 2.3 xlO3
10 3 xlO3 4.1 xlO3
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Figure 3.56: Analysis of mRNA products extracted from KU812 cells
(A) Amplified with actin-specific primers
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
(B) Amplified with B 19-specific primers
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
Lane M. PCR markers
1. Day I, negative serum
2. Day I, lx lO 11 IU/ml inoculum
3. Day 2, negative serum
4. Day 2, lx lO 11 IU/ml inoculum
5. Day 3, negative serum
6. Day 3, 1x10" IU/ml inoculum
7. Day 4, negative serum
8. Day 4, 1x10" IU/ml inoculum
9. Day 5, negative serum
10. Day 5, 1x10“ IU/ml inoculum
11. Day 6, negative serum
12. Day 6, lx lO 11 IU/ml inoculum
13. Day 7, negative serum
14. Day 7, lx lO 11 IU/ml inoculum
15. Day 8, negative serum
16. Day 8, lx lO 11 IU/ml inoculum
17. Day 9, negative serum
18. Day 9, lx lO 11 IU/ml inoculum
19. Day 10, negative serum
20. Day 10, lx lO 11 IU/ml inoculum
M 1 2 3 4 5 6 7 8 9 10 M 11 12 13 14 15 16 17 18 19 20
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As observed with the other two cell lines tested in the first and second experiments
(KU812Ep6 and UT-7/EPO, respectively), the two B 19-specific RT-PCR products of
155bp and 275bp were detected from days 1 to 10 post-infection in KU812 cells.
Although the actin band was present in all samples extracted, it was weaker in lanes 17
to 20 (days 9 and 10), which suggested that a lower amount of mRNA was extracted.
This could explain why the B 19-specific bands from samples harvested on these days
were weaker than the other samples in the studies. The other explanation for this
phenomenon is that the non-specific amplification observed in these studies, may have
reduced amplification of the B19 specific products. A number of uninfected samples
(days 1, 6 and 7; lanes 1, 11 and 13, respectively) seemed to show faint B 19-specific
bands. This was most probably due to a contamination from the neighbouring wells
during loading. Extra care during sample loading was therefore taken in subsequent
experiments.
The fourth and last experiment in this series investigated the time course of the 
suspension cell line UT-7/EPO-S1 (passage n+22) focusing on days 2, 3 and 4 post­
infection which had been shown in the previous experiments to be the optimum times 
for B19 mRNA expression. In addition to investigating the best time for cell harvest, 
this experiment used lower dilutions of the inoculum to study sensitivity. Infection was 
done with dilutions (in phosphate buffer pH 5.7) of the B19 stock virus containing 
lxlO7 IU/ml, lxlO6 IU/ml, lxlO5 IU/ml and lxlO4 IU/ml and the diluent as the negative 
sample. Unlike experiments 1 to 3, extraction was performed on freshly harvested cells 
using the Oligotex direct mRNA extraction method from cell cytoplasm, which was 
shown to be the best method for mRNA extraction (see section II.2.4.3). Since the cell 
count did not seem to differ between cell lines, infected and uninfected samples or over
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time, these parameters were not investigated with the UT-7/EPO-S1 cell line, was
performed using. The multiplex RT-PCR amplification conditions, using B19 primers
(XPP-2 and B19-9; 25pmol/pl) and actin primers (2.5pmol/pl), were 1 cycle at 50°C for
30 minutes, 1 cycle at 95°C for 15 min, 43 cycles at 95°C for 45 seconds, 57°C for 40
seconds and at 72°C for 40 seconds and lastly, 1 cycle at 72°C for 10 minutes. The
amplified products were analysed on a 2% agarose gel, which is shown below on figure
3.57.
Figure 3.57: Analysis of mRNA products extracted from UT-7/EPO-S1 cells 
amplified with XPP2 and B19-9
M 1 2  3 4 5 6  7  8 9  10 11 12 13 14 15 16 M
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bp
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bp
Lane M. PCR markers
1.D ay2, lxlO7 IU/ml inoculum
2. Day 2, lxl()(> IU/ml inoculum
3. Day 2, lxlO5 IU/ml inoculum
4. Day 2, lx l0 4 IU/ml inoculum
5. Day 2, phosphate buffer pH 5.7
6. Day 3, lxlO7 IU/ml inoculum
7. Day 3, lxlO6 IU/ml inoculum
8. Day 3, 1x10s IU/ml inoculum
9. Day 3, 1 x 104 IU/ml inoculum
10. Day 3, phosphate buffer pH 5.7
11. Day 4, 1 x 107 IU/ml inoculum
12. Day 4, lxlO 6 IU/ml inoculum
13. Day 4, lxlO5 IU/ml inoculum
14. Day 4, lxlO4 IU/ml inoculu
15. Day 4, phosphate buffer pH 5.7
16. RNAase-free water
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The first conclusion from the above experiment was that samples from day 4 post­
infection are not reliable since the negative control (lane 16) shows clear, B 19-specific 
bands. This could be due to a contamination problem during mRNA extraction or, less 
likely, multiplex RT-PCR. The end point for harvest and mRNA extraction on days 2 
and 3 post-infection was lxlO6 IU/ml. Although the 262bp band was not visible 2 days 
post-infection and the 125bp band was fainter than that seen 3 days post-infection, the 
end point remained the same.
Overall, since it was useful to reduce the overall time of infectivity assay without loss of 
sensitivity, cell harvest was done 2 days post-infection. Since there did not seem to be 
any difference between the cell lines tested, KU812, KU812Ep6, UT-7/EPO and UT- 
7/EPO-S1, day 2 post-infection was established for cell harvest, mRNA extraction and 
multiplex RT-PCR assays.
III.4.7.2. Comparison of different extraction protocols
The first study, which aimed at finding the most efficient mRNA extraction protocol, 
compared three different nucleic acid isolation methods. These include total nucleic acid 
extraction by the QIAamp DNA mini kit (Qiagen) and the Nuclisens™ kit (Organon 
Teknika), and mRNA isolation from whole cells using the Oligotex direct mRNA mini 
kit (Qiagen). KU812 cell line was infected with 1:10 (lxlO11 IU/ml) and 1:100 (lxlO10 
IU/ml) dilutions of the B19 stock virus (in phosphate buffer pH 5.7). Negative serum 
was used as a negative control in each extraction tested. Cells were harvested three days 
post-infection and the protocols described previously were followed. Separate RT-PCR 
assays were done using the following conditions: 1 cycle at 50°C for 30 minutes, 1 cycle 
at 94°C for 15 min, 43 cycles at 94°C for 45 seconds, 55°C for 45 seconds and at 72°C 
for 2 minutes and lastly, 1 cycle at 72°C for 5 minutes. Amplifications of actin (actin-3
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and actin-4; 25pmol/pl) and B19 genes (B19-6 and B19-9; 25pmol/pl) were done 
separately and the results are shown on figure 3.58, panels A and B, respectively.
All samples showed bright bands for the actin internal controls, suggesting successful 
extractions. Although all three extractions showed similar brightness of the RT-PCR 
products bands, the methods isolating total nucleic acids presented smears on the gels, 
even in the negative samples (lanes 1 and 7). This suggested a lack of specificity of 
these extraction methods. Therefore, as expected, the most specific method for the 
isolation of mRNA was Oligotex direct mRNA extraction from whole frozen cells.
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Figure 3.58: Analysis of mRNA products extracted from KU812 cells
(A) Amplified with actin-specific primers
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bp
(B) Amplified with B19-specific primers
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bp
Lane M: PCR markers 
Lanes 1 to 3: Extraction with QIAamp DNA mini kit
1. Negative serum
2. 1 x 1011 IU/ml inoculum
3. lx lO 10 IU/ml inoculum
Lanes 4 to 6: Extraction with Oligotex direct mRNA mini kit from whole frozen cells
4. Negative serum
5. lx lO 11 IU/ml inoculum
6. lx lO 10 IU/ml inoculum
Lanes 7 to 9: Extraction with Nuclisens™ kit
7. Negative serum
8. B19 lxlO 11 IU/ml inoculum
9. B 19 lx lO 10 IU/ml inoculum 10. RNAase-free water
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The second study compared extraction of mRNA from whole frozen cells with those
from whole fresh cell and cell cytoplasm, using the Oligotex direct mRNA protocol.
Serial dilutions of the B19 stock virus were prepared in phosphate buffer pH 5.7 and
used to infect KU812Ep6 cells (n+58): 30 Jill of dilutions of virus containing lxlO7
IU/ml, lxlO6 IU/ml, lxlO5 IU/ml, lxlO4 IU/ml and phosphate buffer pH 5.7 as the
negative control. Cells were harvested 2 days post-infection and mRNA extracted as
described previously. Nucleic acid amplification by multiplex RT-PCR was performed
with actin (2.5pmol/fxl) and B19 specific primers (B19-6 and B19-9; 25pmol/[xl) and the
amplification conditions were as previously described in the first experiment in this
section. Evaluation of the efficiency of the different extraction methods tested was done
by comparing amplified products on a 2% agarose gel, as shown on figure 3.59.
The agarose gels showed that, as far as efficiency was concerned, the extraction method
using fresh whole cells allowed the detection of mRNA transcripts in cells inoculated by
106 IU/ml. The other two methods, namely Oligotex direct mRNA extraction from
whole frozen cells and from cell cytoplasm were only able to detect mRNA transcripts
in cells inoculated by 107 IU/ml. However, as far as the specificity of the extraction
methods was concerned, extractions using whole cells (fresh and frozen) showed a
number of non-specific bands, suggesting that Oligotex direct mRNA extraction from
cell cytoplasm was a “cleaner” and more specific isolation method. Additionally, the
latter method was less time consuming and more user-friendly than the other two
methods of mRNA isolation. Moreover, the logio 1 difference in the end point between
those methods could most probably be improved by optimising the RT-PCR conditions.
Therefore, Oligotex direct mRNA extraction from cell cytoplasm (Qiagen) was the
method chosen for further research on the infectivity assay for human parvovirus B19.
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Figure 3.59: Analysis of mRNA products extracted from KU812Ep6 cells amplified
by multiplex RT-PCR
M 1 2 3 4 5 M 6 7 8 9 10 11 M 12 13 14 15 16
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 5: Oligotex direct mRNA
extraction from fresh whole cells
1. 1 x 107 IU/ml inoculum
2. lxlO6 IU/ml inoculum
3. lxlO5 IU/ml inoculum
4. lxlO4 IU/ml inoculum
5. Phosphate buffer pH 5.7
Lanes 6 to 10: Oligotex direct mRNA 
extraction from cell cytoplasm
6. lxlO7 IU/ml inoculum
7. lxlO6 IU/ml inoculum
8. 1 x 10s IU/ml inoculum
9. 1x10 IU/ml inoculum
10. Phosphate buffer pH 5.7
11. RNAase-free water
Lanes 12 to 16: Oligotex direct mRNA extraction from whole frozen cells
12. lxlO 7 IU/ml inoculum
13. lxlO 6 IU/ml inoculum
14. lxlO5 IU/ml inoculum
15. lx l0 4 IU/ml inoculum
16. Phosphate buffer pH 5.7
The third study was a comparison of the batch format with the vacuum manifold format
for the Oligotex direct mRNA extraction (Qiagen) from cell cytoplasm (see section
II.2.4.3). UT-7/EPO-S1 cells (passage n+41) were used for this experiment. Serial
dilutions of the B19 stock virus were prepared in phosphate buffer pH 5.7 and cells
were infected with 30 pi of the diluted virus range: lxlO7 IU/ml, lxlO6 IU/ml, lxlO5
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IU/ml, lxlO4 IU/ml and phosphate buffer pH 5.7 as the negative sample. Duplicate cell
samples were infected for each extraction protocol, giving a total of 20 samples. Cells
were harvested 2 days post-infection and mRNA extracted as described. In the vacuum
manifold format, the columns were placed on the manifold (supplied by Qiagen), the
buffers added and a vacuum applied to the columns. For the elution step, the spin
columns were placed in RNAase-free centrifuge tubes for collection of the mRNA.
Since UT-7/EPO-S1 cells were used, the B 19-specific primers (XPP2 and B19-9) and
the multiplex amplification conditions (1 cycle at 50°C for 30 minutes, 1 cycle at 95°C
for 15 min, 43 cycles at 95°C for 45 seconds, 50°C for 40 seconds and at 72°C for 40
seconds and 1 cycle at 72°C for 10 minutes) differed from the previous two
experiments. Comparison of the two formats tested was done by analysing the RT-PCR
products on a 2% agarose gel, as shown on figure 3.60.
A clear difference of logio 1 was observed between the batch format (end point logio 8.5 
inf.u./ml) and the vacuum manifold format (end point logio 7.5 inf.u./ml). Although the 
vacuum manifold format provided a quicker alternative to the classical spin columns 
since less handling was required, the batch format was much gentler for the nucleic 
acids and the yield was higher. The latter was thus chosen as the best method of mRNA 
extraction using Oligotex direct isolation from cell cytoplasm (Qiagen).
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Figure 3.60: Analysis of mRNA products extracted from UT-7/EPO-S1 cells
amplified by multiplex RT-PCR
M l  2 3 4 5 M 6 7 8 9 10 M 11 12 13 14 15 M 16 17 18 19 20 21 22
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bo
Lane M PCR marker
Lanes 1 to 10: extraction with
batch format
1 and 6. lxlO7 IU/ml inoculum
2 and 7. lxlO6 IU/ml inoculum
3 and 8. 1 x 105 IU/ml inoculum
4 and 9. lxlO4 IU/ml inoculum
5 and 10. Phosphate buffer pH 5.7
21. RNAase-free water
22. Positive control
Lanes 11 to 20: extraction with 
vacuum manifold format
11 and 16. lxlO7 IU/ml inoculum
12 and 17. lxlO6 IU/ml inoculum 
3 and 18. 1 x 105 IU/ml inoculum
14 and 19. lxlO4 IU/ml inoculum
15 and 20. Phosphate buffer pH 5.7
III.4.8. Optimisation of RT-PCR
III.4.8.1. Primer combinations
Two combinations of forward and reverse primers were tested using mRNA extracted 
from cells inoculated with serial dilutions of B 19 or mock-infected with PBS-A in order 
to evaluate the sensitivity and specificity of each primer pair.
The first combination of primers, B19-6 and B19-9, was tested using B19 mRNA from
Q g
cells infected with dilutions of the B19 stock virus containing 1x10 IU/ml, 1x10
IU/ml, lxlO7 IU/ml or phosphate buffer pH 5.7 as negative control. The mRNAs used
had previously been extracted from KU812Ep6 cells (106 cells/sample) using the
Oligotex direct mRNA method with fresh, whole cells. The total volume for each RT-
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PCR reaction was 25pl, including 5pl mRNA template. Each reaction contained 5pl
each of RT-PCR buffer and Q buffer, lpl of lOmM dNTP mix, 0.6pl of 25pmol/pl
forward and reverse primers, lpl of RT-PCR enzyme mix and finally 6.8pl of RNAase-
free water to make up the reaction volume to 25pl. The RT-PCR conditions included 1
cycle at 50°C for 30 minutes, 1 cycle at 95°C for 15 minutes, 43 cycles of 95°C for 50
seconds, 55°C for 40 seconds and 72°C for 45 seconds and finally 1 cycle at 72°C for
10 minutes. The RT-PCR products were analysed on a 2% agarose gel and the results
are shown on figure 3.61
This combination of B19-6 and B19-9 primers resulted in two specific RT-PCR 
products (275bp and 155bp) in all three samples inoculated with parvovirus B19 (lanes 
1 to 3 on figure 3.61). No non-specific band could be seen in the negative controls: 
sample inoculated with phosphate buffer only and RT-PCR negative control (RNAase- 
free water), lanes 4 and 5 respectively.
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Figure 3.61: Analysis of mRNA products extracted from KU812Ep6 cells amplified
with B19-6 and B19-9 primer combination
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
M: PCR markers 
l . l x l  09 IU/ml inoculum
2. 1 x 108 IU/ml inoculum
3. lxlO7 IU/ml inoculum
4. Phosphate buffer pH 5.7
5. RNAase-free water
The second experiment was aimed at assessing the sensitivity of the primer combination 
XPP2 and B19-9 compared with that of the B19-6 and B19-9 primer pair. Several 
mRNA samples, which the B19-6/ B19-9 primer pair had not been able to amplify 
previously (results not shown), were processed again with both sets of primers. The 
mRNAs had previously been extracted from synchronised KU812 cells (2x10 
cells/sample) using the Oligotex direct mRNA method with fresh, whole cells infected 
with serial dilutions of the B19 stock virus containing lxlO7 IU/ml, lxlO6 IU/ml, lxlO5 
IU/ml, lxlO4 IU/ml or phosphate buffer pH 5.7 as the negative control. The RT-PCR 
conditions were the same as above but the annealing temperature was raised to 57°C to
-331 -
.......................................................................................................................................................................Chapter III
minimise amplification of non-specific products. The RT-PCR products were analysed
on a 2% agarose gel, which is shown on figure 3.62.
Figure 3.62: Analysis of mRNA products extracted from KU812 cells amplified 
with XPP2 and B19-9 primer combination
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
M 1 2 3 4 5 6 7 M 8 9 10 11 12 13 14
Lane M: PCR markers
Lanes 1 to 7: primer pair B19-6 and B19-9
1. lxlO7 IU/ml inoculum
2. lxlO6 IU/ml inoculum
3. 1x10s IU/m inoculum
4. lxlO4 IU/ml inoculum
5. lxlO 3 IU/ml inoculum
6. Phosphate buffer pH 5.7
7. RNAase-free water
Lanes 7 to 14: primer pair XPP2 and B19-9
7. lxlO7 IU/ml inoculum
8. lxlO 6 IU/ml inoculum
9. lxlO5 IU/ml inoculum
10. 1 x 104 IU/ml inoculum
11. 1 x 103 IU/ml inoculum
12. Phosphate buffer pH 5.7
13. RNAase-free water
As in the previous attempt (not shown), amplification with primers B19-6 and B19-9
was unsuccessful since no bands were seen (lanes 1-5). Possible explanations could be
failure at the infection step or at the mRNA extraction stage, or again low sensitivity of
the RT-PCR step. The second possibility was ruled out because the initial attempt to
amplify the mRNA samples with these primers was done in a multiplex format and
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actin bands, although faint, were seen in all samples (results not shown). The infection
1 f\step was successful since the samples inoculated with 1x10 and 1x10 IU/ml showed 
B 19-specific mRNA transcripts (although faint) amplified by XPP2 and B19-9 primers 
(lanes 8 and 9). Therefore, it appeared that primers XPP2 and B19-9 gave more 
sensitive RT-PCR results than primers B19-6 and B19-9. The primer pair XPP2 and 
B19-9 was thus chosen to amplify mRNA in all further B19 infectivity assays.
III.4.8.2. Multiplex RT-PCR
The optimisation of the multiplex RT-PCR step was achieved by evaluating several 
parameters, namely the use of Q buffer, the concentration of actin primers and the 
annealing temperature of the PCR step.
III.4.8.2.1. Q buffer
The use of Q buffer to increase the sensitivity and specificity of the RT-PCR assay was 
investigated. Two sets of RT-PCR mix were prepared, one containing Q buffer (5pl per 
reaction) and one without Q buffer, and used for the amplification of B19 mRNA using 
the multiplex RT-PCR assay with the B19 primer pair XPP2 and B19-9. The samples 
used consisted of mRNA which had previously been extracted from KU812Ep6 cells
7  6inoculated with serial dilutions of the B19 stock virus containing 1x10 IU/ml, 1x10 
IU/ml, lxlO5 IU/ml, lxlO4 IU/ml and phosphate buffer pH 5.7 as the negative control 
(2xl05 cells/sample). mRNA was extracted from whole, frozen cells using the Oligotex 
direct mRNA protocol described previously (see section II.2.4.2) and the amplification 
conditions were as described in section ffl.4.8.1. Analysed samples are shown on figure 
3.63.
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Figure 3.63: Analysis of mRNA products extracted from KU812Ep6 cells amplified
by multiplex RT-PCR with and without Q buffer
M l  2 3 4 5 6 M 7 8 9 10 11 12
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
Lane M: PCR marker 
Lanes 1 to 6: with Q buffer
1. 1 x 107 IU/ml inoculum
2. lxlO 6 IU/ml inoculum
3. 1 x 10  ^ IU/ml inoculum
4. lxlO4 IU/ml inoculum
5. Phosphate buffer pH 5.7
6. RNAase-free water
Lanes 6 to 11: without Q buffer
7. lxlO7 IU/ml inoculum
8. 1 x 106 IU/ml inoculum
9. lxlO5IU/ml inoculum
10. B 19 International Standard, 2x l04 IU/ml
11. Phosphate buffer pH 5.7
12. RNAase-free water
The actin-specific band was detected in all samples containing mRNA. When Q buffer 
was present in the RT-PCR mix, a faint non-specific band above the larger band specific 
for B19 (305bp) was seen in all samples, even the mock-infected sample (lane 5). In 
addition, some more non-specific faint bands were seen above and below the B 19- 
specific 185bp band. However, when Q solution was not used in the amplification 
reaction, a large number of bright non-specific bands were detected in all samples, 
suggesting a lack of specificity of the amplification reaction in the absence of Q buffer. 
Therefore, Q buffer was considered essential for the nucleic acid amplification reaction.
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III.4.8.2.2. Concentration of actin primers
When the RT-PCR assay was performed separately for actin- and B 19-specific primers, 
the concentration of B19 primers as well as actin-3 and actin-4 stock solutions was 
25pmol/|nl. Although 5|il of template was added per B 19-specific reaction, only 2|il of 
mRNA was needed for actin amplification. Since the volume of each actin primer per 
reaction was 0.6|il, the final primer concentration per reaction was 0.6pmol/|il 
(15pmol/reaction). However, since this concentration may have been sub-optimal in a 
multiplex assay (the concentrations of actin primers could decrease the amplification of 
B19 specific products by interference), four experiments were performed with various 
actin primer concentrations and a constant B19 primer concentration of 25pmol/|il.
In the first experiment, the actin primer working solutions were diluted 1:3, 1:4 and 1:5, 
resulting in respective concentrations of 8.33pmol/|xl, 6.25pmol/jil and 5pmol/|fi. The 
mRNAs used in this experiment had previously been extracted from KU812Ep6 cells
Qinfected with dilutions of the B19 stock virus containing 1x10 IU/ml and 1x10 IU/ml 
as well as cells mock infected with negative plasma. The mRNAs were extracted from 
fresh, whole cells using the Oligotex direct mRNA protocol. The total volume for each 
multiplex reaction was 25jil, including 5jil mRNA template added last. Each reaction 
contained 5pl of RT-PCR buffer and Q buffer, 1 jllI of lOmM dNTP mix and RT-PCR 
enzyme mix, 0.6pl of each primer (actin-3, actin-4, B19-6, B19-9) and finally 5.6jnl of 
RNAase-free water. The conditions for amplification were as described previously in 
section III.4.8.1. The products were analysed on a 2% agarose gel, which is shown on 
figure 3.64.
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Figure 3.64: Analysis of mRNA products extracted from KU812Ep6 cells
amplified by multiplex RT-PCR using various actin primers concentrations
M 1 2 3 4 5 6 7 8 9  10 11 12
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
Lane M: PCR markers
Lanes 1 to 4: actin primers at Lanes 5 to 8: actin primers at
1:3 dilution (8.33pmol/fjj) 1:4 dilution (6.25pmol/pl)
1. Negative serum 5. Negative serum
2. Ix 1()12 IU/ml inoculum 6. lx lO 12 IU/ml inoculum
3. lxlO9 IU/ml inoculum 7. lxlO9 IU/ml inoculum
4. RNAase-free water 8. RNAase-free water
Lanes 9 to 12: actin primers at 1:5 dilution (5pmol/|il)
9. Negative serum
10. lx lO 12 IU/ml inoculum
11. lxlO9 IU/ml inoculum
12. RNAase-free water
This experiment demonstrated that all three primer dilutions were suitable for 
amplification of the actin gene. The fact that the lower band was not present in sample 7 
(inoculated with lxlO9 IU/ml) suggested that the 1:4 actin primers dilution was 
inhibiting the amplification of this B19 transcript. The lower bands in samples 3 and 11 
(inoculated with lxlO9 IU/ml) with dilutions 1:3 and 1:5, respectively, were also very
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faint. Therefore, the lower concentration of actin primers was considered to be
necessary to prevent loss of amplification with the B19 primers.
The second experiment in this series compared actin primer working solutions 
concentrations of 12.5pmol/jil (1:2 dilution), 5pmol/|Lil (1:5 dilution) and 2.5pmol/|il 
(1:10 dilution) using the B 19-specific primers pair XPP2 and B19-9, which were, by 
then, found to be more specific than the B19-6 and B19-9 combination. In addition, in 
order to evaluate the sensitivity of the assay, mRNA from cells infected with lower 
concentrations of parvovirus B19 (compared with the first experiment) were used. Thus, 
the mRNA samples used had previously been extracted from cells infected with 
dilutions of the B19 stock virus containing lxlO7 IU/ml, lxlO6 IU/ml and lxlO5 IU/ml 
and cells mock infected with PBS pH 5.7. The mRNA samples were extracted from UT- 
7/EPO-S1 cell cytoplasm using the Oligotex direct mRNA protocol. The multiplex RT- 
PCR conditions were similar to that of the previous experiments but the annealing step 
was slightly modified by increasing the temperature from 55°C to 57°C and the 
elongation step was reduced from 2 minutes to 40 seconds. The products were analysed 
on 2% agarose gels, as shown on figure 3.65.
As expected, the more diluted the actin primers, the fainter the actin-specific bands on 
the agarose gel. The two B 19-specific bands were visible in samples inoculated with 
lxlO7 IU/ml and lxlO6 IU/ml. These bands were very faint with the 1:2 and 1:5 
dilutions of actin primers whereas they were brighter when 1:10 dilution was used. 
However, in this case, the actin band was very faint (lanes 11 to 14 on figure 3.65). This 
suggests that the 1:10 dilution (2.5pmol/pl) was not sufficient to amplify the 
housekeeping gene transcript in these samples. A lower dilution of actin-3 and actin-4 
primers was therefore tested in a further experiment.
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Figure 3.65: Analysis of mRNA products extracted from UT-7/EPO-S1 cells
amplified by multiplex RT-PCR using various actin primers concentrations
M 1 2 3  4 5  6 7 8  9 10 11 12 13 14 15 M
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bp
Lane M: PCR markers 
Lanes 1 to 5: actin primers 
at 1:2 dilution (12.5pmol/pl)
1. lxlO7 IU/ml inoculum
2. lxlO 6 IU/ml inoculum
3. lxlO5 IU/ml inoculum
4. Phosphate buffer pH 5.7
5. RNAase-free water
Lanes 6 to 10: actin primers 
at 1:5 dilution (5pmol/pI)
6. lxlO7 IU/ml inoculum
7. lxlO 6 IU/ml inoculum
8. 1 x 105 IU/ml inoculum
9. Phosphate buffer pH 5.7
10. RNAase-free water
Lanes 11 to 15: actin primers at 1:10 dilution (2.5pmol/pl)
11. 1 x 107 IU/ml inoculum
12. 1 x 106 IU/ml inoculum
13. lxlO5 IU/ml inoculum
14. Phosphate buffer pH 5.7
15. RNAase-free water
The third experiment investigated actin primer concentrations between 1:5 and 1:10 
dilutions, namely 1:6 (4.16pmol/pl) and 1:8 (3.125pmol/pl). The nucleic acids samples 
used had previously been extracted from UT-7/EPO-S1 cells (passage n+22) using the 
Oligotex direct mRNA protocol from cell cytoplasm. The cells were infected with 1:10 
dilutions of the B19 stock virus containing from lxlO7 IU/ml to lxlO4 IU/ml and a
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negative control (phosphate buffer pH 5.7). The RT-PCR conditions were similar to
those described in the previous experiment. Two separate amplifications were run in
parallel, namely with B 19-specific primers only (B19-9 and XPP2) and multiplex RT-
PCR including both the same B 19-specific primers and actin-specific primers at the
dilutions tested in this experiment (1:6 and 1:8). The amplified products were analysed
on 2% agarose gels shown on figure 3.66 (panel A and B, respectively).
When B 19-specific primers alone were used in the RT-PCR step (panel A, figure 3.66),
the end point was sample 3, cells inoculated with lxlO5 IU/ml. Although the B 19-
specific bands were also detected by multiplex amplification in sample 3, they were
very faint and the 305bp band could not be seen when amplified with actin primers
diluted 1:6. In addition, the actin bands were not well defined and very faint with either
dilution tested and a number of non-specific bands were present on panel B, figure 3.66.
Therefore, the concentration of actin-specific primers seemed to be too low for
consistent detection in the multiplex assay. The actin primer concentration of 1:5
dilution, which had previously been tested, was therefore investigated once again in the
fourth and final experiment.
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Figure 3.66: Analysis of mRNA products extracted from UT-7/EPO-S1 cells
(A) Amplified with B19-specific primers (B19-9 and XPP2)
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bp
(B) Amplified by multiplex RT-PCR with various actin primers concentrations
1:6 dilution 1:8 dilution
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bp
M PCR markers
1. lxlO7 IU/ml inoculum
2. 1 x 106 IU/ml inoculum
3. 1x10s IU/ml inoculum
4. lxlO4 IU/ml
5. Phosphate buffer pH 5.7
6. RNAase-free water (negative control)
7. RT-PCR positive control (lxlO 6 IU/ml)
M l  2 3  4 5 6 M 1 2 3  4 5  6
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The last experiment aiming at determining the optimal actin primers concentration for
multiplex RT-PCR investigated the 1:5 dilution (5pmol/pl) again, using mRNA samples
from different inoculation and extraction experiments in order to evaluate the
reproducibility of the assay. The RNA samples were extracted from UT-7/EPO-S1 cells
(passage n+22) using the Oligotex direct mRNA protocol from cell cytoplasm. The cells
had been inoculated in duplicate with dilutions of the B19 stock virus containing lxlO7
IU/ml, lxlO6 IU/ml and lxlO5 IU/ml and from cells mock infected with phosphate
buffer pH 5.7. Samples were amplified in a multiplex RT-PCR assay with the B 19-
specific primers (B19-9 and XPP2) at a concentration of 25pmol/pl and actin primers
(actin-3 and actin-4) diluted 1:5 (5pmol/|Lil). The RT-PCR conditions were similar to
those described for the two previous experiments and again two separate amplifications
were run in parallel, one with B 19-specific primers only (B19-9 and XPP2) and the
other with both B 19-specific primers and actin-specific primers at the 1:5 dilution in a
multiplex format. The amplified products obtained were analysed on 2% agarose gels,
as shown on figure 3.67, panels A and B, respectively.
When the RT-PCR step was first performed using B 19-specific primers only, the two 
mRNA transcripts were amplified in only one out of two samples inoculated with lxlO6 
IU/ml (panel A, sample 3). On the other hand, when the multiplex RT-PCR (using 
5pmol/pl of actin primers) was performed, both samples inoculated with lxlO6 IU/ml 
showed B 19-specific bands, although only a faint 305bp band was seen in sample 3, 
panel B. The B 19-specific bands in samples 1 and 2 were much brighter with actin 
primers (panel B) than without (panel A). In addition, the actin gene transcript was 
clearly amplified in all samples with extracted mRNA. Therefore, a concentration of 
5pmol/pl for actin-specific primers and 25pmol/pl for B 19-specific primers seemed to
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be the best combination for the optimal amplification of both B19 and actin transcripts
by multiplex RT-PCR.
Figure 3.67: Analysis of mRNA products extracted from UT-7/EPO-S1 cells
(A) Amplified with B19-specific primers (B19-9 and XPP2)
M 1 2 3 4 5 6 7
,000 bp 
750 bp 
500 bp 
300 bp
(B) Amplified by multiplex RT-PCR (1:5 dilution of actin primers)
M I 2 3 4 5 6 7 8 9
1,000 bp
750 bp
500 bp
300 bp 
150 bp
50 bp
*
M PCR markers
1. lx l0 7 IU/ml inoculum
2. lxlO7 IU/ml inoculum
3. lxlO6 IU/ml inoculum
4. lxlO6 IU/ml inoculum
9. RNAase-free water
5. 1x10 IU/ml inoculum
6. 1 x 105 IU/ml inoculum
7. Phosphate buffer pH 5.7
8. Phosphate buffer pH 5.7
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III.4.8.2.3. Annealing temperature
In addition to determining the optimal actin primer concentration as 5pmol/pl, the data 
obtained by testing different primer combinations showed that the most specific primer 
pair was XPP2 and B19-9. When used on their own, the annealing temperature chosen 
for this set of primers was 57°C. However, since the present experiment aimed at 
optimising the annealing temperature for the multiplex RT-PCR, it was lowered in order 
to increase the sensitivity of the assay. Therefore, the temperatures tested were 48°C, 
50°C, 52°C and 55°C, using mRNA samples extracted from UT-7/EPO-S1 cells which 
had been infected with serial dilutions of the three different B19 isolates, namely JS 
(B19 stock virus), JB and LP and extracted from cell cytoplasm using the Oligotex 
direct mRNA protocol. The 1:10 viral dilutions ranged from 10'4 to 10'8 and one sample 
inoculated with phosphate buffer pH 5.7 was also included as the negative control. The 
RT-PCR negative and positive controls were RNAase-free water and mRNA previously 
extracted from UT-7/EPO-S1 cells inoculated with lx l07IU/ml of B19 virus stock, 
respectively. Multiplex RT-PCR using actin-specific primers (actin-3 and actin-4 at 
5pmol/(il) and B 19-specific primers (XPP2 and B19-9 at 25pmol/|il) was set up with the 
following conditions: 1 cycle at 50°C for 30 minutes, 1 cycle at 95°C for 15 minutes, 43 
cycles of 95°C for 45 seconds, 55°C/ 52°C/ 50°C/ 48°C for 45 seconds and 72°C for 40 
seconds and finally 1 cycle at 72°C for 10 minutes. The products of each of the four 
mRNA amplifications at 55°C, 52°C, 50°C and 48°C were analysed on 2% agarose gels 
and are shown on figure 3.68, panels A, B, C and D, respectively.
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Figure 3.68: Analysis of mRNA products extracted from UT-7/EPO-S1 cells
amplified by multiplex RT-PCR
(A) Annealing temperature: 55°C
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
M l  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M M 17 18 19 20 M
(B) Annealing temperature: 52°C
M l  2 3 4 5 6 M 7 8 9 10 11 12 M 13 14 15 16 17 18 19 20 M
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
(C) Annealing temperature: 50°C
M 1 2 3 4 5 6 M 7 8 9 10 11 12 M 13 14 15 16 17 18 19 20 M
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
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(D) Annealing temperature: 48°C
M 1 2 3 4 5 6 M 7 8 9 10 11 12 M 13 14 15 16 17 18 19 20 M
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR marker 
Lanes 1 to 6: JS virus
1. lxlO8 IU/ml
2. lxlO7 IU/ml
3. lxlO6 IU/ml
4. 1 x 105 IU/ml
5. lxlO4 IU/ml
6. Phosphate buffer, pH5.7
19. RNAase-free water (RT-
20. 2x l07 IU/ml (RT-PCR pc
Lanes 7 to 12: JB virus virus
7. 3x l08 IU/ml
8. 3x l07 IU/ml
9. 3x l06 IU/ml
10. 3x l05 IU/ml
11. 3x104 IU/ml
12. Phosphate buffer, pH5.7
1 negative control) 
ve control)
Lanes 13 to 18: LP
13. 5x l0 9 IU/ml
14. 5x l0 8 IU/ml
15. 5 x l07 IU/ml
16. 5x106 IU/ml
17. 5x10s IU/ml
18. Phosphate buffer, pH5.7
The end points for all three inoculi at each annealing temperature tested are shown in 
table 3.11. For the B 19-specific mRNA transcripts, figure 3.68, panels A to D and table 
3.11 all showed that a lower annealing temperature such as 50°C or 48°C resulted in a 
higher sensitivity of the amplification reaction. The optimisation of the multiplex RT- 
PCR was a balance between amplification of B 19-specific mRNA transcripts and the 
housekeeping gene transcripts, to ensure that the amplification of the one did not 
interfere with that of the other. Thus, the second parameter that was investigated was the 
amplification of the actin gene when using decreasing temperatures. At 55°C, many of 
the samples containing mRNA did not show any actin-specific band and, in the samples
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that did show a band, it was very faint. However, when the annealing temperature was
lowered to 52°C, 50°C and 48°C, all samples showed the actin band, although it was
still faint in some samples at 52°C and 48°C.
In conclusion, taking all parameters into account, it appeared that an annealing 
temperature of 50°C would provide the best amplification, in terms of sensitivity, of the 
housekeeping gene (actin) and parvovirus B19 transcripts using the primer pair XPP2 
and B19-9.
Table 3.11: Results of annealing temperature optimisation
B19
isolate
RT-PCR 
annealing 
temperature (°C)
Logio 
DNA titre 
(IU/ml)
End point 
dilution
Logio 
infectious units 
(inf.u./ml)
55 12.0 5.0 8.5
52 12.0 5.0 8.5
JS 50 12.0 5.0 8.5
48 12.0 5.0 8.5
55 12.5 7.0 7.0
52 12.5 5.0 9.0
JB 50 12.5 5.0 9.0
48 12.5 5.0 9.0
55 13.7 6.0 9.2
52 13.7 5.0 10.2
LP 50 13.7 5.0 10.2
48 13.7 5.0 10.2
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III.4.9. Optimised human parvovirus B19 infectivity assay
IQ.4.9.1. Infectivity assay conditions
The infectivity assay was optimised at several levels, including tissue culture, virus 
inoculation and incubation, and mRNA extraction and amplification. Detection of B19 
replication was indeed found to be more sensitive than IFA.
The non-synchronised UT-7/EPO-S1 cell line, at passages between n+14 and n+53, was 
chosen after extensive tissue culture studies. The growth curves for this cell line showed 
that the optimum time for virus inoculation, which was when the cells were multiplying 
the most, was 5 days after splitting them at a concentration of lxlO5 cells/ml.
After being washed with phosphate buffer pH 5.7, 2xl05 cells were inoculated with 
30|il of B19 virus diluted in phosphate buffer pH 5.7. An incubation of 2 hours at 4°C 
was followed by the addition of 1ml of fresh medium (Iscoves modified DMEM, with 
Glutamax-1, 10% FCS, 2 IU/ml EPO, 1% gentamycin, 1% fungizone). The cells were 
incubated at 37°C (5% CO2) and the optimum time for harvesting was 2 days post­
inoculation.
The best method for the extraction of mRNA was found to be from cell cytoplasm using
the Oligotex direct mRNA kit (Qiagen). Isolated mRNA was amplified by multiplex
RT-PCR using the optimum primer combination: B19-9 (forward) and XPP-2 (reverse).
OneStep RT-PCR kit (Qiagen) was used and each reaction contained 5pl of lOx
OneStep RT-PCR buffer, 5jxl of 5x Q buffer solution, lfil of dNTPs, actin primers
(Actin-3 and Actin-4) at a concentration of 3pmol per reaction (0.6|il of 5pmol/jil stock)
and B19 primers (B19-9 and XPP-2) at a concentration of 15pmol per reaction (0.6{il of
15pmol/pl stock), ljil of RT-PCR enzyme mix and 5.6jil of RNAase-free water.
Template (5jnl) was added to complete the volume of a full reaction to 25|il reaction
mix. The amplification conditions were 1 cycle at 50°C for 30 minutes, 1 cycle at 95°C
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for 15 minutes, 43 cycles of 95°C for 45 seconds, 50°C (optimum annealing
temperature) for 40 seconds and 72°C for 40 seconds and finally 1 cycle at 72°C for 10
minutes.
III.4.9.2. Validations studies
The aim of these studies was to determine the limit of detection of the optimised B19 
infectivity assay.
The optimised protocols for inoculation of cells, extraction of mRNA and RT-PCR as 
determined in the initial experiments were used for this study. Briefly, the UT-7/EPO- 
S1 cell line was used at passages between n+48 and n+52 and six assays with duplicate 
sample dilutions of the stock virus were performed. Serial dilutions of the B19 stock 
virus, ranging from 10'5'° to 10'80, were prepared in phosphate buffer pH 5.7 and cells 
were inoculated with 30pl of diluted virus containing lxlO7 IU/ml, lxlO6 5 IU/ml, lxlO6 
IU/ml, lxlO5'5 IU/ml, lxlO5 IU/ml, lxlO4’5 IU/ml, lxlO4 IU/ml and phosphate buffer 
pH 5.7 as the negative sample. The infectivity assay conditions detailed previously 
(section ffl.4.9.1) were applied for these validation studies.
Table 3.12 summaries the detection (+) or absence (-) of B19 specific transcripts for 
each study.
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Table 3.12: Record of B19 specific transcripts presence (+) or absence (-) in the 
validation studies of the optimised infectivity assay
Logio DNA 
concentration of 
inoculum (IU/ml)
7.0 6.5 6.0 5.5 5.0 4.5 4.0
Negative
control
Logio dilution of 
inoculum
-5.0 -5.5 -6.0 -6.5 -7.0 -7.5 -8.0
Negative
control
Study number
1 + + + - + + - -
1 + + + + + - - -
2 + + + + + - - -
2 + + + - - - - -
3 + + + - - - - -
3 + + + - - - - -
4 + + + - + - - -
4 + + + - - - - -
5 + + + + + - - -
5 + + + + + - - -
6 + + + - - - - -
6 + + + + - - - -
Statistical analysis kindly done by A. Heath (Department of Informatics, NIBSC) 
showed that the 95% detection limit for this assay was logio -6.03 dilution (range -5.82 
to -6.24), or logio 5.97 IU/ml (logio 7.53 inf.u./ml) and the 50% detection limit was 
logio -6.67 dilution (range -6.46 to -6.87) or logio 5.35 IU/ml (logio 8.15 inf.u./ml). The 
calculated DNA concentration to infectious unit ratios for this study are shown in the 
table 3.13 The calculated mean ratio for the DNA concentration to infectious units was 
10391:1.
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Table 3.13 Infectivity results and DNA concentration to infectious unit ratio for the
optimised infectivity assay
Study number
Logio DNA 
concentration 
(IU/ml)
Logio infectious 
units/ml
DNA concentration: 
infectious unit ratio
1 12.0 9.0 10“ :1
1 12.0 8.5 10“ :1
2 12.0 8.5 10“ : 1
2 12.0 7.5 10“ : 1
3 12.0 7.5 10“ : 1
3 12.0 7.5 10“ : 1
4 12.0 8.5 10“ :1
4 12.0 7.5 10“ : 1
5 12.0 8.5 10“ :1
5 12.0 8.5 10“ : 1
6 12.0 7.5 10“ : 1
6 12.0 8.0 104O:l
III.4.10. Sequencing of PCR products
The two mRNA transcripts amplified with B19-9 (position 384-405) and XPP-2 
(position 2194-2214), which are shown below, were sequenced. As far as the longer 
transcript was concerned (upper band), only the reverse sequence was obtained, which 
was enough to identify its size and position on the reference genomic DNA (M13178).
Forward primer B19-9: GTT TTT TGT GAG CTA ACT AAC A 
Reverse primer XPP2: ACC GTC CCA CAC ATA ATC AAC
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Longer transcript (305bp on gel) sequenced with the reverse primer XPP-2:
5 ’ CCC ACT AAC ATTC ACGAA ANTGGTCTGCC AAAGGTGTGT AG A AGGCTTCT
TCCCACGATGCAGCTACAACTTCGGAGGAAACTGGGCTTCCGACAAATGAT
TCTCCTGAACTGGTCCCGGGGATGGGCGTACTAGAGCGCGGGGTTTCAGTG
TTCCAGGCGCCTGGGGTGATGAGGTTAAAAAAGCTGCTTTCACTGAGTTCTT
CAGAGCTTTCACCACCACTGCTGCTGATACTGGTGTCTGTGACAATTGGGGT
GGTTTGGAGGTCTGGGTGGAGGGCATCTGTTAGTTAGCTCACAAAAAACAG
3’
Shorter transcript (185bp on agarose gel) sequenced with the reverse primer XPP- 
2:
5’CCCACTAACATTCACGAAACTGGTCTGCCAAAGGTGTGTAGAAGGCTTCT 
TCCCACGATGCAGCTACAACTTCGGAGGAAACTGGGCTTCCGACAAATGAT 
TCTCCTGAACTGGTCCCGGGGATGGGCGTACTAGAGCGCGGGGTTTCAGTG 
TTCCAGGCGCCTGTTAGTTAGCTCACAAAAAACAGGCGC 3 ’
Shorter transcript (185bp on agarose gel) sequenced with the forward primer B19- 
9:
5’GNCGCNCGGNACACTGTANCCCCGCGCTCTAGTACGCCCATCCCCGGGAC 
CAGTTCAGGAGTAATCATTTGTCGGAAGCCCAGTTTCCTCCGAAGTTGTAGC 
TGCATCGTGGGAAGAAGCCTTCTACACACCTTTGGCAGACCAGTTTCGTGAA 
CTGTTAGTTGGGGTTGATTATGTGTGGGACGGTA 3’
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When compared to B19 genomic DNA (Ml3178), the longer transcript (upper band)
corresponds to positions: 384-406 and 1910-2193, with an actual transcript size of 305
bP.
When compared to B19 genomic DNA (M13178), the shorter transcript (lower band) 
corresponds to positions: 384-406 and 2030-2193, with an actual size of 185 bp.
In accordance with previous reports (Ozawa et al., 1987; St Amand et al., 1991), this 
study confirmed the presence of one splicing donor site (GT) and two acceptor sites 
(AG) at position 407-408, 1908-1909 and 2028-2029, respectively. A more recent study 
observed a slice donor site at nt 441 always coupled with the acceptor site at position 
2030 (Brunstein et al., 2000), a splicing pattern that was not found in the present study.
1II.5. Human parvovirus B19 removal/inactivation studies
The results of the DNA assay and infectivity assay for all five virus 
removal/inactivation techniques are given below. The B19 DNA titre was determined 
from the standard curve using the B19 International Standard and the number of 
infectious units/ml for each sample was calculated from the end-point dilution of the 
infectivity assay as described previously.
III.5.1. Virus removal by nanofiltration using Planova® filters: Asahi Kasei 
Pharma
The filtration experiments were performed at NIBSC by Dr S. Satoh (Asahi Kasei 
Pharma Coropration, Japan) and Mr T. Sato (Asahi Kasei Deutchland, Germany). 
Reconstituted 25% human albumin was diluted 1:50 in saline to obtain a 0.5% albumin 
solution (600ml). The latter was prefiltered through a 35N Planova® filter (0.5 bar) in 
order to remove aggregates of protein, which might have been generated by the
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lyophilisation process. Control samples Al and A2 (0.5ml) were taken from the 0.5%
albumin prefiltration feed while samples B1 and B2 (0.5ml) were from the prefiltration
filtrate. The second step included the preparation of the spiked solution by mixing
550ml of the prefiltered albumin with lOOOjxl of stock virus (lxlO12 IU/ml). Spiked
albumin was then filtered through a 35N Planova® filter (0.5 bar).
Controls Cl and C2 (0.5ml) were duplicate samples of the parvovirus B19 spiked
albumin (feed solution) while samples D1 and D2 (0.5ml) were taken after filtration
with the 35N Planova® filter. The melting curve of sample Cl at 1:10,000 dilution on
figure 3.69 showed only the B 19-specific peak at the melting temperature of 84.8°C.
This temperature was within the melting temperature range determined previously for
validation purposes (84.4°C to 85°C).
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Two pore sizes of Planova® filters were tested in this experiment, namely 15N and 20N.
Three different runs were performed for each filter size, using a new filter for each run
(60ml of feed for each run). The filtrations were run under a dead-end mode (figure
3.70), under constant pressure (0.5 bar) and at room temperature in a Class 1
Microbiological Safety cabinet.
Figure 3.70: Dead-end and constant pressure Planova® filtration procedure
F o r c e p s
A ir  v e n t  U p p e r  in le t  n o z z l e  —  
y l P I  )  P r e s s u r e  g a u g e
H e a d e r
C o m p r e s s e d  
a ir  o r  n i t r o g e n  g i i
N o z z l e  c a p
P L A N O V A
F e e d  s o lu t io n  
f l a s k  ( p r e s s u r i z e c  
f k a s k )
F o r c e p s
H e a d e r
F o r c e p s
R e c e i v i n g  f l a s k  o r  t e s t  t u b e
Eluate fractions of ~0.7ml were collected for each filtration. These collection samples 
were numbered 1 to 43 for the first 15N Planova® filter, 44 to 86 for the first 20N 
Planova® filter, 87 to 129 for the second 15N Planova® filter, 130 to 172 for the second 
20N Planova® filter, 173 to 215 for the third 15N Planova® filter and lastly 216 to 258 
for the third 20N Planova® filter. The fractions were stored at -70°C.
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Parvovirus B19 DNA of every other collection sample was extracted, together with a
sample of the B19 IS 99/800, and several negative controls (B 19-antibody negative
plasma provided by Dr J. Saldanha, B 19-antibody negative serum given by Dr B. Cohen
and duplicate RNAse-free water controls). The extracted DNA was then amplified by
LightCycler PCR. Ten-fold dilutions (ranging in concentration from 10 to 10 IU/ml)
of the DNA extracted from the B19 IS were amplified in parallel and the results used to
plot a standard curve. The concentrations of the samples were read off the standard
curve. Fluorescence was generated by both the amplicon and the primer dimers, as
shown by the samples melting curves. Observation of the latter showed that, in samples
whose concentration was less than lxlO3 IU/ml, the fluorescent signal was due to the
generation of primer dimers. Such samples were thus considered to be negative. In order
to test all the samples (and to include dilutions of the B19 international standard for
generation of a standard curve in each run), it was necessary to perform a total of twelve
runs on the LightCycler.
Table 3.14 records the different LightCycler runs with the controls and nanofiltration 
collection samples tested in each run. All three negative controls (negative plasma, 
negative serum and RNAase-free water) were found negative in all the LightCycler 
runs.
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Table 3.14: LightCycler runs and negative controls results for nanofiltration
Run Controls and collection samples tested
1 Al, A2, Bl, B2, Cl, C2, Dl, D2, 1 to 13
2 15 to 41
3 43 to 68
4 68 to 86
5 87 to 107
6 109 to 130
7 132 to 154
8 156 to 173
9 175 to 177
10 179 to 215
11 216 to 244
12 246 to 258
The following tables (3.15 to 3.21) compile the logio of B19 DNA concentrations, as 
well as the gel electrophoresis result for the experimental controls and the collection 
samples for each filter tested. Photos of all the agarose gels can be viewed in appendix 
3.
Table 3.15: Experimental controls for nanofiltration
Control sample Logio DNA concentration (IU/ml) Agarose gel result
Al 3.30 + (faint)
A2 climit of quantitation + (faint)
Bl 3.30 + (faint)
B2 3.00 +
Cl 10.69 +
C2 10.77 +
Dl 9.60 +
D2 9.77 +
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Table 3.16: Results for the first 15N Planova® filter
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Collection sample Logio DNA concentration (IU/ml) Agarose gel result
1 3.69 +
3 4.60 +
5 4.60 +
7 4.60 +
9 4.69 +
11 4.77 +
13 4.84 +
15 4.30 +
17 4.30 +
19 4.30 +
21 4.00 +
23 4.00 +
25 4.00 +
27 4.30 +
29 4.47 +
31 4.00 +
33 4.00 +
35 4.00 +
37 4.00 +
39 4.00 +
41 4.30 +
43 4.30 +
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Table 3.17: Results for the first 20N Planova® filter
Collection sample Logio DNA concentration (IU/ml) Agarose gel result
44 4.00 +
46 4.00 +
48 4.30 +
50 4.30 +
52 4.00 +
54 4.30 +
56 4.47 +
58 4.30 +
60 4.30 +
62 4.30 +
64 4.00 +
66 4.30 +
68 4.47 +
70 4.30 +
72 4.60 +
74 3.84 +
76 3.84 . +
78 3.30 +
80 3.84 +
82 3.69 +
84 3.69 +
86 3.30 +
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Table 3.18: Results for the second 15N Planova® filter
Collection sample Logio DNA concentration (IU/ml) Agarose gel result
87 3.00 +
89 4.00 +
91 4.00 +
93 4.00 +
95 4.00 +
97 3.77 +
99 3.84 +
101 3.47 +
103 4.00 +■.
105 3.77 +
107 3.69 +
109 3.84 +
111 3.69 +
113 3.77
115 3.69 +
117 3.69 +
119 3.84 +
121 3.69 +
123 4.00 +
125 4.00 +
127 3.47 +
129 3.30 +
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Table 3.19: Results for the second 20N Planova® filter
Collection sample Logio DNA concentration (IU/ml) Agarose gel result
130 <limit of quantitation + (faint)
132 3.00 +
134 3.60 +
136 4.00 +
138 3.47 +
140 3.60 +
142 3.60 +
144 3.69 +
146 3.69 +
148 3.60 +
150 4.00 +
152 3.90 +
154 4.00 +
156 3.60 +
158 3.60 +
160 3.30 +
162 3.60 +
164 3.47 +
166 3.00 +
168 3.47 +
170 3.00 +
172 3.30 +
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Table 3.20: Results for the third 15N Planova® filter
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Collection
sample Logio DNA concentration (IU/ml) Agarose gel result
173 climit of quantitation + (faint)
175 3.30 +
177 3.00 +
179 3.30 +
181 3.60 +
183 3.00 +
185 3.30 +
187 3.30 +
189 3.30 +
191 3.00 +
193 3.47 +
195 3.47 +
197 3.00 +
199 3.30 +
201 3.00 +
203 3.47 +
205 3.30 +
207 3.30 +
209 3.17 +
211 3.60 +
213 3.60 +
215 3.69 +
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Table 3.21: Results for the third 20N Planova® filter (N/D: Not Done)
Collection sample Logio DNA concentration (IU/ml) Agarose gel result
216 climit of quantitation N/D
218 climit of quantitation N/D
220 3.00 N/D
222 climit of quantitation N/D
224 3.30 N/D
226 climit of quantitation N/D
228 3.00 N/D
230 climit of quantitation N/D
232 3.00 N/D
234 3.30 N/D
236 climit of quantitation N/D
238 climit of quantitation N/D
240 climit of quantitation N/D
242 climit of quantitation N/D
244 3.30 N/D
246 3.00 +
248 3.30 +
250 3.47 +
252 3.00 +
254 3.30 +
256 3.39 +
258 climit of quantitation +
A summary of the six experiments with 15N and 20N filters is shown in table 3.22, 
where the average logio reduction was calculated.
The statistics were done by Mr A. Heath (Department of Informatics, NIBSC). The 
overall logio reduction mean for the 15N and 20N filters were 5.88 and 6.26, 
respectively, and the standard deviations were 0.44 and 0.51, respectively. Given the 
variability in the data, the difference in logio reduction was found not significant 
(p=0.38) between the two filter sizes, using a t-test. Therefore, both 15N and 20N filters 
can efficiently be used for parvovirus B19 nanofiltration.
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Experiment
number
Filter
size
Pre-filtration logio 
DNA concentration 
(IU/ml)
Post-filtration 
logio DNA 
concentration 
(IU/ml)
Logio
reduction
1 15 9.68 4.27 5.41
2 15 9.68 3.75 5.93
3 15 9.68 3.39 6.29
4 20 9.68 3.89 5.79
5 20 9.68 3.49 6.19
6 20 9.68 2.87 6.81
III.5.2. Virus inactivation by dry-heat treatment at 80°C on the freeze-dried 
8Y product: Bioproducts Laboratory, UK
High titre B19 virus stock (lxlO12 IU/ml) was used by Dr P. Roberts at BPL for the 
inactivation experiment by dry heating. The spiking step, for both controls and test 
samples, was performed at a ratio of 1 in 100 before freeze-drying and dry-heating. 
Three controls were prepared; the spiked product control, the spiked medium control 
and the unspiked 8Y product. The first control contained the product: BPL’s 
intermediate purity factor VIII (8Y), which had been spiked with B19. The second 
control consisted of medium (MEM with FCS), which had also been spiked with human 
parvovirus B19. Finally, the last control was unspiked factor VIII (8Y). Duplicates were 
prepared for each of the control samples. Three additional samples were product spiked 
with B19 and subjected to freeze-drying using the standard cycle for this product. The 
freeze-dried products were either left unheated, as was the case for spiked test sample 1, 
or subjected to dry-heat treatment for various times: spiked test sample 2 was heated to
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80°C for 24 hours while spiked sample 3 was incubated at 80°C for 72 hours. The 
parvovirus B19 DNA titres and the infectivity were determined in all six samples.
Table 3.23 shows the results of the B19 DNA concentrations obtained by LightCycler 
PCR and the number of infectious units per ml obtained by the infectivity assay.
Table 3.23: Results of virus inactivation by dry-heat treatment at 80°C on freeze-
dried factor VIII (8Y), including controls
Sample
Logio DNA concentration 
(IU/ml)
Logio infectious units/ 
ml
Spiked product 
control
10.60 5.0
Spiked medium 
control
10.60 7.0
Unspiked 8Y product 4.46 climit of detection
Spiked test sample 1
(unheated)
10.17 6.0
Spiked test sample 2
(heated at 80°C for 24 
hours)
9.43 3.5
Spiked test sample 3
(heated at 80°C for 72 
hours)
9.49 climit of detection
A contamination of the 8Y unspiked product was detected as the B19 DNA titre was 
found to be 104 IU/ml. However, no infectious units could be detected, suggesting that 
either the infectivity assay was not sensitive enough to detect such low infectivity or the 
virus present was not infectious. The dry-heat treatment at 80°C for 24 hours reduced 
infectivity by logio 2.2 while a longer treatment of 72 hours resulted in a reduction of 
infectivity to such a level that it became undetectable by the assay. Dry-heating
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treatment at 80°C for 72 hours thus seemed to be an effective inactivation method for
human parvovirus B19.
III.5.3. Virus inactivation by SuperFluids™: Aphios Inc., USA
12For each of the six experiments showed in table 3.24, 0.5ml of B19 virus stock (1x10 
IU/ml) was diluted in 12.25ml of normal human plasma (supplied by NIBSC) and 
12.25ml of MEM media (Gibco). All experiments were done at Aphios Inc and three 
supercritical fluids (Freon-22, Freon-23 and N2O/CO2) were used at either 25°C or 
50°C.
Table 3.24: Experimental Conditions for virus inactivation by SuperFluids™
Experiment
number
SuperFluids™
Pressure
(bars)
Temperature
(°C)
Flow
rate
(ml/min)
No. of 
Stages
NIBSC-01 Freon-22 206 50 4 2
NIB SC-02 Freon-22 206 25 4 1
NIBSC-03 Freon-23 206 50 4 1
NIB SC-04 Freon-23 206 25 4 1
NIBSC-05 N20/C 02a 206/137° 50 4 2
NIBSC-06 N20/C 02a 206/137° 25 4 2
aN20/CC>2 : N2O with trace quantities of CO2
b206 bars in first chamber and 137 bars in the second chamber
Five or six samples were produced in each of the six experiments. A 2.5ml aliquot of
the feed was taken at the start of the treatment and stored at 4°C during the run (named
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“before”) and a second 2.5ml sample was placed at the same temperature as the
.SuperFluids™ system for the same duration as a control (named “time and
temperature”). The remaining 20ml of 1:50 diluted B19 was used as feed for the run.
Once the system (isobaric chamber, connecting lines, valves and gauges) was
pressurised with the supercritical fluid, the sample was pumped through the isobaric
chamber at the rate of 4 ml/min. Sample #1 was collected at this stage and was
considered representative of the product stream. The supercritical fluid was then
pumped through the system at a lower flow rate (1 ml/min), in order to displace any
sample remaining in the system, at which stage sample #2 was collected. Finally, the
system was depressurised to atmospheric pressure (l.Olbars) and sample #3 was
collected. Samples #2 and #3 are considered representative of waste streams.
The results of these experiments are shown in tables 3.25 to 3.30.
Table 3.25: Results for experiment NIBSC-01
Sample
Logio DNA concentration 
(IU/ml)
Logio infectious units/ 
ml
“Before” 11.00 5.0
CFI-treated #1 10.69 3.0
CFI-treated #2 11.47 3.5
CFI-treated #2 10.77 3.0
CFI-treated #3 11.69 climit of detection
“Time and temperature” 11.69 5.0
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Table 3.26: Results for experiment NIBSC-02
Sample
Logio DNA 
concentration (IU/ml)
Logio infectious units/ 
ml
“Before” 11.47 5.0
CFI-treated #1 11.30 5.0
CFI-treated #1 11.30 4.5
CFI-treated #2 10.69 5.5
CFI-treated #3 10.90 5.0
“Time and temperature” 10.88 4.0
Table 3.27: Results for experiment NIBSC-03
Sample
Logio DNA 
concentration (IU/ml)
Logio infectious units/ 
ml
“Before” 11.30 4.0
CFI-treated #2 11.95 3.5
CFI-treated #3 (3ml) 11.84 4.0
CFI-treated #3 (3.7ml) 11.23 4.5
“Time and temperature” 11.23 4.5
Table 3.28: Results for experiment NIBSC-04
Sample
Logio DNA 
concentration (IU/ml)
Logio infectious units/ 
ml
“Before” 10.47 4.5
CFI-treated #1 10.47 6.0
CFI-treated #1 10.30 5.5
CFI-treated #2 10.47 4.5
CFI-treated #3 10.00 6.5
“Time and temperature” 10.47 6.0
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Table 3.29: Results for experiment NIBSC-05
Sample
Logio DNA concentration 
(IU/ml)
Logio infectious units/ 
ml
“Before” 10 4.0
CFI-treated #1 10 <limit of detection
CFI-treated #1 10 climit of detection
CFI-treated #2 10.47 4.5
CFI-treated #3 10.47 5.0
“Time and temperature” 10.69 4.5
Table 3.30: Results for experiment NIBSC-06
Sample
Logio DNA concentration 
(IU/ml)
Logio infectious units/ 
ml
“Before” 10.30 5.5
CFI-treated #1 10.30 4.5
CFI-treated #1 10.30 5.0
CFI-treated #2 10.30 6.5
CFI-treated #2 9.90 6.0
“Time and temperature” 10.30 5.0
The B19 DNA titre remained relatively unchanged for all the samples in these 
experiments. In NIBSC-01, with SuperFluids™ Freon-22 at 206 bars and 50°C in a two- 
stage laminar flow CFI unit, no infectivity was detected in “CFI-treated #3” sample 
(infectivity assay repeated twice). This experiment showed that the treatment resulted 
in at least a logio 4 reduction in infectivity. On the other hand, there was no significant 
reduction in the infectivity of the treated samples compared with the controls was 
observed in experiments NIBSC-02, 03, 04 and 06. In experiment NIBSC-05 using a
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mixture of N2O and CO2 at 206 bars at 50°C and a two-stage laminar flow CFI unit,
more than logio 5 of parvovirus B19 spiked into plasma were inactivated.
III.5.4. Virus inactivation by the INACTINE™ system: Vitex, USA
Some B19 virus stock (lxlO12 IU/ml) was sent to VI Technologies, where it was diluted 
1:20 in negative serum and where all inactivation experiments were performed. As 
preliminary experiments, these studies were performed on AS1 RBCs storage solution 
only, which was spiked 10% v/v with the 1:20 virus dilution.
The inactivation experiments were done in duplicate and samples was labelled A and B. 
Samples labelled TS3, TS6, TS18 and TS22 were treated for 3, 6, 18 and 22 hours, 
respectively. Samples labelled PCO and PC22 were controls, which were spiked samples 
incubated for 0 and 22 hours, but not treated with INACTINE™. Three additional 
controls were included in the experiments; the spiked dilution of human parvovirus B19 
(1:20) used for spiking and two cytotoxicity controls. Cytotoxicity control 1 (CC1) 
contained AS1, PEN 110 and the medium used to quench the PEN110 (STS/MOPS). 
Instead of removing PEN 110 to a non-toxic level by cell washing, the PEN 110 
reaction was chemically quenched, which is common practice for virus inactivation 
studies (Lazo et al., 2002). Cytotoxicity control 2 (CC2) consisted of the RBC 
resuspension medium AS1.
In order to evaluate the potential cytotoxic effect of AS1 medium, PEN 110 and 
STS/MOPS medium, both cytotoxicity controls were incubated with UT-7/EPO-S1 
cells following the same protocol as the infectivity assay. CC1 and CC2 were diluted 
into pH 5.7 phosphate buffer and a negative control inoculated with pH 5.7 phosphate 
buffer only was included in the experiment. Two time points were investigated: 2 hours 
after incubation of the cells and controls at 4°C and 2 days post-inoculation. At each
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time point, the cells were examined under the light microscope for cytopathic effects
and the live cells were counted.
The microscopic examination of the UT-7/EPO-S1 cells after 2 hours and 2 days post­
inoculation did not detect any cytopathic effect as compared to the negative controls 
which were inoculated with pH 5.7 phosphate buffer only. The cell counts are shown in 
tables 3.31 (CC1) and 3.32 (CC2). There was no significant difference between the cell 
counts of the negative controls and those of the cytotoxicity controls CC1 and CC2, 
which suggested that AS 1 medium, STS/MOPS medium, STS/MOPS medium and PEN 
110 did not have any cytotoxic effect on UT-7/EPO-S1 cells.
Table 3.31: Cell counts with cytotoxicity control 1 (CC1)
Sample
Cell count after 2 hours 
incubation at 4°C 
(cells/ml)
Cell count 2 days post­
inoculation at 37°C 
(cells/ml)
CC1 neat 2.95 xlO3 4.97 xlO3
CC1 1:10 3.65 xlO3 4.27 xlO3
CC1 1:100 2.52 xlO3 4.35 xlO3
CC1 1:1,000 2.47 xlO3 4.32 xlO3
CC1 1:10,000 2.1 xlO3 4.8 xlO3
Negative control 2.22 xlO3 3.9 xlO3
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Table 3.32: Cell counts with cytotoxicity control 2 (CC2)
Sample
Cell count after 2 hours 
incubation at 4°C 
(cells/ml)
Cell count 2 days post­
inoculation at 37°C 
(cells/ml)
CC1 neat 2.07 xlO3 4.25 xlO3
CC1 1:10 1.82 xlO3 3.65 xlO3
CC1 1:100 2.22 xlO3 4.01 xlO3
CC1 1:1,000 2.1 xlO3 4.15 xlO3
CC1 1:10,000 2 xlO3 4.2 xlO3
Negative control 2.62 xlO3 4.8 xlO3
Samples were tested by the B19 infectivity assay after determination of the B19 DNA 
concentration and the results are shown in table 3.33.
Table 3.33: Results of virus inactivation by INACTINE™ treatment, including
controls
Sample Logio DNA concentration (IU/ml) Logio infectious units/ ml
TS3A 7.30 climit of detection
TS6A 6.47 climit of detection
TS18A 4.47 climit of detection
TS22A 3.60 climit of detection
PC0A 10 5.5
PC22A 10 5
TS3B 5 climit of detection
TS6B 4 climit of detection
TS18B <limit of quantitation climit of detection
TS22B climit of quantitation climit of detection
PC0B 7.47 3.0
PC22B 7.69 1.5
B19 1:20 11.60 7.0
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In experiment A, the results for the non-treated spiked controls (PCOA and PC22A)
showed high DNA titres of logio 10 and comparable logio infectivity titres of 5.5 and 5,
respectively. The DNA titre logio reduction between PCOA and TS3A, the first sample
taken out, was logio 3, which was quite significant after only 3 hours of treatment. Then
the B19 DNA titre in samples decreased by logio 1 at each time point, except between 6
and 18 hours, where the DNA titre decreased by logio 2. Infectivity at the different time
point samples was not detectable, even at the first time point after 3 hours of treatment.
In experiment B, a logio 2 reduction was observed in the DNA titre from time 0 to time
3 hours followed by a further logio 1 reduction after another 3 hours treatment. No B19
DNA could be detected in the following two time points after 18 and 22 hours. As in
experiment A, the infectivity of these time point samples was not detectable, suggesting
a decrease in infectivity when compared to PCOB sample.
III.5.5. Virus inactivation by S-59: the Helinx® technology: Cerus 
Corporation, USA
High titre B19 virus JS isolate (lxlO12 IU/ml) was used for the spiking experiments, 
where it was diluted at 1:10 into PBS, with a final volume of 10ml. A 6 mL aliquot was 
treated with 150pM Amotosalen HC1 (S-59) and 3.0 Joules/cm2 (J/cm2) UVA 
illumination. A 1ml aliquot of the untreated 1:10 sample, which was also a control for 
the shipping and multiple freeze/ thaws was sent back to NIBSC for analysis, along with 
a 3ml aliquot of the treated sample. Aliquots of the same samples were also kept at 
Cerus Corporation to assay in an EliSpot assay.
Parvovirus B19 DNA titres were measured by LightCycler real-time PCR, using B19 
international standard as a reference. In addition, serial dilutions of the samples were
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used to infect UT-7/EPO-S1 cells, from which RNA was extracted after 2 days. The
presence of B 19-specific mRNA transcripts was detected by RT-PCR amplification.
Table 3.34 shows the results obtained at NIBSC for the B19 DNA quantification and the
infectivity assay.
Table 3.34: Results of photochemical inactivation with S-59
Sample Logio DNA concentration (IU/ml) Logio infectious units/ ml
Untreated 10.95 7.5
Treated 3J 9.30 3.0
The results showed that the logio DNA concentration for the untreated and 3J treated 
samples were 8.45 and 3.3, respectively. The infectivity titre for the treated sample was 
logio 2.8 while that of the untreated sample was logio 6.8, suggesting a logio 4 reduction.
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Up to now, model viruses, such as canine (CPV), porcine (PPV) and murine (MVM)
parvoviruses, have been used to study the efficacy of inactivation procedures for human 
parvovirus B19 because of the lack of a reproducible infectivity assay for the latter. 
Although CPV and B19 have similar properties, notably antigenic, there is no cross­
reactivity of antibodies to CPV with B19, indicating different surface structures 
(Chapman and Rossmann, 1993; Agbandje et al., 1994). These differences were 
confirmed by recent studies at the Paul Erlich Institute, Germany. The first study, which 
investigated the efficacy of viral inactivation by pasteurisation using both PPV and B19, 
revealed that heat resistance of B19 markedly differs from heat resistance of animal 
parvoviruses (Blumel, 2004). B19 was inactivated after 10 minutes at 60°C by at least 
logio 4 whereas porcine parvovirus was resistant at 60°C. The second study looked at 
low pH treatment to inactivate MMV and B19 and found that the virus clearance for the 
latter was greater than logio 5 after 2 hours at pH 4, whereas MMV was resistant over 9 
hours (Boschetti et al., 2004). These data show that parvovirus B19 was much more 
vulnerable toward low pH conditions than MMV. These new findings highlight the fact 
that animal parvoviruses are not suitable models to evaluate B19 inactivation since they 
seem to behave differently.
The present study was designed to develop a robust and reproducible infectivity assay 
for parvovirus B19. This assay was then used to evaluate several novel pathogen 
inactivation and removal methods. In addition, a reproducible quantitative DNA assay 
was developed using the WHO International Standard for B19 DNA.
Several approaches were investigated to determine parvovirus B19 infectivity. The 
initial attempts used mobilized stem cells (CD34+) from peripheral blood in a variety of 
formats: IFA staining of inoculated cells, detection of mRNA transcripts specific for 
parvovirus B19 in inoculated cells and a BFU-E reduction assay for B19. The FACS
-376-
........................................................................................................................................................................Chapter IV
results for the CD34+ cell preparations showed that CD34+ cell isolation from
mobilised peripheral blood was not completely efficient since these cells were not the
sole cell population in the samples. However, since the majority of the cells isolated
were actually bearing CD34, this result might not have interfered with the outcome of
the IFA. It was not possible to demonstrate viral replication in any of the samples of
CD34+ cells inoculated with B19 virus with the antibodies tested i.e. mouse monoclonal
antibody anti-VPl/VP2, human monoclonal antibody anti-NSl or rabbit polyclonal
antibody. However, it was possible to amplify B19 specific mRNA transcripts from B19
inoculated cells isolated from the peripheral blood of one of the patients. This result
suggested that viral replication was occurring in these haematopoitic stem cell
progenitors, but at a level that was not detectable by immunofluorescence. In contrast,
when CD34+ cells were plated in Fox’s medium to obtain BFU-E colonies, cells from
the resulting colonies were susceptible to B19 infection and this could be demonstrated
by IFA using anti VP1/VP2 monoclonal antibody. However, this result was not
consistent, and positive results were only obtained with cells from a few patients. Only
a minority of the cells was infected and specific fluorescence, in contrast to detection of
mRNA, could only be detected 3-7 days post infection.
Since cells from different patients were used in the IFA and RT-PCR detection of 
mRNA transcripts, this might account for the difference in results. Such variability had 
already been observed in data from the BFU-E reduction assay, which used apheresis 
cells collected from different patients every week. It would have been better to have 
tested CD34+ cells isolated from the same patient by IFA and mRNA transcript 
amplification but this was not possible due to the limited number of cells obtained from 
any one patient. Another explanation could be that these CD34+ cells might only 
support viral transcription but not translation into proteins, which could account for the
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detection of B19 specific mRNA transcripts by PCR but not detection of viral proteins
by IFA.
The results of the BFU-E reduction assays were dependent on the source of the cells. 
One factor that could have influenced the results of the BFU-E reduction assay was the 
anti-B19 IgG status of the donors and this was tested in some of the samples, where 
serum was available. Theoretically, CD34+ cells from patients who were anti-B19 IgG 
positive could contain sufficient antibody which could neutralise all or part of the B19 
inoculum resulting in a decrease in the BFU-E reduction percentage compared with 
cells from B19 antibody negative patients. In practice, the data showed that this was not 
the case and the figures for donors 17 and 19 were examined more closely. These two 
patients were chosen because the former presented the strongest IFA results and the 
highest cut off value (9.3) for anti-B19 IgG whereas the latter showed no positive 
staining by IFA and a clear negative result in EL When inoculated with the same virus 
dilution, 2xl07 IU/ml, the percentage BFU-E reduction for patient 17 (IgG positive) was 
54.88% whereas that for patient 19 (IgG negative) was 31.01%. These results do not 
support the theory that cells from B19 antibody positive patients lead to a decrease in 
the BFU-E percentage reduction result. Alternatively, the anti-B19 IgG present in the 
serum of patients might not have been neutralising antibodies or that the apheresis 
samples used in this study were free from antibodies.
In addition to the discrepancy of results seen for B19 infection in primary cells from
different patients, other important issues were the availability of these cells and their
accessibility. Since one of the aims of this thesis was to develop an infectivity assay that
could be used widely in research and diagnostic laboratories, it was crucial for the cells
used to be readily available and accessible. This was not the case for either the apheresis
cells or the mobilised peripheral blood from which CD34+ cells could be isolated.
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Therefore, B19 susceptible continuous cell lines, which subsequently became available,
were used for the establishment of a B19 infectivity assay.
When continuous cell lines were investigated, either no immunofluorescence could be 
detected, such as in TF-1 cells, or a very small proportion of cells showed infectivity: 
only -1% of UT-7/EPO-S1 cells, -5% of UT-7/EPO cells and -10% of KU812 and 
KU812Ep6 cells displayed fluorescence when inoculated with high titre parvovirus B19 
(>109 IU/ml) and stained with mouse monoclonal antibody anti-VPl/VP2 (Novocastra). 
The brightest fluorescence was found in KU812Ep6 cells. The semi-permissiveness of 
the cells might account for the lack of sensitivity of the IFA. Alternatively, incomplete 
replication, such as production of replicative intermediates and transcription without 
translation resulting in a non-productive infection or cell death by apoptosis as has been 
observed in previous studies may also explain these results (Leruez et al, 1994; 
Gallinella et al, 2000; Morita et al, 2001). In addition to the other drawbacks, the need 
for very high titre inoculum resulted in the use of this assay being abandoned for a more 
sensitive and reliable assay, which was the detection of mRNA transcripts by nucleic 
acid amplification.
Although there have been several reports in the literature of continuous cell lines, 
usually of erythroid lineage, supporting the replication of parvovirus B19 (Shimomura 
et al., 1992; Munshi et al., 1993; Takahashi et al., 1993; Kumatsu et al. 1993; 
Nakazawa et al., 1989; Miyagawa et al., 1999), the ability of these cells to support 
replication of B19 has been poor compared with other virus-cell culture systems (such 
as polio virus replication in Vero cells (Montagnon et al., 1983).
Early on in this study, a comparison of various continuous cell lines, namely KU812,
KU812Ep6 and UT-7/EPO, showed that the most suitable cells for the B19 infectivity
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assay were KU812Ep6. However, due to a strict confidentiality agreement with the
Japanese laboratory providing those cells, they could not be used to determine the
efficacy of virus removal/ inactivation techniques by private companies. In the
meantime, a clonal cell line, called UT-7/EPO-S1, was reported to be superior to its
parental line (UT-7/EPO) at supporting the replication of B19 (Morita et al., 2001). The
UT-7/EPO-S1 cells were thus tested in the B19 infectivity assay and appeared to be
stable and reliable, giving consistent results at various passages (tested up to passage
n+53). Optimisation of the infectivity assay, which depended on the detection of B19
mRNA transcripts, was done, including the number of cells to be inoculated with the
virus (2xl05 cells), mRNA extraction method (from cell cytoplasm) and time of
extraction post-infection (2 days). The evaluation of the optimal method of nucleic acid
extraction for this particular assay involved the comparison of extraction of total nucleic
acids (Nuclisens™; Organon Teknika) with extraction of poly A+ RNA from whole
cells (Oligotex direct mRNA kit; Qiagen) or from cell cytoplasm (Oligotex direct
mRNA kit; Qiagen). The best method was found to be poly A+ RNA from cell
cytoplasm. This result was to be expected since it would result in a better yield of
mRNA than the extraction of total nucleic acid and since the spliced transcripts would
be found in the cell cytoplasm. The splicing event occurs in the nucleus, where the
transcript is capped at the 5’ end, has the introns removed and is polyadenylated at the
3’ end. The mRNA is then transported through nuclear pores to the cytoplasm, where it
is available to be translated. In conclusion, after establishing that the Oligotex direct
mRNA extraction from cell cytoplasm (Qiagen) was the most suitable and specific
method for the isolation of mRNA, the batch format was also confirmed to be the most
efficient way to provide optimum yield. Replicate infectivity assays of a stock of B19
indicated that the 95% detection limit of this assay was logio -6.03 dilution (range -5.82
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to 6.24), equivalent to logio 5.97 IU/ml and the 50% detection limit was logio -6.67
(range -6.46 to -6.87), equivalent to logio 5.35 IU/ml. This validation study showed
good reproducibility of the infectivity assay, which was much better than that of the
BFU-E reduction assay. This assay was used for the evaluation of the inactivation
protocols investigated. The B19 isolate JS, which had high DNA and infectivity titres,
was used in these studies. High DNA titre inoculi were essential since the ratio of DNA
concentration to infectious units was high (104:1 tol05:l). This phenomenon was mainly
due to the semi-permissive nature of the cell line UT-7/EPO-S1 used in the infectivity
assay, although the presence of a high proportion of defective, non-infectious particles
cannot be ruled out.
Multiplex RT-PCR conditions were also optimised by looking at different primer
combinations, actin primers concentration and annealing temperature. Parvovirus B 19-
specific primers B19-9 and XPP-2 were chosen in the presence of Q buffer for greater
specificity. The optimum concentration of actin-specific primers was found to be
5pmol/|il and the annealing temperature was set at 50°C for best results.
A final parameter examined in this study was the influence of hypoxia on the
susceptibility of cells to B19 infection following the results of a published study which
indicated that cells grown in hypoxic conditions had increased susceptibility to B19
infection (Caillet-Fauquet et al., 2004a). Three sets of conditions were investigated:
normal oxygen concentration (20%) before and after inoculation with JS isolate, normal
oxygen concentration (20%) before but hypoxia (3%) post-inoculation and lastly
hypoxia (3%) before and after inoculation. Extraction of mRNA was performed 24, 48
and 72 hours post-inoculation. No B19 replication could be detected in the first time
point (24 hours). However, in those UT-7/EPO-S1 cells cultured in normal conditions
(20%) before and after inoculation, as well as those first cultured with 20% oxygen then
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3%, the number of infectious particles detected was 107 inf.u./ml after 48 and 72 hours.
When the cells were incubated in hypoxia (3%) before and after inoculation with B19,
the number of infectious particles detected was 108 inf.u./ml after 48 and 72 hours.
Hypoxic conditions only after the addition of the virus did not seem to change the
number of infectious units detected whereas hypoxia before and after infection seem to
improve the results of the infectivity assay slightly (logio 1). Even if this variation was
not due to the assay variability but to the actual hypoxic conditions, it was not
significant enough to justify the use of special equipment that might not be accessible to
all laboratories. Although both the cell lines used in the present study (UT-7/EPO-S1)
and that of Caillet-Fauquet and colleagues (KU812F) were from the erythroid lineage
(Caillet-Fauquet et al., 2004a), they could have reacted differently to hypoxic
conditions, which might explain why their observations could not be reproduced in the
system presented here. It would be interesting to test incubation of the cells in even
more severe hypoxic conditions (1%) since it might increase the number of erythroid
bursts generated from full-term CD34+ (Cipolleschi et al., 1997) and was also claimed
to increase viral capsid protein synthesis, virus replication and virus production in
primary erythroid cells (Pillet et al., 2004).
The establishment of the infectivity assay also allowed the study of parvovirus 
transcription since it was based on the detection of mRNA transcripts. According to a 
research study by Ozawa et al., there is a splicing donor site (GT) at positions 407 and 
408 (on the genome of M l3784) and acceptor sites (AG) at positions 1908 and 1909, as 
well as at positions 2028 and 2029 (Ozawa et al., 1987). The primers used for RT-PCR 
amplification, named B19-9 and XPP-2, were situated at position 384-405 and 2194-
2214, respectively. Therefore, two products were expected of 305bp and 185bp.
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Sequencing of these two transcripts was therefore performed to confirm the nature and
positions of the spliced products specific to parvovirus B19. When compared to B19
genomic DNA (M13178), the longer transcript (upper band) corresponded to positions
384-406 and 1910-2193 while the shorter transcript (lower band) corresponded to
positions 384-406 and 2030-2193. The transcripts sizes were therefore confirmed to be
305 bp and 185 bp, respectively. These results were thus in complete agreement with
those of Ozawa et al. since they recognised the splicing donor site and the two splicing
acceptor sites described in their transcription map (Ozawa et al., 1987). Nevertheless,
the novelty about the present study was that this transcription pattern was observed in
the continuous cell line UT-7/EPO-S1, whereas human erythroid bone marrow cells
obtained from patients with sickle cell disease had been used by Ozawa and colleagues.
This observation thus confirmed that, although semi-permissive to B19 infection, this
cell line was a good substitute to primary cells, which were less readily available.
A reproducible, quantitative B19 DNA NAT assay was successfully established. 
Dilutions of the WHO B19 International Standard were used for quantitation. This 
reagent was calibrated in arbritrary units, International Units (IU), which were closely 
related to the number of genomic copies. Thus, 1IU of this reference reagent 
corresponded to approximately 0.6-0.8 copies, depending on the assay method used 
(Saldanha et al., 2002). Since it is very difficult to accurately quantitate the number of 
copies of viral genome in a sample, this titre represents the nearest approximation to the 
concentration of the virus.
SYBR green was used to detect the amplicons in this assay. However, despite attempts
to reduce the background due to primer dimer formation by taking the fluorescence
reading at a high temperature where the primer dimers would be expected to be
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dissociated, it was clear that some fluorescence due to primer dimers was still obtained.
This resulted in a “titre” which was read off the standard curve. However, examination
of such samples by ethidium bromide agarose gel electrophoresis showed that these
samples were negative as the specific B19 amplicon band was not observed. Therefore,
sample with titres at or below lx l03IU/ml were considered negative and this was taken
as the lower limit of quantitation of the assay. It is now possible to overcome such
problems with the use of fluorescently labeled, specific probes to detect amplicons.
Such probes will only hybridise to the target amplicons and any primer dimers or non-
specifically amplified DNA will not give a signal. Probes exist in a variety of formats,
such as TaqMan, hybridization, Scorpion probes and Molecular Beacons. Programs
exist for the optimum selection and design of primers and probes (Strategene). The
majority of recent quantitative assays use some form of fluorescently-labelled probe to
detect specific amplicons and this would now be the chosen method for any quantitative
assay. However, at the time that this work was initiated, quantitative assays using probe
technology were relatively rare and expensive. Therefore, an assay based on SYBR
green detection was developed for the quantitation of B19 DNA.
The established quantitative assay was very reproducible with a standard deviation of 
the logio titles for replicate assays done on different days of 0.092 i.e. 95% of individual 
results from repeat testing of this sample would be expected to fall within 
approximately two standard deviations of the mean i.e. +/- logio 0.18IU/ml. The assay 
was used to titrate three B19 virus isolates which were used in the study as inoculi (JS, 
LP and JB). In addition, the titres of samples from the inactivation/removal studies were 
obtained with this assay.
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Although the reliability of the infectivity assay was verified by statistical analysis, the
clearance figures obtained with these methods are preliminary and approximate and it
was not possible (due to time constraints and difficulty in repeating the inactivation
protocols several times) to obtain more accurate figures for the inactivation.
Nevertheless, the results of this study are sufficient to indicate the success or otherwise
of these protocols.
According to the WHO guidelines on viral inactivation and removal procedures 
intended to assure the viral safety of human blood plasma products, “a robust, effective, 
reliable process step will be able to remove or inactivate substantial amounts of virus, 
typically logio 4 or more, be easy to model convincingly and be relatively insensitive to 
changes in process conditions” (WHO Expert committee on Biological standardization, 
2001). Moreover, if the logio reduction is equal to or less than 1, it is considered 
insignificant.
The present study investigated five methods of virus removal/inactivation, in 
collaboration with various private companies. The techniques of inactivation were the 
well established dry-heat treatment at 80°C (BPL, UK) and the novel methods of super 
critical fluids (Aphios Inc., USA), INACTINE™ (Vitex, USA) and Helinx® (Cerus 
Corporation, USA). The last two methods of inactivation are similar in that both 
coumpounds used (INACTINE™ and S-59) are able to cross viral membranes and bind 
to and crosslink nucleic acids (DNA and RNA), thereby preventing replication. High 
titre human parvovirus B19 (B19 stock virus: isolate JS) was sent to the companies for 
spiking experiments and samples taken before, during and after the inactivation step 
were tested.
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Viral removal procedures, which include chromatography and nanofiltration, should be
distinguished from viral inactivation methods. In the case of viral removal, nucleic acid
amplification is enough to evaluate the efficacy of the procedure. The latter is assessed
by the viral clearance, which compares the viral load of the spiked material before
removal step and at the end of the procedure. Removal depends on the protein
composition and the separation conditions used, for instance the constant pressure
applied during dead-end nanofiltration. The latter procedure, being non-invasive, has
been the preferred virus removal technique because it can preserve both the structure
and function of the plasma proteins. The efficacy of this method for the removal of B19
has been hampered by the lack of a suitable in vitro infectivity assay. Instead, model
parvoviruses such as BPV (Bumouf-Radosevich et al., 1994; Omar and Kempf, 2002),
PPV (Troccoli et al., 1998) and MVM (Omar and Kempf, 2002) have been used to test
this system. These animal parvoviruses have a diameter between 15 and 20nm, whereas
the B19 virus particles measure between 22 and 24nm in diameter (Cossart et al., 1975).
Thus the removal procedure evaluated in the present study was the nanofiltration using
15N and 20N Planova® filters, in collaboration with Asahi Kasei Pharma, Japan. These
Planova® filters have already been shown to remove more than logio 6.2 of CPV in
IVIG with Planova® 15N and more than logio 4.3 of PPV in factor VIII with Planova®
20N. Therefore, since nanofiltration is dependent on filter pore size, this clearance of
animal parvoviruses suggests that human parvovirus B19 might also be removed by
such a technique. The spiked product used in this study was 0.5% albumin solution. It
was worth noting that the unspiked albumin solution was found to contain a small
amount of B19 DNA (~lxl03 IU/ml in samples A, the prefiltration feed and B, the
prefiltration eluate). Since the presence of parvovirus B19 DNA in albumin batches has
been reported previously (Saldanha and Minor, 1996), in the present study, the albumin
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solution, which was of intermediate quality, might also have been contaminated with a
low level of B19. As far as the nanofiltration efficiency was concerned, a good virus
clearance was observed since the logio reduction was between 5.41 and 6.81, when
looking at 15 and 20N filters, respectively. Although at first glance, it seemed that B19
removal using 20N Planova® filter might be slightly better or almost the same
compared to nanofiltration through a 15N filter, statistical analysis demonstrated that
there was no significant difference between the two filters.
One of the advantages of Planova® filters, apart from its virus clearance properties, is 
the good product recovery rates (>95%) with the Planova® 35N filter for proteins up to 
molecular weight (MW) of about 800,000 (e.g., Factor VIII and IgG), with the Planova® 
20N filter for proteins up to MW about 350,000 (e.g., Factor VIII and IgG), and with 
the Planova® 15N filter for proteins up to MW about 160,000 (e.g., Factor IX and IgG). 
The latter filter can thus allow the passage of the albumin protein used in the present 
study. However, the counterpart of this is the loss of larger proteins, as well as the 
difficult filtration of complex solutions, including whole plasma. The main limitations 
of nanofiltration remain the pore size of the filters and the relatively low flow rates.
Only one other study had already investigated the removal of parvovirus B19 from 
haemoglobin solutions by nanofiltration using a BMM-35 filter (mean pore size 35nm) 
followed by a BMM-15 filter (Abe et al., 2000b). Although the median PCR titre was 
not changed after the BMM-35 filtration step, the second filter with smaller pore size 
resulted in more than logio 6 reduction. Therefore, there was a correlation between the 
results obtained by Abe and colleagues and those presented here. Omar and Kempf used 
a different kind of membrane filter, from Pall Corporation, to determine whether 
antibody-coated viruses become large enough to be retained by nanofiltration with
filters having apparent pore size larger than the free virions (Omar and Kempf, 2002).
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Their theory was that, if the plasma pool would accidentally become contaminated with
B19 from an infected donation, the antibodies present in other donations would bind to
the virus particles, which thereby might lose all or part of their infectivity. These
immune complexes would have an increased diameter, which should facilitate their
removal by nanofiltration. These authors showed that BPV and MVM bound to
antibodies were efficiently eliminated by filtration through Pall 20nm filters. However,
according to their method, and since the filters pore sizes are larger than the diameter of
the free virions, the latter, which are the potentially harmful viruses, would not be
removed from the product. Therefore, this technique seems inappropriate to use in the
manufacturing process of therapeutic products.
The use of filters with smaller pore sizes, such as Planova® 20N and 15N filters, thus 
appears the most suitable option for the effective elimination of human parvovirus B19 
from albumin solution by nanofiltration.
A production process should include two complementary steps of virus 
inactivation/removal. The advantages of two methods acting through different 
mechanisms, frequently an inactivation step by a chemical treatment followed by a 
robust physical removal step, is the large spectrum of viruses susceptible.
As mentioned in chapter I, several cases of parvovirus B19 transmission by dry heat- 
treated coagulation factor concentrates have been reported (Yee et al., 1995; 
Santagostino et al., 1997; Bliimel et al., 2002b). Therefore, the efficacy of dry-heating 
treatment to inactivate human parvovirus B19 needed to be investigated further. In the 
present study, the average DNA concentrations of the spiked product and medium 
controls were 1010 IU/ml whereas the B19 infectivity titres were logio 5.6 and logio 7.6,
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respectively. The logio 2 difference between the product control and the medium control
suggest that there might be some effect of the product on the infectivity assay itself.
However, since the dry-heat treated spiked samples were compared with the unheated
spiked sample, this effect of the product on the assay would not have altered the
outcome of the inactivation experiment. Although the DNA titre of factor VDI 8Y
(unspiked product) was 104 IU/ml, indicating a contamination of the product, no
infectious units could be detected since the assay was not sensitive enough to detect
such low infectivity. When human parvovirus B19 was studied, the dry-heat treatment
at 80°C for 24 hours reduced infectivity by logio 2.2 whereas a longer treatment of 72
hours allowed reduction of infectivity to such a level that it became undetectable in the
infectivity assay. Dry-heating treatment at 80°C for 72 hours thus seemed to be an
effective inactivation method for human parvovirus B19. However, even after such dry-
heat treatment, product 8Y was reported to have transmitted B19 infection to an
immunocompetent individual (Yee et al., 1995). This implies that there must have been
a massive challenge in that particular batch, possibly during an epidemic year.
Although the experimental conditions used here differed from the ones used to study
CPV and BPV, the data obtained suggested that this inactivation method might be more
effective on human parvovirus B19 than on model animal parvoviruses (Roberts and
Hart, 2000). This would be in agreement with the study of human albumin
pasteurisation, where human parvovirus B19 was inactivated much faster than the
animal model PPV (Blumel et al., 2002b). When the dry heat treatment studied here is
compared to pasteurisation, it seems that the latter would be more rapid at inactivating
B19. However, the data presented is preliminary and further studies should be
performed, mainly to evaluate the efficacy of the dry heat procedure at several time
points between 24 and 72 hours. This would allow the study of inactivation kinetics and
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the determination of the best exposure time for a product such as BPL’s intermediate
purity factor VIII (8Y). As briefly mentioned above, the other important point that
should be investigated is the influence of residual moisture in the lyophilised product.
This matter was not taken into consideration in the present study because of its
preliminary nature. However, a report investigating the thermal resistance of BPV
showed that reducing the residual moisture from 2% to less than 1% resulted in the
exposure time at 100°C being prolonged by 2.5 times in order to achieve the same level
of inactivation (Brauniger et al., 2000). Whether inactivation of human parvovirus B19
would also be susceptible to the amount of residual moisture in the lyophilised product
tested remains to be determined. Both pasteurisation and dry heat treatments have been
investigated using these viruses. As far as the former is concerned, although CPV was
inactivated within 30 seconds at 60°C in the presence of 0.1M sodium hydroxide
(NaOH), the model virus was shown to remain unaffected by heat treatment alone, at
60°C for 16 minutes (Borovec et al., 1998). At a similar temperature, BPV also showed
thermal resistance (Brauniger et al., 2000). A recent study compared inactivation of B19
with that of PPV during pasteurisation of human serum albumin (Bliimel et al., 2002b).
The model virus was resistant to treatment at 60°C whereas B19 was inactivated by
logio 4 or more after 10 minutes. This report highlighted that thermal resistance of B19
markedly differs from that of animal parvoviruses. Therefore, inactivation protocol
efficiency data obtained with such animal models might not reflect the behaviour of
human parvovirus B19. When the efficacy of dry heat treatment for the inactivation of
CPV was evaluated, the animal virus presented no residual infectivity after 48 hours at
80°C or 10 hours at 90°C (Hart et al., 1994). An even higher heat resistance was found
for BPV at 100°C (Brauniger et al., 2000). When the inactivation of both CPV and BPV
by dry heating was compared in two high purity factor VIII concentrates, BPV was also
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more resistant to heat treatment than CPV (Roberts and Hart, 2000). The inactivation
after 72 hours at 80°C was indeed logio 1.3 and 3.1, respectively in the first product,
whereas it was logio 0.2 and 1.3, respectively in the second product. This experiment
thus suggested that dry-heat resistance depended not only on the virus itself, but also on
the specific product tested. In contrast, Blumel and coworkers found that inactivation of
B19 was independent of the albumin product tested (5, 20 and 25% albumin from three
manufacturers) and of the specific virus source used for the inactivation (Blumel et al.,
2002b). This divergence of opinion about the influence of the product tested might be
due to the fact that the products investigated were different: factor VIII concentrate in
one case and human serum albumin in the other. Additionally, the viruses used to test
the efficacy of the inactivation procedure were also different: animal parvoviruses (CPV
and BPV) on one side and human parvovirus B19 on the other. Since these viruses have
been shown to behave differently to heat treatment (Blumel et al., 2002b), their thermal
resistance might be influenced by different factors such as virus type or product being
tested. The other possible explanation for the difference in resistance reported between
the products could be differences in the available residual water rather than the products
per se.
A couple of other research groups have studied the effects of pasteurisation on B19
erythrovirus by determining the decrease of viral DNA replication (Southern Blotting)
and viral protein production (enzyme immunoassay) (Schwarz et al., 1992b) or by
infecting the erythroid cell line KU812Ep6, expressing the viral infectivity by its
TCID50 ml (Miyagawa et al., 1999). In the first study, plasma was spiked with B19 and
treated at 60°C (Schwarz et al., 1992b). Southern blot analysis showed no viral DNA
after 20 minutes or more and no viral protein production could be detected in samples
treated for 12 minutes or more. However, it was not possible to determine whether the
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heat treatment completely inactivated parvovirus B19. The second study showed that
B19 infectivity declined from 104 TCID50ml to less than 10 TCID50ml, which was the
lower limit of detection, after 3 hours at 60°C or 30 minutes at 70°C, while it only
decreased to 102'5 TCID50ml in samples treated for 8 hours at 50°C (Miyagawa et al.,
1999).
The third method tested used SuperFluids™ at various temperatures and pressure. In 
NIBSC-01, with SuperFluids™ Freon-22 at 206 bars and 50°C in a two-stage laminar 
flow CFI unit, there was approximately a logio 2 clearance in infectivity titre of samples 
#1 and #2 compared with the untreated sample, but this may not be significant given the 
variability of the infectivity assay. In contrast, no infectivity was detected in “CFI- 
treated #3” sample (infectivity assay repeated twice). The “time and temperature” 
control sample had a similar infectious titre to the untreated sample indicating that the 
loss of infectivity was due to the treatment rather than incubation of the sample at an 
elevated temperature. This experiment showed that the treatment resulted in at least a 
logio 4 reduction in infectivity. On the other hand, there was no significant reduction in 
the infectivity of the treated samples compared with the controls observed in 
experiments NIBSC-02, 03, 04 and 06.
In the NIBSC-05 experiment, more than logio 5 of parvovirus B19 spiked into plasma
were inactivated. The SuperFluid™ was a mixture of N2O and CO2 at 50°C and a two-
stage laminar flow CFI unit was used (206 and 137 bars). The inactivation was more
effective when N2O/CO2 was used compared with Freon-22 and Freon-23. In addition,
higher levels of inactivation were obtained by SuperFluids™ at 50°C compared with
25°C. The absolute effect of temperature by itself was negligible and accounted for in
time and temperature controls. It should be noted that at 25°C, the N2O/CO2 mixture is
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sub-critical whereas the mixture is supercritical at 50°C (the critical temperatures of
N2O and CO2 are respectively 36.41°C and 31.1°C). At 50°C, the N2O/CO2 mixture
was supercritical since its pressure (206 bars) exceeded the critical pressures
(respectively, 72.7 and 73.8 bars) of both N2O and CO2. It appears necessary that these
fluids (N2O/CO2) must be supercritical, which can be achieved at pressures in excess of
74 bars and 37°C, in order to achieve high levels of B19 inactivation. In addition, the
residence time was remarkably short (less than one minute). Finally, the use of
additional isobaric chambers can improve the level of inactivation as seen in the
experiment NIBSC-05 where two chambers were used. Thus, these preliminary studies
showed that the SuperFluids ™ method using N2O/CO2 at 206 bars and 50°C in a two-
stage laminar flow CFI unit seemed to be the most efficient one to inactivate human
parvovirus B19.
The main advantage that SuperFluids™ have over currently available virus inactivation 
techniques is their ability to reduce the viral load of both enveloped and non-enveloped 
viruses. For instance, the viral load of enveloped viruses, such as Sindbis virus, can be 
reduced more than logio 6 (Dr T Castor, personal communication). Similarly, non­
enveloped virus loads, like adenovirus or poliovirus, can be decreased by logio 5 and 4, 
respectively. Additionally, the integrity and therapeutic activity of plasma products 
treated with SuperFluids™ are preserved. However, this technique cannot be used on 
blood donations that still contain red blood cells because these fluids would damage 
them. The other advantages of this technique are the fact that they are readily separated, 
with no toxic residues and that the system can be easily scaled up to production levels 
with continuous flow operations.
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The effect of the INACTINE™ treatment on human parvovirus B19, using PEN 110,
was also investigated. For experiment A, the results for the non-treated spiked controls
(PCOA and PC22A) showed high DNA titres of logio 10 and comparable logio
infectivity titres of 5.5 and 5, respectively. During the treatment, samples were taken at
various time points: 3, 6, 18 and 22 hours. The B19 DNA titre in these samples
decreased by logio 1 at each time point, except between 6 and 18 hours, where the DNA
titre decreased by logio 2. This can be easily explained by the fact that the time interval
was higher between the two samples: 12 hours compared to 3 and 4 hours between the
other time points. On average, B19 DNA titres would thus drop by logio 1 every 3 to 6
hours. Moreover, the DNA titre logio reduction between PCOA and TS3A, the first
sample taken out, was logio 3, which was quite significant after only 3 hours of
treatment. Infectivity at the different time point samples was not detectable, even at the
first time point after 3 hours of treatment with compound A, when the DNA titre was
logio 7.3. Therefore, treatment with compound A seems to be very efficient at
inactivating human parvovirus B19, even after a short incubation of 3 hours. In
experiment B, the untreated spiked controls showed a B19 DNA titre of 107 IU/ml,
whereas the infectivity titres were logio 3.47 and 2.19 infectious units per ml, after 0 and
22 hours (PCOB and PC22B), respectively. A logio 2 reduction was observed in the
DNA titre from time 0 to time 3 hours followed by a further logio 1 reduction after
another 3 hours treatment. No B19 DNA could be detected in the following two time
points after 18 and 22 hours. Similarly to experiment A, the infectivity of these time
point samples was not detectable, suggesting a decrease in infectivity when compared to
PCOB sample.
Although phase I clinical evaluation had shown that the PEN 110 process was able to
inactivate both enveloped and non-enveloped viruses and that treated RBCCs were
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therapeutically useful (AuBuchon et al., 2002), phase III trials had to be suspended in
PRT RBCs transfused repetitively because of the appearance of antibodies to treated
cells (neoantibodies) (Vitex press release, 17th November 2003). The (photo)chemical
treatments can indeed potentially interact with other targets than their intended ones (i.e.
nucleic acid) and thereby yield an immunogen that could cause a response to treated
cells or, by cross-reactivity, to untreated cells (AuBuchon, 2004). Nevertheless, the
efficacy of this technique to inactivate other pathogens had already been proven in red
blood cells with protozoan parasites (Zavizion et al., 2004), WNV (Mather et al., 2003),
duck HBV (DHBV) as a model of HBV (Aytay et al., 2004) and HIV (Ohagen et al.,
2002). In addition, toxicology studies have found that the trace amount of residual 
PEN110 in the purified blood component is well below the level that could present a 
risk of reproductive toxicity to the patient (Chapman et al., 2003). Although the DNA 
titre of the treated sample was not significantly lower than one of the untreated samples 
(greater than logio 2), the number of infectious units, as determined by the infectivity 
assay, was reduced significantly by logio 5.15.
Finally, the Baxter INTERCEPT method (treatment with amotosalen S-59 and UVA), 
also known as the Helinx® technology, has been demonstrated to inactivate a variety of 
blood-borne pathogens, including viruses such as HIV, HBV, HCV (Sawyer et al.,
2003), West Nile virus and SARS coronavirus (Dupuis and Sampson-Johannes, 2003;
Sawyer et al., 2004) and murine CMV (Lin, 2001; Jordan et al., 2004). Bacteria (both
gram negative and positive) and protozoa such as Plasmodium falciparum (Dupuis et
al., 2003) or Trypanosoma cruzi (Van Voorhis et al., 2003) have also been shown to be
inactivated by amotosalen HCL (S-59) and ultraviolet light. However, apart from one
abstract recently submitted to the American Association of Blood Banks (AABB)
-395-
........................................................................................................................................................................Chapter IV
meeting (Hanson et al., 2004), there is no report to date on the efficacy of this method
on human parvovirus B19. The present collaborative study with Cerus Corporation
investigated the efficacy of this photochemical treatment on the inactivation of B19.
The results showed that the logio DNA concentration for the untreated and 3J treated
samples were 8.45 and 3.3, respectively. The infectivity titre for the untreated sample
was logio 6.8 whereas that of the treated sample was logio 2.8, resulting in a logio 4
reduction. Aliquots of the same untreated and treated 3J samples were also tested by
scientists at Cerus using an ELISpot assay (Dr. Kent Dupuis, personnel
communication). The virus reduction was comparable in both the ELISpot and the
infectivity assay developed in the present study. However, the latter seems to be more
sensitive than the ELISpot assay since it was able to detect more infectious particles in
both the untreated and 3J treated materials. The logio reduction was also more than logio
1 greater in the optimised infectivity assay compared with the ELISpot assay.
Unpublished data concerning B19 inactivation were obtained at Cerus and were kindly
communicated by Dr. K Dupuis and Dr. L Sawyer (CA, USA). The restriction linked to
inactivation of non-enveloped viruses such as B19 lies in the time necessary for
amotosalen S-59 to penetrate the virus capsid. The influence of a pre-incubation period
with S-59 prior to UVA illumination was thus investigated. The viable virus titres in
both untreated and treated infected platelet concentrates were evaluated by infection of
CD34+ cells and detection of their progeny by ELISpot assay. Data have shown that the
longer the pre-incubation period with amotosalen, the higher the mean logio reduction
(Hanson et al., 2004). When the sample was pre-incubated for less than 5 minutes, the
mean logi0 reduction was only 2.0 whereas it increased to 4.4 after 45 minutes and to
5.8 after 90 minutes pre-incubation with S-59. In comparison with the present study,
which did not include a pre-incubation period with S-59 prior to illumination with
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UVA, the logio reduction was only slightly lower than a sample pre-incubated for 90
minutes (logio 5.8) and almost equivalent to a 60 minutes pre-incubation period (logio
5.3). However, it was difficult to conclude on this comparison since the methods used to
determine viral infectivity were different: infection of CD34+ cells and ELISpot assay
in one case (Hanson et al. 2004) and infection of UT-7/EPO-S1 cells and RT-PCR assay
in the present experiment. In the latter, the sample was not deliberately pre-incubated
but the time between the addition of S-59 and UVA treatment was around 10-15
minutes. At the time this study was done, the pre-illumination data mentioned above
(Hanson et al., 2004) had not been obtained. Due to the divergence of results, further
work should be undertaken to investigate the exact role of a pre-exposure to S-59 and
whether it is a necessary step in the inactivation of B19.
Platelets constitute an essential component of the coagulation process and may be 
required by patients with bleeding disorders or those undergoing surgery, cancer 
chemotherapy, transplantation. Some of the concerns in introducing a viral inactivation 
step in the manufacture of any product with medicinal properties are the safety aspect as 
well as the retention of the functional characteristics of the treated product. In the case 
of platelet concentrates, both these aspects have been investigated regarding the 
implementation of the Helinx® technology in their preparation. Preclinical safety 
studies of treated platelets concentrates showed no specific target organ toxicity, 
reproductive toxicity or carcinogenicity was observed (Ciaravino, 2001; Ciaravi et al., 
2001). Moreover, the quality of platelet concentrates prepared from pooled buffy coats 
and treated by INTERCEPT (S-59 and UVA) was found compatible with that of 
untreated platelets for up to 7 days of storage (van Rhenen et al., 2000). In addition, a 
recent study reported only minor in vitro effects on the quality of treated platelets 
(Jansen et al., 2004).
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Taking into account that the inactivation rate by this method is related to genome size,
another limiting factor in the inactivation of B19 is the small size of its genome. Large
genomes such as those in leukocytes are indeed much more susceptible to inactivation
than are viruses, such as hepatitis B virus (HBV), which can be inactivated by more
than logio 5 (Wollowitz, 2001). Inactivation of parvovirus B19 (by logio 5.15 and 4)
therefore seemed comparable to that of HBV, which has, however, a smaller genome
than B19 (3.2 kb and 5.5 kb, respectively).
Although the INTERCEPT system appeared to be an efficient method for the 
inactivation of human parvovirus B19, the data obtained in the present experiment are 
preliminary and further research should be carried out to determine the optimum 
conditions that could be applied to blood-bank use.
The results of all the inactivation and removal protocols tested in the present study are 
summarized in table 4.1.
Table 4.1: Summary of virus inactivation/ removal data
PRT Logio reduction Treated product
Nanofiltration
>5 for 15N filter 
>6 for 20N filter
0.5% albumin
Dry heat
>2 after 24 hours 
Not detected after 72 hours
Factor VIII
Super critical fluids >5 Human plasma
PEN 110 (INACTINE™)
Not detected
RBCs storage solution
Psoralen S-59 >5 PBS
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Overall, chemical methods have the advantage that they can be used on cells which do
not have a nucleus (RBCs and platelets). However, the chemical introduced into the
product can potentially be toxic, mitotic or/and carcinogenic and all traces of it need to
be removed, adding another step to the inactivation process. Cell washing is usually
used to remove the chemical at the completion of the red cell treatment. Moreover,
recent press releases from Cerus (Cerus press release, 4 September 2003) and Vitex
(Vitex press release, 23rd November 2004) have exposed the issue of autoantibodies
production by some patients in their phase III clinical trials for S-303-treated RBCs and
INACTINE™-treated RBCs, respectively. Cerus announced that they halted their trials
when two patients who were enrolled indeed showed an antibody response but no
clinical adverse events after transfusion with the S-303 treated RBCs. Similarly, Vitex
announced that it was temporarily suspending enrolment in the ongoing Phase III
surgical study for the INACTINE™ pathogen inactivation system for red blood cells.
This decision was also made following identification of an immune response to treated
RBCs in one patient. Although no clinical consequences of the immune response were
apparent, potential modifications to the INACTINE™ treatment process which may
result in red cells with reduced immunogenicity have already been identified and the
revised process could potentially be ready for clinical trials in the second half of 2005.1
would personally be interested in following the progress of these future trials to find out
whether this improved chemical inactivation method can reduce the risk of
autoantibodies being produced.
On the other hand, physical methods of inactivation have the distinct advantage that no 
chemical is introduced in the treated product, thereby abolishing any risk for toxicity. 
However, theses processes cannot be used to treat cells (RBCs and platelets), which
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would be destroyed by such treatment. The fact that physical methods can only be used
on plasma products is indeed a limiting factor.
In conclusion, this work will enable a better evaluation and characterisation of 
established pathogen removal /inactivation techniques using B19 rather than a model 
virus which may have different properties. The selection of the viral inactivation and 
removal methods to be employed depends on the size and labile nature of the protein 
being prepared, the method(s) of purification the manufacturer wishes to use, and the 
nature and titre of viruses which are of concern. Each method of inactivation and 
removal has special characteristics which need to be taken into account. Whether one or 
more methods of inactivation and removal are used, in addition to viral safety, the 
maintenance of protein structure and function is equally important and must be 
evaluated thoroughly.
Because of its preliminary functions, the present study did not include testing of the 
final product to show whether the removal/inactivation procedure had affected its 
biological and medicinal properties. Further investigations should therefore evaluate 
the product tested before and after the removal/inactivation step. This test seems less 
relevant for a virus removal step by nanofiltration since the protein chosen to be spiked 
should be much smaller than the filter pore size.
As far as the established infectivity assay is concerned, its uses are various. As
mentioned above, further viral inactivation studies should be performed using this assay
to evaluate the efficacy of the technique. In addition, considering the greater incidence
and the possible impact of human parvovirus variants on blood products safety, this
infectivity assay could be utilised to determine whether such variants might be
potentially infectious. It might also be of interest to compare the behaviour of
-400-
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parvovirus variants with that of B19 as far as viral inactivation is concerned. Although
they might be unlikely to differ from B19 when novel inactivation methods are
involved, such as INACTINE™, Helinx®, and Superfluids™, they might show
different properties when physical inactivation such as dry-heat is applied.
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Appendix 1: BFU-E reduction assay results
Table A l.l: BFU-E reduction assay results for patient 1 (a)
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient laWell 1 Well 2 Well 3
Well
4 Total
Control 45 43 37 43 168 N/A
lxlO1* 21 22 19 23 85 49.40
1x10” 25 22 29 23 99 41.07
1x10* 25 32 18 27 102 39.29
1x10” 34 28 28 23 113 32.74
lxlO8 35 29 41 20 125 25.60
1x10” 38 27 26 32 123 26.79
lxlO7 43 45 27 41 156 7.14
Table A1.2: BFU-E reduction assay results for patient 1 (b)
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient lbWell 1 Well 2 Well 3
Well
4 Total
Control 20 19 24 18 81 N/A
lxlO10'5 0 0 0 0 0 100.00
lx l0 lu 3 1 1 0 5 93.83
1x10” 6 7 8 9 30 62.96
1x10* 8 9 12 10 39 51.85
lxlO8'5 13 10 6 12 41 49.38
1x10s 9 7 11 11 38 53.09
Table A1.3: BFU-E reduction assay results for patient 2
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient 2Well 1 Well 2 Well 3
Well
4 Total
Control 124 110 112 118 464 N/A
lxlO1” 33 16 30 26 105 77.37
lxlO10 36 21 33 39 129 72.20
1x10” 60 46 46 61 213 54.09
1x10* 66 50 53 70 239 48.49
1x10” 80 77 61 65 283 39.01
1x10s 62 78 76 65 281 39.44
1x10” 98 92 92 102 384 17.24
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Table A1.4: BFU-E reduction assay results for patient 3
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient 3Well 1 Well 2 Well 3
Well
4 Total
Control 33 38 43 41 155 N/A
Control 42 41 37 39 159 N/A
Control
mean 37.5 39.5 40 40 157 N/A
lxlO11 0 0 0 0 0 100.00
lxlO10'5 0 0 0 0 0 100.00
lxlO10 3 1 1 2 7 95.54
lxlO9'5 10 13 12 13 48 69.43
lxlO9 22 17 18 19 76 51.59
1x10s5 37 35 31 30 133 15.29
Table A1.5: BFU-E reduction assay results for patient 4
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient 4Well 1 Well 2 Well 3
Well
4 Total
Control 34 25 23 29 28 N/A
Control 28 23 20 22 93 N/A
Control
mean 31 24 21.5 25.5 102 N/A
1x10“ 0 0 0 0 0 100.00
lxlO105 0 0 0 0 0 100.00
lxlO10 2 1 2 1 6 94.12
lxlO95 3 3 4 2 12 88.24
lxlO9 14 19 15 25 73 28.43
lxlO8'5 27 25 20 26 98 3.92
Table A1.6: BFU-E reduction assay results for patient 5
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient 5Well 1 Well 2 Well 3
Well
4 Total
Control 3 3 9 10 25 N/A
lxlO12 0 0 0 0 0 100.00
lxlO115 0 0 0 0 0 100.00
1x10" 0 0 0 0 0 100.00
lxlO10'5 0 0 0 0 0 100.00
lx l0 ‘u 0 0 0 0 0 100.00
lxlO95 2 1 0 2 5 80.00
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Table A1.7: BFU-E reduction assay results for patient 6
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient 6Well 1 Well 2 Well 3
Well
4 Total
Control 84 79 105 92 360 N/A
lxlO12 0 0 0 0 0 100.00
lxlO115 0 0 0 0 0 100.00
1x10“ 0 0 0 0 0 100.00
lxlO10'5 0 2 0 3 5 98.61
lxlOlu 34 39 31 40 144 60.00
Table A1.8: BFU-E reduction assay results for patient 7
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient 7Well 1 Well 2 Well 3
Well
4 Total
Control 95 110 91 86 382 N/A
lxlO '2 0 0 0 0 0 100.00
lxlO"'5 1 0 0 0 1 99.74
1x10" 79 90 109 102 380 0.52
lxlO105 N/A N/A 70 82 N/A N/A
lxlO10 67 69 110 123 369 3.40
Table A1.9: BFU-E reduction assay results for patient 8
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient 8Well 1 Well 2 Well 3
Well
4 Total
Control 103 112 97 107 419 N/A
lxlO12 0 0 0 0 0 100.00
lxlO11'5 0 0 0 0 0 100.00
1x10" 0 0 0 1 1 99.76
lxlO105 11 9 6 11 37 91.17
1x10'° 46 29 36 28 139 66.83
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Table A1.10: BFU-E reduction assay results for patient 9
Inoculum
(IU/ml)
Red colony count Percentage BFU-E 
reduction 
Patient 9Well 1 Well 2 Well 3
Well
4 Total
Control 36 21 28 25 110 N/A
Control 28 16 26 21 91 N/A
Control
mean 32 18.5 27 23 100.5 N/A
lx l0 lu 7 9 9 6 31 69.15
lxlO95 16 13 18 12 59 41.29
lxlO9 25 17 19 11 72 28.36in00OHX 20 17 16 N/A N/A N/A
1x10s 23 19 25 18 85 15.42
1x10° 12 27 19 22 80 20.40
Table A l.ll:  BFU-E reduction assay results for patient 10 (a and b)
Inoculum 
(IU/ml) 
Patient 10a
Rec colony count Percentage BFU-E 
reduction 
Patient 10aWell 1 Well 2 Well 3
Well
4 Total
Control 68 87 56 58 269 N/A
1x10“ 0 0 0 0 0 100.00
1x10'" 1 0 0 4 5 98.14
1x10'° 12 11 17 13 53 80.30
1x10" 28 36 32 33 129 52.04
lxlO9 43 38 41 40 162 39.78
X H-* o 0
0 L* 67 52 60 54 233 13.38
Inoculum 
(IU/ml) 
Patient 10b
Rec colony count Percentage BFU-E 
reduction 
Patient 10bWell 1
Well
2 Well 3
Well
4 Total
Control 56 65 61 58 240 N/A
1x10“ 0 0 0 0 0 100.00
lxlO1" 0 0 0 0 0 100.00
lxlO10 3 0 0 0 3 98.75
1x10" 12 9 3 4 28 88.33
lxlO9 30 19 10 15 74 69.17
1x10s5 23 29 19 36 107 55.42
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Table A1.12: BFU-E reduction assay results for patient 11
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 11Well 1 Well 2 Well 3
Well
4 Total
Control 3 6 7 6 22 N/A
1x10“ 0 0 0 0 0 100.00
lxlO1*'5 0 0 0 0 0 100.00
lxlO10 0 0 0 0 0 100.00
1x10“ 0 0 0 0 0 100.00
lxlO9 1 0 0 0 1 95.45
lxlO85 7 6 5 7 25 0.00
Table A1.13: BFU-E reduction assay results for patient 12
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 12Well 1 Well 2 Well 3
Well
4 Total
Control 7 11 8 12 38 N/A
1x10“ 0 0 0 0 0 100.00
lxlO10'5 0 0 0 0 0 100.00
lx l0 lu 0 0 0 0 0 100.00
1x10“ 2 0 2 2 6 84.21
lxlO9 3 1 4 6 14 63.16
1x10“ 11 3 11 12 37 2.63
Table A1.14: BFU-E reduction assay results for patient 13
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 13Well 1 Well 2 Well 3
Well
4 Total
Control 90 96 92 94 372 N/A
1x10“ 4 5 7 5 21 94.35
lxlO9 12 16 17 11 56 84.95
1x10“ 18 21 31 13 83 77.69
lxlO8 25 36 33 23 117 68.55
lxlO7'5 27 38 35 39 139 62.63
lxlO7 50 37 38 32 157 57.80
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Table A1.15: BFU-E reduction assay results for patient 14
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 14Well 1 Well 2 Well 3
Well
4 Total
Control 33 35 27 48 143 N/A
Control 53 35 31 25 144 N/A
Control
mean 43 35 29 36.5 143.5 N/A
lxlO11'5 0 0 0 0 0 100.00
lxlO11 0 0 0 0 0 100.00
1x10*” 3 0 1 1 5 96.52
lxlO10 9 5 4 7 25 82.58
1x10” 14 16 11 10 51 64.46
lxlO9 14 13 18 21 66 54.01
1x10” 15 24 24 21 84 41.46
1x10s 21 20 17 23 81 43.55
lxlO7 5 34 35 42 38 149 0.00
1x10' 28 22 37 29 116 19.16
1x10” 45 51 48 37 181 0.00
1x10" 39 40 40 43 162 0.00
Table A1.16: BFU-E reduction assay results for patient 15
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 15Well 1
Well
2
Well
3
Well
4 Total
Control 27 34 36 35 132 N/A
Control 23 40 41 24 128 N/A
Control mean 25 37 38.5 29.5 130 N/A
1x10” 6 6 3 8 23 82.31
lxlO9 15 21 18 18 72 44.62
1x10” 25 15 24 15 79 39.23
1x10s 26 17 20 22 85 34.62
lxlO” 39 28 31 18 116 10.77
1x10' 34 37 46 19 136 0.00
1x10” 26 43 24 17 n o 15.38
lxlO6 49 36 . 24 48 157 0.00
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Table A1.17: BFU-E reduction assay results for patient 16
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 16Well 1 Well 2
Well
3
Well
4 Total
Control 45 60 54 42 201 N/A
lxlO85 32 24 17 35 108 46.27
lxlO8 37 24 30 29 120 40.30
lxlO7'3 24 43 42 41 150 25.37
lx lO " 36 33 40 31 140 30.35
lxlO3 40 40 36 38 154 23.38
Table A1.18: BFU-E reduction assay results for patient 17
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 17Well 1 Well 2
Well
3
Well
4 Total
Control 112 123 118 108 461 N/A
lxlO75 63 77 66 93 299 35.14
1x10' 53 43 48 64 208 54.88
1x10°3 73 66 95 71 305 33.84
1x10° 92 89 74 72 327 29.07
Table A1.19: BFU-E reduction assay results for patient 18
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 18Well 1 Well 2
Well
3
Well
4 Total
Control 82 90 95 95 362 N/A
Control 67 69 71 73 280 N/A
Control mean 74.5 79.5 83 84 321 N/A
lxlO11'3 0 0 0 0 0 100.00
1x10" 0 0 0 0 0 100.00
lxlO10'3 21 2 7 7 37 88.47
lxlO10 36 6 19 26 87 72.90
lxlO*3 105 56 67 85 313 2.49
1x10* 92 97 105 97 391 0.00
lxlO8'3 68 120 73 75 336 0.00
1x10s 64 73 49 87 273 14.95
lx lO '3 67 58 57 67 249 22.43
1x10' 74 84 67 66 291 9.35
lxlO03 81 58 73 68 280 12.77
1x10° 86 93 62 70 311 3.12
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Table A1.20: BFU-E reduction assay results for patient 19
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 19Well 1 Well 2
Well
3
Well
4 Total
Control 36 27 35 31 129 N/A
lxlO85 28 23 30 18 99 23.26
1x10s 28 25 33 27 113 12.40
lxlO7'5 23 10 19 38 90 30.23
lxlO7 23 25 19 22 89 31.01
lxlO65 24 23 23 39 109 15.50
1x10° 31 24 29 15 99 23.26
Table A1.21: BFU-E reduction assay results for patient 20
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 20Well 1 Well 2
Well
3
Well
4 Total
Control 115 84 71 116 386 N/A
lxlO8'3 20 26 28 31 105 72.80
1x10s 24 27 34 42 127 67.10
lxlO7'3 28 34 38 52 152 60.62
lxlO7 60 46 52 105 263 31.87
lxlO63 99 65 73 108 345 10.62
1x10° 114 112 104 105 435 0.00
Table A1.22: BFU-E reduction assay results for patient 21
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 21Well 1
Well
2 Well 3
Well
4 Total
Control 18 21 20 33 92 N/A
Control 10 9 6 9 34 N/A
Control mean 14 15 13 21 63 N/A
lxlO73 1 3 5 10 19 69.84
lxlO7 7 2 4 10 23 63.49
lxlO63 16 5 4 17 42 33.33
lxlO6 7 10 12 19 48 23.81
1x10“ 27 13 17 12 69 0.00
lxlO3 30 18 23 15 86 0.00
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Table A1.23: BFU-E reduction assay results for patient 22
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 22Well 1
Well
2 Well 3
Well
4 Total
Control 38 21 33 24 116 N/A
Control 22 19 33 23 97 N/A
Control mean 30 20 33 23.5 106.5 N/A
lxlO '3 9 10 18 18 55 48.36
lxlO7 11 11 12 11 45 57.75
1x10“ 24 15 15 18 72 32.39
lxlO6 20 14 18 24 76 28.64
1x10“ 20 18 23 21 82 23.00
lxlO3 19 23 13 27 82 23.00
Table A1.24: BFU-E reduction assay results for patient 23
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 23Well 1
Well
2 Well 3
Well
4 Total
Control 47 40 28 20 135 N/A
Control 30 23 32 31 116 N/A
Control mean 38.5 31.5 30 25.5 125.5 N/A
lx l0 ° 39 14 24 21 98 21.91
lxlO7 21 20 27 28 96 23.51
1x10“ 28 31 20 39 118 5.98
lxlO6 34 29 31 35 129 0.00
1x10“ 29 21 28 35 113 9.96
lxlO3 32 31 31 28 122 2.79
Table A1.25: BFU-E reduction assay results for patient 24
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 24Well 1
Well
2 Well 3
Well
4 Total
Control 34 40 21 31 126 N/A
Control 29 41 36 21 127 N/A
Control mean 31.5 40.5 28.5 26 126.5 N/A
>T H—* o OC 19 37 27 27 110 13.04
lxlO75 23 28 33 37 121 4.35
lxlO7 26 33 29 24 112 11.46
1x10“ 29 33 25 53 140 0.00
1x10° 44 41 34 42 161 0.00
1x10“ 30 48 41 31 150 0.00
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Table A1.26: BFU-E reduction assay results for patient 25
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 25Well 1
Well
2 Well 3
Well
4 Total
Control 85 46 51 38 220 N/A
Control 35 38 38 50 161 N/A
Control mean 60 42 44.5 44 190.5 N/A
lxlO8 33 35 35 36 27.03 27.03
lxlO7'5 35 33 27 40 29.13 29.13
1x10' 39 23 31 49 25.46 25.46
lxlO65 37 29 28 55 21.78 21.78
lxlO6 38 35 23 29 34.38 34.38
lxlO53 53 40 39 31 14.44 14.44
Table A1.27: BFU-E reduction assay results for patient 26
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 26Well 1 Well 2 Well 3
Well
4 Total
Control 29 29 56 38 152 N/A
Control 32 36 45 28 141 N/A
Control mean 30.5 32.5 50.5 33 146.5 N/A
lxlO8 41 16 29 43 129 11.95
lxlO75 24 12 8 24 68 53.58
1x10' 24 19 28 28 99 32.42
lxlO65 27 14 28 26 95 35.15
lxlO5 26 21 20 29 96 34.47
lxlO55 38 23 35 35 131 10.58
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Table A1.28: BFU-E reduction assay results for patient 27
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 27Well 1 Well 2 Well 3
Well
4 Total
Control 13 7 10 6 36 N/A
Control 7 5 2 6 20 N/A
Control mean 10 6 6 6 28 N/A
lxlO10 3 1 0 1 5 82.14
lxlO95 4 1 1 3 9 67.86
lxlO9 3 3 1 2 9 67.86
lxlO85 5 1 2 7 15 46.43
lxlO8 5 7 7 2 21 25.00
lxlO73 4 3 5 8 20 28.57
1x10' 7 4 5 11 27 3.57
lxlO33 3 6 0 3 12 57.14
1x10” 7 7 4 7 25 10.71
lxlO3'3 5 3 9 4 21 25.00
lxlO3 4 5 4 4 17 39.29
Table A1.29: BFU-E reduction assay results for patient 28
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 28Well 1 Well 2 Well 3
Well
4 Total
Control 21 18 11 12 62 N/A
Control 15 24 20 23 82 N/A
Control mean 18 21 15.5 17.5 72 N/A
lxlO9 14 12 20 20 66 8.33
lxlO8'5 7 10 11 19 47 0.00
>T o o
c
15 14 12 14 55 0.00
lxlO7'5 7 4 12 12 35 0.00
lxlO7 8 3 1 5 17 39.29
lxlO6'3 9 6 7 6 28 0.00
lxlO6 12 13 8 13 46 0.00
lxlO33 13 12 11 5 41 0.00
lxlO3 10 13 15 20 58 0.00
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Table A1.30: BFU-E reduction assay results for patient 29
Inoculum
(IU/ml)
Rec colony count Percentage BFU- 
E reduction 
Patient 29Well 1 Well 2 Well 3
Well
4 Total
Control 88 65 110 65 328 N/A
Control 68 99 79 105 351 N/A
Control mean 78 82 94.5 85 339.5 N/A
lxlO1” 4 4 8 11 27 92.05
lxlO10 28 35 36 33 132 61.12
1x10” 43 43 34 45 165 51.40
lxlO9 54 64 52 62 232 31.66
1x10” 72 61 57 67 257 24.30
1x10s 44 61 46 71 222 34.61
1x10” 77 84 85 63 309 8.98
1x10' 87 84 62 87 320 5.74
1x10” 75 85 82 81 323 4.86
lxlOb 81 99 89 70 339 0.15
1x10” 93 85 84 94 356 0.00
Table A1.31: BFU-E reduction assay results for patient 30
Inoculum
(IU/ml)
Red colony count Percentage BFU- 
E reduction 
Patient 30Well 1 Well 2 Well 3
Well
4 Total
Control 48 49 44 38 179 N/A
Control 30 34 28 27 119 N/A
Control mean 39 41.5 36 32.5 149 N/A
lxlO17 0 0 0 0 0 100.00
lxlO11'5 0 0 0 0 0 100.00
1x10" 0 0 1 0 1 99.33
lxlO10'5 7 8 2 8 25 83.22
lx l0 lu 20 19 21 23 83 44.30
1x10” 23 23 23 23 92 38.26
lxlO9 34 27 33 21 115 22.82
1x10” 37 21 26 22 106 28.86
1x10s 26 28 33 36 123 17.45
1x10” 36 35 31 33 135 9.40
lxlO7 43 34 37 38 152 0.00
1x10” 47 38 42 40 167 0.00
lxlO” 50 29 40 40 159 0.00
1x10” 33 49 43 41 166 0.00
lxlO3 55 36 40 35 166 0.00
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Appendix 3: PCR data for viral removal study and RT-PCR data for 
viral inactivation studies
1. Planova study
Figure A3.1: LightCycler PCR products for Planova experimental controls and 
samples 1 to 13 (first 15N filter)
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 M
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 4: IS (99/686, positive control) 5. RNAase-free water (PCR negative control)
1. lxlO60 IU/ml Lanes 6 to 8: Extraction negative controls
2. lxlO50IU/ml 6. Negative plasma
3. lxlO 40IU/ml 7. Negative serum
4. lxlO 30 IU/ml 8. RNAase-free water
Lanes 9 to 16: Planova experimental controls Lanes 17 to 23: Planova samples
9. Sample A1 neat 17. Sample 1 neat
10. Sample A2 neat 18. Sample 3 neat
11. Sample B 1 neat 19. Sample 5 neat
12. Sample B2 neat 20. Sample 7 neat
13. Sample Cl neat 21. Sample 9 neat
14. Sample C2 neat 22. Sample 11 neat
15. Sample D1 neat 23. Sample 13 neat
16. Sample D2 neat
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Figure A3.2: LightCycler PCR products for Planova samples 17 to 41 (first 15N
filter)
M 1 2 3 4 5 6 7 9 10 11 12 13 14 15 16 17 18 M 19 20 21 22 23
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 4: IS (99/686, positive control)
1. lxlO60 IU/ml
2. lxlO50IU/ml
3. 1 x 104 0 IU/ml
4. 1 x 103 0 IU/ml
5. RNAase-free water (PCR negative control) 
Lanes 10 to 23: Planova samples
10. Sample 15 neat
11. Sample 17 neat
12. Sample 19 neat
13. Sample 21 neat
14. Sample 23 neat
15. Sample 25 neat
16. Sample 27 neat
Lanes 6 to 9: Extraction negative controls
6. Negative plasma
7. Negative serum
8. RNAase-free water
9. RNAase-free water
17. Sample 29 neat
18. Sample 31 neat
19. Sample 33 neat
20. Sample 35 neat
21. Sample 37 neat
22. Sample 39 neat
23. Sample 41 neat
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Figure A3.3: LightCycler PCR products for Planova samples 17 to 41 (first 15N
filter)
M 1 2 3 4 5 6 7 8 9 10 11 12 13 M 14 15 16 17 18 19 20 21 22 23
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 4: IS (99/686, positive control)
1. lxlO60 IU/ml
2. lx l0 50 IU/ml
3. 1 x 104 0 IU/ml
4. lxlO30 IU/ml
5. RNAase-free water (PCR negative control) 
Lanes 10 to 23: Planova samples
10. Sample 43 neat
11. Sample 44 neat
12. Sample 46 neat
13. Sample 48 neat
14. Sample 50 neat
15. Sample 52 neat
16. Sample 54 neat
Lanes 6 to 9: Extraction negative controls
6. Negative plasma
7. Negative serum
8. RNAase-free water
9. RNAase-free water
17. Sample 56 neat
18. Sample 58 neat
19. Sample 60 neat
20. Sample 62 neat
21. Sample 64 neat
22. Sample 66 neat
23. Sample 68 neat
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Figure A3.4: LightCycler PCR products for Planova samples 68 to 86 (second 15N
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
M 1 2 3 4 5 6
filter)
7 8 9 10 11 12 13 14 15 16 17
, *4, ■■ ■  1 '
Lane M. PCR markers
Lanes 1 to 4: IS (99/800, positive control)
1. lxlO 60 IU/ml
2. lxlO50 IU/ml
3. lxlO40 IU/ml
4. lxlO30 IU/ml
Lanes 8 to 17: Planova samples
8. Sample 68 neat
9. Sample 70 neat
10. Sample 72 neat
11. Sample 74 neat
12. Sample 76 neat
5. RNAase-free water (PCR negative control)
6. Negative plasma (extraction negative control)
7. Positive control (2x l03 IU/ml)
13. Sample 78 neat
14. Sample 80 neat
15. Sample 82 neat
16. Sample 84 neat
17. Sample 86 neat
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Figure A3.5: LightCycler PCR products for Planova samples 87 to 107 (first 20N
filter)
M l  2 3 4 5 6 7 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 M
,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 4: IS (99/800, positive control)
1. lxlO 60IU/ml
2. lxlO50IU/ml
3. lxlO40IU/ml
4. lxlO 30 IU/ml
5. RNAase-free water (PCR negative control) 
Lanes 6 to 9: IS (99/800, positive control)
6. lxlO60 IU/ml
7. lxlO 50 IU/ml
8. lxlO40 IU/ml
9. lxlO 30 IU/ml
Lanes 14 to 24: Planova samples
14. Sample 87 neat
15. Sample 89 neat
16. Sample 91 neat
17. Sample 93 neat
18. Sample 95 neat
19. Sample 97 neat
Lanes 10 to 13: Extraction negative controls
10. Negative plasma
11. Negative serum
12. RNAase-free water
13. RNAase-free water
20. Sample 99 neat
21. Sample 101 neat
22. Sample 103 neat
23. Sample 105 neat
24. Sample 107 neat
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Figure A3.6: LightCycler PCR products for Planova samples 109 to 130 (first and
second 20N filters)
M 1 2 3 4 5 6 7 x 9 x 11 12 13 M 14 15 16 17 18 19 20 21 22 23 24 25
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 4: IS (99/800, positive control)
lxlO 60 IU/ml
2. lxlO 50 IU/ml
3. lxlO40IU/ml
4. lxlO 30 IU/ml
5. RNAase-free water (PCR negative control) 
Lanes 6 to 9: IS (99/800, positive control)
6. lxlO60 IU/ml
7. lxlO50 IU/ml
9. lxlO30IU/ml
Lanes 14 to 25: Planova samples
14. Sample 109 neat
15. Sample 111 neat
16. Sample 113 neat
17. Sample 115 neat
18. Sample 117 neat
19. Sample 119 neat
x: no sample
Lanes 11 to 13: Extraction negative controlsl.
11. Negative serum
12. RNAase-free water
13. RNAase-free water
20. Sample 121 neat
21. Sample 123 neat
22. Sample 125 neat
23. Sample 127 neat
24. Sample 129 neat
25. Sample 130 neat (second 20N filter)
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Figure A3.7: LightCycler PCR products for Planova samples 132 to 154 (second
20N filter)
M l  2 3 4 5 6 7 8 9 10 11 12 13 M 14 15 16 17 18 19 20 21 22 23 24 25
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 4: IS (99/800, positive control)
1. lxlO 60 IU/ml
2. lxlO 50 IU/ml
3. lxlO40 IU/ml
4. lxlO 30IU/ml
5. RNAase-free water (PCR negative control) 
Lanes 6 to 9: IS (99/800, positive control)
6. lxlO60 IU/ml
7. lxlO 50 IU/ml
8. lx l0 40 IU/ml
9. lxlO 30 IU/ml
Lanes 14 to 25: Planova samples
14. Sample 132 neat
15. Sample 134 neat
16. Sample 136 neat
17. Sample 138 neat
18. Sample 140 neat
19. Sample 142 neat
Lanes 10 to 13: Extraction negative controls
10. Negative plasma
11. Negative serum
12. RNAase-free water
13. RNAase-free water
20. Sample 144 neat
21. Sample 146 neat
22. Sample 148 neat
23. Sample 150 neat
24. Sample 152 neat
25. Sample 154 neat
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Figure A3.8: LightCycler PCR products for Planova samples 156 to 173 (second
20N and third 15N filter)
M l  2 3 4 5 6 7 8 9 10 11 12 13 M 14 15 16 17 18 19 20 21 22 23
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 4: IS (99/800, positive control)
1. lxlO 60 IU/ml
2. lxlO50 IU/ml
3. lxlO40 IU/ml
4. lxlO30 IU/ml
5. RNAase-free water (PCR negative control) 
Lanes 6 to 9: IS (99/800, positive control)
6. IxlO60 IU/ml
7. lxlO50 IU/ml
8. lxlO40 IU/ml
9. lxlO 30 IU/ml
Lanes 14 to 25: Planova samples
14. Sample 156 neat
15. Sample 158 neat
16. Sample 160 neat
17. Sample 162 neat
18. Sample 164 neat
Lanes 10 to 13: Extraction negative controls
10. Negative plasma
11. Negative serum
12. RNAase-free water
13. RNAase-free water
19. Sample 166 neat
20. Sample 168 neat
21. Sample 170 neat
22. Sample 172 neat
23. Sample 173 neat (third 15N fdter)
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Figure A3.9: LightCycler PCR products for Planova samples 175 and 177 (third
15N filter)
M  1 2  3 4  5 6  7
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 4: IS (99/800, positive control)
1. lxlO60 IU/ml
2. lxlO50 IU/ml
3. lxlO40 IU/ml
4. lxlO30 IU/ml
5. RNAase-free water (PCR negative control)
Lanes 6 and 7: Planova samples
6. Sample 175 neat
7. Sample 177 neat
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Figure A3.10: LightCycler PCR products for Planova samples 179 to 215 (third
15N filter)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 M M 18 19 20 21 22 23 24 25 26 27 28 29 30 31
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 4: IS (99/800, positive control)
1. lxlO60 IU/ml
2. lxlO 50 IU/ml
3. lxlO40IU/ml
4. lx l0 30 IU/ml
5. RNAase-free water (PCR negative control) 
Lanes 6 to 9: IS (99/800, positive control)
6. lxlO60 IU/ml
7. lxlO50IU/ml
8. lxlO40IU/ml
9. lxlO30IU/ml
Lanes 13 to 31: Planova samples
13. Sample 179 neat
14. Sample 181 neat
15. Sample 183 neat
16. Sample 185 neat
17. Sample 187 neat
18. Sample 189 neat
19. Sample 191 neat
20. Sample 193 neat
21. Sample 195 neat
22. Sample 197 neat
Lanes 10 to 12: Extraction negative controls
10. Negative plasma
11. Negative serum
12. RNAase-free water
23. Sample 199 neat
24. Sample 201 neat
25. Sample 203 neat
26. Sample 205 neat
27. Sample 207 neat
28. Sample 209 neat
29. Sample 211 neat
30. Sample 213 neat
31. Sample 215 neat
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Figure A3.ll: LightCycler PCR products for Planova samples 246 to 258 (third
20N filter)
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Lane M. PCR markers
Lanes 1 to 4: IS (99/800, positive control)
1. lxlO60 IU/ml
2. lxlO 50 IU/ml
3. I x 104 0 IU/ml
4. lxlO30 IU/ml
5. RNAase-free water (PCR negative control) 
Lanes 6 to 9: IS (99/800, positive control)
6. lxlO60 IU/ml
7. lxlO 50 IU/ml
8. lxlO40 IU/ml
9. lxlO30 IU/ml
Lanes 13 to 19: Plano va samples
13. Sample 246 neat
14. Sample 248 neat
15. Sample 250 neat
16. Sample 252 neat
Lanes 10 to 12: Extraction negative controls
10. Negative plasma
11. Negative serum
12. RNAase-free water
17. Sample 254 neat
18. Sample 256 neat
19. Sample 258 neat
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Figure A3.12: Infectivity assay results for BPL spiked product control
M l  2 3 4 5  6 7 8 M  9 10 11 12 13 14 15 16 17 18
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l0 8 0 IU/ml inoculum
2. 5x l075 IU/ml inoculum
3. 5xl()7 0 IU/ml inoculum
4. 5 x l065 IU/ml inoculum
5. 5x10(> 0 IU/ml inoculum
6. 5x10s 5 IU/ml inoculum
7. 5xlOs o IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 and 18: RT-PCR positive controls
16. 5x l07 0 IU/ml inoculum
17. RNAase-free water
Lanes 9 to 16: BPL spiked product control
9. 4x l0 9 0 IU/ml inoculum
10. 4 x l0 8 5 IU/ml inoculum
11.4x108 0 IU/ml inoculum
12. 4x107 :i IU/ml inoculum
13. 4 x l0 7 0 IU/ml inoculum
14. 4 x l065 IU/ml inoculum
15. 4 x l060 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.13: Infectivity assay results for BPL spiked medium control and spiked
test sample 1
M I 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M 17 18 19 20 21 22 23 24 25 26
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l0 80 IU/ml inoculum
2. 5 x l0 75 IU/ml inoculum
3. 5x l070 IU/ml inoculum
4. 5x1065 IU/ml inoculum
5. 5x10W) IU/ml inoculum
6. 5 x l055 IU/ml inoculum
7. 5 x l050 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: BPL spiked test sample 1
17. 1.5xl070 IU/ml inoculum
18. 1.5xl065 IU/ml inoculum
19. 1.5xl06 0 IU/ml inoculum
20. 1,5xl05 5 IU/ml inoculum
21. 1.5xl050 IU/ml inoculum
22. 1.5x104 5 IU/ml inoculum
23. 1.5x104'0 IU/ml inoculum
Lanes 9 to 16: BPL spiked medium control
9. 4 x l0 7 0 IU/ml inoculum
10. 4x l0 6'5 IU/ml inoculum
11.4x1060 IU/ml inoculum
12. 4x l0 5'5 IU/ml inoculum
13. 4x 105 0 IU/ml inoculum
14. 4x l0 4 5 IU/ml inoculum
15. 4x l040 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. 5x l0 80 IU/ml inoculum
26. RNAase-free water
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Figure A3.14: Infectivity assay results for BPL spiked test sample 2
M l  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l0 8 0 IU/ml inoculum
2. 5 x l07 5 IU/ml inoculum
3. 5 x l0 7 0 IU/ml inoculum
4. 5x106 5 IU/ml inoculum
5. 5x l0 (,n IU/ml inoculum
6. 5xl()ss IU/ml inoculum
7. 5x l0 50 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 and 18: RT-PCR positive controls
17. 5x1070 IU/ml inoculum
18. RNAase-free water
Lanes 9 to 16: BPL spiked test sample 2
9. 2.7x1080 IU/ml inoculum
10. 2 .7xl07 5 IU/ml inoculum
11. 2 .7xl07 0 IU/ml inoculum
12. 2.7x106'5 IU/ml inoculum
13. 2 .7xl06 0 IU/ml inoculum
14. 2.7x105 5 IU/ml inoculum
15. 2 .7xl05 0 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.15: Infectivity assay results for BPL spiked test sample 3
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l0 8 0 IU/ml inoculum
2. 5x l075 IU/ml inoculum
3. 5x l070 IU/ml inoculum
4. 5x106 5 IU/ml inoculum
5. 5x l060 IU/ml inoculum
6. 5x10^ IU/ml inoculum
7. 5 x l0 5 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 13 and 14: RT-PCR positive controls
13. 5 x l070 IU/ml inoculum
14. RNAase-free water
Lanes 9 to 12: BPL spiked test sample 3
9. 3.1x1090 IU/ml inoculum
10. 3.1x108 5 IU/ml inoculum
11.3.1x108 0 IU/ml inoculum
12. Phosphate buffer pH 5.7
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Figure A3.16: Infectivity assay results for BPL unspiked 8Y product
M 1 2 3 4 5 6 7 8 M 9 10 11 12 13 14 15 16
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l0 8 0 IU/ml inoculum
2. 5x 107 ? IU/ml inoculum
3. 5x l07 0 IU/ml inoculum
4. 5x l0 6 5 IU/ml inoculum
5. 5x l060 IU/ml inoculum
6. 5x l0 5 5 IU/ml inoculum
7. 5x l0 50 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 15 and 16: RT-PCR positive controls
17. 5x l0 8 0 IU/ml inoculum
18. RNAase-free water
Lanes 9 to 16: BPL unspiked 8Y product
9. 3x l04 0 IU/ml inoculum
10. 3x l035 IU/ml inoculum
11. 3x l030 IU/ml inoculum
12. 3 x l02r' IU/ml inoculum
13. 3 x l020 IU/ml inoculum
14. Phosphate buffer pH 5.7
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3. Aphios study 
.  NIBSC-01
Figure A3.17: Infectivity assay results for NIBSC-01 “before” (panel A) and CFI- 
treated #1 sam ples (panel B)
(A) (B)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M M 17 18 19 20 21 22 23 24 25 26
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1.5x107 0 IU/ml inoculum
2. 5x l0 65 IU/ml inoculum
3. 5x l0 60 IU/ml inoculum
4. 5x l05 5 IU/ml inoculum
5. 5x l05 0 IU/ml inoculum
6. 5x104 :i IU/ml inoculum
7. 5x104 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-01 CFI-treated #1
17. 5 x l090 IU/ml inoculum
18. 5x108 7 IU/ml inoculum
19. 5x108 0 IU/ml inoculum
20. 5x107 5 IU/ml inoculum
21. 5x l0 70 IU/ml inoculum
22. 5x l0 65 IU/ml inoculum
23. 5x l0 6 0 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-01 “before”
9. lx l 09 0 IU/ml inoculum
10. 1 x 108 5 IU/ml inoculum
11. lx l 08 0 IU/ml inoculum
12. Ix l0 7ri IU/ml inoculum
13. lx l0 70 IU/ml inoculum
14. lx l0 6  ^ IU/ml inoculum
15. lx l0 60 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. lxlO 80 IU/ml inoculum
26. RNAase-free water
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Figure A3.18: Infectivity assay results for NIBSC-01 CFI-treated #2 sam ples
(panels A and B)
(A) (B)
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M M 17 18 19 20 21 22 23 24 25 26
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l07 0 IU/ml inoculum
2. 5 x l06 5 IU/ml inoculum
3. 5x1 ()6'° IU/ml inoculum
4. 5xl()5 5 IU/ml inoculum
5. 5x l0 50 IU/ml inoculum
6. 5x l0 4"-' IU/ml inoculum
7. 5x l0 4() IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-01 CFI-treated #2
17. 6 x l09 0 IU/ml inoculum
18. 6 x l0 85 IU/ml inoculum
19. 6x1080 IU/ml inoculum
20. 6x l0 7 5 IU/ml inoculum
21. 6x l0 70 IU/ml inoculum
22. 6 x l0 65 IU/ml inoculum
23. 6x 1060 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-01 CFI-treated #2
9. 3x l090 IU/ml inoculum
10. 3x l08 5 IU/ml inoculum 
1 1.3x108 0 IU/ml inoculum
12. 3x l07 5 IU/ml inoculum
13. 3x l07 0 IU/ml inoculum
14. 3x l065 IU/ml inoculum
15. 3x l060 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. lxlO70 IU/ml inoculum
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Figure A3.19: Infectivity assay results for NIBSC-01 C FI-treated #3 (panel A) and  
“tim e and tem perature” sam ples (panel B)
(A)
M l  2 3 4 5 6 7 9 10 11 12 13 14 15 16 M
(B)
M 17 18 19 20 21 22 23 24 25 26
l.OOObp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l0 7 0 IU/ml inoculum
2. 5x l065 IU/ml inoculum
3. 5x l0 6 0 IU/ml inoculum
4. 5x l0 5 5 IU/ml inoculum
5. 5x l0 5 0 IU/ml inoculum
6. 5x l04 5 IU/ml inoculum
7. 5x l040 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-01 “Time and temperature” 
controls
17. 5x l090 IU/ml inoculum
18. 5x l0 85 IU/ml inoculum
19. 5x l08 0 IU/ml inoculum
20. 5x l075 IU/ml inoculum
21. 5x l07 0 IU/ml inoculum
22. 5x l065 IU/ml inoculum
23. 5x l060 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-01 CFI-treated #3
9. 5x l0 9 0 IU/ml inoculum
10. 5x l0 8 5 IU/ml inoculum
11. 5x l0 8 0 IU/ml inoculum
12. 5x l07 5 IU/ml inoculum
13. 5x l0 70 IU/ml inoculum
14. 5x l0 6 5 IU/ml inoculum
15. 5x l0 60 IU/ml inoculum
16. Phosphate buffer pH 5.7 
Lanes 25 and 26: RT-PCR positive
25. RNAase-free water
26. lxlO80 IU/ml inoculum
-483  -
Appendix 3
.  N IBSC -02  
Figure A3.20: Infectivity assay results for N IBSC -02 “before” (panel A) and CFI- 
treated #1 sam ples (panel B)
(A) (B)
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M M 17 18 19 20 21 22 23 24 25 26
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l07 0 IU/ml inoculum
2. 5x l065 IU/ml inoculum
3. 5x l06 0 IU/ml inoculum
4. 5x l0 5 5 IU/ml inoculum
5. 5x l0 50 IU/ml inoculum
6. 5x l045 IU/ml inoculum
7. 5x l04 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-02 CFI-treated #1
17. 2x l09'0 IU/ml inoculum
18. 2x108 :i IU/ml inoculum
19. 2x l08 0 IU/ml inoculum
20. 2x l07 5 IU/ml inoculum
21. 2x l07 0 IU/ml inoculum
22. 2 x l065 IU/ml inoculum
23. 2x l060 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-02 “before”
9. 3x l0 9 0 IU/ml inoculum
10. 3 x l08:> IU/ml inoculum
11. 3x l080 IU/ml inoculum
12. 3x l07 5 IU/ml inoculum
13. 3x l070 IU/ml inoculum
14. 3 x l065 IU/ml inoculum
15. 3x l060 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. lxlO 80 IU/ml inoculum
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Figure A3.21: Infectivity assay results for N IBSC -02 C FI-treated #1 sam ple (panels
A and B)
(A) (B)
M 1 2 3 4 5 6 7 M 8 9 10 11 12 13 14 15 16 17
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x1070 IU/ml inoculum
2. 5 x l0 6'5 IU/ml inoculum
3. 5 x l0 5'5 IU/ml inoculum
4. 5 x l0 50 IU/ml inoculum
5. 5 x l04 7 IU/ml inoculum
6. 5x 1040 IU/ml inoculum
7. Phosphate buffer pH 5.7
Lanes 16 and 17: RT-PCR positive controls
16. RNAase-free water
17. lxlO 80 IU/ml inoculum
Lanes 9 to 16: NIBSC-02 CFI-treated #1
8. 2x l0 90 IU/ml inoculum
9. 2x l0 8 :i IU/ml inoculum
10. 2x l0 8 0 IU/ml inoculum
11. 2x l07'5 IU/ml inoculum
12. 2x l0 7 0 IU/ml inoculum
13. 2x l065 IU/ml inoculum
14. 2x l06 0 IU/ml inoculum
15. Phosphate buffer pH 5.7
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Figure A3.22: Infectivity assay results for N IB SC -02 C FI-treated #2 sam ple (panels
A and B)
(A) (B)
M 1 2 3 4 5 6 7 8 M 9 10 11 12 13 14 15 16 17 18
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l07 0 IU/ml inoculum
2. 5x l06 5 IU/ml inoculum
3. 5x l0 60 IU/ml inoculum
4. 5x l05 5 IU/ml inoculum
5. 5x l05 0 IU/ml inoculum
6. 5x 1 ()4 5 IU/ml inoculum
7. 5x l040 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 and 18: RT-PCR positive controls
16. RNAase-free water
17. lxlO70 IU/ml inoculum
Lanes 9 to 16: NIBSC-02 CFI-treated #2
9. 5 x l090 IU/ml inoculum
10. 3x108 :> IU/ml inoculum
11. 5x l0 8 0 IU/ml inoculum
12. 5x107:i IU/ml inoculum
13. 5x l0 7 0 IU/ml inoculum
14. 5x l0 63 IU/ml inoculum
15. 5 x l060 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.23: Infectivity assay results for N IB SC -02 C FI-treated #3 (panel A) and  
“tim e and tem perature” sam ples (panel B)
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l070 IU/ml inoculum
2. 5x l06 5 IU/ml inoculum
3. 5x l06 0 IU/ml inoculum
4. 5 x l05 5 IU/ml inoculum
5. 5x l05 0 IU/ml inoculum
6. 5x l045 IU/ml inoculum
7. 5x l040 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-02 “time and temperature”
17. 7 .6xl09 0 IU/ml inoculum
18. 7.6x1O85 IU/ml inoculum
19. 7.6x1080 IU/ml inoculum
20. 7 .6xl07 5 IU/ml inoculum
21. 7 .6xl070 IU/ml inoculum
22. 7 .6xl06 5 IU/ml inoculum
23. 7 .6xl060 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. lxlO 80 IU/ml inoculum
M 17 18 19 20 21 22 23 24 25 26
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp
Lanes 9 to 16: NIBSC-02 CFI-treated #3
9. 8x l090 IU/ml inoculum
10. 8x l08 5 IU/ml inoculum
11. 8x108 0 IU/ml inoculum
12. 8x l07 5 IU/ml inoculum
13. 8x l07 0 IU/ml inoculum
14. SxlO6'^  IU/ml inoculum
15. 8x l060 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.24: Infectivity assay results for NIBSC-03 “before” and C FI-treated #2 
sam ples
M l  2 3 4 5 6 7 8 9 10 11 12 13 14 M 15 16 17 18 19 20 21 22 23 24 25 26
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1.5x107 0 IU/ml inoculum
2. 5x l0 6'5 IU/ml inoculum
3. 5x l0 6'0 IU/ml inoculum
4. 5x 1 ()5  ^ IU/ml inoculum
5. 5 x l0 5 0 IU/ml inoculum
6. 5x104 5 IU/ml inoculum
7. 5x l040 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-03 CFI-treated #2
17. 9xl()100 IU/ml inoculum
18. 9x l095 IU/ml inoculum
19. 9x 109'° IU/ml inoculum
20. 9 x l085 IU/ml inoculum
21. 9x l0 80 IU/ml inoculum
22. 9x l075 IU/ml inoculum
23. 9x l0 70 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-03 “before”
9. 2xlOl00 IU/ml inoculum
10. 2x l0 9 5 IU/ml inoculum
11. 2x l090 IU/ml inoculum
12. 2 x l085 IU/ml inoculum
13. 2x l0 80 IU/ml inoculum
14. 2x l0 7 5 IU/ml inoculum
15. 2x l0 70 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. 1 x 108 0 IU/ml inoculum
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Figure A3.25: Infectivity assay results for NIBSC-03 CFI-treated #3 samples
M 1 2 3 4 5 6 7 M 9 10 11 12 13 14 15 16 M 17 18 19 20 21 22 23 24 25 26
,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp
■■ v® - 'V 1 -  '  -
1 'vr J '  k- r.' ” i:iS:! ■ V • ■: - >' V
"
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1.5x107 0 IU/ml inoculum
2. 5 x l06 5 IU/ml inoculum
3. 5 x l06 0 IU/ml inoculum
4. 5x l05 5 IU/ml inoculum
5. 5x l05 0 IU/ml inoculum
6. 5x 1 ()4 5 IU/ml inoculum
7. 5xl()40 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-03 CFI-treated #3
17. 1.7xl0110 IU/ml inoculum
18. 1.7xl0105 IU/ml inoculum
19. 1.7xl0100 IU/ml inoculum
20. 1.7xl095 IU/ml inoculum
21. 1.7x109'0 IU/ml inoculum
22. 1.7x10841 IU/ml inoculum
23. 1.7xl080 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-03 CFI-treated #3
9. 7 x l0 10 0 IU/ml inoculum
10. 7x109 :i IU/ml inoculum
11.7x109 0 IU/ml inoculum
12. 7 x 1 0 8 :' IU/ml inoculum
13. 7 x l0 8 0 IU/ml inoculum
14. 7x107 :i IU/ml inoculum
15. 7x l0 7 0 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. lxlO80 IU/ml inoculum
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Figure A3.26: Infectivity assay results for NIBSC-03 “time and temperature”
sample
1 2  3 4 5 6 7 8 9 10 11 12 13 14 15 16 M
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l07 0 IU/ml inoculum
2. 5x l06 5 IU/ml inoculum
3. 5x l0 60 IU/ml inoculum
4. 5x l055 IU/ml inoculum
5. 5x l050 IU/ml inoculum
6. 5x 104 41 IU/ml inoculum
7. 5x l040 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-03 CFI-treated #3
9. 1.7x1 Oiao IU/ml inoculum
10. 1.7xl09 5 IU/ml inoculum
11. 1.7x109-° IU/ml inoculum
12. 1.7xl08ri IU/ml inoculum
13. 1.7xl080 IU/ml inoculum
14. 1.7xl07'5 IU/ml inoculum
15. 1.7xl070 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.27: Infectivity assay results for NIBSC-04 “before” sam ple
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp
50 bp / ii
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l070 IU/ml inoculum
2. 5x l065 IU/ml inoculum
3. 5x l060 IU/ml inoculum
4. 5xl()x:i IU/ml inoculum
5. 5 x l050 IU/ml inoculum
6. 5x104 5 IU/ml inoculum
7. 5x l040 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 and 18: RT-PCR positive controls
17. RNAase-free water
18. lxlO7 0 IU/ml inoculum
Lanes 9 to 16: NIBSC-04 “before”
9. 3x10 100 IU/ml inoculum
10. SxlO9  ^ IU/ml inoculum
11. 3x l090 IU/ml inoculum
12. 3x l08 5 IU/ml inoculum
13. 3x l080 IU/ml inoculum
14. 3x l07'5 IU/ml inoculum
15. 3x l070 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.28: Infectivity assay results for NIBSC-04 CFI-treated #1 samples
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l0 80 IU/ml inoculum
2. 5x l0 7S IU/ml inoculum
3. 5x l0 7 0 IU/ml inoculum
4. 5x l065 IU/ml inoculum
5. 5x l0 6 0 IU/ml inoculum
6. 5x10s 5 IU/ml inoculum
7. 5x10s 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-04 CFI-treated #1
17. 2x l080 IU/ml inoculum
18. 2x107 :' IU/ml inoculum
19. 2x l070 IU/ml inoculum
20. 2 x l065 IU/ml inoculum
21. 2x106H IU/ml inoculum
22. 2x10s 5 IU/ml inoculum
23. 2xlOs o IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-04 CFI-treated #1
9. 3x l08 0 IU/ml inoculum
10. 3x107 s IU/ml inoculum
11. 3x l070 IU/ml inoculum
12. 3x106 s IU/ml inoculum
13. 3x l060 IU/ml inoculum
14. 3x10s 5 IU/ml inoculum
15. 3x l050 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. 5x l0 8 0 IU/ml inoculum
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Figure A3.29: Infectivity assay results for NIBSC-04 CFI-treated #2 sample
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x107 0 IU/ml inoculum
2. 5x106" IU/ml inoculum
3. 5 x l06 0 IU/ml inoculum
4. 5x10s 5 IU/ml inoculum
5. 5 x l050 IU/ml inoculum
6. 5x 1 ()4  ^ IU/ml inoculum
7. 5x104° IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-04 CFI-treated #2
9. 3 x l0 10 0 IU/ml inoculum
10. 3x l09 5 IU/ml inoculum
11. 3x l090 IU/ml inoculum
12. 3 x l085 IU/ml inoculum
13. 3 x l080 IU/ml inoculum
14. 3x l07 5 IU/ml inoculum
15. 3x l070 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.30: Infectivity assay results for NIBSC-04 CFI-treated #3 and “time and
temperature” samples
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l0 80 IU/ml inoculum
2. 5x l0 7 5 IU/ml inoculum
3. 5x l0 7 0 IU/ml inoculum
4. 5x106 :i IU/ml inoculum
5. 5x l060 IU/ml inoculum
6. 5 x l05 5 IU/ml inoculum
7. 5 x l05 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 16 to 24: NIBSC-04 “time and temperature”
17. 3x l080 IU/ml inoculum
18. 3x l075 IU/ml inoculum
19. 3x l070 IU/ml inoculum
20. 3x l065 IU/ml inoculum
21. 3x l060 IU/ml inoculum
22. 3x 105s IU/ml inoculum
23. 3x l050 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. 5 x l07 0 IU/ml inoculum
Lanes 9 to 15: NIBSC-04 CFI-treated #3
9. lxlO 80 IU/ml inoculum
10. lxlO 75 IU/ml inoculum
11. lx l 07 0 IU/ml inoculum
12. lxlO60 IU/ml inoculum
13. lx l0 5 5 IU/ml inoculum
14. lxlO50 IU/ml inoculum
15. Phosphate buffer pH 5.7
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Figure A3.31: Infectivity assay results for NIBSC-05 “before” sample
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
M l  2 3 4 5 6 7 8  9 10 11 12 13 14 15 16 17 18
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x108 0 IU/ml inoculum
2. 5x107 5 IU/ml inoculum
3. 5x l07 0 IU/ml inoculum
4. 5x106 5 IU/ml inoculum
5. 5x l060 IU/ml inoculum
6. 5x l05 5 IU/ml inoculum
7. 5xlOs o IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 and 18: RT-PCR positive controls
17. RNAase-free water
18. lxlO80 IU/ml inoculum
Lanes 9 to 16: NIBSC-05 “before”
9. lxlO 100 IU/ml inoculum
10. lx l 09 5 IU/ml inoculum
11. lx l0 90 IU/ml inoculum
12. 1 x 108 5 IU/ml inoculum
13. lx l0 80 IU/ml inoculum
14. lx l 07  ^ IU/ml inoculum
15. lx l 07 0 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.32: Infectivity assay results for NIBSC-05 CFI-treated #1 samples
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l08 0 IU/ml inoculum
2. 5x107:i IU/ml inoculum
3. 5x l07 0 IU/ml inoculum
4. 5 x l06 5 IU/ml inoculum
5. 5x l060 IU/ml inoculum
6. 5x10s 5 IU/ml inoculum
7. 5x l0s ° IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-05 CFI-treated #1
17. 1 x 10 100 IU/ml inoculum
18. lxlO9 5 IU/ml inoculum
19. lxlO 90 IU/ml inoculum
20. lxlO 85 IU/ml inoculum
21. lxlO 80 IU/ml inoculum
22. lx l0 75 IU/ml inoculum
23. lxlO70 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-05 CFI-treated #1
9. lx lO 100 IU/ml inoculum
10. lx l 09  ^ IU/ml inoculum
11. lx l0 9 0 IU/ml inoculum
12. lx l 08 5 IU/ml inoculum
13. lxlO 80 IU/ml inoculum
14. Ix l0 7s IU/ml inoculum
15. lx l0 70 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. 5 x l0 8 0 IU/ml inoculum
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Figure A3.33: Infectivity assay results for NIBSC-05 CFI-treated #2 samples
M l  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1.5x108 0 IU/ml inoculum
2. 5x 107 :i IU/ml inoculum
3. 5x l07 0 IU/ml inoculum
4. 5x l0 65 IU/ml inoculum
5. 5x l060 IU/ml inoculum
6. 5x l05 5 IU/ml inoculum
7. 5 x l050 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 and 18: RT-PCR positive controls
17. RNAase-free water
18. 5 x l08 0 IU/ml inoculum
Lanes 9 to 16: NIBSC-05 CFI-treated #2
9. 3x108 0 IU/ml inoculum
10. 3x l07 5 IU/ml inoculum
11. 3x l0 7 0 IU/ml inoculum
12. 3x l06 5 IU/ml inoculum
13. 3x l060 IU/ml inoculum
14. 3x l05 5 IU/ml inoculum
15. 3 x l050 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.34: Infectivity assay results for NIBSC-05 CFI-treated #3 samples
M  1 2  3 4  5 6  7  8 9 10 11 12 13 14 15 16 17 18
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
LaneM. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l07 0 IU/ml inoculum
2. 5x l06 5 IU/ml inoculum
3. 5x l0 60 IU/ml inoculum
4. 5x10s 5 IU/ml inoculum
5. 5 x l050 IU/ml inoculum
6. 5x l04'5 IU/ml inoculum
7. 5x l040 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 and 18: RT-PCR positive controls
17. RNAase-free water
18. 5 x l080 IU/ml inoculum
Lanes 9 to 16: NIBSC-05 CFI-treated #3
9. 3x l090 IU/ml inoculum
10. 3x l0 85 IU/ml inoculum
11. 3 x l08 0 IU/ml inoculum
12. 3x l07'5 IU/ml inoculum
13. 3x l070 IU/ml inoculum
14. 3 x l06'5 IU/ml inoculum
15. 3x l060 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.35: Infectivity assay results for NIBSC-05 “time and temperature”
sample
M l  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bp
Lane M. PCR markers 
Lanes 1 to 8: LP isolate (positive control)
1. 5x l070 IU/ml inoculum
2. 5 x l06 5 IU/ml inoculum
3. 5x l060 IU/ml inoculum
4. 5x l05 5 IU/ml inoculum
5. 5x l050 IU/ml inoculum
6. 5x l04 5 IU/ml inoculum
7. 5 x l040 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-05 “time and temperature”
9. 5x l0 90 IU/ml inoculum
10. 5 x l085 IU/ml inoculum
11.5x1080 IU/ml inoculum
12. 5x l075 IU/ml inoculum
13. 5x1070 IU/ml inoculum
14. 5x l065 IU/ml inoculum
15. 5x l0 60 IU/ml inoculum
16. Phosphate buffer pH 5.7 
Lanes 17 and 18: RT-PCR positive controls
17. RNAase-free water
18. 5 x l080 IU/ml inoculum
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Figure A3.36: Infectivity assay results for NIBSC-06 “before” sample
M 1 2  3 4 5 6 7 M 9 10 11 12 13 14 15 16 17 18
1,000 bp 
750 bp 
500 bp
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l08 0 IU/ml inoculum
2. SxlO7  ^ IU/ml inoculum
3. 5x l07 0 IU/ml inoculum
4. 5x l06 5 IU/ml inoculum
5. 5x1060 IU/ml inoculum
6. 5x l0 5 5 IU/ml inoculum
7. 5x l05 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 and 18: RT-PCR positive controls
17. RNAase-free water
18. 5x l0 80 IU/ml inoculum
Lanes 9 to 16: NIBSC-06 “before”
9. 2 x l08 0 IU/ml inoculum
10. 2x 107 :i IU/ml inoculum
11. 2x l07 0 IU/ml inoculum
12. 2x l0 65 IU/ml inoculum
13. 2x l0 60 IU/ml inoculum
14. 2x l05 5 IU/ml inoculum
15. 2x l0 5 0 IU/ml inoculum
16. Phosphate buffer pH 5.7
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Figure A3.37: Infectivity assay results for NIBSC-06 CFI-treated #1 samples
M 1 2  3 4 5 6 7 8 M 9 10 11 12 13 14 15 M 16 17 18 19 20 21 22 23 24
1,000 bp 
750 bp 
500 bp
300 bp 
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l070 IU/ml inoculum
2. 5x1065 IU/ml inoculum
3. 5x l060 IU/ml inoculum
4. 5x l05 5 IU/ml inoculum
5. 5x l0 5 0 IU/ml inoculum
6. 5x l045 IU/ml inoculum
7. 5xl()4 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-06 CFI-treated #1
17. 2x l09'0 IU/ml inoculum
18. 2x10s5 IU/ml inoculum
19. 2x l0 8 0 IU/ml inoculum
20. 2x l075 IU/ml inoculum
21. 2 x l07 0 IU/ml inoculum
22. 2 x l065 IU/ml inoculum
23. 2 x l060 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-06 CFI-treated #1
9. 2 x l090 IU/ml inoculum
10. 2x108 :i IU/ml inoculum
11. 2x l0 8 0 IU/ml inoculum
12. 2x 107 :i IU/ml inoculum
13. 2x 107 0 IU/ml inoculum
14. 2x l065 IU/ml inoculum
15. 2x l060 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. 5x l0 7 0 IU/ml inoculum
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Figure A3.38: Infectivity assay results for NIBSC-06 CFI-treated #2 samples
M l  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M 17 18 19 20 21 22 23 24 25 26
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l08 0 IU/ml inoculum
2. 5x l07 5 IU/ml inoculum
3. 5 x l07 0 IU/ml inoculum
4. 5x106 3 IU/ml inoculum
5. 5x l060 IU/ml inoculum
6. 5x l0 3 3 IU/ml inoculum
7. 5x l05 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: NIBSC-06 CFI-treated #2
17. 8x l070 IU/ml inoculum
18. 8x l063 IU/ml inoculum
19. 8x l060 IU/ml inoculum
20. 8xl03 3 IU/ml inoculum
21. 8x l050 IU/ml inoculum
22. 8xl043 IU/ml inoculum
23. 8xl040 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-06 CFI-treated #2
9. 2 x l08 0 IU/ml inoculum
10. 2 x l07 3 IU/ml inoculum
11. 2 x l07 0 IU/ml inoculum
12. 2x 106 :’ IU/ml inoculum
13. 2 x l060 IU/ml inoculum
14. 2 x l05 3 IU/ml inoculum
15. 2x l030 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. RNAase-free water
26. 5 x l0 8 0 IU/ml inoculum
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Figure A3.39: Infectivity assay results for NIBSC-06 CFI-treated “time and 
temperature” sample
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 M 17 18
1,000 bp 
750 bp 
500 bp
300 bp
150 bp
50 bo
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
I .5x107 0 IU/ml inoculum
2. 5x106 5 IU/ml inoculum
3. 5x l060 IU/ml inoculum
4. 5x105  ^ IU/ml inoculum
5. 5x l05'0 IU/ml inoculum
6. 5x1 O'4 5 IU/ml inoculum
7. 5 x l04 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 9 to 16: NIBSC-06 “time and temperature”
9. 2x l090 IU/ml inoculum
10. 2 x l083 IU/ml inoculum
II . 2x108() IU/ml inoculum
12. 2x107? IU/ml inoculum
13. 2 x l07 0 IU/ml inoculum
14. 2x l065 IU/ml inoculum
15. 2 x l060 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 17 and 18: RT-PCR positive controls
17. RNAase-free water
18. 5 x l0 80 IU/ml inoculum
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4. Vitex study
Figure A3.40: Infectivity assay results for Vitex TS3A and TS6A samples
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1.5x108 0 IU/ml inoculum
2. 5 x l07 5 IU/ml inoculum
3. 5x1070 IU/ml inoculum
4. 5x l065 IU/ml inoculum
5. 5x l060 IU/ml inoculum
6. 5x l0 55 IU/ml inoculum
7. 5x l0 5 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 15 to 20: Vitex TS6A sample
15. 3x1060 IU/ml inoculum
16. 3x105 :i IU/ml inoculum
17. 3x l050 IU/ml inoculum
18. 3x104 :i IU/ml inoculum
19. 3x l040 IU/ml inoculum
20. Phosphate buffer pH 5.7
Lanes 9 to 14: Vitex TS3A sample
9. 2 x l07 0 IU/ml inoculum
10. 2x 106 :' IU/ml inoculum
11. 2x 1060 IU/ml inoculum
12. 2x l05 5 IU/ml inoculum
13. 2x l055 IU/ml inoculum
14. Phosphate buffer pH 5.7
Lanes 21 and 22: RT-PCR positive controls
21. 5 x l0 8 0 IU/ml inoculum
22. RNAase-free water
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Figure A3.41: Infectivity assay results for Vitex TS18A, TS22A and PCOA samples
M 1 2  3 4 5 6 7 8 9 10 11 12 13 14 15 16 M 17 18 19 20 21 22 23 24 25 26
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l0 8 0 IU/ml inoculum
2. SxlO771 IU/ml inoculum
3. 5 x l07 0 IU/ml inoculum
4. 5x l06 5 IU/ml inoculum
5. 5x l060 IU/ml inoculum
6. 5x l05 5 IU/ml inoculum
7. 5x l0 5 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 24: Vitex PCOA sample
17. lxlO 80 IU/ml inoculum
18. lx l0 75 IU/ml inoculum
19. lxlO70 IU/ml inoculum
20. lx l O6 5 IU/ml inoculum
21. lxlO 60 IU/ml inoculum
22. lxlO 55 IU/ml inoculum
23. lxlO 50 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 12: Vitex TS18A sample
9. 3x l04 0 IU/ml inoculum
10. 3x l0 33 IU/ml inoculum
11. 3x l030 IU/ml inoculum
12. Phosphate buffer pH 5.7
Lanes 13 to 16: Vitex TS22A sample
13. 4 x l0 3 0 IU/ml inoculum
14. 4 x l0 2 5 IU/ml inoculum
15. 4 x l0 25 IU/ml inoculum
16. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. 5x l0 7 0 IU/ml inoculum
26. RNAase-free water
-505  -
............................................................................................................................................................Appendix 3
Figure A3.42: Infectivity assay results for Vitex PC22A and TS3B samples
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 M 19 20 21 22 23 24 25 26
1,000 bp 
750 bp 
500 bp 
300 bp 
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5 x l080 IU/ml inoculum
2. 5x l0 7 5 IU/ml inoculum
3. 5x107 0 IU/ml inoculum
4. 5x l065 IU/ml inoculum
5. 5 x l060 IU/ml inoculum
6. 5x 105 5 IU/ml inoculum
7. 5x l050 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 19 to 24: Vitex TS3B sample
19. lxlO50IU/ml inoculum
20. 1 x 104  ^ IU/ml inoculum
21. lxlO40 IU/ml inoculum
22. lx l 03 5 IU/ml inoculum
23. 1 x 103 0 IU/ml inoculum
24. Phosphate buffer pH 5.7
Lanes 9 to 18: Vitex PC22A sample
9. lxlO 90 IU/ml inoculum
10. lxlO 85 IU/ml inoculum
11. lxlO80 IU/ml inoculum
12. 1 x 107  ^ IU/ml inoculum
13. lx l 07 0 IU/ml inoculum
14. lx l0 63 IU/ml inoculum
15. lxlO 60 IU/ml inoculum
16. 1 x 105 5 IU/ml inoculum
17. lxlO 50 IU/ml inoculum
18. Phosphate buffer pH 5.7
Lanes 25 and 26: RT-PCR positive controls
25. 5 x l0 80 IU/ml inoculum
26. RNAase-free water
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Figure A3.43: Infectivity assay results for Vitex TS6B, TS18B and TS22B samples
M l  2 3 4 5 6 7 8 M 9 10 11 12 13 14 15 16 17 18 19 20 21 22
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x108 0 IU/ml inoculum
2. 5x l0 7 5 IU/ml inoculum
3. 5x l0 7 0 IU/ml inoculum
4. 5x l0 6 5 IU/ml inoculum
5. 5xl()60 IU/ml inoculum
6. 5 x l05 5 IU/ml inoculum
7. 5x103 () IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 17 to 20: Vitex TS3B sample
17. neat inoculum
18. 10 ° 5 dilution inoculum
19. 10 10 dilution inoculum
20. Phosphate buffer pH 5.7
Lanes 9 to 12: Vitex TS6B sample
9. lx l0 4 0 IU/ml inoculum
10. lx l 03 5 IU/ml inoculum
11. lx l 03 0 IU/ml inoculum
12. Phosphate buffer pH 5.7
Lanes 13 to 16: Vitex TS18B sample
13. neat inoculum
14. 10 ° 5 dilution inoculum
15. 10 10 dilution inoculum
16. Phosphate buffer pH 5.7
Lanes 21 and 22: RT-PCR positive controls
25. 5 x l080 IU/ml inoculum
26. RNAase-free water
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Figure A3.44: Infectivity assay results for Vitex PCOB sample
M l  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1.5x108 0 IU/ml inoculum
2. 5x l0 73 IU/ml inoculum
3. 5x l07 0 IU/ml inoculum
4. 5x l0 63 IU/ml inoculum
5. 5x l0 60 IU/ml inoculum
6. 5x I03:i IU/ml inoculum
7. 5x l050 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 15 to 20: RT-PCR positive controls
15. 5x l0 80 IU/ml inoculum
16. RNAase-free water
Lanes 9 to 14: Vitex PCOB sample
9. 3x l07 0 IU/ml inoculum
10. 3x l06 5 IU/ml inoculum
11. 3x l06 0 IU/ml inoculum
12. 3x l053 IU/ml inoculum
13. 3x10s 3 IU/ml inoculum
14. Phosphate buffer pH 5.7
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Figure A3.45: Infectivity assay results for Vitex PC22B and B19 1:20 dilution
samples
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1. 5x l0 8 0 IU/ml inoculum
2. 5x l0 7 5 IU/ml inoculum
3. 5x l07 0 IU/ml inoculum
4. 5x l06 5 IU/ml inoculum
5. 5 x l060 IU/ml inoculum
6. 5x l05 3 IU/ml inoculum
7. 5x l03 0 IU/ml inoculum
8. Phosphate buffer pH 5.7 
Lanes 13 to 20: B19 1:20 dilution
13. 4x1080 IU/ml inoculum
14. 4 x l0 75 IU/ml inoculum
15. 4 x l070 IU/ml inoculum
16. 4x l0 6 5 IU/ml inoculum
17. 4x l0 60 IU/ml inoculum
18. 4x 105 5 IU/ml inoculum
19. 4x1050 IU/ml inoculum
20. Phosphate buffer pH 5.7
Lanes 9 to 12: Vitex PC22B sample
9. 3x l07 0 IU/ml inoculum
10. 3x l06 5 IU/ml inoculum 
1 1. 3xl060 IU/ml inoculum
12. Phosphate buffer pH 5.7
Lanes 21 and 22: RT-PCR positive controls
21. 5x l08 0 IU/ml inoculum
22. RNAase-free water
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5. Cerus study
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Figure A3.46: Infectivity assay results for Cerus untreated sample
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control)
1.5x108 0 IU/ml inoculum
2. 5x10 IU/ml inoculum
3. 5x l070 IU/ml inoculum
4. 5x l0 65 IU/ml inoculum
5. 5x l0 60 IU/ml inoculum
6. 5x l05 5 IU/ml inoculum
7. 5x l05 0 IU/ml inoculum
8. Phosphate buffer pH 5.7
Lanes 16 and 17: RT-PCR positive controls
16. 5x l080 IU/ml inoculum
17. RNAase-free water
Lanes 9 to 15: Cerus untreated
9. 8x l06 0 IU/ml inoculum
10. 8x l05 5 IU/ml inoculum
11. 8x l05 0 IU/ml inoculum
12. 8xl045 IU/ml inoculum
13. 8xl04 0 IU/ml inoculum
14. 8x l03 5 IU/ml inoculum
15. Phosphate buffer pH 5.7
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Figure A3.47: Infectivity assay results for Cerus treated 3J sample
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
1,000 bp 
750 bp 
500 bp 
300 bp
150 bp 
50 bp
Lane M. PCR markers
Lanes 1 to 8: LP isolate (positive control) Lanes 9 to 18: Cerus treated 3J
9. 2x l0 9 0 IU/ml inoculum
10. 2x l0 85 IU/ml inoculum
11. 2x 108 0 IU/ml inoculum
12. 2x l0 75 IU/ml inoculum
13. 2 x l07 0 IU/ml inoculum
14. 2x l06 5 IU/ml inoculum
15. 2x l060 IU/ml inoculum
16. 2x10s 5 IU/ml inoculum
17. 2x10 s0 IU/ml inoculum
18. Phosphate buffer pH 5.7 
Lanes 19 and 20: RT-PCR positive controls
19. 5x l0 8 0 IU/ml inoculum
20. RNAase-free water
1. 5x1080 IU/ml inoculum
2. 5xI07 S IU/ml inoculum
3. 5x1070 IU/ml inoculum
4. 5x l0 (,s IU/ml inoculum
5. 5x106H IU/ml inoculum
6. 5x10s 5 IU/ml inoculum
7. 5x l0 so IU/ml inoculum
8. Phosphate buffer pH 5.7
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